

CURRICULUM VITAE

Javed Butler, MD, MPH, MBA

President, Baylor Scott and White Research Institute
Senior Vice President, Baylor Scott and White Health
Distinguished Professor of Medicine, University of Mississippi Medical Center

Date of appointment January 2018
Citizenship Naturalized US citizen

PREVIOUS ACADEMIC AND PROFESSIONAL APPOINTMENTS

1. *Instructor*, Department of Medicine, Yale University, 1994-1995
2. *Assistant Professor of Medicine*, Vanderbilt University, 1999-2006
3. *Associate Professor of Medicine*, Emory University, 2007-2010
4. *Professor of Medicine*, Emory University, 2010-2014
5. *Deputy Chief Science Officer*, American Heart Association, 2009–2017
6. *Adjunct Professor of Nursing*, Emory University, 2011-2014
7. *Professor of Medicine*, Stony Brook University, 2014-2017
8. *Professor of Physiology and Biophysics*, Stony Brook University, 2014-2017
9. *Adjunct Professor of Nursing*, Stony Brook University, 2014-2017
10. *Professor of Medicine*, University of Mississippi Medical Center, 2018-2022
11. *Professor of Physiology and Biophysics*, University of Mississippi Medical Center, 2018-2022

PREVIOUS ADMINISTRATIVE AND/OR CLINICAL APPOINTMENTS

1. *Director*, Heart Transplant Program, Tennessee Valley Healthcare, Nashville VA, 1999-05
Associate Clinical Coordinator, Center for Healthcare Quality. Tennessee's Medicare Peer Review and Quality Improvement Organization, 1999-05
2. *Co-Director*, Heart Failure Program, Vanderbilt University, 2001-05
3. *Medical Director*, Heart Transplant Program, Vanderbilt University, 2003-05
4. *Medical Director*, Heart-Lung Transplant Program, Vanderbilt University, 2003-05
5. *Director*, Heart Failure Research, Emory University, 2006 – 2014
6. *Director*, Cardiology Faculty Mentoring Program, Emory University, 2011-2014
7. *Director*, Division of Cardiovascular Medicine, Stony Brook University, 2014-2017
8. *Co-Director*, Heart Institute, Stony Brook University, 2014-2017
12. *Patrick H. Lehan Chair in Cardiovascular Research*, University of Mississippi Medical Center, 2018-2022
13. *Chair*, Department of Medicine, University of Mississippi Medical Center, 2018-2022

BOARDS/CERTIFICATION

1990 Educational Commission for Foreign Medical Graduates Part I and II (ECFMG)
1992 Federal Licensure Examination, Pennsylvania (FLEX)
1994 - 04 American Board of Internal Medicine, *Internal Medicine*
2006 - 16 American Board of Internal Medicine, *Internal Medicine Recertification*

SPECIALTY BOARDS/CERTIFICATION

1998 - 2008 American Board of Internal Medicine, *Cardiovascular Medicine*
2004 United Network for Organ Sharing (UNOS) certified transplant cardiologist
2006 Nuclear Physics Certification (200 hours), St. Elizabeth Hospital, Boston
2006 -2016 Certification Board of Nuclear Cardiology. *Diplomate, Nuclear Cardiology*
2006 Cardiac Computed Tomography Level III Training
2008 - 2018 American Board of Internal Medicine *Cardiovascular Medicine Recertification*
2010 - 2019 American Board of Internal Medicine. *Advanced Heart Failure and Cardiac Transplantation*
2014 Executive Residency–Business and Health Care Policy-The Washington Campus
2020 - American Board of Internal Medicine *Cardiovascular Medicine Recertification*
2020 - American Board of Internal Medicine. *Advanced Heart Failure and Cardiac Transplantation*

PROFESSIONAL AFFILIATIONS

1. Fellow, American Heart Association
2. Fellow, American College of Cardiology
3. Fellow, European Society of Cardiology
4. Fellow, Heart Failure Society of America
5. Fellow, Heart Failure Association of the European Society of Cardiology
6. Fellow, American College of Physicians

LICENSURE

1994–98 Connecticut
1999-05 Tennessee
2005-06 Massachusetts
2006 - Georgia
2014 - New York
2018- Mississippi

EDUCATION

7/82 – 6/84 *HSC, Adamjee Science College*
Karachi, Pakistan
7/85 - 11/90 *MBBS (Bachelor of Medicine, Bachelor of Surgery)*
Aga Khan University
Karachi, Pakistan
7/96 - 12/98 *MPH (Master of Public Health)*
Harvard School of Public Health, Boston MA
7/13 – 4/15 *MBA (Master's in Business Administration)*
Emory University Goizueta Business School, Atlanta GA

POST-GRADUATE TRAINING

7/91 - 6/94 *Intern/Resident*
Internal Medicine/Primary Care
Yale University, New Haven CT

7/94 - 6/95 *Chief Resident*
Internal Medicine/Primary Care
 Yale University, New Haven CT

7/95 - 6/97 *Fellowship*
Cardiovascular Disease
 Vanderbilt University, Nashville TN

7/97 – 6/98 *Fellowship*
Heart Failure and Transplant
 Vanderbilt University, Nashville TN

7/05 – 6/06 *Fellowship*
Cardiac Imaging.
 Radiology Department
 Massachusetts General Hospital, Harvard University, Boston MA

MEDIA TRAINING

Annual professional media training
 AHA officers and board members - 2011

LEADERSHIP TRAINING

Woodruff Leadership Academy

Emory University - January-May 2010

Selection to the Woodruff Leadership Academy is based on leadership potential, triumphs, and an enthusiastic, ambassador personality. Each year 20 individuals from various disciplines are chosen. Training is focused on developing strategic thinking and interpersonal skills needed for effective leadership. Faculty includes nationally renowned leaders from various industries, faculty from the Goizueta School of Business Executive, and senior leadership from Woodruff Health Sciences Center and from the various schools within Emory. In addition to faculty, invited experts and accomplished leaders from various fields provide insight and strong leadership perspectives. Mandatory classes are combined with team project requiring outside-of-class group work focused on teamwork approach to problem solving, planning, and operational implementation.

PROFESSIONAL SERVICE

American Heart Association

1. **Get With The Guidelines:** Heart Failure Clinical Work Group
2. **Advocacy:** Involved in multiple advocacy initiatives related to research and healthcare
3. **Registry and Quality Improvement:** Mission Lifeline: STEMI systems of care quality improvement initiative. Involved in various capacities for the GWTG program for Coronary Disease, Heart Failure, and Stroke. Development team member, GWTG Outpatient, in collaboration with the ACS and ADA and electronic health record vendors
4. **Databases:** Science Staff Member, Executive Database Steering Committee
5. **Scientific Session:** Staff member on Committee for Scientific Session Planning for the AHA Annual Scientific Sessions. Annual participation in various activities for the Annual Scientific Session, Quality of Care and Outcomes Research Meeting, and Epidemiology/Nutrition, Physical Activity and Metabolism Meeting
6. **Worksite Wellness Program:** Science staff, Workplace Wellness Initiative
7. **Business Models Evaluation Team:** Science liaison for the 2020 business model task force aligned with the AHA mission, including, Consumer Membership, Rehabilitation,

Hospital Centers of Excellence Certification, ExerGaming and Health, Clinical Decision Support System, and Quality Improvement Coaching.

8. **Informatics/Health IT:** Member, Health Information Technology and Electronic Health Records Initiative group to provide feedback to the Government regarding adoptions, standards, and development of EHR
9. **Sodium:** Science advisor on optimal daily sodium intake recommendation, an AHA initiative in conjunction with the CDC report on salt intake
10. **Smoking:** Science reviewer for the effect of second hand smoke and public smoking bans on CV risk – an AHA initiative in conjunction with the IOM
11. **Partnership for Health Prevention:** AHA representative to the Partnership for Health Prevention (PHP), a joint group formed by the AHA, ACS and ADA.
12. **Obesity:** Staff member, Childhood Obesity Program of the AHA with the William J. Clinton Foundation
13. **Food/Nutrition:** Staff scientist, FreshFit food certification program with Subway Inc
14. **Miscellaneous:** Member, AHA and Joint Commission Heart Failure Accreditation program. Member staff, Heart 360 and Hypertension Initiative by AHA in collaboration with the HealthVault by Microsoft . AHA representative for the disparities in clinical trials working group by the CDC. Member, Operation Stroke, 2000-01. Member, Pharmaceutical Roundtable Outcomes Research Study Section 2002 – 2009
15. **Media:** Science review for all AHA conferences news media releases including, a) Annual Scientific Session, b) Quality of Care and Outcomes Research Meeting, c) Epidemiology/Nutrition, Physical Activity and Metabolism, d) International Stroke Conference, e) High Blood Pressure Research Conference, and f) Arteriosclerosis, Thrombosis, Vascular Biology
16. **RTI:** Science staff, 20-year cardiovascular disease prevalence and cost projection.
17. **Hospital Certification:** Science staff member on AHA initiative to certify hospital for comprehensive cardiovascular and stroke quality of care
18. **Research Committee:** Science staff on AHA research committee.
19. **Experience collaboration on behalf of the AHA:** Agency for Healthcare Research and Quality, American Cancer Society, American Diabetes Association, Centers for Disease Control and Prevention, Cable New Network (CNN), Duke Clinical Research Institute, ECRI Institute, Food and Drug Administration, Intel Corporation, The Joint Commission, MicroSoft Inc., National Institutes of Health, Pan American Health Organization, World Health Organization, Partnership for Health Prevention, RTI International, Subway Inc. and William J. Clinton Foundation

American College of Cardiology

1. Steering Committee Member, 2020 ACC/AHA Key Data Elements and Definitions for Heart Failure
2. Co-Chair, ACC's program for Women - Clinical Research Trials: Upping Your Game, 2019, 2020
3. Discussant, CV Clinical Research in the COVID-19 Era: FDA Regulations 2020
4. Member, Clinical Pathways – Heart Failure Committee, 2016 -
5. Member, Heart Failure Guidelines Update Committee 2015-
6. Member, Acute Heart Failure Working Group, 2014
7. Member, Taskforce for Standardizing Definitions for Diagnosis and Management of HF 2013
8. Member, Heart Failure Guidelines Committee 2011-2012
9. American College of Cardiology Self-Assessment Program 8, Chapter on Heart Failure Risk, Prognosis Determination, and Quality of Life 2010
10. Member, Heart Failure and Transplant Committee 2007-09

11. Member: Heart Failure Guidelines Implementation Working Group 2007-08
12. ACC Reviewer
 - a. Guidelines for the Diagnosis and Management of Heart Failure in Adults. 2009
 - b. ACC/SCAI/STS/AHA /ASNC, 2009 Appropriateness Criteria for Coronary Revascularization 2008
 - c. Hypertension 2009
13. Scientific Abstract Reviewer, 2002-06

Department of Health and Human Services

1. Stakeholder Committee, Developing Evidence to Inform Decisions about Effectiveness (DEClDE) Cardiovascular Consortium, Agency for Healthcare Research and Quality, 2010, 2011, 2012

Heart Failure Society of America

1. Chair, Publications and Scientific Statements Committee, 2020-2022
2. Chair, 2020 HFSA Scientific Program
3. Member, Development Committee, 2016-
4. Member, Annual Scientific Program Committee, 2014-2016
5. Member, Board of Directors, 2012-2016
6. Faculty, Heart Failure Board Review Course, 2011, 2012, 2014
7. Faculty, Annual Faculty Mentorship Session, 2012, 2013
8. Member, Guidelines Committee, 2010
9. HFSA representative - rating panel for the ACC Appropriateness Criteria for Imaging in HF 2010
10. Section Head for the Heart Failure Board Review Course for the inaugural Heart Failure Board Examination offered by the American Board of Internal Medicine (2010)
11. Member: Advocacy Committee, 2009
12. Participant, Future Planning retreat, 2007
13. Scientific Abstract Reviewer, 2002-16

National Institutes of Health

1. Chair, NIH Heart Failure Network Ancillary Studies Committee 2013-2018
2. NHLBI pilot trial study section, 2016
3. NHLBI AIDS Working Group: Advancing HIV/AIDS Research in Heart, Lung, and Blood Diseases, 2015
4. NHLBI Heart Failure in HIV patients working group, 2015
5. NHLBI clinical trial study section, 2015
6. NHLBI Working Group: Designing Clinical Studies to Evaluate the Role of Nutrition and Diet in Heart Failure Management, 2013
7. NIH Heart Failure Clinical Trials Network – Biomarker Study Committee 2012-14
8. HIV and AIDS study section, 2012, 2014, 2015
9. NHLBI AIDS Working Group: Advancing HIV/AIDS Research in Heart, Lung, and Blood Diseases, 2012
10. Member, Ancillary Studies Review Section, 2012
11. Grant Reviewer, Special Emphasis Panel
 - a. Hemodialysis and Markers of Heart Failure, Center for Scientific Review, December 2011
 - b. Brain Disorders and Clinical Neuroscience, Center for Scientific Review, June 2011

- c. Mechanistic Cardiac Function Study Group, Center for Scientific Review, October 2009
- 12. Grant Reviewer, Center for Scientific Review, Challenge Grants, July 2009
- 13. Cardiovascular Phenotype Working Group, Health ABC Study, 2009-15
- 14. Working Group on Future Research Opportunities in Women's Health Initiative: July 2008

Food and Drug Administration

- 1. Member, FDA Cardio-Renal Advisory Panel, 2020-
- 2. Symposium Co-Chair, Heart Failure Collaboratory Special Focus Meeting: Interpreting and Implementing New Clinical Trials Data
- 3. Symposium Chair: Relevance of non-primary outcomes in RCTs, 2019
- 4. Symposium Chair: Role of Phase II trials in Heart Failure, 2016
- 5. Symposium Co-Chair: Novel Endpoints in Heart Failure with Preserved Ejection Fraction, 2015
- 6. Symposium Co-Chair: Drug Development in Heart Failure, 2015
- 7. Symposium Co-Chair: State of the Cardiovascular Clinical Trials in the United States, 2014
- 8. Symposium presenter: Hospitalized Heart Failure with Preserved Ejection Fraction, February 2013
- 9. Symposium moderator: Site Selection for Heart Failure Trials, February 2012
- 10. Presenter – Public Hearing on External Automated Cardiac Defibrillators: Standard and Approval Criteria, 2010

Veterans Administration

- 1. Member, National Veterans Affairs Thoracic Organ Transplant Board, 2001-05
- 2. Chair, Clinical Management National Workgroup on Left Ventricular Assist Devices, 2003-05
- 3. Member, Purchase Committee, Nashville VAMC, 2001-2003

The Joint Commission

- 1. Member, Comprehensive Cardiovascular Certification Task Force, 2014
- 2. Member, Advanced Certification in Heart Failure Care Performance Measures Task Force 2010

Others

- 1. Member, Association of University Cardiologists (AUC) 2015-
- 2. Member, Board of Directors, National Forum 2015-2018
- 3. Member, Econometrica Task Force on Evaluation of Affordable Care Act, 2013
- 4. Member, Developing Patient Reported Outcome Measure for HF. Janssen Pharmaceutical, 2013
- 5. Duke Clinical Research Institute/Agency for HealthCare Research and Quality: Stakeholder member, AHRQ/DCRI Evidence Based Practice Center Cardiovascular Group
 - a. Technical Expert Panel:
 - i. Atrial Fibrillation, 2011
 - ii. Stroke Prevention, 2011
 - iii. ACEIs & ARBs for Treating Essential Hypertension
 - b. Topic Refinement: Noninvasive Technologies for the Diagnosis of Coronary Artery Disease in Women. 2010

- c. Value of Information Approaches in Research Prioritization: ACE inhibitors versus Angiotensin Receptor Blocker Use in Ischemic Heart Disease. 2010
- d. Topic Refinement: Treatment of Women with Coronary Artery Disease. 2010
- 6. Reviewer, Grants for the American Association for the Advancement of Science, New York, NY, 2007-2009
- 7. Member, Faculty of 1000 – Medicine, 2008-09
- 8. BMJ Group and Cerner Millennium® for developing pathways and CV order sets. 2008
- 9. Health-Core Integrated Research Network consultant 2008-2009
- 10. Member, Scientific Board, International Academy of Cardiology 2006
- 11. Member, Scientific Advisory Committee, World Congress on Heart Disease 2006
- 12. Member, Transplant Outcomes and Research Group, 1999-00
- 13. Scientific Session Committee - Connecticut Chapter of the ACP, 1994-95

REGIONAL AND STATE

- 1. Member, Cardiovascular Steering Committee, TennCare Centers of Excellence, Tennessee, 2002
- 2. Member, Get With The Guidelines Committee – Tennessee Chapter - AHA, 2000-02
- 3. Tennessee representative, Heart Failure PRO Intervention Enhancement (CHF-PIE) Project – Centers for Medicare and Medicaid Services (CMS), 1999-01
- 4. Tennessee Clinical Representative in CMS 6th and 7th Scope of Work Quality Improvement Initiatives, 1999-2001
 - National Heart Failure Project
 - National Myocardial Infarction Project
 - National Stroke and Atrial Fibrillation Project

INSTITUTIONAL SERVICE

University of Mississippi Medical Center (Insitutional outside of the Department of Medicine)

- 1. Medical Executive Committee
- 2. Administrative Advisory Council
- 3. Council of Clinical Chairs
- 4. Leadership Rounds
- 5. Several Search Committees
- 6. Mississippi Center for Clinical and Translational Research Advisory Board
- 7. Clinical Cabinet
- 8. Specialty Pharmacy Executive Committee
- 9. Cancer Center Board
- 10. Documentation Task Force
- 11. Faculty Practice Revenue Cycle Workgroup
- 12. UMMC/VA Affiliation Partnership Council
- 13. COVID 19 Executive Planning Committee

Stony Brook University

- 1. Stony Brook Hospital Medical Board – 2016
- 2. Stony Brook Physican Engagement Committee – 2016

3. Member, Search Committee for Chief Nursing Officer, 2016
4. Chair, Search Committee - Director of the Cardiac and Thoracic Surgery Division – 2015
5. Department of Medicine Pilot Grants Review Committee
6. Department of Medicine Research Committee
7. Delivery System Reform Incentive Payment Program –Suffolk County Hypertension Project

Emory University

1. Department of Medicine “Fostering Academic Mission at Emory” (FAME) Task Force 2008
2. Department of Medicine Awards Sub-Committee 2007- 2009
7. Cardiology Section Head, Emory Internal Medicine Board Review Course 2007-2010
8. Cardiology lead for Electronic Medical Record (EeMR) development and implementation for the Heart Failure and Transplant program 2007-2009
9. Atlanta Clinical & Translational Science Institute Scientific Advisory Committee 2009-15
10. Member, Clinical Informatics Council 2009-2010
11. Faculty Development Committee, Department of Medicine, 2010-11
12. Member, Advisory Committee, Center of Research Excellence in Pediatric Cardiology, 2010
13. Member, Cardiology Division Research Strategic Advisory Committee, 2010
14. Member, Clinical Research Advisory Committee, 2011
15. Faculty Councilor to the Investment Committee of the Emory University Board of Trustees, 2012-
16. Director, Cardiology Division Faculty Mentoring Program, 2011-

Harvard University

1. Reviewer, Grants and Applications for the Center for Medicine and Innovative Technology (CIMIT), Harvard Medical School and Massachusetts Institutes of Technology, 2006-2009

Vanderbilt University

1. Course Director, Grand Rounds, Cardiology Division, 2003-05
2. Cardiology representative, hospital Computerized Physician Order Entry (CPOE) system implementation committee, 2002-05
3. Cardiology representative, Guidelines and Pathways Implementation committee, 2003-05
4. Cardiology representative for hospital myocardial infarction and heart failure quality improvement initiative for JACHO and CMS measures, 2001-2004
5. Director, Mortality and Morbidity, Cardiology Division, 2002-03
6. Member, Medical Advisory Committee, Vanderbilt Health Plan, 2001- 04
7. Cardiovascular Care Committee, Meharry-Vanderbilt Alliance, 2001-02
8. Institutional Review Board , 1999-2001
9. Purchase Committee – Nashville VAMC, 2000- 02
10. Task Force on Cost Containment, Department of Medicine, Vanderbilt University, 2000
11. Lead physician, Physician Initiated Quality Improvement Project: Role of Opinion Leaders in Outpatient Quality Improvement for Heart Failure, Tennessee Peer Review Organization, 1999-01
12. Heart Failure Physician Leader, Institute for Healthcare Improvement Collaborative on Improving End of Life Care, Vanderbilt University Medical Center, 1999

Yale University

1. Residency Review Committee, Department of Medicine, Yale University, 1993-95

2. Internship Selection Committee, Department of Medicine, Yale University, 1993-95

MEDICAL JOURNAL AFFILIATIONS

Guest Editor in Chief

2020- Journal of the American College of Cardiology

Associate Editor

2020 – European Heart Journal
2014 - European Journal of Heart Failure
2012 - 2014 Current Heart Failure Reports
2008 - 2014 Journal of Cardiac Failure
2009 - 2012 Congestive Heart Failure

Editorial Board

2020- Mississippi State Medical Association Publications Committee
2016- Circulation
2015 – Section Editor – Heart Failure - Journal of the American College of Cardiology
2008 - Circulation Cardiovascular Quality and Outcomes
2008 - American Heart Journal
2006 - 2008 Journal of Cardiac Failure
2005 - 2009 Congestive Heart Failure
2003 - 2012 Journal of the American College of Cardiology

Consulting Editor

2012 – Journal of the American College of Cardiology – Heart Failure
2012 - Heart Failure Clinics

GUEST EDITOR

American Heart Journal

Manuscript Reviewer

2003 - American Heart Journal
2004 - American Journal of Cardiology
2005 - 2006 American Journal of Kidney Diseases
2002 - 2003 American Journal of Managed Care
2004 - 2005 American Journal of Medical Sciences
2003 - 2005 American Journal of Medicine
2008 - 2010 American Journal of Transplantation
2011- 2012 Annals of Internal Medicine
2004 - 2005 Annals of Psychosomatic Research
2004 - 2006 Annals of Thoracic Surgery
2003 - 2004 Canadian Medical Association Journal
2010 - 2011 Cardiovascular Engineering and Technology
1999 - Circulation
2008 - Circulation: Heart Failure
2008 - Circulation: Cardiovascular Quality and Outcomes
2009- Circulation: Cardiovascular Imaging
2008- 2010 Clinical Cardiology
2003 - 2012 Congestive Heart Failure
2006 - 2007 Coronary Artery Disease

2005 - 2007 Current Cardiology Reviews
 2004 - European Heart Journal
 2011 - 2012 Expert Review of Cardiovascular Therapy
 2004 - 2005 Expert Review of Medical Devices
 2002 - 2003 Heart
 2010 - 2011 Heart Failure Reviews
 2007 - 2008 International Journal of Cardiology
 2001 - 2003 Johns Hopkins Advanced Studies in Medicine
 2003 - 2004 Journal of the American Board of Family Medicine
 1998 - Journal of the American College of Cardiology - JACC
 2010 - Journal of the American College of Cardiology – Cardiovascular Imaging
 2009- Journal of the American Medical Association – JAMA
 2015- Journal of the American Medical Association - JAMA Cardiology
 2000 - Journal of Cardiac Failure
 2010 - 2011 Journal of Cardiovascular Medicine
 2007 - 2008 Journal of Gerontology
 1999 - 2008 Journal of Heart and Lung Transplantation
 2004 - 2006 Nephrology and Hypertension
 2011 – New England Journal of Medicine
 2008 -2009 Psychosomatic Medicine

External Manuscripts And Proposal Reviewer

1. Cardiovascular Health Study, National Heart Lung and Blood Institute
2. Health Aging and Body Composition Study, National Institute of Aging

HONORS AND AWARDS

1. Keynote Speaker in Pulse 2021, Aga Khan University’s Second Annual Cardiovascular Conference, January 2020
2. Keynote Speaker, 5th China International Heart Failure Congress, 2020
3. Keynote Speaker, American Association of Heart Failure Nurses Conference, 2020
4. Keynote Speaker, Northwestern University Annual Heart Failure Symposium, 2016
5. Fellow – Heart Failure Association of European Society of Cardiology, 2016
6. Fellow - Heart Failure Society of America, 2016
7. Keynote Speaker, Bridgeport Hospital Annual Seminar, Yale University affiliate, 2015
8. Fellow – European Society of Cardiology, 2014
9. Judge, American College of Cardiology Annual Young Investigator Award Competition, 2014
10. Keynote Speaker: Emory Residents Research Day, 2014
11. Keynote Speaker: Age Khan University Post Graduate Medical Education Ceremony, 2013
12. Excellent in Clinical Trials Performance, NIH Heart Failure Network, 2012
13. Time Feeling and Focus Award, American Heart Association, 2010
14. Top Doctors in Atlanta: Cardiovascular Diseases – Atlanta Magazine 2009, 2010, 2011, 2012
15. Simon Dack Award - American College of Cardiology 2009
16. Fellow – American Heart Association, 2007
17. *Elite Reviewer*, Journal of the American College of Cardiology, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013
18. Included in “Best Doctors in America” 2005-2010
19. Fellow – American College of Cardiology, 2000
20. Fellow – Society of Geriatric Cardiology, 2000
21. Roche/CTRD Young Investigator Award, 1999

22. First prize, Research Presentation, American College of Physicians, 1993
23. Cited in various different Who's Who since 1994 onward
24. Begum Zia-ul-Haq Scholarship, Aga Khan University 1989

SOCIETY MEMBERSHIPS

1. American College of Cardiology 1995 – current
2. American Heart Association 1995 – current
3. American College of Physicians/American Society of Internal Medicine 1993-1997
4. Heart Failure Society of America 1998 – current
5. International Society of Heart and Lung Transplant 1998 – current
6. National Healthcare Cost and Quality Association 1999-2000
7. Society of Cardiovascular Computed Tomography 2006 – 2008
8. Society of Geriatric Cardiology 2000 – 2004
9. European Society of Cardiology, 2014-current

ORGANIZATION OF CONFERENCES

Administrative positions

1. Program Committee, Heart Failure Society of America Annual Scientific Session 2014-16
2. Program Committee, American Heart Association Annual Scientific Session 2013
3. Member, Organizing Committee, World Congress on Heart Disease 2007
4. Co-Director, Heart Failure Board Review Course, 2010
5. Eat Healthy, Live Healthy, Lets Walk – A Healthier Chicago. Department of Health and Human Services, 2011

Session as Chair/Moderator/Discussant

1. *Emerging Role of Natriuretic Peptides*: ACC 2003
2. *Biomarkers in Heart Failure*: ACC 2003
3. *Left Ventricular Assist Devices – New Indications*: ACC 2004
4. *Advances in the management of acutely decompensated heart failure*. AHA 2006
5. *Metabolic Syndrome and Heart Failure*. HFSA 2006
6. *Diuretics to Aquaretics: Removing Fluid in Heart Failure*. HFSA 2007
7. *Acute Decompensated Heart Failure: Ask the Experts*. Moderator. AHA 2008
8. *What Are the Best Treatment Strategies for the Cardio-renal Syndrome?* ACC 2009
9. *Heart Transplantation for Unusual Disease*: ISHLT, Paris, France 2009
10. *Outcomes Research In Heart Failure*: Moderator, AHA 2009
11. *Epidemiology, Medication and Advanced Directives*, ACC 2010
12. *Management of Patients with Ventricular Assist Devices*. AHA Annual Scientific Session 2010
13. *Emerging Concepts in Pulmonary Hypertension with Left Ventricular Dysfunction*. AHA 2010
14. *Focus on Stable Angina*. Joint symposium – Italian Society of Cardiology and American Heart Association. 71st Annual Scientific Session of the Italian Society of Cardiology, Rome, Italy 2010
15. *Therapies for Advanced Heart Failure* - AHA Annual Scientific Session 2011
16. *Pathogenic and Therapeutic Insights From Experimental Heart Failure Models* – ACC 2012
17. *Featured Oral Abstract Session*, HFSA 2012
18. *Hydralazine and Isosorbide Dinitrate Therapy in Heart Failure: Past, Present, and Future* HFSA 2012

19. *Help, it is not in the guidelines! What can I do for my challenging patients?* ACC 2013
20. *Biomarker Guided Management in Heart Failure: Is it Ready for Prime Time:* ACC 2013
21. *Using Cohort Studies:* Young Investigators Forum. Panel Discussant Annual EPI/NPAM, 2013
22. *Personalized Medicine in Heart Failure: Current Applications.* University of North Carolina Annual Heart Failure Management Symposium 2013
23. *The Prevention of Heart Failure: HFSA/AHA Joint Session* HFSA 2013
24. *Can Heart Failure Be Prevented: HFSA/AHA Joint Session* HFSA 2014
25. *Moderator: Debates - HFSA* 2014
26. *Discussant Late Breaker Clinical Trials.* HFSA 2014
27. *Diabetes, Metabolism, Hypertension, and Heart Failure,* ACC, 2015
28. *How to interpret biomarkers in heart failure – ESC,* Heart Failure Association, Seville, Spain 2015
29. Chair: *Hyperkalemia in Heart Failure: New Data, Emerging Options,* HFSA, , 2015
30. Moderator in the *Preventing Heart Failure Readmission and Progression: What Does the Future Hold,* HFSA, 2015
31. Chair Session: *680 Diabetes, Metabolism, Hypertension, and Heart Failure,* ACC, 2015
32. Co-Chair Session: *Diet and Exercise in Heart Failure: Let's Debate,* ACC 2016
33. Discussant / Late Breaking Trials I: *Focus on acute heart failure,* HFA, Florence, Italy 2016
34. *Chair: Patient journey in Acute Heart Failure,* HFA, Florence, Italy 2016
35. Chair: *Biomarkers in heart failure and ventricular dysfunction: update 2016,* ESC, Rome, 2016
36. Moderator: *Guidelines Should be Practical for the Benefit of Practicing Clinicians,* HFSA 2016
37. Moderator: *Case Based Debate,* HFSA Annual Scientific Meeting, Orlando, 2016
38. Moderator: *Nutrition and the Heart: Dietary Approaches to Prevent Heart Failure,* AHA 2016
39. *Discussant: Guiding the Momentum to Effect HF Outcomes-Ironing out the Wrinkles,* AHA, 2016
40. *Co-Morbidities in chronic HF-time for paradigm shifts in the management of hyperkalemia and iron deficiency,* European Society of Cardiology, Munich 2018
41. *Reducing premature CV Mortality in patients with type 2 diabetes: best practice in cardiology,* European Society of Cardiology Conference, Munich 2018
42. *Help or Harm? Common Controversies in the Management of HF,* HFSA 2018
43. *Chair: Guidelines in daily practice I: Potassium binders ,* HFA, Athens, 2019
44. *Chair: Advances in therapeutic interventions in acute heart failure,* HFA. Athens, 2019
45. *Chair: The evolving role of cardiologists: can we help decrease the cardiovascular event burden in patients with type 2 diabetes?* HFA, Athens 2019
46. *Chair: Cardiovascular, Metabolic, and Renal Outcomes in Multi-Morbid Heart Failure Patients with Type 2 Diabetes,* Philadelphia, HFSA 2019
47. Chair, *Acute and Chronic Complications Results of the eValuation of ERTugliflozin Efficacy and Safety CardioVascular Outcomes Trial (VERTIS-CV),* American Diabetes Association Conference, June 12-15. 2020
48. Chair, *2020 HFSA Scientific Program*
49. Moderator, *e-SPACE conference on Heart Failure,* July 11-14, 2020
50. Chair, *The Prevention and Management of Heart Failure, Annual Heart in Diabetes Conference,* 21-24, August 2020
51. Discussant, *New approaches for better care of co-morbidities in HF,* Guidelines Forum, October 19-20, 2020
52. Chair, *SGLT2 inhibition. 1st Global web-Conference on the Cardio-Renal-Metabolic Syndrome,* January 22-24, 2021

53. Chair, Anemia and Iron Deficiency. 1st Global web-Conference on the Cardio-Renal-Metabolic Syndrome, January 22-24, 2021
54. Moderator & Panelist, Plenary session 4: Distinguishing good from bad research proposals, ACC CTR Steering Committee Meeting, April 12-13, 2021
55. Discussant, Lay of the Land: Flavors of Clinical Trials, ACC Scientific Sessions, May 15-18, 2021
56. Discussant, Device Based approach to Heart Failure Management, American Association of HF Nurses Symposium, June 17-18, 2021
57. Co-Chair Practice-Changing Trials in Heart Failure and Kidney Disease with SGLT2 Inhibitors, American Diabetes Association Conference, June 25-29, 2021
58. Commentary : Update on SCORED and SOLOIST Cardiovascular and Kidney Outcomes Trials, American Diabetes Association Conference, June 25-29, 2021
59. Panelist, Potential Opportunities and Challenges for Novel Therapies as Components of the Polypharmacy of Heart Failure: Latest Clinical Perspectives, Heart Failure Management Conference, July 17-18, 2021
60. Chair, Diabetes and kidney disease in heart failure: how should we treat the terrible triplets? European Society of Cardiology, August 27-31, 2021
61. Chair, Resolving Ongoing Controversies in Cardiovascular Disease: Heart Failure & Advance Heart Failure, Toronto-Ottawa Heart Summit, September 24-25, 2021
62. Co-Moderator, Balancing RAASi Therapy and Potassium, eSpace Heart Failure 2021, October 9, 2021
63. Chair, Device for HF therapy, Heart Failure Guidelines Forum, October 12, 2021
64. Co-morbidities and Enablement Strategies, Heart Failure Guidelines Forum, October 12, 2021
65. Moderator, Where Should New Heart Failure Guidelines Change in 2021? AHA Scientific Sessions, November 13-15, 2021
66. Moderator & Lecturer, The Role of SGLT2 Inhibitors Across the Spectrum of Heart Failure, THT Satellite symposium, February 1-2, 2022

RESEARCH FOCUS

1. Assess risk factors and prediction of outcomes in heart failure across the spectrum of prevention to advanced heart failure patients undergoing cardiac transplantation or ventricular assist device implantation. Considering the worsening heart failure epidemic and the growing elderly population, I have focused my research efforts in developing a solid foundation to further the understanding of heart failure development and progression, including development of a risk prediction model, assessing race-gender based differences in risk, further exploring known and novel risk markers, and assessing population attributable risks.
2. Investigate novel markers of heart failure outcomes and their incremental value in risk prediction
3. Extensive experience with government and industry-supported clinical trials and cohort studies. I developed and managed the Atlanta Cardiomyopathy Consortium, a prospective cohort study conducted in the various teaching hospitals in Atlanta. Received funding for the NIH supported Heart Failure Network Regional Center at Emory, for which we received an excellence award for performance by the NIH. Besides site-based participation, I have extensively served on steering committee, clinical events committees, and data safety monitoring committee of several multi-site clinical trials.
4. Understanding the science of the conduct of clinical trials and how it affects outcomes, and the trends of clinical trials conduct globally.

5. Regulatory aspects of clinical trials and drug development.

CLINICAL SERVICE CONTRIBUTIONS

2015 -	Half day weekly outpatient practice
2015 - 2017	4-6-week inpatient service on clinical cardiology and consult services.
2010 – 2014	Same as 2006-2009 except attending physician on heart failure and transplant service at Emory University Hospital for 2 months a year.
2006 - 2009	Attending physician on heart failure and transplant service at Emory University Hospital 3 months a year. Heart failure clinic 2 half-day session/week. Heart transplant clinics 4 morning sessions per week when on inpatient service
2004-2005	Developed and implemented AMI and CHF computerized physician order entry systems based on JCAHO and CMS directive
1999-2005	Attending physician on heart failure and transplant service, Vanderbilt University Medical Center and Nashville VAMC (3 months/yr). Heart failure and transplant clinics (2-3 1/2-day session/wk).
1999-2005	Responsible for all the cardiac transplantation patient evaluation and follow up at the Nashville VAMC
1999-2005	Attending physician, Heart Station (ECG and Holter interpretation), Vanderbilt University Medical Center and Nashville VAMC (1 month/yr)
1999-2002	Attending physician, CCU service, Nashville VAMC (2 months/yr)
1999-2003	Attending physician, cardiology consult service, Nashville VAMC (2 months/yr)
1999-2000	Reorganized the national VAMC fiscal responsibility policy for transplant and LVAD costs sharing between central, referring, and recipient VAMC.

FORMAL TEACHING

Medical Student Teaching

University of Mississippi Medical Center

2018- Medical student lectures – students rotating through the Department of Medicine

Stony Brook University

2014-17 Medical student lectures – students rotating through Cardiology

Emory University

2007 Sophomore Elective Course

Vanderbilt University

2004-05	Transplantation Course, 4th year medical student
2004-05	Cardiovascular Core Curriculum Lecture Series, 4th year medical student
1999-01	Physiology course, 1 st year medical student
1999-01	Laboratory diagnosis course, 2 nd year medical students
1999-02	Clinical pharmacology course, 2 nd year medical students
1996-00	Preventive medicine course, 4 th year medical students

Yale University

1994-95	Physical Diagnosis Rounds, 3 rd and 4 th year medical students
1994-95	ECG reading, 3 rd and 4 th year medical students

Graduate Program

2003-05 Meharry-Vanderbilt Pharmacology Course
2004-05 Lecturer, Vanderbilt Nursing School

Training programs

Participated in numerous (>200) local and national programs over the last decade as a speaker related to training of cardiologists, primary care physicians, and nurses.

Residency/Fellowship program

University of Mississippi Medical Center

2018- Resident noon conferences
2018- Medicine and sub-specialty grand rounds

Stony Brook University

2015 - Cardiology Fellows morning conference lectures – four times a year
2015 - Medical student and resident teaching round during in-patient service
2015- Cardiology Journal Club - montly

Emory University

2006- Medical student and resident teaching round daily during in-patient service
2006- Resident core curriculum lectures – once a year
2006- Cardiology Fellows morning conference lectures – once a year
2006- Monday/Friday morning clinical conferences – twice a year
2007- Cardiology Fellows Journal Club – once a year

Vanderbilt University

2001-05 Ambulatory Clerkship Curriculum for Residents
2001-05 Cardiology Boot Camp Lecturer, Cardiology Fellow
1999-05 Medical student and resident teaching round for 2-4 hr. daily during in-patient service
1999-05 Clinic supervision for medical students and residents during outpatient clinics
1999-05 Formal weekly case discussion on “interesting” cases during in-patient service

Supervisory Teaching and Research Mentorship

Medical Students

1.	Jack Wu - Vanderbilt Medical School	2001-2002
2.	Monique Cadogan - Maherry Medical School	2003-2004
3.	Mary Alice Nadine - Vanderbilt Medical School	2004-2006

Graduate and Doctoral Students

1.	Asli Ozdas - PhD Student, Vanderbilt University <i>Improving Quality of Care for Heart Failure by Improved Utilization of Care Pathways Facilitated by Computerized Physician Order Entry Systems</i>	2002-2003
2.	Theodore Addai, MD - MPH Student, Vanderbilt University <i>Similarities and Differences in Systolic and Diastolic Dysfunction among White and Black Patients</i>	2003-2005
3.	Robert Huang, MD - MPH Student, Vanderbilt University <i>Improving Time to Coronary Intervention for Acute Myocardial Infarction</i>	2004-2006

4. Jennifer Schuberth, MD - MPH Student, Vanderbilt University 2005-2006
Changes in Residency Work Hour: The Impact of the Short Call Team on Length of Stay and Quality of Care for Acute Decompensated Heart Failure
5. Digant Bhatt, MD - MPH Student, Georgia State University 2007-2008
Racial Differences in Outcomes Post Heart Transplant
6. Deepa Mangalat, MD - MS Student, Emory University 2008-2009
Serum Albumin and Risk for Heart Failure
7. Vikas Bhalla, MD - MS Student, Emory University 2009-2010
Biomarkers of Collagen Matrix Turnover and Risk for Mortality Among Heart Failure

Patients

8. Louise Savoye, MD – MPH candidate, Emory University 2009 - 2010
Effectiveness of Cardiac Resynchronization Therapy
9. Catherine Norton, MD - MSCR Student, Emory University 2011 – 2013
Tumor Necrosis Factor alpha receptors 1 and 2, and risk for incident heart failure in the elderly
10. Andreas Kalogeropoulos, MD - MPH Student, Emory University 2011 - 2013
Sodium Intake and Cardiovascular Outcomes among Elderly
11. Vasiliki Georgiopoulos, MD - MPH Student, Emory University 2011 - 2013
Exercise Habits in the Elderly and Risk for Heart Failure
12. Nancy McCabe, RN - PhD Student, Emory University 2012 - 2014
Self-care behaviors in adults with congenital heart disease

Post-Graduate Trainees

1. Mark Stankewicz, MD 1999-2001
Current position: Cardiology Division, St. Thomas Hospital, Nashville TN
2. Ghazanfar Khadim, MD 1999-2003
Current position: Interventional Cardiology Practice, Tampa, FL
3. Kimberly M. Paul, MD MS 2001-2002
Current position: Cardiology Private Practice, Atlanta GA
4. Rhonda Belue, MS, PhD 2001-2002
Current position: Associate Professor, Department of Biostatistics
Pennsylvania State University, Hershey PA
5. Cesar Simbaqueba, MD 2003-2004
Current position: Geriatrics Private Practice, Memphis TN
6. Carrie Geisburg, MD 2004-2006
Current Position: Assistant Professor of Medicine, University of Louisville,
Louisville, KY
7. Joann Goring, MD 2004-2006
Current Position: Cardiology fellowship Emory University, then private practice
8. Jennifer Listerman, MD 2004-2006
Current Position: Cardiology fellowship at University of Alabama, then private practice
9. Atif Rashad, MD 2006–2007
Current position: Not known.
10. Grigorios Giamouzis, MD PhD 2006-2008
Current position: Assistant Professor, University of Thessaly, Larrisa, Greece
11. Syed A Agha, MD 2007-2009
Current position: Private Practive cardiology
12. Perry Anarado, MD 2008-2009
Current position: Cardiology Fellow, University of Illinois, Chicago, IL
13. Imad Husain, MD 2008-2010
Current position: Assistant Professor, Cardiology Division, Baylor University

14. Mahdi Choudhary, MD 2008-2010
Current position: Cardiology Fellow, Brigham and Womens Hospital, Boston, MA
15. Charu Gupta, MD
Current position: Assistant Professor, Northwell Zucker School of
Medicine 2009-2010
16. Amanda Methvin, MD 2008-2010
Current position: Emory University, Atlanta, GA
17. Vasiliki Georgiopoulou, MD 2007-2010
Current position: Hospital administrator, Patras, Greece
18. Andreas Kalogeropoulos, MD 2007-2012
Current position: Assistant Professor, Cardiology Division, Stony Brook University, Stony
Brook, NY
19. Kathy Nilles, MD
Current position: Medical Resident, Emory University, Atlanta, GA 2009-2010
20. Catherine Norton Marti, MD 2009- 2015
Current position: Assistant Professor, Cardiology Division, Mercer University
Atlanta GA
21. Kunal Bhatt, MD 2009- 2010
Current position: Assistant Professor, Cardiology Division, Emory University,
Atlanta GA
22. Alanna Morris, MD 2009- 2011
Current position: Assistant Professor, Cardiology Division, Emory University, Atlanta GA
23. Song Li, MD 2012- 2014
Current position: Assistant Professor, Cardiology Division, University of Washington,
Seattle, WA
24. Anita Kelkar, MD 2012-2015
Current position: Heart Failure practice, North Carolina,
25. Ayman Tahhan, MD 2012-2015
Current position: Cardiology Fellow, Emory University, Atlanta GA
26. Lampros Papadimitriou, MD 2012-2017
Current position: Assistant Professor, University of Mississippi Medical Center,
Jackson, MS
27. Stella Kyung, MD 2015-2017
Current position: Cardiology Fellow, Rush Presbyterian Hospital, Chicago, IL
28. Bicki Viticharia, MD 2015-
Current position: Cardiology Fellow, Stony Brook University, Atlanta GA
29. Jennifer Chee, MD 2015-2017
Current position: Cardiology Fellow, Stony Brook University, Atlanta GA
30. Julia Sackheim, DO 2015-2017
Current position: Cardiology Fellow, University of Florida, Gainesville, FL
31. Carine Hamo, MD 2015-2017
Current position: Cardiology Fellow, Johns Hopkins University, Baltimore, MD
32. Shahbaz Sarwar, MD 2015- 2018
Current position: Cardiology Fellow, Stony Brook University, Atlanta GA

LECTURES, INVITED SEMINARS, VISITING PROFESSORSHIPS

1. Heart Failure with Reduced and Mid range Ejection Fraction and Acute Decompensated Heart Failure, Mount Sinai Grand Rounds, November 18, 2021

2. Incorporation of Natriuretic Peptides With Clinical Risk-Scores to Predict Heart Failure Among Individuals With Dysglycemia. AHA Scientific Sessions, November 13-15,2021
3. The Cutting Edge of Cardiovascular Care Quality Improvement, AHA Scientific Sessions, November 13-15,2021
4. Heart Failure and Atrial Fibrillation - New Directions, AHA Scientific Sessions, November 13-15,2021
5. Post MI Heart Failure, eSpace Heart Failure, October 18, 2021
6. Biomarkers in HF : Managemenet and Mechanisms Session, Transatlantic Heart Failure Biomarker Working Group, October 2, 2021
7. EMPEROR-Preserved: context, design and population, European Association for the Study of Diabetes, September 30, 2021
8. Management of HF – What Should the Guidelines Be? 5th Heart in Diabetes Conference, September 10-12, 2021
9. Defining HF Based on Symptoms and Signs, Heart Failure Society of America Conference, September 10-13, 2021
10. Hippocrates Oath! The #1 Reason for High Heart Failure Mortality, Heart Failure Society of America Conference, September 10-13, 2021
11. CHF and Diabetes Treatment Intersection – SGLT2 Inhibitors to Improve CV Outcomes, Heart Failure Management Conference, July 16-17, 2021
12. Role of SGLT2 inhibitors in Heart Failure: beyond diabetes, ESC Heart Failure 2021, June 29-July 1, 2021
13. Heart failure specifics in Chronic Kidney Disease, ESC Heart Failure 2021, June 29-July 1, 2021
14. HFpEF, University of Saskatchewan, Canada, October 29, 2021
15. Potential Use of SGLT2 Inhibitors, Oklahoma Heart Hospital, October 29, 2021
16. Lessons Learned from Recent Heart Failure Trials, University of Maryland Cardiology Grand Rounds, October 7, 2021
17. HFpEF, Lincoln Medical Center Bronx NY, September 24, 2021
18. Lessons Learned From Recent Heart Failure Clinical Trials, 18th Annual Peter F. Cohn Lecture, Stony Brook University, May 26, 2021
19. Lessons Learned from Recent Heart Failure Clinical Trials, Baylor College of Medicine, April 28, 2021
20. What does “Preserved EF” Mean? Re-evaluating the Use of Ejection Fraction in Patients With Heart Failure? Charleston HFpEF Conference, April 16, 2021
21. HFpEF: recent updates in management , Egyptian Society of Cardiology, Universal Definition & Classification of Heart Failure, April 16, 2021
22. Practice for Heart Failure with Preserved Ejection Fraction, Advocate Aurora Health, February 22, 2021
23. Lessons Learned from Recent HF Clinical Trials, Harvard University, Cardiology Grand Rounds, February 10, 2021
24. Emerging treatment approaches for HF on the topic: Potassium binders. 1st Global web-Conference on the Cardio-Renal-Metabolic Syndrome, January 22-24, 2021
25. Totality of evidence on renal benefits in CRM trials – focus on SGLT2 inhibitors. 1st Global web-Conference on the Cardio-Renal-Metabolic Syndrome, January 22-24, 2021
26. EMPEROR-Reduced – quality of life and functional capacity analyses. 1st Global web-Conference on the Cardio-Renal-Metabolic Syndrome, January 22-24, 2021
27. The Spectrum of Clinical Research, ACC’s Clinical Trial Research Steering Committee, November 9-10, 2020
28. The guidelines, Covid-19 and the results of clinical trials: The clinicians approach, Gudelines Forum, October 19-20, 2020

29. The Challenge of Chronic Hyperkalemia in Cardiometabolic Patients: Advances and Opportunities, Cardiometabolic Health Congress, October 19-20, 2020
30. Where Does Vericiguat Fit in the Contemporary Standard of Care Management of HFrEF Care? HFSA Annual Scientific Meeting, September 30-October 5, 2020
31. On the Horizon: Upcoming Trials with SGLT2 Inhibitors . HFSA Annual Scientific Meeting, September 30-October 5, 2020
32. Background and study design: Empagliflozin for chronic heart failure and a reduced ejection fraction in patients with and without diabetes: primary results of the EMPEROR-Reduced trial European Association for the Study of Diabetes (EASD) Annual Meeting, 21 – 25 September 2020
33. *Role of GLP1-RA in Trials in HF Patients, Annual Heart in Diabetes Conference, 21-24, August 2020*
34. *Hyperkalemia in HF, e-SPACE conference on Heart Failure, July 11-14, 2020*
35. What's New with HFpFF? American Association of Heart Failure Nurses Conference, June 25-28, 2020
36. *Debate—Drawing the Line between Primary and Secondary Prevention—Necessary or Too Simplistic , American Diabetes Association Online Conference, 2020*
37. *Lessons Learned in Drug Development, Yale University, January 2020*
38. *Why Are We Doing Clinical Trials in Acute Heart Failure? The University of Alabama at Birmingham, December 2019*
39. *RAASi enabling and cardiovascular/kidney disease outcome trials for new potassium binders. Why and when are they needed? CVCT Conference, December 2019*
40. *Societal and cultural acceptance of toxicities in oncology vs cardiology, CVCT Conference, December 2019*
41. *Iron therapy for heart failure: the evidence so far. Is oral iron out? CVCT Conference, December 2019*
42. *Whose Responsibility is it to Prescribe Glycemic Agents, AHA Scientific Sessions, November 2019*
43. *Let Your Patients With Heart Failure Enjoy Their Pretzels, AHA Scientific Sessions, November 2019*
44. *Lessons Learned in Drug Development, DUKE University, November 2019*
45. *Can we prevent Heart Failure? European Association for the Study of Diabetes Annual Meeting, 2019*
46. *SGLT2 Inhibitors and GLP1 Receptor Agonists in Diabetes and HF: Mechanisms to Clinical Trials, HFSA Annual Scientific Meeting, 2019*
47. *Routine Serial Echo Assessment is Helpful in Guiding Heart Failure, HFSA Annual Scientific Meeting, 2019*
48. *Management of Acute Heart Failure, Baptist Grand Rounds, Jackson, Mississippi, 2019*
49. *HFpEF: current diagnosis and management, Heart Failure & World Congress on Acute Heart Failure, May 2019*
50. *Treatment choices to optimize benefits for heart failure patients, Heart Failure & World Congress on Acute Heart Failure, May 2019*
51. *Making critical choices for patients at the right time, Heart Failure & World Congress on Acute Heart Failure, May 2019*
52. *A crosstalk between diabetes and heart failure, Heart Failure & World Congress on Acute Heart Failure, May 2019*
53. *Treatment of type 2 diabetes with/without heart failure: pending results from ongoing trials. Heart Failure & World Congress on Acute Heart Failure, May 2019*
54. *Guideline Directed Management of a NYHA Class III Patient: How to Titrate, What to Avoid, Tools for Success and Practical Pearls, ACC Scientific Sessions, 2019*

55. *Lowering Salt intake in Patients with Heart Failure – Good Idea? University of Mississippi, 2019*
56. *Obesity, Hypertension and Cardiorenal Diseases: Pathophysiology and Clinical Preespectives, University of Mississippi, January 2019*
57. *Late Breaking Clinical Trial: Novel Approaches to CV Prevention, AHA 2018*
58. *3-Day Readmissions: Can't Live with Them, Can Patients Live without Them? HFSA 2018*
59. *Decision making in the selection of candidates for advanced heart failure therapies, HFSA 2018*
60. *HFSA/AHA Joint Session An Imperative for Public Health: Heart Failure Prevention, HFSA 2018*
61. *Acute Heart Failure: What's Now? Emergency Grand Rounds, Vanderbilt Medical Center, August 2018*
62. *Acute Heart Failure: Failure to find a cure for a non-existing disease, Vanderbilt University, 2018*
63. *Heart Failure Guidelines–US perspective, Cardiac Society of Australia and NZ, Brisbane, 2018*
64. *Role of Biomarkers in Cardiovascular Clinical Trials, ESC Congress, Munich, August 2018*
65. *Diagnosing residual congestion before discharging heart failure patients, ESC Congress, August 2018*
66. *HF Outcomes in Diabetes Cardiovascular Outcomes Trials, ADA, Orlando, June 2018*
67. *Groundbreaking Studies in the Practice of Cardiovascular Medicine, AHA, California, 2017*
68. *Organ dysfunction in acute heart failure, Heart Failure Association Conference of the ESC, Paris, 2017*
69. *Novel drugs in acute heart failure: hurdles, hype and hope: HNO Donors, ESC-HFA, Paris, 2017*
70. *The Heavy Heart: Practicing Heart Failure Cardiology in an Obesity Epidemic, ACC 2017*
71. *Readmission in Heart Failure: Questions Unanswered, ACC Scientific Sessions, Washington 2017*
72. *SGLT2 inhibitors and the risk for heart failure. Annual Cardiovascular Symposium, Hong Kong 2016*
73. *Pragmatic clinical trials: difficulties and limitations? Global Hyperkalemia Council, New York 2016*
74. *Developing Effective Therapies for Worsening Heart Failure: Challenges and Opportunities, Cardiology Grand Rounds - Columbia University, New York, December 2016*
75. *Aldosterone Targeted NeuroHormonal CombinEd With Natriuresis TherApy in Heart Failure (ATHENA-HF) Trial, AHA Scientific Sessions, New Orleans, 2016*
76. *State of the Art in Cardiooncology: ESC Annual Scientific Session, Rome, Italy, 2016*
77. *Late Breaking Clinical Trial: A phase IIa, single-blind, placebo-controlled, crossover, multi-center, randomized study to assess the safety, tolerability, and preliminary efficacy of a single intravenous dose of ischemia-tolerant allogeneic mesenchymal bone marrow cells to subjects with heart failure of non-ischemic etiology. ESC, Rome, Italy, 2016*
78. *Novel Therapies for Acute Heart Failure: Cardioxyl: ESC Annual Scientific Session, Rome, Italy, 2016*
79. *Diabetes and Cardiovascular Outcomes – Selection of Patients for Clinical trials. CVCT, 2016*
80. *Optimizing RASS inhibitors using binder: Need for more data? The Guidelines Forum, Nice, 2016*
81. *Acute Heart Failure: Will We Ever Improve Outcomes? Lenox Hill Hospital, New York, October 2016*
82. *Heart Failure with Preserved Ejection Fraction, Beyond 2000 Symposium (XXII), Montreal, 2016*

83. *Overview of Clinical Trials for the Management of Hyperkalemia. Barcelona, Spain, 2016*
84. *Acute Heart Failure, Cardiology Grand Rounds - University of California, San Diego, September 2016*
85. *SGC-cGMP Pathway – Novel Therapeutic Pathway for Patients with HFrEF. Tokyo, Japan, 2016*
86. *Implementing Novel Therapies to Improve Outcomes for Our Patients, HFSA, 2016*
87. *Current Evidence Based Treatment Options for HF, HFSA Annual Scientific Meeting, Orlando, 2016*
88. *How-to: Integrating Nutrition into HF Management, HFSA Annual Scientific Meeting, Orlando, 2016*
89. *Implementing Novel Therapies to Improve Outcomes for our Patients, HFSA, 2016*
90. *Dietary Sodium Intake - Severe Restriction is Not Necessary. AHA, 2015*
91. *Regenerative Therapies to Improve Cardiac Function in Heart Failure. AHA, 2015*
92. *Unmet Needs in Heart Failure. Frankfurt, Germany 2015*
93. *Epidemiology of Heart Failure with Preserved Ejection Fraction. FDA, Bethesda, Maryland, 2015*
94. *Cardiac Remodeling Concepts. Stressa, Italy, 2015*
95. *Hospital Discharge Criteria for Patients with Acute Heart Failure. Vienna, Austria, 2015*
96. *Cardiorenal Syndrome – ESC, Heart Failure Association, Seville, Spain 2015*
97. *Unmet medical needs in HFrEF and possible ways to address them – ESC-HFA, Seville, Spain 2015*
98. *Pathophysiology of Acute Heart Failure. Columbia University, New York, NY 2015*
99. *Acute Heart Failure – Cardiology Grand Rounds, SUNY Buffalo, Buffalo, New York, 2015*
100. *Biased Ligands and Acute Heart Failure. CVCT, DC, 2015*
101. *Impact of Hyperkalemia in Patients with Heart Failure. HFSA, 2015*
102. *Development of Novel Therapeutics in Heart Failure. Bridgeport Hospital, Bridgeport CT 2015*
103. *Update in Heart Failure Clinical Trials. Annual Cardiovascular Symposium. Emory University, 2015*
104. *Team Approaches to Reduce Heart Failure Readmission. HFSA, 2015*
105. *Neprilysin Inhibition in Heart Failure: Lessons from Recent Trials. University of North Carolina Annual Symposium, Amelia Island FL 2015*
106. *Moving from Acute or Worsening Heart Failure. CVCT, 2015*
107. *Management of Heart Failure for the Internist. Milwaukee, WI 2015*
108. *PARAMOUNT Trial – The Ultimate Design? CVCT, Washington DC, 2015*
109. *Next General Clinical Trials in Heart Failure. Mount Sinai Beth Israel Hospital, New York, 2015*
110. *Importance of Sub-Clinical Congestion. University of Palermo, Palermo, Italy, 2014*
111. *Heart Failure 2015. Medicine Grand Rounds, Stony Brook University, Stony Brook, New York, 2014*
112. *Heart Failure Readmissions. University of South Florida, Tampa, Florida, 2014*
113. *Unmet Needs in Worsening Heart Failure. ESC - HFA, Greece, 2014*
114. *Definition and characteristics of vulnerable phase post. ESC - HFA, Greece, 2014*
115. *How to manage co-morbid renal dysfunction in heart failure? ESC - HFA, Greece, 2014*
116. *Development of pulmonary hypertension: the pivotal role of the left atrium. ESC-HFA, Greece, 2014*
117. *Why Have Clinical Trials in Acute Heart Failure Failed? Mayo Clinic Symposium. Dana Point, CA, 2014*
118. *Is There Any Role for Ultrafiltration after CARRESS trial? Mayo Clinic Symposium, Dana Point, 2014*
119. *What is New with Treatment Strategies in Systolic HF? Hydralazine/Nitrates. ACC, 2014*

120. *The Challenge of Definitions and Classifications of the Cardiorenal Syndrome.* ACC, 2014
121. *Core Curriculum – Chronic Systolic Heart Failure and Acute Heart Failure.* ACC, 2014
122. *Clinical Relevance of Sub-Clinical Congestion.* Convegno - Palermo, Italy, 2013
123. *Mechanisms And Relevance Of Insufficient sGC/cGMP Signaling In Heart Failure.* CVCT, Paris, 2013
124. *Defining biomarker guided therapy: What is the target? Drug doses or the biology?* CVCT, Paris, 2103
125. *Critical appraisal of aquapheresis.* Cardiovascular Clinical Trialist Forum, Paris, France, 2013
126. *Novel Therapies in Acute Heart Failure.* Medscape Roundtable Discussion, Amelia Island, FL, 2013
127. *Role of Biomarkers in Cardiovascular Care of the Elderly with Heart Failure.* University of North Carolina Annual Heart Failure Symposium, Amelia Island, FL, 2013
128. *Controversies in Heart Failure with Preserved Ejection Fraction.* Rutgers-Robert Wood Johnson University, New Brunswick NJ, 2013
129. *Impediments in Heart Failure Research: Potential Solutions.* Christiana Care Newark, DE, 2013
130. *Heart Failure Research In The Next Decade.* Stony Brook University Long Island, NY, 2013
131. *What have we learned from HFpEF Clinical Trials?* Bayer Symposium on Animal Models for Heart Failure Dusseldorf, Germany, 2013
132. *Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy.* Medscape Roundtable San Francisco, CA, 2013
133. *Renal Function, Worsening Renal Function, and Heart Failure Outcomes.* ESC Amsterdam, 2013
134. *Sub-clinical Congestions and Heart Failure Outcomes.* Annual Asia Pacific Annual Cardiology Meeting, Kuala Lumpur, Malaysia, 2013
135. *Acute Heart Failure: Past Failures Guiding the Future,* National University Singapore, 2013
136. *Fluid Management Strategies and Challenges,* Vascular Biology Working Group San Francisco, 2013
137. *Therapeutic Target For Novel Drug Development in HFPEF.* Bayer Pharmaceutical, Frankfurt, 2013
138. *The Human and Economic Cost of Heart Failure Readmission.* Medtronic Summit, Las Vegas, 2013
139. *What have we learned from AHF trial in the last two decades?* University of Alberta, 2013
140. *Advanced Heart Failure Therapies: Can We Afford It?* University of Alberta, Edmonton, 2013
141. *Early Detection of Heart Failure Risk and Management Options* 6th Annual Biomarkers and Personalized Medicine Conference, Cannes, France, 2012
142. *Heart Failure Risk Prediction.* AHA Annual Scientific Session, Los Angeles, CA, 2012
143. *Relationship between site enrollment and outcomes in acute heart failure.* ESC Munich, 2012
144. *Back in the Hospital. Leading Up to Admission (ADHERE).* HFSA, Seattle, WA, 2012
145. *HFSA 2012 Recommendations on the use of MRA.* HFSA, WA, 2012
146. *Hydralazine and Nitrate in Heart Failure: Unanswered Questions.* HFSA, Seattle, WA, 2012
147. *AHF: Strategies to Improve Care Cardiovascular.* St. Joseph Hospital, Atlanta, GA, 2012

148. *Why don't we have any proven therapies for heart failure?* Cleveland Clinic, Cleveland, OH, 2012
149. *Advanced Heart Failure: Past Failure and Future Directions.* Indiana University Indianapolis, IN, 2012
150. *What Truly Is Cardio-Renal Syndrome? Insights into Pathophysiology.* ACC, Chicago, , 2011
151. *High Risk Patients For Heart Failure – Detection Strategies.* AHA Orlando, FL, 2011
152. *Renal Function in Acute Heart Failure.* Romanian Society of Cardiology, Bucharest, 2011
153. *Epidemiology and Outcomes in Heart Failure.* Advanced Heart Failure and Transplant Board Review Course, Chicago, IL, 2011
154. *Risk Factors and Prognosis Determination in Heart Failure.* Advanced Heart Failure and Transplant Board Review Course, Chicago, IL, 2011
155. *Heart Failure Quality of Care, Accreditation, and Certification.* Advanced Heart Failure and Transplant Board Review Course, Chicago, IL, 2011
156. *Diuretic Use in Heart Failure.* HFSA Annual Scientific Session Boston, MA, 2011
157. *Management of Left Ventricular Assist Device.* AHA Annual Scientific Session Orlando, FL, 2011
158. *Biomarkers for Early Cardiovascular Risk Determination.* UNC HF Summit Amelia Island, 2011
159. *Diabetes Management in Heart Failure.* UNC Heart Failure Summit Amelia Island, FL, 2011
160. *HF Prevention: How to Think and How to Act.* Case Western Reserve University Cleveland, 2011
161. *Clinical Presentation of the Cardiorenal Syndrome.* ACC, New Orleans, LA, 2010
162. *Automated External Defibrillators: Technologic Advances and User Training.* FDA Public Hearing Invited Presentation Washington DC, 2010
163. *Update on Stable Angina.* Italian Society of Cardiology, Rome, Italy, 2010
164. *Emerging Biomarker for Heart Failure.* Morehouse Medical School, Atlanta, GA, 2010
165. *Diabetes Mellitus to Heart Failure: Pathophysiologic Insights.* HFSA, San Diego, CA, 2010
166. *Assessing Pulmonary Hypertension in Heart Failure: Defining Preoperative Risk for Transplant and Implantation of LVAD.* AHA, Chicago, IL, 2010
167. *Epidemiology and Outcomes in Heart Failure.* Board Review Course, HFSA, Minneapolis, MN, 2010
168. *Risk Factors and Prognosis Determination in Heart Failure.* Board Review Course, HFSA, Minneapolis, 2010
169. *Heart Failure in Women.* Methodist LeBonheur Healthcare, Memphis, 2010
170. *Heart Failure Epidemiology.* Southern Medical Association's 2010, Kissimmee, FL 2010
171. *Improving risk stratification for heart failure. Is there a role for B-type natriuretic peptides?* Cardiology Congress of Central Greece, Larissa, Greece 2010
172. *Diabetes and Dyslipidemia in Heart Failure: Management Considerations.* UNC Heart Failure Symposium, Amelia Island, FL 2010
173. *Novel Research Designs for Assessing Clinical Utility of New Biomarkers in Heart Failure.* 6th Annual Biomarkers and Personalized Medicine Conference, Cannes, France, 2010
174. *Phenotyping and Personalized Medicine.* 6th Annual Biomarkers and Personalized Medicine Conference, Cannes, France, 2010
175. *Approaches for Early Cardiovascular Risk Detection.* 6th Annual Biomarkers and Personalized Medicine Conference, Cannes, France, 2010

176. *New Therapies for the Management of Heart Failure.* ACC Georgia Chapter, Lake Oconee, GA, 2010
177. *Diabetes and Heart Failure.* ACC Annual Scientific Meeting, Atlanta, GA 2010
178. *Epidemiology of Cardio-Renal Syndrome.* ACC Annual Scientific Meeting, Atlanta, GA 2010
179. *Population Based Heart Failure Preventions.* University of Minnesota, Minneapolis, MN 2009
180. *Prediction Models in Advanced Heart Failure.* University of Thessaly, Larissa, Greece 2009
181. *Cardio-Renal Interactions in Heart Failure.* University of Thessaly, Larissa, Greece 2009
182. *Managing Right Ventricle in Patients with Left Ventricular Assist Devices.* HFSA, Boston MA, 2009
183. *Predicting Incident Heart Failure.* Inter-American Society of Cardiology and ACC, Fajardo Puerto Rico, 2009
184. *Epidemiologic Trends in New Onset Heart Failure.* Inter-American Congress of Cardiology and ACC, Fajardo Puerto Rico, 2009
185. *Heart Failure Epidemic and the Aging US Population.* Emory University, Atlanta, GA, 2009
186. *Cardiorenal Syndrome: Is it the Heart's Problem or the Kidney's?* New York Cardiological Society and New York Chapter of the ACC, New Paltz NY, 2009
187. *Worsening HF Epidemic: Causes and Solutions.* Emory School of Public Health, Atlanta, 2009
188. *Incident Heart Failure Prediction Models: Are We As Good As Predicting Coronary Artery Disease.* AHA, New Orleans LA, 2008
189. *New Developments in the Management of Acute Heart Failure.* Halifax Hospital, Daytona FL, 2008
190. *Renal Function, Diuretics, and Heart Failure Outcomes.* ACC, Chicago IL, 2008
191. *The Future of Cardiovascular Disease: Heart Failure.* AHA Cardiovascular Disease Epidemiology and Prevention, and Nutrition, Physical Activity and Metabolism, Colorado Springs CO, 2008
192. *Systems Biology Approach to Heart Failure: Emory TACC Initiative.* Emory University, Atlanta, 2008
193. *Anemia and outcomes in heart failure.* Renal Grand Rounds, Emory University, Atlanta, 2008
194. *Evaluation and Management of New Onset Heart Failure.* Grady Memorial Hospital, Atlanta, 2008
195. *Identification of Coronary Artery Disease: Role of CT Angiography.* ACC, New Orleans, 2007
196. *Renal Insufficiency: Managing Comorbidity to Improve HF Outcomes.* ACC, New Orleans, 2007
197. *Cardiac CT: Is the hype justified?* Medical Grand Rounds, Emory University, Atlanta GA, 2007
198. *Research Applications for Cardiac MDCT in Cardiomyopathies.* Brigham and Womens Hospital, Harvard Medical School, Boston MA, 2006
199. *Emerging indications for cardiac computed tomography.* Cardiology Grand Rounds, Emory University, Atlanta, 2006
200. *Role of cardiac MDCT in heart failure patients.* Duke Clinical Research Institute, Durham NC, 2006
201. *Risk Determination: A Risky Business!* Ochsner Clinic Foundation, New Orleans LA, 2006

202. *Predicting Future! God's Whim or a Mathematics.* Northwestern University, Chicago, 2006
203. *Cardiac Computed Tomography—Current and Future Clinical Implications.* University of Iowa, 2005
204. *Inflammation is associated with both vulnerable and stable coronary plaques.* Massachusetts General Hospital, Boston MA, 2005
205. *Controversies in heart failure management.* Western Michigan State University, Kalamazoo, 2005
206. *Neurohormonal therapy, how many drugs, in what order?* Kansas University, Kansas City MO, 2005
207. *Heart Failure Update.* Mid America Heart Institute, Kansas City MO, 2005
208. *ACE inhibitors, beta-blockers, angiotensin receptor blocker, aldosterone antagonist: All, when, who?* Ochsner Clinic Foundation, New Orleans LA, 2005
209. *Update in medical management of heart failure.* Tulane University, New Orleans LA, 2005
210. *The emerging role of aldosterone antagonism in HF.* Louisiana State University, New Orleans, 2005
211. *After ACE inhibitors – what's next?* East Tennessee State University, Johnson City, 2005
212. *The Drugs, The Devices, The Dos, and The Don'ts of Heart Failure.* University of North Texas Health Science Center, Fort Worth TX, 2004
213. *Angiotensin II and Cardiovascular Risk.* University of Tennessee College of Medicine, Erlanger Medical Center, Chattanooga TN, 2004
214. *Heart Failure: The new vascular biology imperative to blunt progression.* UT Knoxville, 2004
215. *Heart Failure Management: Drugs and Devices.* Marshall University, Huntington WV, 2004
216. *Neurohormonal Modulation in HF: Reaching A Ceiling?* Tulane University, New Orleans, 2003
217. *Changing Indications for Cardiac Transplantation.* University of Cincinnati, Cincinnati OH, 2003
218. *Selection of Candidates for Heart Transplantation.* Temple University, Philadelphia, 2003
219. *The Unsympathetic Adrenergic Nervous System.* Wayne State University, Detroit, 2002
220. *Predictability of Prediction Models.* University of Chicago, Chicago IL, 200
221. *Mortality and Quality: Grades that Fade.* Vanderbilt University, Nashville TN, 200
222. *Patient Selection for Heart Transplant: How can we maximize post-transplant outcomes?* University of Alabama at Birmingham, Birmingham AL, 2000
223. *Cardiac Output Response to Exercise in HF.* Oregon Health Sciences Center, Portland, 1999
224. *Prognosis Determination in Chronic Heart Failure.* University of Tennessee, Memphis TN, 1998
225. *Exercise Intolerance In Chronic Heart Failure.* Vanderbilt University, Nashville TN, 1997
226. *Pathophysiology Of Diastolic Dysfunction.* Griffin Hospital, Derby CT, 1995

CLINICAL TRIALS, REGISTRIES, MULTI-CENTER STUDIES

Consultant

Ad hoc consultant for clinical trials or registry protocol development for Alere, Abbott, Adrenomed, Amgen, Applied Therapeutics, Array, Astra Zeneca, Bayer, BerlinCures, BG Medicine, Bristol Myers Squibb, Boehringer Ingelheim, Cardiocell, Cardior, Celladon, CardioMEMS, Covis, Cuoralia, CVRx, G3 Pharma, Gambro, GE Healthcare, Gilead, Foundry,

Harvest Technologies, Imbria, Impulse Dynamics, Innolife, Janssen, Johnson and Johnson, Juventas, LivaNova, Luitpold, Medpace, Medtronic, Merck, Novartis, NovoNordisk, Ono Pharma, Otsuka, PharmalIn, Reate, Relypsa, Roche, Sanofi, SC Pharma, Sequana Medical, Stealthpeptide, Stemedica, Trevena, Takeda, V-Wave Limited, Vifor Pharma, Zensun, ZS Pharma

Data Safety Monitoring Board

Chair

1. STRONG HF - Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP and GDF-15, of Heart Failure Therapies
Roche Diagnostics 2017-
2. NOVEL-HF - Neuregulin-1 Effect On Survival And Hospitalizations In Chronic Systolic Heart Failure
Zensun Pharmaceutical - 2013-15
3. CARE-Hep C - Longitudinal Assessment of Cardiovascular and Renal Health in Patients with Hepatitis-C
Bristol Myer Squib - 2013-2017

Member

1. SCAN-MP - Screening for Cardiac Amyloidosis with Nuclear imaging in Minority Populations
NIH 2019-
2. ARRAY 797-301 - A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
Array Pharmaceuticals 2017-
3. RELIEVE-HF - Reducing Lung Congestion Symptoms Using the V-wave Shunt in Advanced Heart Failure
Cardiovascular Research Foundation 2017-
5. METEORIC HF - A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects with Heart Failure with Reduced Ejection Fraction and Decreased Exercise Tolerance
AMGEN 2017-
6. STAND-UP HF - A Randomized, Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986224 in Healthy Subjects and Chronic Heart Failure Patients With Reduced Ejection Fraction
Bristol Myers Squibb 2017-
7. GALACTIC-HF - A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects with Chronic HFrEF
AMGEN-Cytokinetics 2016-
8. HNO Donor Cardioxyl Phase II Dose Ranging Study BMS 986231 and 986232
Bristol Myers Squibb 2016 -
9. Myosin Activation to Increase Contractility in Heart Failure Trial in Japan
AMGEN 2016-
10. REDUCE LAP-HF - A Study To Evaluate The Corvia Medical, Inc. IASD® System II To REDUCE Elevated Left Atrial Pressure In Patients With Heart Failure
CORVIA 2015-2016
11. COSMIC HF - Chronic Oral Study Of Myosin Activation To Increase Contractility In Heart Failure Trial AMGEN 2013- 15

12. A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Chronic Migraine Prevention
Amgen 2014 - 16

Steering Committee / Executive Committee

Chair

1. VICTOR HF – Vericiguat in patients with stable heart failure with reduced ejection fraction.
Merck 2021
2. AIM HIGHer - Assessment of Cardiac Contractility Modulation Effectiveness in preserved EF HF patients
Impulse Dynamics – 2021
3. EMPACT-MI - EMPagliflozin for the prevention of Chronic heart failure and mortality after an acute Myocardial Infarction
Boehringer Ingelheim 2020
4. DIAMOND HF - A Multicenter, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Group Study Of Patiromer For The Management Of Hyperkalemia In Subjects Receiving Renin Angiotensin-Aldosterone System Inhibitor (RAASI) Medications For The Treatment Of Heart Failure
Vifor Pharma - 2019
5. ALLEVIATE HF - Algorithm Using LINQ Sensors For Evaluation And Treatment Of Heart Failure
Medtronic - 2019
6. EMPEROR Preserved - Empagliflozin Outcome Trial In Patients With Chronic Heart Failure With Preserved Ejection Fraction
Boehringer Ingelheim - 2017
7. CHART HF - Diastolic Dysfunction in Human Immunodeficiency Virus Infection
NHLBI - 2016-18
8. ATHENA-HF - Aldosterone Targeted NeuroHormonal Combined with Natriuresis Therapy – HF
NIH - 2014-17
9. PROHIBIT Sodium - Prevent Adverse Outcomes In Heart Failure By Limiting Sodium Trial
NHLBI - 2014-17
10. STEM-104-M-CHF - A phase IIa, single-blind, placebo-controlled, crossover, multi-center, randomized study to assess the safety, tolerability, and preliminary efficacy of a single intravenous dose of ischemia-tolerant allogeneic mesenchymal bone marrow cells to subjects with heart failure of non-ischemic etiology
Cardiocyte - 2013-16

Member

1. FAIR-HF2 - Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality
2021
2. TRANSFORM Heart Failure with Reduced Ejection Fraction: TRANSFORM-HFrEF
A Randomized Registry Trial to Evaluate Best Practices and Improve Adherence to Guideline Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction
American College of Cardiology 2020
3. STEPP HF- Effect of semaglutide s.c. 2.4 mg once weekly on function and symptoms in subjects with obesity-related heart failure with preserved ejection fraction
NovoNordisk - 2020

4. STEPP HF-DM Effect of semaglutide s.c. 2.4 mg once weekly on function and symptoms in subjects with diabetes and heart failure with preserved ejection fraction
NovoNordisk - 2020
5. ANTHEM-HFrEF Pivotal Study - Autonomic Regulation Therapy To Enhance Myocardial Function And Reduce Progression Of Heart Failure With Reduced Ejection Fraction
LivaNova 2017-
6. Trientine -A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of INL1 in Patients with Heart Failure and Reduced Ejection Fraction
InnoLife 2017-
7. Adrenomedulin Guided Acute Heart Failure Therapy
Adrenomed 2017-
8. ADOPT-HF - Asian Diabetes Outcomes Prevention Trial
Singapore Government 2017-
9. REALISM HF - Real Life Monitoring In Patients With Heart Failure: A Pilot Study Evaluating Continuous Remote Monitoring Of Mobility And Patient Reported Outcomes As Potential Digital Endpoints In Future Heart Failure Trials
Bayer 2017
10. CHAMP HF - Change the Management of Heart Failure
Novartis 2017-
11. VITALITY-HFpEF - A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Multi-Center Trial To Evaluate The Efficacy And Safety Of The Oral Sgc Stimulator Vericiguat To Improve Physical Functioning In Activities Of Daily Living In Patients With Heart Failure And Preserved Ejection Fraction
Bayer-Merck 2017-
12. EMPEROR Reduced - Empagliflozin Outcome Trial In Patients With Chronic Heart Failure With Reduced Ejection Fraction
Boehringer Ingelheim 2017-
13. HEART-FID - Rationale and Design of the Randomized, Double-Blind, Placebo-Controlled Trial of Ferric Carboxymaltose as Treatment for Heart Failure with Iron Deficiency
Luitpold 2017-
14. INTERVENE HF - Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
Medtronic 2017-
15. CONNECT HF - Care Optimization Through Patient And Hospital Engagement Clinical Trial For Heart Failure
Novartis 2017-
16. PANTHOEN - A Multicenter, Randomized, Parallel Group, Double Blind, Dose-Finding Phase II Trial To Study The Efficacy, Safety, Pharmacokinetic And Pharmacodynamic Effects Of The Oral Partial Adenosine A1 Receptor Agonist BAY 1067197 Over 20 Weeks In Patients With Chronic Heart Failure With Reduced Ejection Fraction
Bayer 2017-
17. PROVE HF - Entresto (sacubitril and valsartan) and Cardiovascular Outcomes, Remodeling, and Biomarkers in Heart Failure
Novartis 2015
18. IDDEA HF - A Phase 2 Open-Label Study to Evaluate the Effects of Multiple 2 hour Intravenous Infusions of MTP-131 in Subjects with Stable Heart Failure Due to Reduced Ejection Fraction
StealthPeptide 2017-
19. FERIC-RO - FiER deficit in Insuficienta Cardiaca in Romania. Observational Registry of Anemia in Heart Failure
Vifor Pharma 2017-

20. A Randomized, Double-Blind, Placebo-Controlled Trial To Investigate The Safety And Efficacy Of BC007 In Patients With Beta-1-Adrenoceptor Autoantibodies And Chronic Heart Failure With Reduced Ejection Fraction
Berlin Cures 2017-
21. Safety And Efficacy For Ambulatory Use Of SQ Furosemide Delivery System In A Clinical Setting Of Heart Failure
SC Pharma 2017-
22. VICTORIA - A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial Of Efficacy And Safety Of The Oral Sgc Stimulator Vericiguat (BAY 1021189) In Patients With HF And Reduced Ejection Fraction (HFREF) - *Vericiguat Global Study In Patients With Heart Failure And Reduced Ejection Fraction*
Bayer-Merck 2016-
23. LIFE HF - Valsartan Sacubitril (LCZ696) In Hospitalized Advanced Heart Failure
NHLBI, 2016
24. INDIE HF - Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure with Preserved Ejection Fraction
NHLBI 2016
25. A Phase IIa Study of the Effect of Continuous 42-Hour Intravenous Infusions of CXL-1427 on Hospitalization Parameters and Functional Status in Patients with Systolic Heart Failure Admitted to Observation
Cardioxyl 2015
26. Global Hyperkalemia Council
Relypa 2015-
27. PARSIFAL - A Double Blinded, Placebo Controlled, Study to Investigate the Safety, Tolerability, Pharmacokinetics and Acute Cardiovascular Responses of a 7 Day Oral Treatment With the Partial Adenosine A1 Receptor Agonist BAY1067197 in Patients With Chronic Systolic Heart Failure. Multiple Dose Study in Heart Failure of BAY 1067197
Bayer 2014-16
28. IRONOUT - Oral Iron Repletion Effects On Oxygen Uptake in Heart Failure
NHLBI 2014
29. PRESERVE - Promotion of Renal Sodium Excretion by Renal Sympathetic Denervation in Congestive Heart Failure
NIH 2013
30. FIGHT - Functional Impact of GLP-1 for Heart Failure Treatment
NIH 2013
31. SOCRATES Reduced - Soluble Guanylate Cyclase stimulator *heart failure studies in heart failure with reduced EF*
Bayer 2013
32. SOCRATES Preserved - Soluble Guanylate Cyclase stimulator *heart failure studies in heart failure with preserved EF*
Bayer 2013
33. BLAST AHF - A Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure
Trevena 2012
34. CUPID II - Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure
Celladon 2012-2015
35. REGAL-HF - Reduction in events with Galactin-3 and Aldosterone Blockade in acute heart failure
BG Pharma 2012-14

36. ROSE-HF - Renal Optimization Strategies Evaluation In Acute Heart Failure
NIH 2012
37. EXACT HF - Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients
NIH 2012
38. ASCEND-HF - Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure Trial
Johnson and Johnson 2006-2011

Clinical Events Committee

Chair/Co-Chair

1. BEAT-HF - Barostim Neo® - Baroreflex Activation Therapy® for Heart Failure
CVRx 2017-
2. RELAX-AHF-2 - Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure
Novartis 2013-17
3. RELIANT - Randomized Evaluation of the Novacor® LVAS In A Non-Transplant Population
WorldHeart Inc, Oakland CA 2006 - 2007

Member

1. ATRIA - Heart failure adjudication of subject cases from the emergency department and outpatient setting
Abbott 2017-
2. Alinity i STAT High Sensitive Troponin-I assay
Abbott 2017-
3. MIRACLE EF - A prospective, randomized, controlled, double-blinded, global multi-center, Cardiac Resynchronization Therapy in Heart Failure clinical study
Medtronic 2013-14
4. RELAX-AHF - Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure
Novartis / Corthera 2010
5. Levacor Clinical Trial
WorldHeart Inc 2009-2010

REGIONAL / NATIONAL LEADER

1. EMPERIAL Reduced - Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms
Boehringer Ingelheim 2017 -
2. EMPERIAL Preserved - Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms
Boehringer Ingelheim 2017-
3. RED HF - A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin alfa Treatment on Mortality and Morbidity in Heart Failure Subjects with Symptomatic Left Ventricular Systolic Dysfunction and Anemia
AMGEN 2007-2012
4. STAMINA HF - Symptoms in Patients with Heart Failure
Amgen 2002-04

BIBLIOGRAPHY

1. Hanumanthu SK, **Butler J**, Chomsky DB, Wilson JR. Effect Of A Heart Failure Program On Hospitalization Frequency And Exercise Tolerance. *Circulation* 1997; 96: 2842-48
2. Lang C, Chomsky DB, **Butler J**, Kapoor S, Wilson JR. Prostaglandin Production Contributes To Exercise Induced Vasodilation In Heart Failure. *J App Physiol* 1997; 83:1933-40
3. **Butler J**, Hanumanthu SK, Chomsky DB, Wilson JR. Frequency Of Low Risk Hospital Admission For Heart Failure. *Am J Cardiol* 1998; 81: 41-44
4. Krumholz HM, **Butler J**, Miller J, Vaccarino V, Williams CS, Mendes de Leon CF, Seeman TE, Kasl SV, Berkman LF. The Prognostic Significance Of Emotional Support For Elderly Patients Hospitalized With Heart Failure. *Circulation* 1998; 97: 958-64
5. Wilson JR, Chomsky DB, Hanumanthu SK, **Butler J**. Cardiologist Directed Heart Failure Programs and the Management of Patients with Heart Failure. *Heart Failure* 1998;14:19-25
6. Chen YT, Vaccarino V, Williams CS, **Butler J**, Berkman LF, Krumholz HM. Risk Factors for Heart Failure in the Elderly: A Prospective Community Based Study. *Am J Med* 1999; 106: 605-12
7. **Butler J**, Chomsky DB, Wilson JR. Pulmonary Vascular Resistance and Exercise Response in Patients with Heart Failure. *J Am Coll Cardiol* 1999;34:1802-06
8. Friesinger GC, **Butler J**. End of Life Care for Elderly Patients with Heart Failure. *Clinics in Geriatric Medicine* 1999;16:3; 663-675
9. Whiting JF, Evans R, First MR, Keown P, Martin J, Pinson CW, Schnitzler M, Schroeder T, Zavala E, DeMarinis R, Fastenau J, Pendergast M, Sorrentino M, Alonso E, Belle S, Bucuvalas J, **Butler J**, Burdick J, Cohen D, Conanan M, Cowling T, Dew MA, Douzdzian V, Dunn J, Elick B, Friedman A, Goldberg L, Kiberd B, Kim WR, Payne J, Perryman J, Saltzberg M, Selby B, Shield C, Valentine V, Vanness D, Woodward RS, for the Transplant Outcomes Research Group. Standards for Economic and Quality of Life Studies in Transplantation. *Transplantation* 2000; 70: 1115-1121
10. Streiff N, Feurer I, Speroff T, Davis SF, **Butler J**, Donaldson T, Webb J, Merrill WH, Drinkwater DC, Pierson III RN, Pinson CW. The Effects Of Rejection Episodes, Obesity, And Osteopenia On Functional Performance And Health-Related Quality Of Life After Heart Transplantation. *Transplantation Proceedings* 2001,33:3533-3535
11. Pierson RN III, Howser R, Donaldson T, Merrill WH, Dignan R, Drinkwater DC Jr., Christian KG, **Butler J**, Chomsky DC, Clark R, Davis SF. Left Ventricular Assist Device Implant via Left Thoracotomy: Alternative or Adjunct to Repeat Sternotomy. *Ann Thoracic Surg* 2002, 73:997-9
12. Gottlieb SS, Abraham WT, **Butler J**, Forman DE, Wang Y, O'Connor CM, Loh E, Massie BM, Rich MW, Warner-Stevenson L, Young JB, and Krumholz HM. The Prognostic Importance of Different Definitions of Worsening Renal Function in Congestive Heart Failure. *J Card Fail* 2002;8:136-141
13. **Butler J**, Argobast PG, Belue R, Daugherty J, Jain MK, Ray WA, Griffin MR. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. *J Am Coll Cardiol* 2002;40:1589-95
14. **Butler J**, Weingarten JP, Weddle JA, Jain MK. Differences among hospitals in delivery of care for heart failure. *J Healthcare Qual* 2003;25:4-9
15. **Butler J**, Khadim G, Belue R, Chomsky DB, Dittus RS, Griffin M and Wilson JR. Tolerability to beta-blocker therapy among heart failure patients in clinical practice. *J Card Fail* 2003;9:203-209
16. **Butler J**, Feurer I, Speroff T, Davis SF, Drinkwater DC, Pierson III RN, Pinson CW. Post-Transplant Comorbidities And Health-Related Quality Of Life After Heart Transplantation. *J Heart Lung Transplant* 2003;22:1149-1156
17. Moore D, Feurer I, Speroff T, Shaffer D, Nylander W, Kizilisik T, **Butler J**, Awad J, Gorden DL, Chari R, Wright JK, Pinson CW. Survival and quality of life after organ transplantation in veterans and non-veterans. *Am J Surg*, 2003,186:476-480

18. Jain MK, **Butler J**, Mirvis DM. Heart Failure: Do we deliver quality care? Tennessee Medicine 2003; 96:81-84
19. **Butler J**, Arbogast P, Jain M, Griffin MR. Adherence to therapy with beta-blocking agent after acute myocardial infarction. Cardiology Review 2003;20:39-44
20. Forman DE, **Butler J**, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, Loh E, Massie BM, Rich MW, Warner-Stevenson L, Young JB, and Krumholz HM. Incidence, Predictors and Impact of Worsening Renal Function among Patients Hospitalized with Heart Failure. J Am Coll Cardiol; 2004: 43;61-67
21. **Butler J**, Emerman C, Peacock WF, Mathur VS, and Young JB, On Behalf of the VMAC Study Investigators. The Efficacy and Safety of B-Type Natriuretic Peptide (Nesiritide) in Patients with Renal Insufficiency and Acutely Decompensated Congestive Heart Failure. Neph Dialy Transplant 2004;19:391-399
22. **Butler J**, Forman DE, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, Loh E, Massie BM, Rich MW, Warner-Stevenson L, Young JB, and Krumholz HM. Relationship Between Heart Failure Treatment And Development Of Worsening Renal Function Among Hospitalized Patients. Am Heart J 2004;147; 331-338
23. **Butler J**, Khadim G, Paul KM, Davis SF, Dittus RS, Kronenberg MW, Chomsky DB, Pierson RN, Wilson JR. Selection of Patients for Cardiac Transplantation in the Era of Beta-Blocker Therapy. J Am Coll Cardiol 2004;43;787-93
24. Holvoet P, Kritchevsky SB, Tracy RP, Mertens A, Rubin SM, **Butler J**, Goodpaster B, and Harris TB. The Metabolic Syndrome, Circulating Oxidized LDL And Risk Of Myocardial Infarction In Well-Functioning Elders In The Health, ABC Cohort. Diabetes 2004;53;1068-1073
25. **Butler J**, Arbogast PG, Daugherty J, Jain MK, Ray WA, and Griffin MR. Outpatient utilization of angiotensin converting enzyme inhibitors among heart failure patients after hospital discharge. J Am Coll Cardiol, 2004;43:2036-43
26. BeLue R, **Butler J**, Kuder JM. Implications of patient and physician decision making: an illustration in treatment options for coronary artery disease. J Ambul Care Manage 2004;27:305-313
27. **Butler J**, Howser R, Portner Peer, Pierson III RN. Body Mass Index and Outcomes After Left Ventricular Assist Device Placement. Ann Thor Surg 2005;79:66-73
28. Shaklee JF, Talbot TR, Muldowney JA, Vaughan DE, **Butler J**, House F, Crowe JE, Smith LH, Edwards KM. Smallpox vaccination does not elevate systemic levels of prothrombotic proteins associated with ischemic cardiac events. J Inf Dis 2005;191:724-30
29. **Butler J**, Stankewicz MA, Chomsky DB, Howser R, Wu J, Khadim G, Davis SF, Pierson RN, Drinkwater DC, and Wilson JR. Pre-Transplant Reversible Pulmonary Hypertension Predicts Higher Risk for Mortality Post Cardiac Transplantation. J Heart Lung Transp 2005; 24:170-177
30. Rodondi N, Vittinghoff E, Cornuz J, **Butler J**, Ding J, Satterfield S, Newman AB, Harris TB, Hulley SB, Bauer D, for the Health, Aging, and Body Composition Study research group. Aspirin Use for the Primary Prevention of Coronary Heart Disease in a Biracial Cohort of Older Adults: a Prospective Study. Am J Med 2005;118:1288-97
31. **Butler J**, Howser R, Portner Peer, Pierson III RN. Diabetes and Outcomes After Left Ventricular Assist Device Placement. J Card Fail 2005;11:510-515
32. Ozdas A, Speroff T, Waitman LR, Ozbolt J, **Butler J**, Miller RA. Integrating "best of care protocols" into clinicians' workflow via care provider order entry: impact on quality of care indicators for acute myocardial infarction. JAMIA 2006;13(2):188-96
33. **Butler J**, Speroff T, Arbogast PG, Newton M, Waitman LR, Stiles R, Miller RA, Ray W, Griffin MR. Improved discharge planning with computerized physician order entry system. Am Heart J 2006;151(3):643-53

34. Abbara S, Desai JC, Cury R, **Butler J**, Nieman K, Reddy V. Mapping Epicardial Fat with Multi Detector Computed Tomography to Facilitate Percutaneous Trans-Epicardial Arrhythmia Ablation. *Eur J Radiol* 2006;57(3):417-22
35. Hoffmann U, **Butler J**. Noninvasive Detection of Coronary Atherosclerotic Plaque by Multi-detector row Computed Tomography. *Int J Obesity* 2005;29:S46-S53
36. **Butler J**, Hoffman U. Atherosclerotic Plaque Detection by Multidetector Computed Tomography. *Curr Cardiol Rev* 2006;2:1-9
37. Geisberg C, **Butler J**. Heart Failure, Renal Failure, and the Cardiorenal Syndrome. *Cleveland J Med*, 2006;73:485-491
38. Huang R, Listerman J, Geisberg C, **Butler J**. Risk Factors for Development of Heart Failure. *Curr Cardiol Rev* 2006;2:79-88
39. **Butler J**, Zhu Y, Vaughan DE, Figaro K, Satterfield S, Newman AB, Goodpaster B, Ding J, Bauer D, Holvoet P, Harris TB, de Rekeneire N, Rodondi N, Rubin S, Kritchevsky SB for the Health ABC Study. Metabolic syndrome and the risk of cardiovascular disease in older adults. *J Am Coll Cardiol* 2006;47 1595-1602
40. **Butler J**, Geisberg C, Howser R, Portner P, Rogers J, Deng M, Pierson III RN. Renal function and its relationship with left ventricular assist device placement. *Ann Thor Surg* 2006;81(5):1745-51
41. **Butler J**, Young JB, Abraham WT, Bourge RC, Adams KF, Clare R, and O'Connor C, for the ESCAPE Investigators. Beta-Blocker Use and Outcomes Among Hospitalized Heart Failure Patients. *J Am Coll Cardiol* 2006;47:2462-2469
42. Geisberg C, Goring J, Listerman J, Nading MA, Huang RL, **Butler J**. Impact of optimal heart failure medical therapy on heart transplant listing. *Transplant Proc* 2006;38(5):1493-5
43. Huang R, Geisberg C, Howser R, Portner P, Rogers J, Deng M, Pierson RN, **Butler J**. Effect of age on outcomes after left ventricular assist device placement. *Transplant Proc* 2006;38(5):1496-8
44. Geisberg C, Goring J, Huang RL, Listerman J, Nading MA, and **Butler J**. Anemia in heart failure may warrant more aggressive listing for cardiac transplantation. *Transplant Proc* 2006;38 (5):1499-500
45. Huang RL, Listerman J, Goring J, Geisberg C, Nading MA, and **Butler J**. β -Blocker Therapy for Heart Failure: Should the Therapeutic Target be Dose or Heart Rate Reduction? *Congest Heart Fail* 2006;12(4):206-10.
46. Figaro MK, Kritchevsky SB, Resnick HE, Shorr RI, **Butler J**, Shintani A, de Rekeneire N, Penninx BW, Goodpaster B, Rubin SM, Schwartz AV, Simonsick EM, Harris TB. Inflammation, Diabetes And Functional Decline In Older Adults: The Health ABC Study. *Diabetes Care* 2006;29(9):2039-45\
47. Hoffmann U, Nagurney JT, Moselewski F, Pena A, Ferencik M, Chae CU, Cury RC, **Butler J**, Abbara S, Brown DF, Manini A, Nichols JH, Achenbach S, Brady TH. Coronary Multidetector Computed Tomography in the Assessment of Patients with Acute Chest Pain. *Circulation* 2006;114:2251-60
48. **Butler J**, Shapiro M, Jassal D, Neilan T, Nichols J, Ferencik M, Brady T, Hoffmann U, Cury R. Comparison of Multi-Detector Computed Tomography and Two-Dimensional Transthoracic Echocardiography for Left Ventricular Assessment in Patients with Heart Failure. *Am J Cardiol* 2007;99:247-9
49. Abbara S, Pena A, Maurovich-Horvat P, **Butler J**, Lembcke A, Cury R, Hoffmann U, Ferencik M, Brady T. Feasibility and Optimization of Aortic Valve Planimetry with Multi-detector Computed Tomography. *Am J Roentgen* 2007 188:356-60
50. **Butler J**, Shapiro M, Reiber J, Sheth T, Ferencik M, Kurtz E, Nichols J, Pena A, Cury R, Brady T, Hoffmann U. Extent and distribution of coronary atherosclerosis: A comparative study of invasive vs. non-invasive angiography with 64-slice multi-detector computed tomography. *Am Heart J* 2007;153(3):378-84

51. Listerman J, Goring J, Geisberg C, Nading MA, Huang R, and **Butler J**. Hemodynamic response and exercise capacity among anemic and non-anemic heart failure patients. *Congest Heart Fail* 2007;13(2):71-77
52. Shapiro M, **Butler J**, Reiber J, Sheth T, Cury R, Pena A, Nichols J, Brady T, Hoffmann U. Analytic Approaches to Establish the Diagnostic Accuracy of Coronary Computed Tomography Angiography as a Tool for Clinical Decision-making. *Am J Cardiol* 2007 15;99(8):1122-7
53. **Butler, J**. The Emerging Role of Cardiac MDCT in Patients with Heart Failure. *J Card Fail* 2007 13(3):215-26
54. Ferencik M, Gregory SA, **Butler J**, Achenbach S, Yeh RW, Hoffmann U, Inglessis I, Cury RC, Nieman K, Mc Nulty IA, Laffan JA, Brady TJ, Semigran MJ, Jang IK. Analysis of Cardiac Dimensions, Mass, and Function in Heart Transplant Recipients using 64-slice Multi-detector Computed Tomography. *J Heart Lung Transplant* 2007 26(5):478-84.
55. Rogers JG, **Butler J**, Pierson R, Portner P, Pasque MK, for the INTrEPID Investigators. Chronic Mechanical Circulatory Support for Inotrope-Dependent Heart Failure Patients Who Are Not Transplant Candidates: The Results of the INTrEPID Trial. *J Am Coll Cardiol* 2007;50(8):741-7
56. Listerman J, Huang R, **Butler J**. Risk Factors for Progression and Prognosis Determination in Heart Failure. *Curr Cardiol Rev* 2007;3:1-9
57. Gheorghiade M, Cotts W, Rossi J, Hellkamp AS, Pina IL, Fonarow GC, DeMarco T, Pauly DF, Rogers JG, DiSalvo T, **Butler J**, Hare JM, Francis GS, Gattis Stough W, O'Connor CM. Characterization and Prognostic Value of Persistent Hyponatremia in Patients with Severe Heart Failure in the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) Trial. *Arch Int Med* 2007;167(18) :1998-2005
58. Shapiro MD, Neilan TG, Jassal DS, Samy B, Nasir K, Hoffmann U, Sarwar A, **Butler J**, Brady TJ, Cury RC. Multi-detector Computed Tomography for the Detection of Left Atrial Appendage Thrombus – A Comparative Study with Transesophageal Echocardiography. *J Comp Assisted Tomo* 2007;31(6):905-909
59. Giamouzis G, Sui X, Love TE, **Butler J**, Young JB, Ahmad A. A propensity matched study of the association of cardiothoracic ratio and natural history end points in chronic heart failure. *Am J Cardiol* 2008;101(3):343-7
60. **Butler J**, Mooyaart E, Shapiro M, Nichols J, Brady T, Hoffmann U. Characteristics and distribution of atherosclerotic plaque distribution among patients with and without metabolic syndrome. *Am J Cardiol* 2008;101(8):1127-30
61. Schuberth JL, Roumie CL, **Butler J**, Greevy R, Speroff T, Dittus RS, Elasy TA. The Effect of Short Call admission on Length of Stay and Quality of Care for Acute Decompensated Heart Failure. *Circulation* 2008, 117(20):2637-44
62. Rodondi N, Cornuz J, Marques-Vidal PM, **Butler J**, Hayoz D, Pécoud A, Paccaud F, Waeber G, Vollenweider P. Limited appropriateness of aspirin use for the primary prevention of coronary heart disease: a population-based study in Switzerland. *Preventive Med* 2008, 46(2):137-44
63. Bamberg F, Dannemann N, Shapiro MD, Seneviratne SK, Ferencik M, **Butler J**, Koenig W, Nasir K, Cury RC, Tawakol A, Achenbach S, Brady TJ, Hoffmann U. Association Between Cardiovascular Risk Profiles and the Presence and Extent of Different Types of Coronary Atherosclerotic Plaque as Detected by Multidetector Computed Tomography. *Arterioscl Throm Vasc Biol* 2008;28(3):568-74
64. Gambassi G, Agha SA, Sui X, Yancy CW, **Butler J**, Giamouzis G, Love TE, Ahmed A. Race and the Natural History of Chronic Heart Failure. A Propensity-Matched Study. *J Card Fail* 2008;14(5):373-8

65. **Butler J**, Kalogeropoulos A, Georgiopoulou V, Belue R, Rodondi N, Garcia M, Bauer DC, Satterfield S, Smith AL, Vaccarino V, Newman AB, Harris TB, Wilson PWF, Kritchevsky SB for the Health ABC Study. Incident Heart Failure Prediction in the Elderly: The Health ABC Heart Failure Score. *Circ Heart Fail* 2008;1:125-133
66. Cury RC, Nieman K, Shapiro MD, **Butler J**, Nomura CH, Ferencik M, Hoffmann U, Abbara S, Jassal D, Gold HK, Jang IK, Brady TJ. Comprehensive Assessment of Left Ventricular Function and Myocardial Perfusion by 64-slice CT in Patients after Acute Myocardial Infarction. *Radiology* 2008;248(2):466-75
67. Rieber J, Sheth TN, Mooyaart EA, Shapiro MD, **Butler J**, Ferencik M, Brady TJ, Klauss V, Hoffmann U. Assessment of the presence and extent of coronary collateralization by coronary computed tomographic angiography in total occlusions. *Int J Cardiovasc Imaging*.2009 25:331–337
68. Manini AF, Dannemann N, Brown DF, **Butler J**, Bamberg F, Nagurney JT, Nichols JH, Hoffmann U; on behalf of the Rule-Out Myocardial Infarction using Coronary Artery Tomography (ROMICAT) Study Investigators. Limitations of risk score models in patients with acute chest pain. *Am J Emer Med* 2009;27(1):43-48.
69. Kalogeropoulos A, Georgiopoulou V, Giamouzis G, Smith AL, Agha SA, Arnado P, Waheed S, Rashad SA, Bavikati V, Book W, Laskar S, Puskas J, Dunbar S, Vega D, Wilson PW, Levy WC, and **Butler J**. Utility Of The Seattle Heart Failure Model In Advanced Heart Failure. *J Am Coll Cardiol* 2009;53(4):334-342.
70. Giamouzis G, Kalogeropoulos AP, Georgiopoulou VV, Agha SA, Rashad MA, Laskar SR, Smith AL, **Butler J**. Incremental value of renal function in risk prediction with the Seattle Heart Failure Model. *Am Heart J* 2009;157(2):299-305
71. Bamberg F, Schlett CL, Truong QA, Rogers IS, Koenig W, Nagurney JT, Lehman S, Cury RC, Abbara S, **Butler J**, Brady TJ, Hoffmann U Presence and Extent of Coronary Artery Disease as Measured by Coronary Computed Tomography and Risk for Acute Coronary Syndrome among Cocaine Users in Patients with Chest Pain. *Am J Cardiol* 2009;103(5):620-5
72. Georgiopoulou V, Kalogeropoulos A, Giamouzis G, Agha SA, Rashad MA, Laskar SR, Smith AL, and **Butler J**. Utility of Digoxin in Patients with Advanced Heart Failure on Contemporary Optimal Medical Therapy. *Circ Heart Fail* 2009;2:90-97
73. Kalogeropoulos A, Georgiopoulou V, Kritchevsky SB, Psaty BM, Smith NL, Newman AB, Rodondi NR, Satterfield S, Bauer DC, Bibbins-Domingo K, Smith AL, Wilson PWF, Vasani RS, Harris TB, and **Butler J**, for the Health ABC Study. Epidemiology of Incident Heart Failure in a Contemporary Elderly Population: The Health, Aging, and Body Composition Study. *Arch Int Med* 2009;169(7):708-15
74. Hoffmann U, Bamberg F, Chae C, Nichols JH, Rogers I, Seneviratne SK, Truong Q, Cury R, Abbara S, Shapiro MD, Moloo J, **Butler J**, Ferencik M, Lee H, Jang IK, Parry B, Brown D, Udelson J, Achenbach S, Brady T, Nagurney J. Coronary Computed Tomography Angiography For Early Triage of Patients with Acute Chest Pain - The Rule Out Myocardial Infarction Using Computer Assisted Tomography (ROMICAT) Trial. *J Am Coll Cardiol* 2009;53:1642–50
75. Khush KK, Tasissa G, **Butler J**, McGlothlin D, De Marco T, for the ESCAPE Investigators Effect of Pulmonary Hypertension on Clinical Outcomes in Acute Decompensated Heart Failure: Analysis of the ESCAPE Database. *Am Heart Jour* 2009, 57(6):1026-1034
76. **Butler J**, Kalogeropoulos A, Georgiopoulou V, de Rekeneire N, Rodondi N, Smith AL, Hoffmann U, Kanaya A, Newman AB, Kritchevsky SB, Vasani RS, Wilson PWF, and Harris TB for the Health ABC Study. Serum Resistin Concentrations and Risk of New Onset Heart Failure in the Elderly. The Health Aging Body and Composition Study. *Arterio Thromb Vascul Biol* 2009;29:1144-1149

77. Kalogeropoulos AP, Georgiopoulou VV, Giamouzis G, Pernetz MA, Anadiotis A, McConnell M, Lerakis S, **Butler J**, Book WM, Martin RP. Myocardial deformation imaging of the systemic right ventricle by two-dimensional strain echocardiography in patients with D-transposition of the great arteries. *Hellenic J Cardiol* 2009;50(4):275-82
78. Agha SA, Kalogeropoulos A, Shih J, Georgiopoulou V, Giamouzis G, Anarado P, Mangalat D, Hussain I, Book W, Laskar RS, Smith AL, Martin R, **Butler J**. Echocardiography and Risk Prediction in Advanced Heart Failure: Incremental Value over Clinical Markers. *J Card Fail* 2009;15(7):586-92
79. Kalogeropoulos A, Georgiopoulou V, Harris TB, Kritchevsky SB, Bauer DC, Smith AL, Strotmeyer E, Newman AB, Wilson PWF, Psaty BM, **Butler J** for the Health ABC Study Glycemic Status and Incident Heart Failure in Elderly without History of Diabetes Mellitus: The Health, Aging, and Body Composition Study. *J Card Fail* 2009;15(7):593-9
80. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, and **Butler J**. The sympathetic nervous system in heart failure: Physiology, Pathophysiology, and Clinical Implications. *J Am Coll Cardiol* 2009;54:1747-62
81. Mangalat D, Kalogeropoulos A, Georgiopoulou V, Stillman A, **Butler J**. Value of Cardiac Computed Tomography in Heart Failure. *Curr Cardiovascular Imag Report* 2009;2:6:410-417
82. Adams K, Pina I, Ghali J, Wagoner L, Dunlap SH, Schwartz T, Gattis Stough W, Mehra M, Felker GM, Chiong JR, Patterson JH, Kim J, **Butler J**, Oren R. Prospective Evaluation of the Association Between Hemoglobin Concentration and Quality of Life in Patients with Heart Failure. *Am Heart J*. 2009;158(6):965-71
83. Giamouzis G, Agha SA, Aban I, Love TE, Daniels C, **Butler J**, Ahmed A. Incident Coronary Revascularization and Subsequent Mortality in Chronic Heart Failure: A Propensity-Matched Study. *Int J Cardiol*, 2010;140: 55–59
84. Methvin A, Georgiopoulou VV, Kalogeropoulos AP, Malik A, Anarado P, Chowdhury M, Hussain I, Book WM, Laskar SR, Vega JD, Smith AL, **Butler J**. Cardiac Index, Peak Exercise Oxygen Consumption, and Listing Priority for Cardiac Transplantation. *Am J Cardiol* 2010;105(9):1353-5
85. Kalogeropoulos AP, Georgiopoulou VV, Psaty BM, Rodondi N, Smith ALS, Harrison DG, Liu Y, Hoffmann U, Bauer DC, Newman AB, Kritchevsky SB, Harris TB, and **Butler J** for the Health ABC Study Inflammatory Markers and Incident Heart Failure Risk in Older Adults: The Health, Aging, and Body Composition Study. *J Am Coll Cardiol* 2010;55:2129–37
86. Kalogeropoulos A, Psaty BM, Vasan RS, Georgiopoulou V, Smith AL, Smith ML, Kritchevsky SB, Wilson PWF, Newman AB, Harris TB, **Butler J** for the Cardiovascular Health Study. External Validation of the Health ABC Heart Failure Model. *The Cardiovascular Health Study*, *Circ Heart Fail* 2010;3(4):495-502
87. Bhalla V, Kalogeropoulos A, Georgiopoulou V, **Butler J**. Serum Resistin: Physiology, Pathophysiology, and Implications for Heart Failure. *Biomark Med* 2010;4(3):445-52
88. Kalogeropoulos AP, Border WL, Georgiopoulou VV, Pernetz MA, Howell S, McConnell M, Lerakis S, **Butler J**, Book WM, Martin RP. Right Ventricular Function in Patients with Eisenmenger Physiology: Insights from Quantitative Echocardiography. *Echocardiography* 2010;27(8):937-45
89. Mangalat D, Kalogeropoulos AP, Georgiopoulou VV, Tang WH, Methvin A, Smith AL, Bauer DC, Newman AB, Kim L, Harris TB, Kritchevsky SB, **Butler J**, for the Health ABC Study. Serum Albumin Concentration and Heart Failure Risk: The Health, Aging, and Body Composition Study *Am Heart J* 2010;160(2):279-85
90. Sica D, Oren RM, Gottwald MD, Mills RM; and Scios 351 Investigators. Natriuretic and neurohormonal responses to nesiritide, furosemide, and combined nesiritide and furosemide in patients with stable systolic dysfunction. *Clin Cardiol* 2010;33(6):330-6.

91. Rodondi N, Marques-Vidal P, **Butler J**, Sutton-Tyrrell K, Cornuz J, Satterfield S, Harris T, Bauer DC, Ferrucci L, Vittinghoff E, Newman AB for the Health ABC study. Markers of Atherosclerosis and of Inflammation for Prediction of Coronary Heart Disease in Older Adults. *Am J Epidemiol* 2010 1;171(5):540-9
92. Wahl P, Rodgers K, Schneeweiss S, Gage B, **Butler J**, Wilmer C, Nash M, Esper G, Gitlin M, Osborn N, Short LJ, Bohn RL. Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. *Pharmacoepidemiology Drug Saf* 2010;19(6):596-603
93. **Butler J**, Anand I, Carson P, Cohn J. on behalf of the ValHeFT investigators. Digoxin and cardiovascular outcomes in a contemporary group of heart failure patients. *Congest Heart Fail* 2010;16(5):191-195
94. Mujib M, Giamouzis G, Agha SA, Aban I, Sathiakumar N, Ekundayo OJ, Zamrini E, Allman RM, **Butler J**, Ahmed A. Epidemiology of Stroke in Chronic Heart Failure Patients with Normal Sinus Rhythm: Findings from the DIG Stroke Sub-Study. *Int J Cardiol* 2010;144:389–393
95. Georgiopoulous VV, Kalogeropoulos AP, Raggi P, **Butler J**. Prevention, Treatment, and Control of Hypertensive Heart Disease. *Cardiol Clin North America* 2010;28(4):675-91
96. Giamouzis G, **Butler J**, Starling RC, Economou D, Karayannis G, Parisi C, Rovithis D, Nastas I, Kyrlidis T, Tsaknakis T, Skoularigis J, Triposkiadis F, The Impact of Dopamine Infusion on Renal Function in Hospitalized Heart Failure Patients: Results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. *J Card Fail* 2010; 16(12):922-30.
97. **Butler J**, Chirovsky D, McNeil A, Phatak H, Cody R. Renal function, health outcomes, and resource utilization in acute heart failure. A systematic review. *Circ Heart Fail* 2010;1;3(6):726-45
98. Goyal A, Norton CR, Thomas TN, Davis RL, **Butler J**, Ashok V, Zhao L, Vaccarino V, Wilson PWF. Predictors of Incident Heart Failure in a Large Insured Population: a One Million Person-year Follow-up Study. *Circ Heart Fail* 2010 1;3(6):698-705
99. Fonarow GC, Gregory T, Driskill M, Beam C, **Butler J**, Jacobs AK, Meltzer NM, Peterson ED, Schwamm LH, Spertus JA, Yancy CW, Tomaselli GF, Sacco RL. Hospital Certification for Optimizing Cardiovascular Disease and Stroke Quality of Care and Outcomes. *Circulation* 2010, 7;122:2459-69
100. Giamouzis G, Kalogeropoulos A, Georgiopoulou V, Dunbar S, Triposkiadis F, Smith AL, **Butler J**. Heart Failure Hospitalization Epidemic: Risk Factors, Risk Prediction, and Future Directions. *J Card Fail* 2011;17(1):54-75.
101. Malik AS, Giamouzis G, Georgiopoulou VV, Fike LV, Kalogeropoulos AP, Norton CR, Sorescu D, Laskar SR, Smith AL, Dunbar SB, **Butler J**. Patient perception versus medical record entry of health-related conditions among patients with heart failure. *Am J Cardiol* 2011 15;107(4):569-72
102. Chaudhry SI, Herrin J, Phillips C, **Butler J**, Mukerjee S, Murillo J, Onwuanyi A, Seto TB, Spertus J, Krumholz HM. Racial Disparities in Health Literacy and Access to Care among Patients with Heart Failure. *J Card Fail* 2011;17(2):122-7
103. Norton C, Georgiopoulou VV, Kalogeropoulos A, **Butler, J**. Chronic Stable Angina: Pathophysiology and Innovations in Treatment. *J Cardiovascular Med* 2011;12(3):218-9
104. Karayannis G, Giamouzis G, Alexandridis E, Kamvrogiannis P, **Butler J**, Skoularigis J, Triposkiadis F. Prevalence of impaired coronary flow reserve and its association with left ventricular diastolic function in asymptomatic individuals with major cardiovascular risk factors. *Eur J Cardiovascular Prev Rehab* 2011;18(2):326-33
105. Georgiopoulou V, Kalogeropoulos A, Harris TB, Butler A, Rodondi N, Kritchevsky SB, Bauer DC, Smith AL, Newman AB, Psaty BM, **Butler J** for the Health ABC Study. Abnormal lung volumes and risk for heart failure in the elderly: The Health Aging and Body Composition Study. *Am J Med* 2011;124(4):334-41

106. Kalogeropoulos AP, Savoye LP, Georgiopoulou VV, Raj L, Lloyd MS, Lerakis S, Chiladakis J, Apostolakis D, Alexopoulos D, **Butler J**. Long-term Response of the Left Ventricle to Cardiac Resynchronization Therapy: Insights from Standard and Strain Echocardiography. *Congest Heart Fail* 2011;17(2):71-9
107. Chen J, Kalogeropoulos A, Verdes-Moreiras L, **Butler J**, Garcia E. Left-ventricular Systolic and Diastolic Dyssynchrony as Assessed by Multi-harmonic Phase Analysis of Gated SPECT Myocardial Perfusion Imaging in Patients with End-stage Renal Disease and Normal LVEF. *J Nuc Cardiol* 2011;18(2):299-308
108. Heidenreich P, Trogdon JG, Khavjou OA, **Butler J**, Dracup K, Ezekowitz JA, Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, Nelson SA, Nichol G, Orenstein D, Wilson PWF, Woo YJ. Forecasting the Future of Cardiovascular Disease in the United States: AHA Policy Statement. *Circulation* 2011; 1;123(8):933-44
109. Cole RT, Kalogeropoulos AP, Georgiopoulou VV, Gheorghide M, Quyyumi A, Yancy C, **Butler J**. Hydralazine and Isosorbide Dinitrate in Heart Failure: Historical Perspective, Mechanisms, and Future Directions. *Circulation* 2011, 123(21):2414-22
110. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JVJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, **Butler J**, Clausell N, Corbalán R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Méndez GV, Metra M, Mittal, S, Oh B, Pereira NL, Ponikowski P, Tang WHW, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM The Effect of Nesiritide in Patients with Acute Decompensated Heart Failure. *NEJM* 2011; 365:32-43
111. Georgiopoulou VV, Kalogeropoulos AP, **Butler J**. Dilemmas of Blood Pressure Management for Heart Failure Prevention. *Circ Heart Fail* 2011 1;4(4):528-33
112. Giamouzis G, **Butler J**, Triposkiadis F. Renal Dysfunction in Advanced Heart Failure. *Congest Heart Fail* 2011;17(4):180-8
113. **Butler J**, Kalogeropoulos AP, Georgiopoulou VV, Bibbins-Domingo K, Najjar S, Sutton-Tyrrell K, Harris T, Kritchevsky SB, Lloyd-Jones DM, Newman AB, Psaty BM Systolic Blood Pressure and Incident Heart Failure in the Elderly: The Cardiovascular Health Study & the Health, Aging, and Body Composition Study. *Heart* 2011;97(16):1304-11
114. Bhalla V, Georgiopoulou VV, Kalogeropoulos AP, Norton CP, Cole RT, Laskar SR, DeStaerake C, Hooper WC, Smith AL, **Butler J**. Matrix Metalloproteinases, Tissue Inhibitors of Metalloproteinases, and Heart Failure Outcomes. *Int J Cardiol* 2011 1;151(2):237-9
115. Kalogeropoulos AP, Georgiopoulou VV, **Butler J**. From Risk Factors to Structural Heart Disease: The Role of Inflammation. *Heart Fail Clin* 2012; 8(1):113-23
116. Bamberg F, Truong Q, König W, Schlett C, Nasir K, **Butler J**, Kurtz E, Nikolaou K, Hoffmann U, Januzzi J. Differential Associations between Blood Biomarkers of Inflammation, Oxidation, and Lipid Metabolism with Varying Forms of Coronary Atherosclerotic Plaque as Quantified by Coronary CT Angiography. *Int J Cardiovascular Imag* 2010 2012;28(1):183-92
117. Norton CR, Georgiopoulou VV, Kalogeropoulos AP, **Butler J** Epidemiology and Cost of Advanced Heart Failure. *Prog Cardiovascular Dis* 2011;54(2):78-85
118. Triposkiadis F, Starling RC, Boudoulas H, Giamouzis G, **Butler J**, The Cardiorenal Syndrome in Heart Failure: Cardiac? Renal? Syndrome? *Heart Failure Rev* 2012;17(3):355-66
119. Kalogeropoulos AP, Georgiopoulou VV, Gheorghide M, **Butler J**. Echocardiographic Quantification of Left Ventricular Structure and Function in Clinical Trial. State of the Art and Potential Applications. *J Card Fail* 2012; 18(2):159-72

120. Kalogeropoulos AP, Georgiopoulou VV, DiFilippi C, Gottdeiner, **Butler J.** for the Cardiovascular Health Study: Echocardiography, Natriuretic Peptides, and Risk for Incident Heart Failure in Older Adults: The Cardiovascular Health Study. *JACC Cardiovascular Imag* 2012;5(2):131-40
121. ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. Coronary Revascularization Writing Group, American College of Cardiology Foundation. *J Thorac Cardiovasc Surg.* 2012;143(4):780-803.
122. **Butler J,** Ezekowitz JA, Collins SP, Givertz MM, Teerlink JR, Walsh MN, Albert NM, Canary CAW, Carson PEC, Colvin-Adams M, Fang JC, Hernandez AF, Hershberger RE, Katz SD, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WHW, Stough WG, Starling RC. Heart Failure Society of America Guidelines Committee. Aldosterone Antagonists Use in Heart Failure with Reduced Left Ventricular Ejection Fraction. *J Card Fail* 2012;18(4):265-81
123. Kalogeropoulos AP, Deka A, Border W, Pernetz MA, Georgiopoulou VV, Kiani J, McConnell M, Lerakis S, **Butler J,** Martin RP, Book WM. Right Ventricular Function with Standard and Speckle-Tracking Echocardiography and Clinical Events in Adults with D-Transposition of the Great Arteries Post Atrial Switch. *J Am Soc Echo* 2012;25(3):304-12
124. Rodondi N, Locatelli I, Aujesky D, **Butler J,** Cornuz J, Vittinghoff E, Wilson PWF, Pletcher MJ, Newman AB, Satterfield S, Simonsick E, Bauer D for the Health ABC Study Framingham Risk Score and Alternatives for Prediction of Coronary Heart Disease in Older Adults: The Health ABC Study. *PLoS One* 2012;7(3):e34287
125. Auer R, Bauer D, **Butler J,** Cornuz J, Kim L, Newman A, Satterfield S, Rodondi N. The association between minor and major ECG changes and incidence of cardiovascular outcomes: The Health ABC Study. *JAMA* 2012 11;307(14):1497-505
126. Gupta D, Georgiopoulou V, Kalogeropoulos A, Dunbar S, Reilly C, Sand J, Fonarow G, Jessup M, Yancy C, **Butler J.** Dietary Sodium Intake in Heart Failure. *Circulation* 2012 24;126(4):479-85.
127. Mastrogiannis D, Giamouzis G, Dardiotis E, Karayannis G, Chroub-Papavaïou A, Kremeti D, Spiliopoulos K, Georgoulas P, Koutsias S, Bonotis K, Mantzorou M, Skoularigis J, Hadjigeorgiou GM, **Butler J,** and Triposkiadis F. Depression in Patients with Cardiovascular Disease. *Cardiol Res Prac* 2012;794762
128. Kalogeropoulos AP, Georgiopoulou VV, **Butler J.** Clinical adoption of prognostic biomarkers: the case for heart failure. *Prog Cardiovascular Dis* 2012;55(1):3-13
129. Vaduganathan M, Ambrosy AP, Greene SJ, Mentz RJ, Subacius HP, Maggioni AP, Swedberg K, Nodari S, Zannad F, Konstam MA, **Butler J,** Gheorghiade M on behalf of the EVEREST trial investigators The predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: Insights from the EVEREST trial. *Circ Heart Fail* 2012 1;5(6):750-758
130. Marti CN, Georgiopoulou VV, Kalogeropoulos AP, Fike LV, Giamouzis G, Laskar SR, Cole RT, Smith AL, Tang WHW, Dunbar S, **Butler J** Patient-Reported Selective Adherence to Heart Failure Self-Care Recommendations: A Prospective Cohort Study: The Atlanta Cardiomyopathy Consortium. *Cong Heart Fail* 2012 9;1751-7133
131. Felker GM, Hasselblad V, Tang WHW, Hernandez AF, Armstrong PW, Fonarow GC, Voors AA, Metra M, McMurray JJV, **Butler J,** Heizer GM, Dickstein K, Massie BM, Atar D, Troughton RW, Anker SD, Califf RM, Starling RC, O'Connor CM. High Sensitivity Troponin I

- in Acute Decompensated Heart Failure: Insights from the ASCEND-HF Study. *Eur J Heart Fail* 2012;14(11):1257-64
132. Georgiopoulou VV, Kalogeropoulos AP, **Butler J**. Heart failure in hypertension: prevention and treatment. *Drugs* 2012;9;72(10):1373-98
 133. Greene SJ, Harinstein ME, Vaduganathan M, Subacius H, Konstam MA, Zannad F, Maggioni A, Swedberg K, **Butler J**, Gheorghiade M, on behalf of the EVEREST trial investigators Prognostic Value of Monocyte Count in Patients Hospitalized for Heart Failure with Reduced Ejection Fraction (From the EVEREST Trial). *Am J Cardiol* 2012 1;110(11):1657-62
 134. **Butler J**, Marti C, Pina I, Defilippi C. Scope of heart failure hospitalization. *Congest Heart Fail* 2012;18-1:S1-4
 135. Cole RT, Masoumi A, Triposkiadis F, Giamouzis G, Georgiopoulou V, Kalogeropoulos A, **Butler J**. Renal dysfunction in heart failure. *Med Clin North America* 2012;96(5):955-74.
 136. Brandimarte F, Vaduganathan M, Mureddu GF, Cacciatore G, Sabbah HN, Fonarow GC, Goldsmith SR, **Butler J**, Fedele F, Gheorghiade M. Prognostic Implications of Renal Dysfunction in Patients Hospitalized with Heart Failure: Data from the Last Decade of Clinical Investigations. *Heart Fail Rev* 2013;18(2):167-76
 137. Gheorghiade M, Pang PS, Ambrosy A, Vaduganathan M, Campia U, Maggioni A, Sabbah H, Mehra M, Ponikowski P, Nodari S, Filippatos G, Cleland J, Mebazaa A, Fedele F, Metra M, Fonarow G, Komajda M. **Butler J**. Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. *Heart Fail Rev* 2013;18(2):107-22.
 138. Gheorghiade M, Marti C, Sabbah H, Roessig L, Campia U, Cleland JG, Collins S, Filippatos G, Fonarow GC, Greene S, Levy P, Metra M, Pitt B, Ponikowski P, Voors A, Peter Stasch J, **Butler J** Soluble Guanylate Cyclase: A Potential Therapeutic Target for Heart Failure. *Heart Fail Rev* 2013;18(2):123-34.
 139. Bhalla V, Georgiopoulou VV, Kalogeropoulos AP, Marti CN, Cole RT, Gupta D, **Butler J** Contemporary Outcomes of Optimally Treated Heart Failure Patients With Sleep Apnea. Case for Urgency in Evaluation of Newer Interventions? From The Atlanta Cardiomyopathy Consortium. *Int J Cardiol* 2013;10:366-8
 140. Gheorghiade M, Vaduganathan M, Fonarow GC, Greene SJ, Greenberg BH, Liu PP, Massie BM, Mehra MR, Metra M, Zannad F, Cleland JGF, Veldhuisen DJV, Shah AN, **Butler J** Anticoagulation in Heart Failure: Current Status and Future Direction. *Heart Fail Rev* 2013 Nov;18(6):797-813.
 141. Mentz RJ, **Butler J**, Schelbert EB, Ardehali H, Cleland JG, Fonarow G, Gheorghiade M. Hospitalization for Heart Failure in 2013: A Paradigm Shift. *Nature Outlook*
 142. Vaduganathan M, Greene SJ, **Butler J**, Sabbah HN, Shantsila E, Lip GYH, Gheorghiade M. The Immunological Axis in Heart Failure: Importance of the Leukocyte Differential. *Heart Fail Rev*
 143. Gheorghiade M; Vaduganathan M; Greene SJ; Mentz RJ; Adams Jr KF; Anker SD; Arnold M; Baschiera F; Cleland JGF; Cotter G; Fonarow GC; Giordano C; Metra M; Misselwitz F; Mühlhofer E; Nodari S; Peacock WF; Pieske BM; Sabbah HN; Sato N; Shah MR; Stockbridge NL; Teerlink JR; van Veldhuisen DJ; Zalewski A; Zannad F; **Butler J**: Site Selection in Global Clinical Trials in Patients Hospitalized for Heart Failure: Perceived Problems and Potential Solutions. *Heart Fail Rev* 2014 Mar;19(2):135-52
 144. **Butler J**, Subacius H, Vaduganathan M, Ambrosy A, Konstam MA, Maggioni A, Mertz R, Swedberg K, Zannad F, Gheorghiade M, on behalf of the EVEREST investigators. Relationship Between Clinical Trial Site Enrollment with Participant Characteristics, Protocol Completion, and Outcomes. Insights from the EVEREST Trial, *J Am Coll Cardiol* 2013 5;61(5):571-9

145. Vaduganathan M, Greene, S Ambrosy A, Gheorghiade M, **Butler J**. Drug Development for Patients Hospitalized for Heart Failure: Disconnect Between Phase II and Phase III Trials. *Nature Rev Cardiol* 2013;10(2):85-97
146. Kalogeropoulos AP, Georgiopoulou VV, **Butler J**. Biomarkers in Acute Heart Failure: From Risk Markers to Therapeutic Targets. *Congest Heart Fail* 2013;19(2):51-2
147. Givertz, MM, Teerlink JR, Albert NM, Westlake CA, Collins SP, Colvin-Adams M, Ezekowitz JA, Fang JC, Hernandez AF, Katz SD, Krishnamani R, Gattis-Stough W, Walsh MN, **Butler J**, Carson PE, Dimarco JP, Hershberger RE, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WHW, Starling RC Acute Decompensated Heart Failure: Update on New and Emerging Evidence and Directions for Future Research. *J Card Fail* 2013;19(6):371-89
148. Georgiopoulou VV, Kalogeropoulos AP, Borlaug BA, Gheorghiade M, Butler J Left Ventricular Dysfunction with Pulmonary Hypertension Part 1: Epidemiology, Pathophysiology, and Definitions, *Circ Heart Fail*, 2013;1;6(2):344-54
149. Kalogeropoulos AP, Georgiopoulou VV, Borlaug BA, Gheorghiade M, Butler J, Left Ventricular Dysfunction with Pulmonary Hypertension Part 2: Prognosis, Noninvasive Evaluation, Treatment, and Future Research *Circ Heart Fail* 2013;6:584-93
150. Gheorghiade M, Shah AN, Vaduganathan M, **Butler J**, Bonow RO, Rosano GMC, Taylor S, Kupfer S, Misselwitz F, Sharma A, Fonarow GC. Recognizing Hospitalized Heart Failure as an Entity and Developing New Therapies to Improve Outcomes: Academics, Clinicians, Industry, Regulators, and Payers Perspective. *Heart Fail Clin* 2013;9(3):285-90
151. Schragger J, Wheatley M, Georgiopoulou V, Osborne A, Kalogeropoulos A, Hung O, **Butler J**, Ross M. Favorable bed utilization and readmission rates for emergency department 1 observation unit heart failure patients. *Acad Emerg Med* 2013;20:554-61
152. Barnett CF, Vaduganathan M, Lan G, **Butler J**, Gheorghiade M A Critical Reappraisal of Pulmonary Artery Catheterization and Invasive Hemodynamic Monitoring in Acute Heart Failure. *Expert Reviews in Cardiovascular Therap* 2013;11(4):417-24
153. Dunbar, SB, Butts, B, Reilly, CM, Gary, RA, Higgins MK, Ferranti, EP, Culler, S, **Butler J**. A Pilot Test Of An Integrated Self-Care Intervention For Persons With Heart Failure And Concomitant Diabetes. *Nursing Outlook* 2014 Mar-Apr;62(2):97-111.
154. Dickert Jr. N, Helpern S, **Butler J**. Incentivizing Recruitment and Retention to Address Enrollment Challenges in Clinical Research. *Circ Cardiovasc Qual Outcomes* 2013;6:367-70
155. Vaduganathan M, Kalogeropoulos A, Marti CN, Georgiopoulou VV, **Butler J**. Classification of Patients Hospitalized for Heart Failure. *Heart Fail Clin* 2013;9(3):277-83
156. Gheorghiade MD, Fonarow, GC, Veldhuisen DJ, Cleland JGF, **Butler J**, Epstein A, Patel K, Aban IB, Aronow W, Anker SD, Ahmed A Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: Findings from post hoc propensity-matched analysis of the AFFIRM trial. *Eur Heart J* 2013;34:1489-97
157. **Butler J**, Fonarow GC, Gheorghiade M. Strategies and Opportunities for Drug Development for Hospitalized Heart Failure Patients. *JAMA* 2013;28:1-2
158. Yancy CW, Jessup MD, Bozkurt B, **Butler J**, Casey DE, Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peteron PN, Riegel B, Sam F, Stevenson LW, Tang WWH, Tsai EJ, Wilkoff BL - 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: *Developed in Collaboration With the American Academy of Family Physicians, American College of Chest Physicians, Heart Rhythm Society and International Society for Heart and Lung Transplantation. In press*, *Circulation* and *J Am Coll Cardiol*
159. Golwala HB, Thadani U, Liang L, Stavrakis S, **Butler J**, Yancy CW, Bhatt DL, Hernandez AF, Fonarow GC Use of Hydralazine-Isosorbide Dinitrate Combination in African

- American and other Race/Ethnic Group Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction, *J Am Heart Asso* 2013, 21;2(4):e000214
160. Heidenreich PA, Albert N, Allen LA, Bluemke DA, **Butler J**, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, Nichol G, Pham M, Piña I, Trogon JG. Forecasting the Impact of Heart Failure in the United States: A Policy Statement from the American Heart Association Advocacy Coordinating Committee. *Circ Heart Fail* 2013;6:606-19
 161. Gupta D, Georgiopoulos VV, Kalogeropoulos AP, Marti CN, Yancy CW, Gheorghiade M, Fonarow GC, Konstam MA, **Butler J**. Nitrate Therapy for Heart Failure: Benefits and Strategies to Overcome Tolerance. *JACC Heart Fail* 2013;1:3;183-91
 162. Morris A, Cole R, Veledar E, Bellam N, Laskar SR, Smith AL, Gebel HM, Bray RA, **Butler J** Influence of Race/Ethnic Differences in Pre-Transplant Panel Reactive Antibody on Outcomes in Heart Transplant Recipients, *J Am Coll Cardiol* 17;62(24):2308-15.
 163. Kay J, Dorbala S, Goyal A, Fazel R, Di Carli MF, Einstein AJ, Beanlands RS, Merhige ME, Williams BA, Veledar E, Chow BJW, Min JK, Berman DS, Shah S, Bellam N, **Butler J**, Shaw LJ, PhD Influence of Gender on Risk Stratification with Stress Myocardial Perfusion Rb-82 Positron Emission Tomography: Results from the PET Prognosis Multicenter Registry. *J Am Coll Cardiol* 12;62(20):1866-76.
 164. Greene SJ; Gheorghiade M; Vaduganathan M; Ambrosy AP; Mentz RJ; Subacius H; Maggioni AP; Nodari S; Konstam MA; **Butler J**; Filippatos G; on behalf of the EVEREST Trial investigators. Hemoconcentration, Renal Function, and Post-discharge Outcomes in Patients Hospitalized for Heart Failure with Reduced Ejection Fraction: Insights from the EVEREST Trial. *Eur J Heart Fail* 15(12):1401-11
 165. Vaduganathan M, Gheorghiade M, **Butler J**. Expanding the Scope of the "Polypill" to Heart Failure. *J Card Fail*, 2013;19(8):540-1
 166. Marti CN, Fonarow GC, Gheorghiade M, **Butler J** Timing and Duration of Interventions in Clinical Trials for Hospitalized Heart Failure Patients. *Circ Heart Fail*. 2013; 1;6(5):1095-101
 167. Vaduganathan M, Greene SJ, Ambrosy AP, Mentz RJ, Fonarow GC, Zannad F, Maggioni AP, Konstam MA, Subacius HP, Nodari S, **Butler J**, Gheorghiade M. Relation of Serum Magnesium Levels and Postdischarge Outcomes in Patients Hospitalized for Heart Failure (From the EVEREST Trial). *Am J Cardiol* 2013 1;112(11):1763-9
 168. Mandyam MC, Soliman EZ, Alonso A, Dewland TA, Heckbert SR, Vittinghoff E, Cummings SR, Ellinor PT, Chaitman BR, Stocke K, Applegate WB, Arking DE, **Butler J**, Loehr LR, Magnani JW, Murphy RA, Satterfield S, Newman AB, Marcus GM. The QT interval and risk of incident atrial fibrillation. *Heart Rhythm* 2013,10(10):1562-8
 169. Vaduganathan M, **Butler J**, Fonarow GC, Gheorghiade M. Progress or Lack of Progress in Hospitalized Heart Failure. *Exp Rev Cardiovascular Ther* 2013;11(9):1079-83
 170. Greene SJ, Vaduganathan M, Wilcox JE, Harinstein ME, Maggioni AP, Subacius H, Zannad F, Konstam MA, Yancy CW, Swedberg K, **Butler J**, Bonow RO, Gheorghiade M on behalf of the EVEREST Trial Investigators. The Prognostic Significance of Heart Rate in Patients Hospitalized for Heart Failure with Reduced Ejection Fraction in Sinus Rhythm: Insights from the EVEREST Trial. *J Am Coll Cardiol Heart Failure*2013;1(6):488-96.
 171. Giamouzis G, Kalogeropoulos AP, **Butler J**, Karayannis G, Georgiopoulos VV, Skoularigis J, Triposkiadis F. Epidemiology and Importance of Renal Dysfunction in Heart Failure Patients. *Curr Heart Fail Rep* 2013;10(4):411-20
 172. Khan H, Kalogeropoulos AP, Georgiopoulos VV, Newman AB, Harris TB, Rodondi, N, Bauer DC, Kritchevsky S, **Butler J**. Frailty and Risk for Heart Failure in Older Adults The Health, Aging, and Body Composition Study. *Am Heart J* 2013; 166(5):887-94
 173. **Butler J**, Fonarow GC, Zile M, Lam C, Roessig L, Schelbert ES, Shah S, Ahmed A, Bonow RC, Cleland JGF, Cody R, Collins S, Dunnmon P, Filippatos G, Lefkowitz M, Marti CN, McMurray J, Misselwitz F, Nodari S, O'Connor C, Pfeffer M, Pieske B, Pitt B, Rosano G,

- Sabbah HN, Senni M, Solomon S, Stockbridge N, Teerlink J, Georgiopoulou VV, Gheorghiade M Developing Therapies for Heart Failure with Preserved Ejection Fraction: Current State and Future Directions. *JACC Heart Fail* 2014;2(2):97-112
174. Karayannis G, Triposkiadis F, Skoularigis J, Georgoulas P, Butler J, Giamouzis G The Emerging Role of Galectin-3 and ST2 in Heart Failure: Practical Considerations and Pitfalls Using Novel Biomarkers. *Curr Heart Fail Rep* 2013;10(4):441-9
175. Wong TC, Piehler KM, Zareba KM, Lin K, Phrampus A, Patel A, Moon JC, Ugander M, Valeti U, Holtz JE, Fu B, Chang CCH, Mathier M, Kellman P, **Butler J**, Gheorghiade M, Schelbert EB. Myocardial damage detected by late gadolinium enhancement cardiovascular magnetic resonance is associated with subsequent hospitalization for heart failure. *J Am Heart Asso* 2013 18;2(6):e000416
176. Khan H, Kunutsor S, Rauramaa R, Savonen K, Kalogeropoulos AP, Georgiopoulou VV, **Butler J**, Laukkanen JA. Cardiorespiratory Fitness and Risk of Heart Failure: A Population-Based Follow-Up Study. *Eur J Heart Fail* 2014;16(2):180-8
177. Marti CN, Khan H, Mann DL, Georgiopoulou VV, Bibbins-Domingo K, Harris T, Koster A, Newman A, Kritchevsky SB, Kalogeropoulos AP, **Butler J**, Soluble Tumor Necrosis Factor Receptors and Heart Failure Risk in Older Adults. The Health, Aging, and Body Composition Study. *Circ Heart Fail*;7(1):5-11
178. Ambrosy AP, Fonarow GC, **Butler J**, Nodari S, Chioncel O, Greene SJ, Vaduganathan M, Lam CSP, Sato N, Shah AP, Gheorghiade M. The Global Health and Economic Burden of Hospitalizations for Heart Failure: Lessons Learned from HHF Registries. *J Am Coll Cardiol* 1;63(12):1123-1133
179. Mentz RJ, Subacius HP, Shah A, Greene SJ, Ambrosy AP, Vaduganathan M, Swedberg K, Maggioni AP, Nodari S, Ponikowski P, Anker SK, **Butler J**, Gheorghiade M Clinical Profile and Prognostic Value of Anemia at the Time of Admission and Discharge Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. Findings From the EVEREST Trial *Circ Heart Fail* 2014;7(3):401-8
180. Greenberg B, Yaroshinsky A, Zsebo KM, **Butler J**, Felker GM, Voors AA, Rudy JJ, Hajjar RJ. CUPID 2: Design of a Phase 2b Trial of Intracoronary Administration of AAV1/SERCA2a in Patients with Advanced Heart Failure. *J Am Coll Cardiol Heart Failure* 2014;2(1):84-92.
181. Adams KF, Ghali JK, Patterson JH, Gattis-Stough W, **Butler J**, Bauman JL, Ventura HO, Sabbah H, Mackowiak JI, van Veldhuisen DJ A Perspective on Reevaluating Digoxin's Role in the Current Management of Patients with Systolic Heart Failure: Reducing Hospitalizations and Ensuring Safety by Targeting Serum Concentration. *Eur J Heart Fail* 2014;16(5):483-93
182. Hayek S, Sims DB, Markham DW, **Butler J**, Kalogeropoulos AP. Assessment of Right Ventricular Function in Left Ventricular Assist Device Candidates. *Circ Cardiovascular Imaging* 1;7(2):379-89
183. Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, Bart BA, Bull DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL, O'Meara E, Tang WHW, Starling RC, **Butler J**, Deswal A, Felker GM, O'Connor CM, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, Dávila-Román VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM, for the NHLBI Heart Failure Clinical Research Network. Low Dose Dopamine or Low Dose Nesiritide in Acute Heart Failure with Renal Dysfunction: The ROSE Acute Heart Failure Randomized Trial. *JAMA* 18;310(23):2533-43
184. Kalogeropoulos AP, Siwamogsatham S, Hayek S, Li S, Deka A, Marti CN, Georgiopoulou VV, **Butler J**, Echocardiographic Assessment of Pulmonary Artery Systolic Pressure and Outcomes in Ambulatory Heart Failure Patients. *J Am Heart Asso* 2014 3;3(1):e000363. doi: 10.1161/JAHA. 113.000363.

185. **Butler J**, Fonarow GC, Gheorghiade M. Need for increased awareness and evidence-based therapies for patients hospitalized for heart failure. *JAMA* 2013;310:2035-36
186. Triposkiadis FK, **Butler J**, Karayannis G, Starling RC, Filippatos G, Wolski K, Parissis J, Parisi C, Rovithis D, Koutrakis K, Skoularigis J, Antoniou CK, Chrysohoou C, Pitsavos C, Stefanadis C, Nastas J, Tsaknakis T, Mantziari L, Giannakoulas G, Karvounis H, Kalogeropoulos AP, Giamouzis G. Efficacy and Safety of High Dose versus Low Dose Furosemide with or without Dopamine Infusion: The Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) Trial. *Int J Cardiol* 2014 1;172(1):115-21.
187. Greene SJ, Gheorghiade M, Borlaug BA, Pieske B, Vaduganathan M, Burnett JC Jr, Roessig L, Stasch JP, Solomon SD, Paulus WJ, Butler J. The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. *J Am Heart Asso* 2013 Dec 11;2(6):e00053
188. Ambrosy A, **Butler J**, Veldheusen DV, Colucci W, Gheorghiade M. The Use of Digoxin in Patients with Worsening Chronic Heart Failure: Reconsidering an Old Drug to Reduce Hospital Admissions, *J Am Coll Cardiol* 2014 May 13;63(18):1823-1832.
189. Vaduganathan M, Greene, SJ, Fonarow, GC, Bonow, RO, Butler, J, Gheorghiade, M. Coronary Artery Disease in Patients with Heart Failure: Incidental, Coincidental, or a Target for Therapy? *Am J Med* 2014 Jul;127(7):574-8
190. Khan H, Kalogeropoulos AP, Zannad F, Marti CN, Georgiopoulou VV, Kanaya AM, Newman AB, Schelbert E, Harris TB, Kritchevsky S, Yancy C, Gheorghiade M, Fonarow GC, **Butler J**. Incident Heart Failure in Relation to Vascular Disease: Insights from the Health, Aging, and Body Composition Study. *Eur J Heart Fail* 2014;16(5):526-34
191. Schelbert EB, Fonarow GC, Bonow RO, **Butler J**, Gheorghiade M. Therapeutic Targets in Heart Failure: Refocusing on the Myocardial Interstitium. *J Am Coll Cardiol* 2014 3;63(21):2188-2198
192. Bayeva M, **Butler J**, Gheorghiade M, Ardehali H. Molecular and Cellular Basis of Viable but Dysfunctional Myocardium. *Circ Heart Fail* 2014;7(4):680-91
193. Bhushan S, Kondo K, Polhemus D, Nicholson C, Tao YX, Huang H, Georgiopoulou VV, Murohara T, Calvert JW, **Butler J**, Lefler DJ. Nitrite Therapy Improves Left Ventricular Function During Heart Failure via Restoration of Nitric Oxide (NO) and Nitrosothiol Mediated Cytoprotective Signaling. *Circ Res* 2014 Apr 11;114(8):1281-91
194. Felker GM, Teerlink JR, **Butler J**, Hernandez A, Miller A, Cotter G, Davison BA, Filippatos G, Greenberg BH, Ponikowski P, Voors A, Hua TA, Severin T, Unemori E, Metra M. Effect of Serelaxin on Mode of Death in Acute Heart Failure: Results from the RELAX-AHF Study. *J Am Coll Cardiol* 2014;64(15):1591-8
195. Cole RT, Gupta D, **Butler J**. Current Perspectives on Hydralazine and Nitrate Therapies in Heart Failure. *Heart Fail Clin* 2014;10(4):565-76.
196. Kalogeropoulos AP, Tang WH, Hsu A, Felker GM, Hernandez AF, Troughton RW, Voors AA, Anker SD, Metra M, McMurray JJ, Massie BM, Ezekowitz JA, Califf RM, O'Connor CM, Starling RC, **Butler J**. High sensitivity C-reactive protein in acute heart failure: Insights from the ASCEND-HF trial. *J Card Fail* 2014 May;20(5):319-26
197. Khan SS, Butler J, Gheorghiade M. Management of comorbid diabetes mellitus and worsening heart failure. *JAMA* 2014;311(23):2379
198. Inampudi C, Parvataneni S, Morgan CJ, Deedwania P, Fonarow GC, Sanders PW, Prabhu SD, **Butler J**, Forman DE, Aronow WS, Allman RM, Ahmed A. Spironolactone Use and Higher Hospital Readmission for Medicare Beneficiaries With Heart Failure, Left Ventricular Ejection Fraction <45%, and Estimated Glomerular Filtration Rate <45 ml/min/1.73 m². *Am J Cardiol* 1;114(1):79-82
199. Pieske B, **Butler J**, Filippatos G, Lam C, Maggioni AP, Ponikowski P, Shah S, Solomon S, Kraigher-Krainer E, Samano ET, Scalise AV, Müller K, Roessig L, Gheorghiade M on behalf of the SOCRATES Investigators and Coordinators. Rationale and Design of the

- SOluble guanylate Cyclase stimulator in heArT failurE Studies (SOCRATES). *Eur J Heart Fail* 2014;16(9):1026-38.
200. Polhemus DJ, Calvert JW, **Butler J**, Lefer D. The Cardioprotective Actions of Hydrogen Sulfide in Acute Myocardial Infarction and Heart Failure. *Scientifica* 2014; ID 768607, 8 pages, doi:10.1155/2014/768607
 201. Gencer B, **Butler J**, Bauer DC, Auer R, Kalogeropoulos AP, Marques-Vidal P, Applegate WB, Satterfield S, Harris T, Newman AB, Vittinghoff E, Rodondi N, for the Health ABC Study. Association of Electrocardiogram Abnormalities and Incident Heart Failure Events. *Am Heart J* 2014;167(6):869-875
 202. Kalogeropoulos AP, Marti CN, Georgiopoulou VV, **Butler J**. Inotrope Use and Outcomes Among Patients Hospitalized for Heart Failure: Impact of Systolic Blood Pressure, Cardiac Index, and Etiology. *J Card Fail* 2014;20(8):593-601
 203. Greene SJ, Shah AN MD, Butler J, Ambrosy AP, Anker SD, Chioncel O, Collins SP, Dinh W, Fonarow GC, Mentz RJ, Lam SCP, Pieske B, Roessig L, Sato N, Vaduganathan M, Gheorghiade M Designing Effective Drug and Device Development Programs for Hospitalized Heart Failure: A Proposal for Pre-trial Registries. *Am Heart J* 2014;168(2):142-9
 204. Remick J, Georgiopoulou V, Marti C, Ofotokun I, Kalogeropoulos A, Lewis W, **Butler J**. Heart failure in patients with human immunodeficiency virus infection: epidemiology, pathophysiology, treatment, and future research. *Circulation*. 2014;129(17):1781-9
 205. **Butler J**, Braunwald E, Gheorghiade M. Recognizing Worsening Heart Failure as an Entity and an Endpoint in Heart Failure Clinical Trials. *JAMA* 2014;312(8):789-90
 206. Vaduganathan M, Greene SJ, Fonarow GC, Voors AA, **Butler J**, Gheorghiade M. Hemoconcentration-Guided Diuresis in Heart Failure. *Am J Med* 2014;127(12):1154-1159
 207. Parrinello G, Greene SJ, Torres D, Alderman M, Bonventre JV, di Pasquale P, Gargani L, Nohria A, Fonarow GC, Vaduganathan M, **Butler J**, Paterna S, Stevenson LW, Gheorghiade M. Water and Sodium in Heart Failure: A Spotlight on Congestion. *Heart Failure Reviews* 2015;20(1):13-24.
 208. Vaduganathan M; Dei Cas A; Mentz RJ; Greene SJ; Khan S; Subacius HP; Chioncel O; Maggioni AP; Konstam MA; Senni M; Fonarow GC; **Butler J**; Gheorghiade M on behalf of the EVEREST trial investigators. Mineralocorticoid Receptor Antagonist Use in Hospitalized Patients with Heart Failure, Reduced Ejection Fraction, and Diabetes Mellitus. *Am J Cardiol* 2014;114(5):743-50
 209. **Butler J**, Givertz MM. Inhibiting the Renin Angiotensin Aldosterone System in Heart Failure and Renal Dysfunction: Common Sense or Nonsense? *Circ Heart Fail* 2014;7(3):537-40
 210. Khan H, Kunutsor SK, Kauhanen J, Kurl S, Gorodeski EZ, Adler AI, **Butler J**, Laukkanen JA Fasting plasma glucose and incident heart failure risk: a population-based cohort study and new meta-analysis. *J Card Failure* 2014;20(8):584-92.
 211. Edelman S, **Butler J**, Hershatter BW, Khan MK. The Effects of Androgen Deprivation Therapy on Cardiac Function and Heart Failure. Implications for Management of Prostate Cancer. *Clinical Genitourinary Cancer* 2014;12(6):399-407
 212. Maisel A, Xue Y, van Veldhuisen DJ, Voors AA, Jaarsma T, Pang PS, **Butler J**, Pitt B, Clopton P, de Boer RA. Effect of Spironolactone on 30-Day Death and Heart Failure Rehospitalization: From the COACH Study. *Am J Cardiol* 2014;114(5):737-42.
 213. Ambrosy A, Mentz R, Chioncel O, Gheorghiade M, **Butler J**. Global Perspectives in Hospitalized Heart Failure – Regional and Ethnic Variation. *Curr Heart Fail Reports* 2014;11(4):416-27
 214. Cheng RK, Cox M, Neely ML, Heidenreich PA, Bhatt DL, Eapen ZJ, Hernandez AF, **Butler J**, Yancy CW, Fonarow GC Outcomes in Heart Failure Patients with Preserved,

- Borderline, and Reduced Ejection Fraction in the Medicare Population. *Am Heart J* 2014;168(5):721-30
215. Butler J, Binney Z, Kalogeropoulos AP, Owen M, Clevenger C, Gunter D, Georgiopoulos VV, Quest T. Advance Directives among Hospitalized Heart Failure Patients. *JACC Heart Fail.* 2015 Feb;3(2):112-21.
 216. Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CSP, Cowie MR, Kjeldsen K, Jankowska EA, Atar D, **Butler J**, Fiuzat M, Zannad F, Pitt B, O'Connor CM. Non-Cardiac Comorbidities in Heart Failure with Reduced versus Preserved Ejection Fraction. *J Am Coll Cardiol* 2014;64(21):2281-93
 217. Vaduganathan M; Greene SJ; Ambrosy AP; Mentz RJ; Subacius HP; Chioncel O; Maggioni AP; Swedberg K; Zannad F; Konstam MA; Senni M; Givertz MM; **Butler J**; Gheorghiade M; on behalf of the EVEREST trial investigators Relation of Serum Uric Acid Levels and Outcomes among Patients Hospitalized for Worsening Heart Failure with Reduced Ejection Fraction (From the EVEREST Trial). *Am J Cardiol* 2014;114(11):1713-21
 218. Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CS, Cowie MR, Kjeldsen K, Jankowska EA, Atar D, **Butler J**, Fiuzat M, Zannad F, Pitt B, O'Connor CM. Noncardiac comorbidities in HF with reduced versus preserved ejection fraction. *J Am Coll Cardiol.* 2014 Dec 2;64(21):2281-93.
 219. Des Cas A, Fonarow G, Gheorghiade M, **Butler J**. Concomitant Diabetes Mellitus and Heart Failure. *Current Problems in Cardiology* 2015;40(1):7-43
 220. Tang WH, Dupont M, Hernandez AF, Voors AA, Hsu AP, Felker GM, **Butler J**, Metra M, Anker SD, Troughton RW, Gottlieb SS, McMurray JJ, Armstrong PW, Massie BM, Califf RM, O'Connor CM, Starling RC. Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. *JACC Heart Fail.* 2015 Jan;3(1):40-9.
 221. Felker GM, **Butler J**, Collins SP, Cotter G, Davison BA, Ezekowitz JA, Filippatos G, Levy PD, Metra M, Ponikowski P, Soergel DG, Teerlink JR, Violin JD, Voors AA, Pang PS Heart Failure Therapeutics Based on a Biased Ligand of the Angiotensin-2 Type 1 Receptor: Rationale and Design of the Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure (BLAST-AHF) Study. *JACC Heart Fail.* 2015 Mar;3(3):193-201
 222. Morris AA, Cole RT, Butler J, Gupta D. Oral sodium and potassium binders in heart failure. *Curr Heart Fail Rep.* 2015 Apr;12(2):107-11.
Collins S, Storrow AB, Albert N, **Butler J**, Ezekowitz JA, Felker GM, Fermann GJ, Fonarow GC, Givertz MM, Hiestand B, Hollander J, Lanfear D, Levy PD, Pang PS, Peacock WF, Sawyer DB, Teerlink J, Lenihan DJ. Early Management of Patients with Acute Heart Failure: State of the Art and Future Directions. A Consensus Document from the Society of Academic Emergency Medicine / Heart Failure Society of America - Acute Heart Failure Working Group. *Academic Emergency Medicine* 2015;22(1):94-112
 223. Khan H, Kunutsor S, Kalogeropoulos AP, Georgiopoulos VV, Newman AB, Harris TB, Bibbins-Domingo K, Kauhanen J, Gheorghiade M, Fonarow GC, Kritchevsky SB, Laukkanen JA, **Butler J**. Resting heart rate and risk of incident heart failure: three prospective cohort studies and a systematic meta-analysis. *J Am Heart Assoc.* 2015;4(1). pii: e001364. doi: 10.1161/JAHA.114.001364.
 224. Collins SP, Pang PS, **Butler J**, Fonarow G, Metra M, Gheorghiade M. Revisiting cardiac injury during acute heart failure: further characterization and a possible target for therapy. *Am J Cardiol.* 2015;115(1):141-6
 225. Tang WH, Dupont M, Hernandez AF, Voors AA, Hsu AP, Felker GM, **Butler J**, Metra M, Anker SD, Troughton RW, Gottlieb SS, McMurray JJ, Armstrong PW, Massie BM, Califf RM, O'Connor CM, Starling RC. Comparative Assessment of Short-Term Adverse Events in Acute Heart Failure With Cystatin C and Other Estimates of Renal Function: Results From the ASCEND-HF Trial. *JACC Heart Fail.* 2015;3(1):40-9

226. Maisel A, Xue Y, Greene SJ, Pang PS, Januzzi JL, Piña IL, DeFilippi C, **Butler J**. The Potential Role of Natriuretic Peptide Guided Management for Patients Hospitalized for Heart Failure. *J Card Fail*. 2014 Nov 26. pii: S1071-9164(14)01308-6
227. Rossi A, Gheorghiade M, Triposkiadis F, Solomon SD, Pieske B, Butler J. Left atrium in heart failure with preserved ejection fraction: structure, function, and significance. *Circ Heart Fail*. 2014 Nov;7(6):1042-9
228. Ambrosy AP, Gheorghiade M, Chioncel O, Mentz RJ, Butler J. Global Perspectives in Hospitalized Heart Failure: Regional 5 and Ethnic Variation in Patient Characteristics, Management, and Outcomes *Curr Heart Fail Rep*. 2014 Dec;11(4):416-27
229. Cas DA, Khan SS, **Butler J**, Mentz RJ, Bonow RO, Avogaro A, Tschoepe D, Doehner W, Greene SJ, Senni M, Gheorghiade M, Fonarow GC. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. *JACC Heart Fail*. 2015 Feb;3(2):136-45.
230. Khan SS, Campia U, Chioncel O, Zannad F, Rossignol P, Maggioni AP, Swedberg K, Konstam MA, Senni M, Nodari S, Vaduganathan M, Subacius H, **Butler J**, Gheorghiade M; EVEREST Trial Investigators. Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial). *Am J Cardiol*. 2015 Mar 15;115(6):790-6.
231. **Butler J**, Fonarow GC, O'Connor C, Adams K, Bonow RO, Cody RJ, Collins SP, Dunnmon P, Dinh W, Fiuzat M, Georgiopoulou VV, Grant S, Kim SY, Kupfer S, Lefkowitz M, Mentz RJ, Misselwitz F, Pitt B, Roessig L, Schelbert E, Shah M, Solomon S, Stockbridge N, Yancy C, Gheorghiade M. Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators. *Am Heart J*. 2015 Mar;169(3):305-14.
232. Clements IP, Garcia EV, Chen J, Folks RD, **Butler J**, Jacobson AF. Quantitative iodine-123-metaiodobenzylguanidine (MIBG) SPECT imaging in heart failure with left ventricular systolic dysfunction: Development and validation of automated procedures in conjunction with technetium-99m tetrofosmin myocardial perfusion SPECT. *J Nucl Cardiol*. 2015 Mar 19. [Epub ahead of print]
233. Morris AA, Cole RT, Laskar SR, Kalogeropoulos A, Vega JD, Smith A, **Butler J**. Improved Outcomes for Women on the Heart Transplant Wait List in the Modern Era. *J Card Fail*. 2015 Jul;21(7):555-60.
234. Mehra MR, **Butler J**. The hi-tech age of heart failure management. *Heart Fail Clin*. 2015 Apr;11(2):xi-xii.
235. Greene SJ, Fonarow GC, Vaduganathan M, Khan SS, **Butler J**, Gheorghiade M. The vulnerable phase after hospitalization for heart failure. *Nat Rev Cardiol*. 2015 Apr;12(4):220-9.
236. Kelly JP, Mentz RJ, Mebazaa A, Voors AA, **Butler J**, Roessig L, Fiuzat M, Zannad F, Pitt B, O'Connor CM, Lam CS. Patient selection in heart failure with preserved ejection fraction clinical trials. *J Am Coll Cardiol*. 2015 Apr 28;65(16):1668-82.
237. Khan H, Greene SJ, Fonarow GC, Kalogeropoulos AP, Ambrosy AP, Maggioni AP, Zannad F, Konstam MA, Swedberg K, Yancy CW, Gheorghiade M, **Butler J**; EVEREST Trial Investigators. Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial. *Eur J Heart Fail*. 2015 May [Epub ahead of print]
238. **Butler J**, Papadimitriou L, Georgiopoulou V, Skopicki H, Dunbar S, Kalogeropoulos A. Comparing Sodium Intake Strategies in Heart Failure: Rationale and Design of the Prevent Adverse Outcomes in Heart Failure by Limiting Sodium (PROHIBIT) Study. *Circ Heart Fail*. 2015 May;8(3):636-45.

239. Koutrolou-Sotiropoulou P, Parikh PB, Miller C, Lima FV, **Butler J**, Stergiopoulos K. Impact of Heart Disease on Maternal and Fetal Outcomes in Pregnant Women. *Am J Cardiol*. 2015 May 9.
240. Butts B, Gary RA, Dunbar SB, **Butler J**. The Importance of NLRP3 Inflammasome in Heart Failure. *J Card Fail*. 2015 Jul;21(7):586-93.
241. Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, **Butler J**, Tang WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O'Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF; NHLBI Heart Failure Clinical Research Network*. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. *Circulation*. 2015 May 19;131(20):1763-71
242. Echouffo-Tcheugui JB, Greene SJ, Papadimitriou L, Zannad F, Yancy CW, Gheorghiade M, **Butler J**. Population risk prediction models for incident heart failure: a systematic review. *Circ Heart Fail*. 2015 May;8(3):438-47.
243. Georgiopoulou VV, Deka A, Li S, Niazi AA, Farooq K, Kalogeropoulos AP, **Butler J**, Alexopoulos D. Pulmonary function testing and outcomes in subjects with heart failure listed for heart transplantation. *Respir Care*. 2015 May;60(5):731-9.
244. Dunbar SB, Reilly CM, Gary R, Higgins MK, Culler S, Butts B, **Butler J**. Randomized Clinical Trial of an Integrated Self-care Intervention for Persons with Heart Failure and Diabetes: Quality of Life and Physical Functioning Outcomes. *J Card Fail*. 2015 May 28.
245. Parrinello G, Torres D, Testani JM, Almasio PL, Bellanca M, Pizzo G, Cuttitta F, Pinto A, **Butler J**, Paterna S. Blood urea nitrogen to creatinine ratio is associated with congestion and mortality in heart failure patients with renal dysfunction. *Intern Emerg Med*. 2015 Jun 3. [Epub ahead of print]
246. Fang JC, Ewald GA, Allen LA, **Butler J**, Westlake Canary CA, Colvin-Adams M, Dickinson MG, Levy P, Stough WG, Sweitzer NK, Teerlink JR, Whellan DJ, Albert NM, Krishnamani R, Rich MW, Walsh MN, Bonnell MR, Carson PE, Chan MC, Dries DL, Hernandez AF, Hershberger RE, Katz SD, Moore S, Rodgers JE, Rogers JG, Vest AR, Givertz MM. Advanced (stage d) heart failure: a statement from the heart failure society of america guidelines committee. *J Card Fail*. 2015 Jun;21(6):519-34.
247. Pererra AA, Kalogeropoulos AP, Zhao L, Owen M, Raja Laskar S, David Vega J, Smith A, **Butler J**. Race and ethnic differences in the epidemiology and risk factors for graft failure after heart transplantation. *J Heart Lung Transplant*. 2015 Jun;34(6):825-31.
248. Vaduganathan M, **Butler J**, Roessig L, Fonarow GC, Greene SJ, Metra M, Cotter G, Kupfer S, Zalewski A, Sato N, Filippatos G, Gheorghiade M. Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations. *Heart Fail Rev*. 2015 Jul;20(4):393-400
249. Vaduganathan M, Tahhan AS, Greene SJ, Kelkar AA, Georgiopoulou VV, Kalogeropoulos AP, Fonarow GC, Gheorghiade M, **Butler J**. Contemporary Cardiovascular Device Clinical Trials (Trends and Patterns 2001 to 2012). *Am J Cardiol*. 2015 Jul 15;116(2):307-12.
250. Harinstein ME, **Butler J**, Greene SJ, Fonarow GC, Stockbridge NL, O'Connor CM, Pfeffer MA, Mehra MR, Solomon SD, Yancy CW, Fiuzat M, Mentz RJ, Collins SP, McMurray JJ, Vaduganathan M, Dunnmon PM, Rosano GM, Dinh W, Misselwitz F, Bonow RO, Gheorghiade M. Site selection for heart failure clinical trials in the USA. *Heart Fail Rev*. 2015 Jul;20(4):375-83
251. Bhatia V, Bajaj NS, Sanam K, Hashim T, Morgan CJ, Prabhu SD, Fonarow GC, Deedwania P, **Butler J**, Carson P, Love TE, Kheirbek R, Aronow WS, Anker SD, Waagstein F, Fletcher R, Allman RM, Ahmed A. Beta-Blocker Use and 30-Day All-Cause Readmission in Medicare Beneficiaries with Systolic Heart Failure. *Am J Med*. 2015 Jul;128(7):715-21.

252. Samman Tahhan A, Vaduganathan M, Kelkar A, Georgiopoulou VV, Kalogeropoulos AP, Greene SJ, Fonarow GC, Gheorghiade M, **Butler J**. Trends in Heart Failure Clinical Trials from 2001-2012. *J Card Fail*. 2015 Jun 21. pii: S1071-9164(15)00190-6 (Epub ahead of print)
253. Vaduganathan M, Mentz RJ, Greene SJ, Senni M, Sato N, Nodari S, **Butler J**, Gheorghiade M. Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists. *Expert Rev Cardiovasc Ther*. 2015 Jul;13(7):799-809
254. Maisel A, Xue Y, Greene SJ, Pang PS, Januzzi JL, Piña IL, DeFilippi C, **Butler J**. The potential role of natriuretic peptide guided management for patients hospitalized for heart failure. *J Card Fail*. 2015 Mar;21(3):233-9.
255. Tang WH, Dupont M, Hernandez AF, Voors AA, Hsu AP, Felker GM, **Butler J**, Metra M, Anker SD, Troughton RW, Gottlieb SS, McMurray JJ, Armstrong PW, Massie BM, Califf RM, O'Connor CM, Starling RC. Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. *JACC Heart Fail*. 2015 Jan;3(1):40-9.
256. Kalogeropoulos AP, Kelkar A, Weinberger JF, Morris AA, Georgiopoulou VV, Markham DW, **Butler J**, Vega JD, Smith AL. Validation of Clinical Scores for Right Ventricular Failure Prediction After Implantation of Continuous-Flow Left Ventricular Assist Devices. *J Heart Lung Transplant*. 2015 Jun 1. pii: S1053-2498(15)01262-0. doi: 10.1016/j.healun.2015.05.005.
257. Vaduganathan M, **Butler J**, Pitt B, Gheorghiade M. Contemporary Drug Development in Heart Failure. A Call for Hemodynamically Neutral Therapies. *Circ Heart Fail*. 2015; July 2015; 8:4 826-831
258. Golwala H, Pandey A, Ju C, **Butler J**, Yancy C, Bhatt D, Hernandez A, Fonarow GC. Temporal Trends and Factors Associated With Cardiac Rehabilitation Referral Among Patients Hospitalized With Heart Failure: Findings From Get With The Guidelines–Heart Failure Registry. *J Am Coll Cardiol*. 2015;66(8):917-926.
259. Wilcox JE, Fonarow GC, Bonow RO, Butler J, Sauer AJ, Epstein SE, Khan SS, Kim RJ, Sabbah HN, Díez J, Gheorghiade M. Targeting the Heart in Heart Failure: Myocardial Recovery in Patients with Heart Failure and Systolic Dysfunction. *JACC Heart Fail*. 2015 Sep;3(9):661-9. doi: 10.1016/j.jchf.2015.04.011.
260. Vaduganathan M, Marti CN, Mentz RJ, Greene SJ, Ambrosy AP, Subacius HP, Fonarow GC, Chioncel O, Bazari H, Maggioni AP, Zannad F, Konstam MA, Sato N, Gheorghiade M, **Butler J**; on behalf of the EVEREST trial investigators. Serum Osmolality and Post-Discharge Outcomes after Heart Failure Hospitalization: Insights from the EVEREST Trial. *Am J Cardiol*. 2016 Jan 14.
261. **Butler J**, Gheorghiade M, Kelkar AA, Fonarow GC, Anker S, Greene SJ, Papadimitriou L, Collins S, Ruschitzka F, Yancy CW, Teerlink JR, Adams K, Cotter G, Ponikowski P, Felker GF, Metra M, Filippatos G. In-Hospital Worsening Heart Failure. *Eur J Heart Fail*. 2015 Nov;17(11):1104-13.
262. Brown K; Chee J, Kyung S, Vettichira B, Papadimitriou L, Butler J. Mineralocorticoid Receptor Antagonism in Acute Heart Failure. *Curr Treat Options Cardiovasc Med*. 2015 Sep;17(9):402.
263. Wilcox JE, Fonarow GC, Ardehali, H, Bonow RO, **Butler J**, Sauer AJ, Epstein SE, Khan SS, Kim RJ, Sabbah HN, Díez J, Gheorghiade G. Targeting the Heart' in Heart Failure: Myocardial Recovery in Heart Failure with Reduced Ejection Fraction. *JACC Heart Fail*. 2015 Sep;3(9):661-9
264. Ahmed A, Patel K, Fonarow GC, Morgan C, **Butler J**, Bittner V, Kulczycki A, Kheirbek R, Aronow W, Fletcher R, Brown C, Ahmed A. Higher risk for incident heart failure and

- cardiovascular mortality among community-dwelling octogenarians without pneumococcal vaccination. *ESC Heart Fail.* 2016 Mar;3(1):11-17.
265. Kelkar A, **Butler J**, Schelbert EB, Greene SJ, Quyyumi AA, Bonow RO, Cohen R, Gheorghide M, Lipinski MJ, Sun W, Luger D, Epstein SE. Mechanisms Contributing to Progression of Ischemic and Nonischemic Dilated Cardiomyopathy and the Possible Role of Stem Cell Therapy. *J Am Coll Cardiol.* 2015 Nov 3;66(18):2038-47
 266. Echouffo-Tcheugui JB, **Butler J**, Yancy CW, Fonarow GC. Association of Physical Activity or Fitness with Incident Heart Failure: A Systematic Review and Meta-analysis. *Circulation: Heart Failure. Circ Heart Fail.* 2015 Sep;8(5):853-61
 267. Kalogeropoulos A, Al-Anbari R, Pekarek A, Wittersheim K, Pernetz MA, Hampton A, Steinberg J, Georgiopolou V, Butler J, Vega JD, Smith AL. The Right Ventricular Function after Left Ventricular Assist Device (RVF-LVAD) study: rationale and preliminary results. *Eur Heart J Cardiovasc Imaging.* 2015 Jul 9
 268. Paterna S, di Gaudio F, La Rocca V, Balistreri F, Greco M, Torres D, Lupo U, Rizzo G, di Pasquale P, Indelicato S, **Butler J**, Parrinello G. Hypertonic Saline in Conjunction with High-Dose Furosemide Improves Dose-Response Curves in Worsening Refractory Congestive Heart Failure. *Adv Ther.* 2015 Oct;32(10):971-82. doi: 10.1007/s12325-015-0254-9. Epub 2015 Oct 31.
 269. D'Elia E, Vaduganathan M, Gori M, Gavazzi A, Butler J, Senni M. The Role of Biomarkers in Phenotyping Heart Failure with Preserved Ejection Fraction: Critical Appraisal and Practical Use. *Eur J Heart Fail.* 2015 Oct 23. doi: 10.1002/ejhf.430. [Epub ahead of print]
 270. Greene SJ, Fonarow GC, Vaduganathan M, Khan SS, Butler J, Gheorghide M. The Vulnerable Phase after Hospitalization for Heart Failure. *Nat Rev Cardiol.* 2015 Apr;12(4):220-9. doi: 10.1038/nrcardio.2015.14. Epub 2015 Feb 10.
 271. Khazanie P, Liang Li, Curtis LH, **Butler J**, Eapen ZJ, Fonarow GC, Heidenreich PA, Peterson ED, Yancy CW, Bhatt DL, Hernandez AF. Examining Real World Clinical Effectiveness of Hydralazine-Isosorbide Dinitrates in Blacks and Non-Blacks with Heart Failure and Reduced Ejection Fraction: Findings from the GWTG-HF Registry
 272. Grodin JL, Stevens SR, De las Fuentes L, Kiernan M, Birati EY, Gupta D, Bart BA, Felker GM, Chen HH, **Butler J**, Dávila-Román VG, Margulies KB, Hernandez A, Anstrom K, Tang WH. Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure. *J Card Fail.* 2016 Jan;22(1):26-32
 273. Papadimitriou L, Georgiopolou VV, Kort S, **Butler J**, Kalogeropoulos A. Echocardiography in Acute Heart Failure: Current Perspectives. *J Card Fail.* 2015 Aug 12. pii: S1071-9164(15)00667-3.
 274. Ambrosy AP, Hernandez AF, Armstrong PW, **Butler J**, Califf RM, Dunning A, Ezekowitz JA, Felker GM, Greene SJ, Kaul P, McMurray JJ, Metra M, Connor CM, Reed SD, Schulte P, Starling RC, Tang WHW, Voors AA, Mentz RJ. The Clinical Course of Health Status and Association with Outcomes in Patients Hospitalized for Heart Failure - Insights from ASCEND-HF. *Eur J Heart Fail.* 2015 Oct 14. doi: 10.1002/ejhf.420.
 275. Morris AA, Pekarek A, Wittersheim K, Cole RT, Gupta D, Nguyen D, Laskar SR, **Butler J**, Smith AL, Vega JD. Gender differences in risk of stroke during support with continuous flow left ventricular assist device (LVAD). *J Heart Lung Transplant.* 2015 Sep 3. pii: S1053-2498(15)01388-1. doi: 10.1016/j.healun
 276. Clements IP, Kelkar A, Garcia EV, **Butler J**, Chen J, Folks R, Jacobson AF. Prognostic Significance 123I-mIBG SPECT Myocardial Imaging in Heart Failure. Differences Between Ischemic and Non-ischemic Heart Failure. *Eur Heart J Cardiovasc Imaging.* 2015 Nov 20. pii: jev295.
 277. Ferreira JP, Girerd N, Medeiros PB, Santos M, Carvalho HC, Bettencourt P, Kénizou D, **Butler J**, Zannad F, Rossignol P. Spot Urine Sodium Excretion as Prognostic Marker in

- Acutely Decompensated Heart Failure: The Spironolactone Effect. *Clin Res Cardiol*. 2015 Nov 28.
278. Gheorghiade M, Greene SJ, **Butler J**, Filippatos G, Lam CS, Maggioni AP, Ponikowski P, Shah SJ, Solomon SD, Kraigher-Krainer E, Samano ET, Müller K, Roessig L, Pieske B; SOCRATES-REDUCED Investigators and Coordinators. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. *JAMA*. 2015 Dec 1;314(21):2251-2262. doi: 10.1001/jama.2015.15734.
279. D'Elia E, Vaduganathan M, Gori M, Gavazzi A, **Butler J**, Senni M. Role of Biomarkers in Cardiac Structure Phenotyping Heart Failure with Preserved Ejection Fraction: critical appraisal and practical use. *Eur J Heart Fail*. 2015 Oct 23. doi: 10.1002/ejhf.430. [Epub ahead of print]
280. Vaduganathan M, Goldsmith SR, **Butler J**, Gheorghiade M. Contrasting Acute and Chronic Effects of Tolvaptan on Serum Osmolality: Relationship to Outcomes in the EVEREST Trial. *Eur J Heart Fail*. 2015 Oct 7. doi: 10.1002/ejhf.415. [Epub ahead of print]
281. Grodin JL, Perez A, Wu Y, Hernandez AF, **Butler J**, Metra M, Felker GM, Voors AA, McMurray JJ, Armstrong PW, Califf RM, Starling RC, O'Connor CM, Tang W. Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure: Insights from the ASCEND-HF Trial. *JACC Heart Fail*. 2015 Oct;3(10):777-85.
282. Smith SA, Mentz RJ, Roessig L, Mebazza A, Longrois D, Gheorghiade M, Pitt B, Zannad F, **Butler J**, Abraham WT. Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials. *Am J Cardiol*. 2015 Oct 15;116(8):1304-10
283. Greene SJ, Epstein SE, Kim RJ, Quyyumi AA, Cole RT, Anderson AS, Wilcox JE, Skopicki HA, Sikora S, Verkh L, Tankovich NI; Gheorghiade M, **Butler J**. Rationale and Design of a Randomized Controlled Trial of Allogeneic Mesenchymal Stem Cells in Patients with Non-Ischemic Cardiomyopathy. *J Cardiovasc Transl Res*. 2014 Dec;7(9):769-80
284. Patel N, Macon C, Ju C, Thadani U, Schulte PJ, Hernandez AF, Bhatt DL, **Butler J**, Yancy CW, Fonarow CG. Temporal Trends of Digoxin Use in Patients Hospitalized with Heart Failure: Analysis from the American Heart Association Get With The Guidelines-Heart Failure Registry. *JACC Heart Fail*. 2016 May;4(5):348-56.
285. Miller CR, **Butler J**, Culler SD, Gary RA, Higgins M, Schindler P, Butts B, Dunbar SB. An Economic Evaluation of a Self-Care Intervention in Persons with Heart Failure and Diabetes. *J Card Fail*. 2015 Sep;21(9):730-7.
286. Senni M, Gavazzi A, Gheorghiade M, **Butler J**. Heart Failure at Crossroads. Moving Beyond Blaming Stakeholders to Targeting the Heart. *Eur J Heart Fail*. 2015 Aug;17(8):760-3.
287. McCabe NC, Dunbar SB, **Butler J**, Higgins M, Book W, Reilly C. Antecedents of Self-Care in Adults with Congenital Heart Defects. *Int J Cardiol*. 2015 Dec 15;201:610-5. doi: 10.1016/j.ijcard.2015.08.125. Epub 2015 Aug 16.
288. Khan SS, **Butler J**, Subacius H, Gheorghiade M. Reply: Are Changes in Serum Potassium Levels During Admissions for Acute Decompensated Heart Failure Irrelevant for Prognosis: The End of the Story? *Am J Cardiol*. 2015 Sep 1;116(5):825-6
289. Hammadah M, Georgiopoulou VV, Kalogeropoulos AP, Weber M, Wang X, Samara MA, Gul Z, Wu Y, Hazen SL, **Butler J**, Tang WHW. Elevated soluble Fms-like tyrosine kinase 1 and placental-like growth factor levels are associated with development and mortality risk in heart failure. *Circ Heart Fail*. 2016 Jan;9(1):e002115.
290. Greenberg B, **Butler J**, Felker GM, Ponikowski P, Voors AA, Pogoda JM, Provos R, Guerrero J, Hajjar RJ, Zsebo KM. Prevalence of AAV1 Neutralizing Antibodies and Consequences for a Clinical Trial of Gene Transfer for Advanced Heart Failure. *Gene Ther*. 2015 Dec 24. doi: 10.1038/gt.2015.109. [Epub ahead of print]

291. Schelbert EB, Piehler KM, Zareba KM, Moon JC, Ugander M, Messroghli DR, Valeti US, Chang CCH, Shroff SG, Diez J, Miller CA, Schmitt M, Kellman P, **Butler J**, Gheorghiade M, Wong TC. Myocardial fibrosis quantified by extracellular volume is associated with subsequent hospitalization for heart failure, death, or both across the spectrum of ejection fraction and heart failure stage. *J Am Heart Assoc*. 2015 Dec 18;4(12).
292. Samsky M, Teerlink JR; Armstrong PW, Starling RC, TANG Wh, Ezekowitz JA, Metra M, Voors AA, McMurray JVJ, O'Connor CM, **Butler J**, Mentz RJ, DeVore A, Hernandez A, Patel C, Regnier Y. Liver Function tests in patients with acute heart failure and associated outcomes: Insights from ACSEND-HF. *Eur J Heart Fail*. 2015 Dec 28. doi: 10.1002/ejhf.440.
293. **Butler J**, Tahhan AS, Georgiopoulou V, Kelkar A, Lee M, Khan B, Peterson E, Fonarow GC, Kalogeropoulos AP, Gheorghiade M. Trends in Characteristics of Cardiovascular Clinical Trials 2001-2012. *Am Heart J*. 2015 Aug;170(2):263-72
294. Vaduganathan M, Michel A, Hall K, Mulligan C, Shah SJ, Senni M, Triggiani M, **Butler J**, Gheorghiade M. Spectrum of Epidemiologic and Clinical Findings in Patients with Heart Failure with Preserved Ejection Fraction Stratified by Study Design: A Systematic Review. *Eur J Heart Fail*. 2016 Jan;18(1):54-65.
295. Reilly CM, Butler J, Culler Gary RA, Higgins M, Schindler P, Dunbar SB. An Economic Evaluation of a Self-Care Intervention in Persons with Heart Failure and Diabetes. *J Card Fail*. 2015 Sep;21(9):730-7.
296. Greene SJ, Temporelli PL; Campia U, Vaduganathan M, Esposti LD, Buda S, Veronesi C, **Butler J**; Nodari S. Effects of Polyunsaturated Fatty Acid Treatment on Post-discharge Outcomes After Acute Myocardial Infarction. *Am J Cardiol*. 2016 Feb 1;117(3):340-6.
297. Bloom MW, Hamo CE, Cardinale D, Ky B, Nohria A, Baer L, Skopicki H, Lenihan DJ, Gheorghiade M, Lyon AR, **Butler J**. Cancer Therapy-Related Cardiac Dysfunction and Heart Failure. Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging. *Circ Heart Fail*. 2016 Jan;9(1):e002661.
298. Chioncel O, Collins SP, Greene SJ, Ambrosy AP, Vaduganathan M, Macarie C, Butler J, Gheorghiade M. Natriuretic peptide-guided management in heart failure. *J Cardiovasc Med (Hagerstown)*. *J Cardiovasc Med (Hagerstown)*. 2016 Apr 22. [Epub ahead of print]
299. Hamo CE, Bloom MW, Cardinale D, Ky B, Nohria A, Baer L, Skopicki H, Lenihan DJ, Gheorghiade M, Lyon AR, **Butler J**. Cancer Therapy-Related Cardiac Dysfunction and Heart Failure. Part 2: Prevention, Treatment, Guidelines, and Future Directions. *Circ Heart Fail*. 2016 Feb;9(2):e002843.
300. Sudden Cardiac Death in Heart Failure with Preserved Ejection Fraction: A Target for Therapy? Vaduganathan V, Patel RB, Shah SJ, **Butler J**. *Heart Fail Rev*. 2016 Jan 13.
301. Liang L, Curtis LH, **Butler J**, Eapen ZJ, Fonarow GC, Heidenreich PA, Peterson, ED, Yancy CW, Bhatt DL, Hernandez AF. Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the GWTG-HF Registry. *Circulation: Heart Failure*.
302. Cook TD, Greene SJ, Kalogeropoulos AP, Fonarow GC, Zea R, Swedberg K, Zannad F, Maggioni AP, Konstam MA, Gheorghiade M, **Butler J**. Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the Everest Trial). *Am J Cardiol*. 2016 Feb 15;117(4):611-6.
303. Greenberg B, **Butler J**, Felker GM, Ponikowski P, Voors AA, Desai AS, Barnard D, Bouchard A, Jaski B, Lyon AR, Pogoda JM, Rudy JJ, Zsebo KM. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. *Lancet*. 2016 Jan 21. pii: S0140-6736
304. Gencer B, Auer R, de Rekeneire N, **Butler J**, Kalogeropoulos A, Bauer DC, Kritchevsky SB, Miljkovic I, Vittinghoff E, Harris T, Rodondi N. Association between resistin levels and

- cardiovascular disease events in older adults: The health, aging and body composition study. *Atherosclerosis*. 2016 Feb;245:181-6. doi: 10.1016
305. Cook TD, Greene SJ, Kalogeropoulos AP, Fonarow GC, Zea R, Swedberg K, Zannad F, Maggioni AP, Konstam MA, Gheorghiade M, **Butler J**. Temporal Changes in Post-Discharge Mortality Risk Following Hospitalization for Heart Failure (from the EVEREST Trial). *Am J Cardiol*. 2016 Feb 15;117(4):611-6.
 306. Greene SJ, Sabbah HN, **Butler J**, Voors AA, Albrecht-Küpper BE, Düngen HD, Dinh W, Gheorghiade M. Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. *Heart Fail Rev*. 2016 Jan;21(1):95-102. doi: 10.1007/s10741-015-9522-7.
 307. Butts B, Gary RA, Dunbar SB, **Butler J**. Methylation of Apoptosis-Associated Speck-Like Protein With a Caspase Recruitment Domain and Outcomes in Heart Failure. *J Card Fail*. 2015 Dec 14. pii: S1071-9164(15)01213-0. doi: 10.1016/j.cardfail.2015.12.004. [Epub ahead of print]
 308. Sharma A, Fonarow GC, **Butler J**, Ezekowitz JA, Felker GM. Coenzyme Q10 in the treatment of heart failure: A State-of-the-Art Review. *Circ Heart Fail*. 2016 Apr;9(4)
 309. Hamo CE, **Butler J**. How to Best Identify Elderly Individuals Who May Develop Heart Failure. *Curr Cardiovasc Risk Rep* (2016) 10:19 DOI 10.1007/s12170-016-0500-y
 310. Papadimitriou L, Smith-Jones P, Sarwar C, Norton C, Skopicki H, Yaddanapudi K, Gheorghiade M, Parsey R, **Butler J**. Utility of Positron Emission Tomography For Drug Development for Heart Failure. *Am Heart J*. 2016 May;175:142-52
 311. **Butler J**, M. Metra, M. Gheorghiade. Moving Away From Symptoms Based Heart Failure Treatment Misperceptions And Real Risks For Patients With Heart Failure. *Eur J Heart Fail*. 2016 Mar 17. doi: 10.1002/ejhf.507. [Epub ahead of print]
 312. Mecklai A, Subačius H, Konsta MA, Gheorghiade M, **Butler J**, Katz SD. In-Hospital Diuretic Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure. Insights from the EVEREST Trial. *JACC Heart Fail*. 2016 Mar 25. pii: S2213-1779(16)00104-9. doi: 10.1016/j.jchf.2016.02.008. [Epub ahead of print]
 313. Magnani JW, Wang N, Benjamin EJ, Garcia ME, Bauer D, **Butler J**, Ellinor PT, Kritchevsky S, Marcus GM, Newman A, Phillips CL, Sasai H, Satterfield S, Sullivan LM, Harris TB; for the Health, Aging, and Body Composition Study. Atrial Fibrillation and Declining Physical Function in Older Adults: the Health, Aging and Body Composition Study (Health ABC). *Circ Arrhythm Electrophysiol*. 2016 May;9(5):
 314. Bjork BJ, Alton KK, Georgiopoulou VV, **Butler J**, Kalogeropoulos AP. Defining Defining Advanced Heart Failure: A Systematic Review of Criteria Used in Clinical Trials. *J Card Fail*. 2016 Mar 11. pii: S1071-9164(16)00076-2. doi: 10.1016/j.cardfail.2016.03.003.
 315. Moin DS, Bloom MW, Papadimitriou L, **Butler J**. Serelaxin for the treatment of heart failure. *Expert Rev Cardiovasc Ther*. 2016 Jun;14(6):667-75
 316. Kelkar AA, Spertus J, Pang P, Pierson RF, Cody RJ, Pina IL, Hernandez A, **Butler J**. Utility of Patient-Reported Outcome Instruments in Heart Failure. *JACC Heart Fail*. 2016 Mar;4(3):165-75. doi: 10.1016/j.jchf.2015.10.015. Epub 2016 Feb 10
 317. Perez AL, Grodin JL, Wu Y2, Hernandez AF, **Butler J**, Metra M, Felker GM, Voors AA, McMurray JJ, Armstrong PW, Starling RC, O'Connor CM, Tang WH. *Eur J Heart Fail*. 2016 Mar;18(3):290-7. doi: 10.1002/ejhf.456. Epub 2015 Dec 14. Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy.
 318. Giamouzis G, Schelbert EB, **Butler J**. Growing Evidence Linking Microvascular Dysfunction With Heart Failure With Preserved Ejection Fraction. *J Am Heart Assoc*. 2016 Feb 23;5(2)
 319. Gheorghiade M, Larson CJ, Shah SJ, Greene SJ, Cleland JGF, Colucci WS, Dunnmon P, Epstein SE, Kim RJ, Parsey RV, Stockbridge N, Carr J, Dinh W, Krahn T, Kramer F, Wahlander K, Deckelbaum LI, Crandall D, Okada S, Senni M, Sikora S, Sabbah H, **Butler J**.

Developing New Treatments for Heart Failure: Focus on the Heart. *Circ Heart Fail.* 2016 May;9(5).

320. Smith JG, Felix JF, Morrison AC, Kalogeropoulos A, Trompet S, Wilk JB, Gidlöf O, Wang X, Morley M, Mendelson M, Joehanes R, Lighthart S, Shan X, Bis JC, Wang YA, Sjögren M, Ngwa J, Brandimarto J, Stott DJ, Aguilar D, Rice KM, Sesso HD, Demissie S, Buckley BM, Taylor KD, Ford I, Yao C, Liu C; CHARGE-SCD consortium; EchoGen consortium; QT-IGC consortium; CHARGE-QRS consortium, Sotoodehnia N, van der Harst P, Stricker BH, Kritchevsky SB, Liu Y, Gaziano JM, Hofman A, Moravec CS, Uitterlinden AG, Kellis M, van Meurs JB, Margulies KB, Dehghan A, Levy D, Olde B, Psaty BM, Cupples LA, Jukema JW, Djousse L, Franco OH, Boerwinkle E, Boyer LA, Newton-Cheh C, **Butler J**, Vasani RS, Cappola TP, Smith NL. Discovery of Genetic Variation on Chromosome 5q22 Associated with Mortality in Heart Failure. *PLoS Genet.* 2016 May 5;12(5):e1006034. doi: 10.1371/journal.pgen.1006034. eCollection 2016 May.
321. Patel R, Vaduganathan M, Samman-Tahhan A, Kalogeropoulos A, Georgiopoulou V, Fonarow G, Gheorghiade M, **Butler J**. Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials: A Systematic Review. *Am J Cardiol.* 2016 Jun 1;117(11):1845-50.
322. Muthiah Vaduganathan, Patel RV, Samman-Tahhan A, Kalogeropoulos AP, Georgiopoulou VV, Fonarow GC, Gheorghiade M, **Butler J**. Cardiovascular Clinical Trials with Noninferiority or Equivalence Designs from 2001 to 2012. *Int J Cardiol.* 2016 Jul 1;214:16-8
323. Ambrosy AP, Khan H, Mentz RJ, Chioncel O, Greene SJ, Vaduganathan M, Konstam MA, Swedberg K, Zannad F, Maggioni AP, Gheorghiade M, **Butler J**. Changes in Dyspnea Status During Hospitalization and Post-Discharge Health-Related Quality of Life in Hospitalized Heart Failure Patients. Findings from the EVEREST Trial. *Circ Heart Fail.* 2016 May;9(5).
324. Vaduganathan M, Pallais JC, Fenves AZ, **Butler J**, Gheorghiade M. Serum chloride in heart failure: a salty prognosis. *Eur J Heart Fail.* 2016 Apr 27.
325. Kunutsor SK, Laukkanen JA, Bluemke DA, **Butler J**, Khan H. Baseline and long-term gamma-glutamyltransferase, heart failure and cardiac arrhythmias in middle-aged Finnish men: Prospective study and pooled analysis of published evidence. *Eur J Prev Cardiol.* 2016 Apr 15
326. Yancy CW, Jessup M, Bozkurt B, **Butler J**, Casey DE Jr, Colvin MM, Drazner MH, Filippatos G, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *J Am Coll Cardiol.* 2016 May 17. pii: S0735-1097(16)33024-8. doi: 10.1016/j.jacc.2016.05.011
327. Yancy CW, Jessup M, Bozkurt B, **Butler J**, Casey DE Jr, Colvin MM, Drazner MH, Filippatos G, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *Circulation.* 2016 May 20. pii: CIR.0000000000000435. [Epub ahead of print]
328. Georgiopoulou V, Tang WH, Giamouzis G, Li S, Deka A, Dunbar S, **Javed B**, Kalogeropoulos A. Renal Biomarkers and Outcomes in Outpatients with Heart Failure: The Atlanta Cardiomyopathy Consortium. *Int J Cardiol.* 2016 May 13;218:136-143

329. Kapoor JR, Kapoor R, Ju C, Heidenreich PA, Eapen ZJ, Hernandez AF, **Butler J**, Yancy CW, Fonarow GC. Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized with Heart Failure with Reduced, Borderline and Preserved Ejection Fraction. *JACC: Heart Failure*, Volume 4, Issue 6, June 2016, Pages 464–472
330. Donahey EE, Polly DM, Vega JD, Lyon M, Butler J, Nguyen D, Pekarek A, Wittersheim K, Kilgo P, Paciullo C. Multidrug Resistant Organism Infections In Patients With Left Ventricular Assist Devices. *Tex Heart Inst J*. 2015 Dec 1;42(6):522-7.
331. Zannad F, Rossignol P, Stough WG, Epstein M, Alonso A, Bakris GL, **Butler J**, Kosiborod M, Berman L, Mebazaa A, Rasmussen HS, Ruilope LM, Stockbridge N, Thompson A, Wittes J, Pitt B. New Drugs for Managing Hyperkalemia in Patients Receiving Renin Angiotensin Aldosterone Inhibitor Therapy: Considerations for Clinical Trial Design and Regulatory Approval. *Int J Cardiol*. 2016 Aug 1;216:46-51.
332. Tang W, Wu Y, Grodin JL, Hsu AP, Hernandez AF, Butler J, Metra M, Voors AA, Felker GM, Troughton RW, Mills RM, McMurray JJ, Armstrong PW, Califf RM, O'Connor CM, Starling RC. Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. *JACC Heart Fail*. 2016 Jan;4(1):68-77.
333. Collins SP, Levy PD, Martindale JL, Dunlap ME, Storrow AB, Pang PS, Albert NM, Felker GM, Fermann GJ, Fonarow GC, Givertz MM, Hollander JE, Lanfear DJ, Lenihan DJ, Lindenfeld JM, Frank Peacock W, Sawyer DB, Teerlink JR, **Butler J**. Clinical and Research Considerations for Patients with Hypertensive Acute Heart Failure A Consensus Statement from the Society of Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. *Acad Emerg Med*. 2016 Jun 10.
334. Kerkhoff LA, **Butler J**, Kelkar AA, Shore S, Speight CD, Wall LK, Dickert NW. Trends in Consent for Clinical Trials in Cardiovascular Disease. *J Am Heart Assoc*. 2016 Jun 17;5(6).
335. Sanam K, Bhatia V, Bajaj N, Gaba S, Morgan CJ, Fonarow G, **Butler J**, Deedwania P, Prabhu S, Wu WC, White M, Love T, Aronow W, Fletcher RS, Allman A. Renin-Angiotensin System Inhibition and Lower 30-day All-cause Readmission in Medicare Beneficiaries with Heart Failure. *Am J Med*. 2016 Oct;129(10):1067-73.
336. Bhatt KN, Kalogeropoulos AP, Dunbar SB, **Butler J**, Georgiopoulou VV. Depression in heart failure: Can PHQ-9 help? *Int J Cardiol*. 2016 Jul 5;221:246-250. doi: 10.1016/j.ijcard.2016.07.057. [Epub ahead of print]
337. Collins SP, Levy PD, Martindale JL, Dunlap ME, Storrow AB, Pang PS, Albert NM, Felker GM, Fermann GJ, Fonarow GC, Givertz MM, Hollander JE, Lanfear DJ, Lenihan DJ, Lindenfeld JM, Frank Peacock W, Sawyer DB, Teerlink JR, **Butler J**. Clinical and Research Considerations for Patients with Hypertensive Acute Heart Failure A Consensus Statement from the Society of Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. *Journal of Cardiac Failure* Volume 22, Issue 8, August 2016, Pages 618–627
338. Ahmed A, Sanam K, Bhatia V, Bajaj N, Gaba S, Morgan C, Fonarow GC, **Butler J**, Deedwania P. Renin-Angiotensin System Inhibition and Lower 30-Day All-Cause Readmission in Hospitalized Medicare Beneficiaries with Heart Failure and Reduced Ejection Fraction. *Am J Med*. 2016 Jun 2. pii: S0002-9343(16)30541-
339. Kalogeropoulos AP, Fonarow GC, Georgiopoulou V, Burkman G, Siwamogsatham S, Patel A, Li S, Papadimitriou L, **Butler J**. Heart Failure with Recovered Versus Preserved Ejection Fraction in Outpatients: Characteristics and Outcomes. *JAMA Cardiol*. 2016 Jul 6. doi: 10.1001/jamacardio.2016.132
340. Adams KF, **Butler J**, Patterson JH, Gattis Stough W, Bauman JL, van Veldhuisen DJ, Schwartz TA, Sabbah HN, Mackowiak JI, Ventura HO, Ghali JK. Dose Response

- Characterization of the Association of Serum Digoxin Concentration with Mortality Outcomes in the Digitalis Investigation Group Trial. *Eur J Heart Fail.* 2016 Aug;18(8):1072-81
341. Greene SJ, Hernandez AF, Sun JL, Metra M, **Butler J**, Ambrosy AA, Ezekowitz JA, Starling RC, Teerlink JR, Schulte PJ, Voors AA, Amstrong PW, O'Connor CM, Mentz RJ. Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and Endpoints: Insights from the ASCEND-HF Trial. *Circ Heart Fail.* 2016 Sep;9(9). pii: e002986.
 342. Triposkiadis F, Pieske B, **Butler J**, Parissis J, Giamouzis G, Skoularigis J, Brutsaert D, Boudoulas H. Global Left Atrial Dysfunction in Heart Failure. *Eur J Heart Fail.* 2016;18(11):1307-1320
 343. Echouffo-Tcheugui JB, Xu H, DeVore AD, Schulte P, **Butler J**, Yancy CW, Bhatt D, Hernandez AF, Heidenreich AP, Fonarow GC. Temporal Trends and Factors Associated With Diabetes Mellitus Among Patients Hospitalized With Heart Failure - Findings From Get With The Guidelines-Heart Failure Registry. *Am Heart J.* 2016 Dec;182:9-20.
 344. **Butler J**, Hernandez AF, Anstrom KJ, Kalogeropoulos A, Redfield MM, Konstam MA, Tang WH, Felker GM, Shah MR, Braunwald E. Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. *JACC Heart Fail.* 2016 Jul 30.
 345. Braun LT, Grady KL, Kutner JS, Adler E, Berlinger N, Boss R, **Butler J**, Enguidanos S, Friebert S, Gardner TJ, Higgins P, Holloway R, Konig M, Meier D, Morrissey MB, Quest TE, Wiegand DL, Coombs-Lee B, Fitchett G, Gupta C, Roach WH Jr. Palliative Care and Cardiovascular Disease and Stroke: A Policy Statement From the American Heart Association/American Stroke Association/American Heart Association Advocacy Coordinating Committee. *Circulation.* 2016; 8
 346. Moin DS, Sackheim J, Hamo CE, **Butler J**. Cardiac Myosin Activators in Systolic Heart Failure: More Friend than Foe? *Curr Cardiol Rep* (2016) 18: 100. doi:10.1007/s11886-016-0778-x
 347. Vaduganathan M, **Butler J**, Gheorghiade M. Transforming Drug Development in Heart Failure. Navigating the Regulatory Crossroads. *Circ Heart Fail.* 2016 Oct;9(10). pii: e003192.
 348. Patel RB, Vaduganathan M, Shah SJ, Butler J. Atrial Fibrillation in Heart Failure with Preserved Ejection Fraction: Insights into Mechanisms and Therapeutics. *Pharmacol Ther.* 2016 Oct 20. pii: S0163-7258(16)30198-X.
 349. Arundel C, Lam PH, Khosla R, Blackman MR, Fonarow GC, Morgan C, Zeng Q, Fletcher RD, Butler J, Wu WC, Deedwania P, Love TE, White M10, Aronow WS, Anker SD, Allman RM, Ahmed A. Association of 30-Day All-Cause Readmission with Long-Term Outcomes in Hospitalized Older Medicare Beneficiaries with Heart Failure *Am J Med.* 2016 Nov;129(11):1178-1184. doi: 10.1016/j.amjmed.2016.06.018. Epub 2016 Jul 9.
 350. Angelidis G, Giamouzis G, Karayannis G, **Butler J**, Tsougos I; Valotassiou V, Giannakoulas G, Dimakopoulos N, Xanthopoulos A, Skoularigis J, Triposkiadis F, Georgoulas P. SPECT and PET in Ischemic Heart Failure. *Heart Fail Rev.* 2017 Feb 2 (epub ahead of print)
 351. Greene SJ, Fonarow GC, Solomon SD, Subacius HP, Ambrosy AP, Vaduganathan M, Maggioni AP, Böhm M, Lewis EF, Zannad F; **Butler J**, Gheorghiade M, for the ASTRONAUT Investigators and Coordinators. Influence of Atrial Fibrillation on Post-discharge Natriuretic Peptide Trajectory and Clinical Outcomes Among Patients Hospitalized for Heart Failure: Insights from the ASTRONAUT Trial Running head: Atrial fibrillation and natriuretic peptide trajectory. *Eur J Heart Fail.* 2016 Oct 17. doi: 10.1002/ejhf.674.
 352. **Butler J**, Konstam MA. Dilemmas with Race and Heart Failure Treatment. *Circ Heart Fail.* 2016 Oct;9(10). pii: e003384.

353. **Butler J**, Hamo CE, Udelson JE, Pitt B, Yancy C, Shah SJ, Desvigne-Nickens P, Bernstein HS, Clark RL, Depre C, Dinh W, Hamer A, Kay-Mugford P, Kramer F, Lefkowitz M, Lewis K, Maya J, Maybaum S, Patel MJ, Pollack PS, Roessig L, Rotman S, Salsali A, Sims JJ, Senni M, Rosano G, Dunnmon P, Stockbridge N, Anker SD, Zile MR, Gheorghiade M. Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. *Circ Heart Fail*. 2016 Nov;9(11). pii: e003358.
354. Medamana J, Clark RA, **Butler J**. Platelet-Derived Growth Factor in Heart Failure. *Handb Exp Pharmacol*. 2016 Oct 8.
355. Sarwar CM, Papadimitriou L, Pitt B, Piña I, Zannad F, Anker SD, Gheorghiade M, **Butler J**. Hyperkalemia in Heart Failure. *J Am Coll Cardiol*. 2016 Oct 4;68(14):1575-89. doi: 10.1016/j.jacc.2016.06.060. Review.
356. Kitai T, Grodin JL, Mentz RJ, Hernandez AF, **Butler J**, Metra M, McMurray JJ, Armstrong PW, Starling RC, O'Connor CM, Swedberg K, Tang WWH. Insufficient Reduction in Heart Rate During Hospitalization Despite Beta-blocker Treatment in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. *Eur J Heart Fail*. 2016 Sep 16. doi: 10.1002/ejhf.629.
357. Voors AA, Düngen HD, Senni M, Nodari S, Agostoni P, Ponikowski P, Bax JJ, **Butler J**, Kim RJ, Dorhout B, Dinh W, Gheorghiade M. Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients with Chronic Heart Failure. *J Clin Pharmacol*. 2016 Sep 14. doi: 10.1002/jcph.828.
358. Greene SJ, Hernandez AF, Sun JL, Metra M, **Butler J**, Ambrosy AP, Ezekowitz JA, Starling RC, Teerlink JR, Schulte PJ, Voors AA, Armstrong PW, O'Connor CM, Mentz RJ. Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). *Circ Heart Fail*. 2016 Sep;9(9). pii: e002986. doi: 10.1161/CIRCHEARTFAILURE.116.002986.
359. Triposkiadis F, Parissis J, Giamouzis G, **Butler J**, Starling RC, Boudoulas H, Skoularigis J, Filippatos G. Reframing the Association and Significance of Comorbidities in Heart Failure. *Eur J Heart Fail*. 2016 Jul;18(7):744-58.
360. Ferreira JP, Girerd N, Pellicori P, Duarte K, Girerd S, Pfeffer MA, McMurray JJ, Pitt B, Dickstein K, Jacobs L, Staessen JA, **Butler J**, Latini R, Masson S, Mebazaa A, Rocca HP, Delles C, Heymans S, Sattar N, Jukema JW, Cleland JG, Zannad F, Rossignol P; Heart 'OMics' in AGEing (HOMAGE) initiative and the High-Risk Myocardial Infarction database initiative. Renal function estimation and Cockcroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart 'OMics' in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. *BMC Med*. 2016 Nov 10;14(1):181.
361. Georgiopoulou V, Kalogeropoulos AP, Chowdhury R, Binongo J, Smith AL, Bibbins-Domingo K, Rodondi N, Simonsick E, Harris T, Newman AB, Kritchevsky SB, **Butler J**, for the Health ABC Study. Exercise Capacity, Mortality, and Risk for Heart Failure in Older Adults: The Health, Aging, and Body Composition Study. *Am J Prev Med*. 2016 Nov 14:369. Lam PH, Dooley DJ, Inampudi C, Arundel C, Fonarow GC, **Butler J**, Wu WC, Blackman MR, Anker MS, Deedwania P, White M, Prabhu SD, Morgan CJ, Love TE, Aronow WS, Allman RM, Ahmed A. Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone. *Int J Cardiol*. 2016 Nov 4. pii: S0167-5273(16)33408-8.
370. Brown D, Perry J, Allen M, Sabbah H, Stauffer B, Shaikh S, Cleland J, Colucci W, **Butler J**, Voors A, Anker S, Pitt B, Pieske B, Filippatos G, Greene S, Gheorghiade M. Mitochondrial Function as a Therapeutic Target in Heart Failure. *Nat Rev Cardiol*. 2016 Dec 22. doi: 10.1038/nrcardio.2016.203.

371. Boudoulas KD, Triposkiadis F, Parissis J, **Butler J**, Boudoulas H. The Cardio-Renal Interrelationship. *Prog Cardiovasc Dis*. 2016 Dec 16. pii: S0033-0620(16)30140-2. doi: 10.1016/j.pcad.2016.12.003. [Epub ahead of print]
372. Sharma P, Rehman M, Bloom M, **Butler J**. Biomarkers and Cancer Therapy Related Cardiac Dysfunction. In Press, *Current Cardiovascular Risk Reports*
373. Vaduganathan M, Samman-Tahhan A, Patel RB, Kelkar A, Papadimitriou L, Georgiopoulou VV, Greene SJ, Kalogeropoulos AP, Peterson, EP, Fonarow GC, Gheorghiade M, **Butler J**, Association Between Funding Sources and the Scope and Outcomes of Cardiovascular Clinical Trials: A Systematic Review. *Int J Cardiol*. 2016 Dec 22.
374. Arundel C, Lam PH, Khosla R, Blackman MR, Fonarow GC, Morgan C, Zeng Q, Fletcher RD, **Butler J**, Wu WC, Deedwania P, Love TE, White M, Aronow WS, Anker SD, Allman RM, Ahmed A. Association of 30-Day All-Cause Readmission with Long-Term Outcomes in Hospitalized Older Medicare Beneficiaries with Heart Failure. *Am J Med*. 2016 Nov;129(11):1178-1184
375. Xanthopoulos A, Giamouzis G, Tryposkiadis K, Paraskevopoulou E, Paraskevopoulou P, Karagiannis G, Patsilinos S, Parissis J, Farmakis D, **Butler J**, Skoularigis J, Triposkiadis F. A simple score for early risk stratification in acute heart failure. *Int J Cardiol*. 2017 Mar 1;230:248-254.
376. **Butler J**, Epstein SE, Greene SJ, Quyyumi AA, Sikora S, Kim RJ, Anderson AS, Wilcox JE, Tankovich NI, Lipinski MJ, Margulies KB, Cole RT, Skopicki HA, Gheorghiade M. Intravenous Allogeneic Mesenchymal Stem Cells for Non-ischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-a Randomized Trial. *Circ Res*. 2016: [Epub ahead of print]
377. Vaduganathan M, Patel RV, Michel A, Shah SJ, Senni M, Papa Giovanni AO, Gheorghiade M, **Butler J**. Mode of Death in Heart Failure with Preserved Ejection Fraction: A Systematic Review. In Press, *Journal of the American College of Cardiology*, 2016
378. Butts B, **Butler J**, Dunbar SB, Corwin E, Gary RA. ASC Methylation and Interleukin-1 β Are Associated with Aerobic Capacity in Heart Failure. *Med Sci Sports Exerc*. 2017 Jan 9.
379. Dianati-Maleki N, **Butler J**. Diabetes Mellitus in Patients With Heart Failure: Bad for All, Worse for Some. *JACC Heart Fail*. 2017 Jan;5(1):25-27. doi: 10.1016/j.jchf.2016.11.002.
380. Lewis KS, **Butler J**, Bauersachs J, Sandner P. The Three-Decade Long Journey in Heart Failure Drug Development. *Handb Exp Pharmacol*. 2016 Dec 20. [Epub ahead of print]
381. Pandey A, Khan H, Newman AB, Lakatta EG, Forman DE, **Butler J**, Berry JD. Arterial Stiffness and Risk of Overall Heart Failure, Heart Failure With Preserved Ejection Fraction, and Heart Failure With Reduced Ejection Fraction: The Health ABC Study (Health, Aging, and Body Composition). *Hypertension*. 2016 Dec 19. pii: HYPERTENSIONAHA.116.08327.
382. Fermann GJ, Levy PM, Pang P, **Butler J**, Ayaz SI, Char D, Dunn P, Jenkins CA, Kampe C, Khan Y, Kumar VA, Lindenfeld J, Liu D, Miller K, Peacock WF, Rizk S, Robichaux C, Rothman RL, Schrock J, Singer A, Sterling SA, Storrow AB, Walsh C, Wilburn J, Collins SB. Design and Rationale of a Randomized Trial of a Care Transition Strategy in Patients with Acute Heart Failure Discharged from the Emergency Department: GUIDED-HF. *Circ Heart Fail*. 2017 Feb;10(2)
383. Papadimitriou L, **Butler J**, Hamo C. Heart failure guidelines: What's new? *Trends Cardiovasc Med*. 2017 Jan 11.
384. Khan MS, Fatima K, Riaz IB, **Butler J**, Manning WJ, Khosa F. The 20 most-cited articles in echocardiography literature. A Bibliometric Analysis discussed by the six authors. *Eur Heart J*. 2017 Jan 7;38(2):74-78
385. **Butler J**. Cardiovascular Safety of Medications for Type 2 Diabetes Mellitus. *J Fam Pract*. 2017 Apr;66(4 Suppl):S16-S21

386. Grodin JL, **Butler J**, Metra Felker GM, Voors AA, McMurray JJ, PW Armstrong, Hernandez AF, O'Connor C, Starling RC, Tang TW. Circulating Cardiac Troponin I Levels Measured by an "Ultrasensitive" Assay in Acute Decompensated Heart Failure: Insights from the ASCEND-HF Trial. Accepted in Am Journal of Med
387. Jacobs L, Efremov L, Ferreira JP, Thijs L, Yang YW, Zhang ZU, Latini R, Masson S, Agabiti N, Sever P, Delle C, Sattar N, **Butler J**, Cleland JGF, Kuznetsova T, Staessen JA, MD, Zannad F. On behalf of the Heart 'omics' in AGEing (HOMAGE) investigators. Risk for incident heart failure: a subject-level meta-analysis from the Heart 'omics' in AGEing study. *J Am Heart Assoc.* 2017
388. Giamouzis G, **Butler J**. Glycaemic control in heart failure: a PARADIGM shift for patients with concomitant diabetes? *Lancet Diabetes Endocrinol.* 2017 Mar 17
389. Kramer F, Sabbah HN, Januzzi JJ, Zannad F, Peter van Tintelen J, Schelbert EB, Kim RJ, Milting H, Vonk R, Neudeck B, Clark R, Witte K, Dinh W, Pieske B, **Butler J**, Gheorghiade M. Redefining the role of biomarkers in heart failure trials: expert consensus document. *Heart Fail Rev.* 2017 Mar 23. doi: 10.1007/s10741-017-9608-5.
390. **Butler J**, Hamo CE, Udelson JE, O'Connor C, Sabbah HN, Metra M, Shah SJ, Kitzman DW, Teerlink JR, Bernstein HS, Brooks G, Depre C, DeSouza MM, Dinh W, Donovan M, Frische-Danielson R, Frost RJ, Garza D, Gohring UM, Hellawell J, Hsia J, Ishihara S, Kay-Mugford P, Koglin J, Kozinn M, Larson CJ, Mayo M, Gan LM, Mugnier P, Mushonga S, Roessig L, Russo C, Salsali A, Satler C, Shi V, Ticho B, van der Laan M, Yancy C, Stockbridge N, Gheorghiade M. Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations. *Circ Heart Fail.* 2017 Apr;10(4).
391. Pieske B, Maggioni AP, Lam CS, Pieske-Kraigher E, Filippatos G, **Butler J**, Ponikowski P, Shah SJ, Solomon SD, Scalise AV, Mueller K, Roessig L, Gheorghiade M. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOLuble guanylate Cyclase stimulator in heart failure patientS with PRESERVED EF (SOCRATES-PRESERVED) study. *Eur Heart J.* 2017 Mar 22.
392. Sarwar CM, Bhagat AA, Anker SD, **Butler J**. Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders. *Handb Exp Pharmacol.* 2017 Apr 6. doi: 10.1007/164_2017_25. [Epub ahead of print]
393. Greene SJ, Hernandez AF, Dunning A, Ambrosy AP, Armstrong PW, **Butler J**, Cerbin LP, Coles A, Ezekowitz JA, Metra M, Starling RC, Teerlink JR, Voors AA, O'Connor CM, Mentz RJ. Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: Insights from the ASCEND-HF Trial. Accepted in the Journal of the American College of Cardiology
394. Ambrosy A, Hernandez A, **Butler J**, Felker GM, DeVore A, Kelly J, Greene S. The Clinical Course of Congestion during Hospitalization for Acute Heart Failure Stratified by Ejection Fraction – Findings from The Heart Failure Network. *Am J Cardiol.* 2017 Jul 1;120(1):98-105.
395. McCabe N, **Butler J**, Dunbar SB, Higgins M, Reilly C. Six-Minute Walk Distance Predicts Re-hospitalization and Emergency Visits After Heart Failure Hospitalization. *Heart Lung.* 2017 May 24. pii: S0147-9563(17)30122-X. doi: 10.1016/j.hrtlng.2017.04.001.
396. Kalogeropoulos AP, Samman-Tahhan A, Hedley JF, McCue AM, Bjork JB, Markham DW, Bhatt KN, Georgiopoulou VV, Smith AL, **Butler J**. Progression to Stage D Heart Failure Among Outpatients With Stage C Heart Failure and Reduced Ejection Fraction. Accepted in *JACC: Heart Failure*
397. Hamo CE, **Butler J**, Gheorghiade M, Chioncel O. The bumpy road to drug development for acute heart failure. *European Heart Journal of Cardiology* (2016) 18(Supplement G), G19–G32
398. Papadimitriou L, Hamo CE, **Butler J**. Heart Failure Guidelines on Pharmacotherapy. *Handb Exp Pharmacol.* 2017 Apr 28. doi: 10.1007/164_2017_24. [Epub ahead of print]

399. Butt AA, Yan P, Chew KW, Currier J, Corey K, Chung RT, Shuaib A, Abou-Samra AB, **Butler J**. Risk of Acute Myocardial Infarction Among HCV+ and HCV- Men at Various Lipid Levels: Results from ERCHIVES. *Clin Infect Dis*. 2017 Apr 24. doi: 10.1093/cid/cix359. [Epub ahead of print]
400. Pang PS, **Butler J**, Collins SP, Cotter G, Davison BA, Ezekowitz JA, Filippatos G, Levy PD, Metra M, Ponikowski P, Teerlink JR, Voors AA, Bharucha D, Goin K, Soergel DG, Felker GM. Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). *Eur Heart J*. 2017 Apr 27. doi: 10.1093/eurheartj/ehx196.
401. Yancy CW, Jessup M, Bozkurt B, **Butler J**, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *Circulation*. 2017 Apr 28. pii: CIR.0000000000000509.
402. DeVore AD, Thomas L, Albert NM, **Butler J**, Hernandez AF, Patterson H, Spertus JA, Williams FB, Turner SJ, Chan WW, Duffy CI, McCague K, Mi X, Fonarow GC. Change the Management of Patients with Heart Failure: Rationale and Design of the CHAMP-HF Registry. *Am Heart J*. 2017 Jul;189:177-183.
403. Schelbert EB, Sabbah HN, **Butler J**, Gheorghiade M. Employing Extracellular Volume Cardiovascular Magnetic Resonance Measures of Myocardial Fibrosis to Foster Novel Therapeutics. *Circ Cardiovasc Imaging*. 2017 Jun;10(6)
404. Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, Tang WHW, LaRue SJ, Redfield MM, Semigran MJ, Givertz MM, Van Buren P, Whellan D, Anstrom KJ, Shah MR, Desvigne-Nickens P, **Butler J**, Braunwald E; NHLBI Heart Failure Clinical Research Network. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. *JAMA*. 2017 May 16;317(19):1958-1966. doi: 10.1001/jama.2017.5427.
405. Sheriff HM, Thogaripally MR, Panjra G, Arundel C, Zeng Q, Fonarow GC, **Butler J**, Fletcher RD, Morgan C, Blackman MR, Deedwania P, Love TE, Aronow WS, Anker SD, Allman RM, Ahmed A. Digoxin and 30-Day All-Cause Readmission in Long-Term Care Residents Hospitalized for Heart Failure. *J Am Med Dir Assoc*. 2017 May 11.
406. Rafique Z, Weir MR, Onuigbo M, Pitt B, Lafayette R, **Butler J**, Lopes M, Farnum C, Peacock WF. Expert Panel Recommendations for the Identification and Management of Hyperkalemia and Role of Patiromer in Patients with Chronic Kidney Disease and Heart Failure. *J Manag Care Spec Pharm*. 2017 Apr
407. Ambrosy AP, Bhatt AS, Gallup D, Anstrom KJ, **Butler J**, DeVore AD, Felker GM, Fudim M, Greene SJ, Hernandez AF, Kelly JP, Samsky MD, Mentz RJ. Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network). *Am J Cardiol*. 2017 Apr 12.
408. Senni M, Greene SJ, **Butler J**, Fonarow GC, Gheorghiade M. Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle? *Can J Cardiol*. 2017 Jun;33(6):768-776.
409. Vaduganathan M, Patel RB, **Butler J**, Metra M. Integrating electronic health records into the study of heart failure: promises and pitfalls. *Eur J Heart Fail*. 2017 May 25. doi: 10.1002/ejhf.878.
410. Ambrosy AP, Butler J, Gheorghiade M. Clinical trials in acute heart failure: beginning of the end or end of the beginning? *Eur J Heart Fail*. 2017 Jun 28

411. Filippatos G, Maggioni AP, Lam CSP, Pieske-Kraigher E, **Butler J**, Spertus J, Ponikowski P, Shah SJ, Solomon SD, Scalise AV, Mueller K, Roessig L, Bamber L, Gheorghiade M, Pieske B. Patient-reported outcomes in the SOLuble guanylate Cyclase stimulatO in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. *Eur J Heart Fail.* 2017 Jun;19(6):782-791.
412. Hammadah M, Kalogeropoulos AP, Georgiopoulou VV, Weber M, Wu Y, Hazen SL, **Butler J**, Tang W. High-density lipoprotein-associated paraoxonase-1 activity for prediction of adverse outcomes in outpatients with chronic heart failure. *Eur J Heart Fail.* 2017 Jun;19(6):748-755
413. **Butler J**, Anstrom KJ, Felker GM, Givertz MM, Kalogeropoulos AP, Konstam MA, Mann DL, Margulies KB, McNulty SE, Mentz RJ; Redfield MM, Tang WHW, Whellan DJ, Shah M, Desvigne-Nickens P, Hernandez AF, and Braunwald E, on behalf of the National Heart Lung and Blood Institute Heart Failure Clinical Research Network. High Dose Spironolactone in Acute Heart Failure. The ATHENA-HF Randomized Clinical Trial. Accepted in *JAMA Cardiology*
414. Goyfman M, Zamudio P, Jang K, Chee J, Miranda C, **Butler J**, Wadhwa N. Combined aquaretic and diuretic therapy in acute heart failure. *Int J Nephrol Renovasc Dis.* 2017 Jun 6;10:129-134.
415. Schelbert EB, Fridman Y, Wong TC, Daya HA, Piehler KA, Kadakkal A, Miller CA, Ugander M, Maanja M, Kellman P, Shah DH, Abebe KZ, Simon MA, Quarta G, Senni M, **Butler J**, Diez J, Redfield MM, Gheorghiade M. Myocardial fibrosis may precede heart 1 failure with preserved ejection fraction and associate with baseline disease severity and subsequent outcome. *JAMA Cardiol.* 2017 Aug 2. doi: 10.1001/jamacardio.2017.2511.
416. Januzzi L, **Butler J**, Jarolim P, Sattar N, Vijapurkar U, Desai M, Davies MJ. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes. *J Am Coll Cardiol.* 2017 Jun 9. pii: S0735-1097
417. Khosa F, Khan MS, Bhulani N, Miao TL, **Butler J**, Nasir K, Raggi P. Leadership in cardiology. *Eur Heart J.* 2017 Aug 7;38(30):2323.
418. Khan MS, Fonarow GC, Ahmed A, Greene SJ, Vaduganathan M, Khan H, Marti C, Gheorghiade M, **Butler J**. Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis. *Circ Heart Fail.* 2017 Aug;10(8).
419. Packer M, Anker SD, **Butler J**, Filippatos G, Zannad F. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action. *JAMA Cardiol.* 2017 Aug 2. [Epub ahead of print]
420. Sarwar CMS, Vaduganathan M, **Butler J**. Impact of Site Selection and Study Conduct on Outcomes in Global Clinical Trials. *Curr Heart Fail Rep.* 2017 Aug;14(4):203-209.
421. Hamo CE, Gheorghiade M, **Butler J**. Novel Endpoints for Heart Failure Clinical Trials. *Curr Heart Fail Rep.* 2017 Aug;14(4):210-216.
422. Patel RB, Shah SJ, Fonarow GC, **Butler J**, Vaduganathan M. Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT. *Curr Heart Fail Rep.* 2017 Aug;14(4):217-222.-216.
423. Collins S, Levy P, Michelle, Khan Y, Israel T, Grieser T, Butler J, Fonarow G, Alikhaani J, Sarno E, Yancy C. Incorporating Patient and Caregiver Experiences into Clinical Trial Design. *JAMA Cardiol.* 2017 Oct 11. doi: 10.1001/jamacardio.2017.3606.
424. Forman DE, Santanasto AJ, Boudreau R, Harris T, Kanaya AM, Satterfield S, Simonsick EM, **Butler J**, Kizer KR, Newman AB. The Impact of Incident Heart Failure on Body Composition Over Time in the Health ABC Study Population. Accepted in *Circulation: Heart Failure*
425. Greene SJ, **Butler J**, Fonarow GC, Subacius HP, Ambrosy AP, Vaduganathan M, Triggiani M, Solomon SD, Lewis EF, Maggioni AP, Böhm M, Chioncel O, Nodari S, Senni

- M, Zannad F, Gheorghiade M, for the ASTRONAUT Investigators and Coordinators . Pre-discharge and Early Post-Discharge Troponin Elevation Among Patients Hospitalized for Heart Failure with Reduced Ejection Fraction: Insights from the ASTRONAUT Trial. *Eur J Heart Fail.* 2018 Feb;20(2):281-291.
426. Bloom MW, Greenberg B, Jaarsma T, Januzzi JL, Lam SPM, Maggioni AP, Trochu9 JN, **Butler J**. Heart failure with reduced ejection fraction. *Nat Rev Dis Primers.* 2017 Aug 24;3:17058
427. **Butler J**, Hamo CE, Filippatos G, Pocock SJ, Bernstein RA, Brueckmann M, Cheung AK, George JT, Green JB, Januzzi JL, Kaul S, Lam CSP, Lip GYH, Marx N, McCullough PA, Mehta CR, Ponikowski P, Rosenstock J, Sattar N, Salsali A, Scirica BM, Shah SJ, Tsutsui H, Verma S, Wanner C, Woerle HJ, Zannad F, Anker SD; EMPEROR Trials Program. The Potential Role and Rationale for Treatment of Heart Failure with SGLT2 Inhibitors. *European Journal of Heart Failure.* *Eur J Heart Fail.* 2017 Nov;19(11):1390-1400.
428. Cotter G, Davison BA, **Butler J**, Collins SP, Ezekowitz JA, Felker GM, Filippatos G, Levy FD, Metra M, Ponikowsk Pi, Teerlink JR, Voors AA, Bharucha D; Goin K; Soergel DG, Pang PS. Relationship between improvements in long term outcomes and baseline systolic blood pressure in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF. *Clin Res Cardiol.* 2017 Oct 6. doi: 10.1007/s00392-017-1168-0. [Epub ahead of print]
429. Lam PH, Dooley DJ Fonarow GC, **Butler J**, Bhatt DL, Filippatos GS, Deedwania P, Forman DE, White M, Fletcher RD, Arundel C, Blackman MR1, Adamopoulos C, Kanonidis IE, Aban IB, Patel K, Aronow WS, Allman RM, Anker SD, Pitt B, Ahmed A. Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial. *European Journal of Heart Failure* (2018) 20, 359–369
430. Yancy CW, Januzzi, JL, Allen LA, **Butler J**, Davis LS, Fonarow GC, Ibrahim NE, Jessup M, Lindenfeld J, Maddox TM, Motiwala SR, Patterson JH, Walsh MD, Wasserman A. 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 pivotal questions about heart failure with reduced ejection fraction. A Report of the American College of Cardiology Expert Consensus Decision Pathways Task Force. *J Am Coll Cardiol.* 2018 Jan 16;71(2):201-230.
431. Usman MS, Siddiqi TJ, Khan MS, Fatima K, **Butler J**, Manning WJ, Khosa F. A Scientific Analysis of the 100 Citation Classics of Valvular Heart Disease. *Am J Cardiol.* 2017 Oct 15;120(8):1440-1449.
432. Khan MS, Fonarow GC, Khan H, Greene SJ, Anker SD, Gheorghiade M, **Butler J**. Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis. *ESC Heart Fail.* 2017 Sep 4. doi: 10.1002/ehf2.12204.
433. Kalogeropoulos AP, **Butler J**. Heart rate in heart failure with preserved ejection fraction: target or marker? *Eur J Heart Fail.* 2017 Sep 11. doi: 10.1002/ejhf.92
434. **Butler J**, Stockbridge N, Gheorghiade M. Past, present, and future of acute heart failure clinical trials-a high-risk population in search of a strategy. *Eur J Heart Fail.* 2017 Sep 18. doi: 10.1002/ejhf.987. [Epub ahead of print]
435. Vaduganathan M, DeFilippis EM, Fonarow GC, **Butler J**, Mehra MR. Postmarketing Adverse Events Related to the CardioMEMS HF System. *JAMA Cardiol.* 2017 Nov 1;2(11):1277-1279.
436. Lam PH, Dooley DJ, Deedwania P, Singh SN, Bhatt DL, Morgan CJ, **Butler J**, Mohammed SF, Wu WC, Panjrath G, Zile MR, White M, Arundel C, Love TE, Blackman MR, Allman RM, Aronow WS, Anker SD, Fonarow GC, Ahmed A. Heart Rate and Outcomes in Hospitalized Patients With Heart Failure With Preserved Ejection Fraction. *J Am Coll Cardiol.* 2017 Oct 10;70(15):1861-1871. doi: 10.1016/j.jacc.2017.08.022.
437. Ferreira JP, Machu JL, Gierd N, Jaisser F, Thum T, **Butler J**, González A, Diez J, Heymans S, McDonald K, Gyöngyösi M, Firat H, Rossignol P, Pizard A, Zannad F.

- Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. *ESC Heart Fail* 2018 Feb;5(1):139-148.
438. Collins SP, Levy PD, Fermann GJ, Givertz MM, Martindale JM, Pang PS, Storrow AB, Diercks DD, Felker GM, Fonarow GC, Lanfear DJ, Lenihan DJ, Lindenfeld JM, Frank Peacock W, Sawyer DM, Teerlink JM, **Butler J**. What's Next for Acute Heart Failure Research? *Acad Emerg Med*. 2018 Jan;25(1):85-93
439. Fitchett D, **Butler J**, van de Borne P, Zinman B, Lachin JM, Wanner C, Woerle HJ, Hantel S, George JT, Johansen OE, Inzucchi SE; EMPA-REG OUTCOME® trial investigators. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. *Eur Heart J*. 2018 Feb 1;39(5):363-370.
440. Zhang Y, Zhang J, **Butler J**, Yang X, Xie P, Guo D, Wei T, Yu J, Wu Z, Gao Y, Han X, Zhang X, Wen S, Anker SD, Filippatos G, Fonarow GC, Gan T, Zhang R; China-HF investigators. Contemporary Epidemiology, Management, and Outcomes of Patients Hospitalized for Heart Failure in China: Results from the China Heart Failure (China-HF) Registry. *J Card Fail*. 2017 Dec;23(12):868-875.
441. **Butler J**, Vaduganathan M. Glucose-Lowering Therapies in Patients With Concomitant Diabetes Mellitus and Heart Failure: Finding the Sweet Spot. *JACC Heart Fail*. 2018 Jan;6(1):27-29
442. Armstrong PW, Roessig M, Patel M, Anstrom KJ, **Butler J**, Voors AA, Lam CSP, Ponikowski P, Temple T, Pieske B, Ezekowitz J, Hernandez AF, Koglin J, O'Connor C. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral sGC Stimulator Vericiguat - VerIciguaT GLObal Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA). *JACC Heart Fail*. 2018 Feb;6(2):96-104
443. **Butler J**, Anker SD. The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure? *Circulation*. 2017 Oct 17;136(16):1459-1461.
444. Cheema B, Ambrosy AP, Kaplan RM, Senni M, Fonarow GC, Chioncel O, **Butler J**, Gheorghiade M. Lessons learned in acute heart failure. *Eur J Heart Fail*. 2017 Oct 29. doi: 10.1002/ejhf.1042. [Epub ahead of print] Review.
445. Vaduganathan M, Nagarur A, Qamar A, Patel RB, Navar AM, Peterson ED, Bhatt DL, Fonarow GC, Yancy CW, **Butler J**. Availability and Use of Shared Data From Cardiometabolic Clinical Trials. *Circulation*. 2018 Feb 27;137(9):938-947
446. DeFilippis EM, **Butler J**, Vaduganathan M. Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction: A Window of Opportunity. *Circ Heart Fail*. 2017 Nov;10(11).
447. Vaduganathan M, Cheema B, Cleveland E, Sankar K, Subacius H, Fonarow GC, Solomon SD, Lewis EF, Greene SJ, Maggioni AP, Böhm M, Zannad F, **Butler J**, Gheorghiade M. Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial Brief. *Eur J Heart Fail*. 2017 Nov 16. doi: 10.1002/ejhf.973. [Epub ahead of print]
448. Lima FV, Koutrolou-Sotiropoulou P, Parikh PB, Avila C, **Butler J**, Stergiopoulos K. Pregnant women with heart disease: Placental characteristics and their association with fetal adverse events. *Acute Card Care*. 2016 Sep;18(3):56-64. Epub 2017 Nov 22
449. Pang PS, Collins SP, Gheorghiade M, **Butler J**. Acute Dyspnea and Decompensated Heart Failure. *Cardiol Clin*. 2018 Feb;36(1):63-72. doi: 10.1016/j.ccl.2017.09.003. Review.
450. Chioncel o, Collins SP, Greene SJ, Pang PS, Ambrosy AP, Antohi AL, Mthiah Vaduganathan M, **Butler J**, Gheorghiade M. Predictors of Post-discharge Mortality Among Patients Hospitalized for Acute Heart Failure. *Cardiac Failure Review (CFR) issue 3.2*, 2017

451. Bhatt A, Cooper L, Ambrosy A, Clare R, Coles A, Joyce E, Krishnamoorthy A, **Butler J**, Felker GM, Ezekowitz J, Armstrong P, Hernandez A, O'Connor C, Mentz Robert. The Interaction of Body Mass Index on The Association Between NT-proBNP and Post-Discharge Morbidity and Mortality in Patients with Acute Heart Failure: Findings from ASCEND-HF. *J Am Heart Assoc.* 2018;3;7(3).
452. Pandey A, Khera R, Park B, Haykowsky M, Borlaug BA, Lewis GD, Kitzman DW, **Butler J**, Berry JD. Relative Impairments in Hemodynamic Exercise Reserve Parameters in Heart Failure With Preserved Ejection Fraction A Study-Level Pooled Analysis. *JACC Heart Fail.* 2018 Feb;6(2):117-126.
453. Parikh PB, Novotny S, Jeremias A, **Butler J**, Yang J, Yin D, Gruberg L. Impact of chronic kidney disease on mortality in adults undergoing balloon aortic valvuloplasty. *Cardiovasc Revasc Med.* 2017 Oct 26 (Epub ahead of print)
454. Pang PS, Collins SP, Gheorghide M, **Butler J**: Acute Dyspnea and Decompensated Heart Failure. *Emergency Cardiology: From ED to CCU.* *Cardiol Clin.* 2018 Feb;36(1):63-72
455. Vijayakumar S, Vaduganathan M, **Butler J**. Exploring heart failure events in contemporary cardiovascular outcomes trials in type 2 diabetes mellitus. *Expert Rev Cardiovasc Ther.* 2018 Feb;16(2):123-131
456. Al Danaf J, **Butler J**, Yehya A. Updates on Device-Based Therapies for Patients with Heart Failure. *Curr Heart Fail Rep.* 2018 Apr;15(2):53-60
457. Singh P, Vijayakumar S, Kalogeropoulos A, **Butler J**. Multiple Avenues of Modulating the Nitric Oxide Pathway in Heart Failure Clinical Trials. *Curr Heart Fail Rep.* 2018 Apr;15(2):44-52
458. Dryer K, Gajjar M, Narang N, Lee M, Paul J, Shah A, Nathan S, Butler J, Davidson C, Fearon W, Shah S, and Blair JE. Coronary Microvascular Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction. *Am J Physiol Heart Circ Physiol.* 2018 Feb 9.
459. Radenovic S, Loncar G, Busjahn A, Apostolovic S, Zdravkovic M, Karlicic V, Veskovic J, Tahirovic E, **Butler J**, Dungen HD. Systemic Inflammation and Functional Capacity in Elderly Heart Failure Patients. *Clin Res Cardiol.* 2018 Apr;107(4):362-367. doi: 10.1007/s00392-017-1195-x. Epub 2018 Feb 2.
460. Tahhan AS, Vaduganathan M, Greene SJ, Okafor M, Kumar S, **Butler J**. Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment. *Curr Heart Fail Rep.* 2018 Feb;15(1):10-16. doi: 10.1007/s11897-018-0374-z.
461. Kiernan MS, Stevens SR, Tang WHW, **Butler J**, Anstrom KJ, Birati EY, Grodin JL, Gupta D, Margulies KB, LaRue S, Dávila-Román VG, Hernandez AF, De las Fuentes L: on behalf of the NHLBI Heart Failure Clinical Trials Network Investigators. Determinants of diuretic responsiveness and associated outcomes during acute heart failure hospitalization: An analysis from the NHLBI Heart Failure Network Clinical Trials. *J Card Fail.* 2018 Mar 1. pii: S1071-9164(18)30066-6. doi: 10.1016/j.cardfail.2018.02.002.
462. **Butler J**, Kalogeropoulos AP, Anstrom KJ, Hsue PY, Kim RJ, Scherzer R, Shah SJ, Shah SH, Velazquez EJ, Hernandez AF, Desvigne-Nickens P, Braunwald E. Diastolic Dysfunction in Individuals with Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Anti-Retroviral Therapy (CHART) Study *J Card Fail.* 2018 Apr;24(4):255-265. doi: 10.1016/j.cardfail.2018.02.001. Epub 2018 Mar 2
463. Ahmed A, Arundel C, Singh S, Morgan CJ, Faselis C, Deedwania P, **Butler J**, Aronow W, Yancy C. Systolic Blood Pressure and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. Accepted in *JAMA Cardiology*
464. Williams FB, Gregg CG, Mi X, Thoma Ls, Hernandez A, DeVore A, **Butler J**, Patterson H., Sharma P, Mccague K, Duffy C, Albert N. Health Status Disparities by Gender,

Race/Ethnicity, and Socioeconomic Status in Outpatients with Heart Failure. Accepted in JACC HF

465. Clark D, Cain LR, Blaha MJ, DeFilippis AP, Mentz RJ, Kamimura D, White WB, KR Butler, Robertson RM, Bhatnagar A, **Butler J**, Correa A, Benjamin EJ, Hall ME. Cigarette Smoking and Subclinical Peripheral Arterial Disease in African Americans of the Jackson Heart Study. *Clinical Research in Cardiology*
466. Hall ME, Benjamin EJ, Cain L, White W, Blaha M, Defilippis A, Fox E, Rodriguez C, Keith R, **Butler J**, Robertson RM, Bhatnagar A, Correa AD, Winniford MD, Mentz R. Cigarette smoking and incident heart failure: Insights from the Jackson Heart Study. Accepted in *Circulation*
467. Vaduganathan M, Samman Tahhan A, Greene SJ, Okafor M, Kumar S, **Butler J**. Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years. *Eur J Heart Fail*. 2018 Jun;20(6):1068-1071.
468. Gary R, Dunbar SB, Higgins M, Butts B, Corwin E, Hepburn K, **Butler J**, Miller AH. An Intervention to Improve Physical Function and Caregiver Perceptions in Family Caregivers of Persons With Heart Failure. *J Appl Gerontol*. 2018 Jan 1:733464817746757.
469. Samman Tahhan A, Vaduganathan M, Greene SJ, Okafor M, Kumar S, **Butler J**. Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment. *Curr Heart Fail Rep*. 2018 Feb;15(1):10-16
470. Chioncel O, Collins SP, Greene SJ, Pang PS, Ambrosy AP, Antohi EL, Vaduganathan M, **Butler J**, Gheorghiade M. Predictors of Post-discharge Mortality Among Patients Hospitalized for Acute Heart Failure. *Card Fail Rev*. 2017 Nov;3(2):122-129.
471. Radenovic S, Loncar G, Busjahn A, Apostolovic S, Zdravkovic M, Karlicic V, Veskovc J, Tahirovic E, **Butler J**, Düngen HD. Systemic inflammation and functional capacity in elderly heart failure patients. *Clin Res Cardiol*. 2018 Apr;107(4):362-367
472. Srivastava P, **Butler J**, Shroyer AL, Lacey M, Parikh PB. Impact of Depressive Disorder on Access and Quality of Care in Veterans With Prevalent Cardiovascular Disease. *Am J Cardiol*. 2018 Jun 15;121(12):1629-1633.
473. Greene SJ, Vaduganathan M, Khan MS, Bakris GL, Weir MR, Seltzer JH, Sattar N, McGuire DK, Januzzi JL, Stockbridge N, **Butler J**. Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. *J Am Coll Cardiol*. 2018 Mar 27;71(12):1379-1390.
474. Cerbin LP, Ambrosy AP, Greene SJ, Armstrong PW, **Butler J**, Coles A, DeVore AD, Ezekowitz JA, Hernandez AF, Metra M, Starling RC, Tang W, Teerlink JR, Voors AA, Wu A, O'Connor CM, Mentz RJ. Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial. *JACC Heart Fail*. 2018 Apr;6(4):298-307. doi: 10.1016/j.jchf.2018.01.018. Epub 2018 Mar 7.
475. Georgiopoulou VV, Velayati A, Burkman G, Li S, Farooq K, Samman-Tahhan A, Papadimitriou L, **Butler J**, Kalogeropoulos AP. Comorbidities, Sociodemographic Factors, and Hospitalizations in Outpatients With Heart Failure and Preserved Ejection Fraction. *Am J Cardiol*. 2018 May 15;121(10):1207-1213. doi: 10.1016/j.amjcard.2018.01.040. Epub 2018 Feb 12.
476. Correale M, Monaco I, Brunetti ND, Di Biase M, Metra M, Nodari S, **Butler J**, Gheorghiade M; Redefining biomarkers in heart failure. Master Program Students on Drug Development for Heart Failure. *Heart Fail Rev*. 2018 Mar;23(2):237-253. doi: 10.1007/s10741-018-9683-2. Review.
477. Vijayakumar S, Vaduganathan M, **Butler J**. Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions. *Circulation*. 2018 Mar 6;137(10):1060-1073
478. **Butler J**, Kalogeropoulos AP, Anstrom KJ, Hsue PY, Kim RJ, Scherzer R, Shah SJ, Shah SH, Velazquez EJ, Hernandez AF, Desvigne-Nickens P, Braunwald E. Diastolic

Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study. *J Card Fail.* 2018 Apr;24(4):255-265. doi: 10.1016/j.cardfail.2018.02.001. Epub 2018 Mar 2

479. Kiernan MS, Stevens SR, Tang WHW, Butler J, Anstrom KJ, Birati EY, Grodin JL, Gupta D, Margulies KB, LaRue S, Dávila-Román VG, Hernandez AF, de Las Fuentes L; NHLBI Heart Failure Clinical Trials Network Investigators. Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials. *J Card Fail.* 2018 Jul;24(7):428-438. doi: 10.1016/j.cardfail.2018.02.002.
480. Singh P, Vijayakumar S, Kalogeropoulos A, **Butler J**. Multiple Avenues of Modulating the Nitric Oxide Pathway in Heart Failure Clinical Trials. *Curr Heart Fail Rep.* 2018 Apr;15(2):44-52. doi: 10.1007/s11897-018-0383-y. Review.
481. Al Danaf J, **Butler J**, Yehya A. Updates on Device-Based Therapies for Patients with Heart Failure. *Curr Heart Fail Rep.* 2018 Apr;15(2):53-60. doi: 10.1007/s11897-018-0384-x. Review.
482. Tsimploulis A, Lam PH, Arundel C, Singh SN, Morgan CJ, Faselis C, Deedwania P, **Butler J**, Aronow WS, Yancy CW, Fonarow GC, Ahmed A. Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. *JAMA Cardiol.* 2018 Apr 1;3(4):288-297. doi: 10.1001/jamacardio.2017.5365.
483. Bhatt AS, Cooper LB, Ambrosy AP, Clare RM, Coles A, Joyce E, Krishnamoorthy A, **Butler J**, Felker GM, Ezekowitz JA, Armstrong PW, Hernandez AF, O'Connor CM, Mentz RJ. Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). *J Am Heart Assoc.* 2018 Feb 3;7(3). pii: e006740. doi: 10.1161/JAHA.117.006740.
484. Dryer K, Gajjar M, Narang N, Lee M, Paul J, Shah AP, Nathan S, **Butler J**, Davidson CJ, Fearon WF, Shah SJ, Blair JEA. Coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. *Am J Physiol Heart Circ Physiol.* 2018 May 1;314(5):H1033-H1042.
485. Pandey A, Khera R, Park B, Haykowsky M, Borlaug BA, Lewis GD, Kitzman DW, **Butler J**, Berry JD. Relative Impairments in Hemodynamic Exercise Reserve Parameters in Heart Failure With Preserved Ejection Fraction: A Study-Level Pooled Analysis. *JACC Heart Fail.* 2018 Feb;6(2):117-126. doi: 10.1016/j.jchf.2017.10.014.
486. Huston JH, Ferre R, Pang PS, Chioncel O, **Butler J**, Collins S. Optimal Endpoints of Acute Heart Failure Therapy. *Am J Ther.* 2018 Jul/Aug;25(4):e465-e474.
487. Gracia E, Singh P, Collins S, Chioncel O, Pang P, **Butler J**. The Vulnerable Phase of Heart Failure. *Am J Ther.* 2018 Jul/Aug;25(4):e456-e464
488. Mahmood SS, Patel RB, **Butler J**, Vaduganathan M. Epirubicin and long-term heart failure risk in breast cancer survivors. *Eur J Heart Fail.* 2018 Oct;20(10):1454-1456
489. Dungen HD, Petroni R, Correale M, Coiro S, Monitillo F, Triggiani M, Leone M, Antohi EL, Ishihara S, Sarwar CMS, Sabbah HN, Memo M, Metra M, **Butler J**, Nodari S, Gheorghiade M. A new educational program in heart failure drug development: the Brescia international master program. *J Cardiovasc Med (Hagerstown).* 2018 Aug;19(8):411-421
490. Patel RB, Vaduganathan M, Greene SJ, **Butler J**. Nomenclature in heart failure: a call for objective, reproducible, and biologically-driven terminology. *Eur J Heart Fail.* 2018 Oct;20(10):1379-1381. doi: 10.1002/ejhf.1231. Epub 2018 Jun 26
491. Sarwar CMS, Vaduganathan M, Anker SD, Coiro S, Papadimitriou L, Saltz J, Schoenfeld ER, Clark RL, Dinh W, Kramer F, Gheorghiade M, Fonarow GC, **Butler J**. Mobile health applications in cardiovascular research. *Int J Cardiol.* 2018 Oct 15;269:265-271.

492. Pang PS, Collins SP, **Butler J**, Chioncel O. Mihai Gheorghiade, MD-Life and Concepts. *Am J Ther.* 2018 Jul/Aug;25(4):e453-e455
493. DeVore AD, Mi X, Thomas L, Sharma PP, Albert NM, **Butler J**, Hernandez AF, Patterson JH, Spertus JA, Williams FB, Duffy CI, McCague K, Fonarow GC. Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial. *J Am Heart Assoc.* 2018 Jun 12;7(12)
494. **Butler J**, Vijayakumar S, Pitt B. Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists. *Eur J Heart Fail.* 2018 Sep;20(9):1247-1251. doi: 10.1002/ejhf.1217. Epub 2018 Jun 8.
495. Nodari S, **Butler J**, Temporelli PL. Questioning the Associations of ω -3 Fatty Acid Supplement Use With Cardiovascular Disease Risks. *JAMA Cardiol.* 2018 Aug 1;3(8):781. doi: 10.1001/jamacardio.2018.1309
496. Khariton Y, Nassif ME, Thomas L, Fonarow GC, Mi X, DeVore AD, Duffy C, Sharma PP, Albert NM, Patterson JH, **Butler J**, Hernandez AF, Williams FB, McCague K, Spertus JA. Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure. *JACC Heart Fail.* 2018 Jun;6(6):465-473
497. Januzzi JL, **Butler J**, Fombu E, Maisel A, McCague K, Piña IL, Prescott MF, Riebman JB, Solomon S. Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF). *Am Heart J.* 2018 May;199:130-136
498. Vaduganathan M, Patel RB, Mentz RJ, Subacius H, Chatterjee NA, Greene SJ, Ambrosy AP, Maggioni AP, Udelson JE, Swedberg K, Konstam MA, O'Connor CM, **Butler J**, Gheorghiade M, Zannad F. Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). *J Cardiol.* 2018 Jul 15;122(2):255-260
499. Bhatt KN, **Butler J**. Myocardial Energetics and Heart Failure: a Review of Recent Therapeutic Trials. *Curr Heart Fail Rep.* 2018 Jun;15(3):191-197
500. Butts B, **Butler J**, Dunbar SB, Corwin E, Gary RA. Effects of Exercise on ASC Methylation and IL-1 Cytokines in Heart Failure. *Med Sci Sports Exerc.* 2018 Sep;50(9):1757-1766
501. Kamimura D, Cain LR, Mentz RJ, White WB, Blaha MJ, DeFilippis AP, Fox ER, Rodriguez CJ, Keith RJ, Benjamin EJ, **Butler J**, Bhatnagar A, Robertson RM, Winniford MD, Correa A, Hall ME. Cigarette Smoking and Incident Heart Failure: Insights From the Jackson Heart Study. *Circulation.* 2018 Jun 12;137(24):2572-2582
502. González A, Schelbert EB, Díez J, **Butler J**. Myocardial Interstitial Fibrosis in Heart Failure: Biological and Translational Perspectives. *J Am Coll Cardiol.* 2018 Apr 17;71(15):1696-1706.
503. Khariton Y, Hernandez AF, Fonarow GC, Sharma PP, Duffy CI, Thomas L, Mi X, Albert NM, **Butler J**, McCague K, Nassif ME, Williams FB, DeVore A, Patterson JH, Spertus JA. Health Status Variation Across Practices in Outpatients With Heart Failure: Insights From the CHAMP-HF (Change the Management of Patients With Heart Failure) Registry. *Circ Cardiovasc Qual Outcomes.* 2018 Apr;11(4):e004668
504. Scherzer R, Shah SJ, Secemsky E, **Butler J**, Grunfeld C, Shlipak MG, Hsue PY. Association of Biomarker Clusters With Cardiac Phenotypes and Mortality in Patients With HIV Infection. *Circ Heart Fail.* 2018 Apr;11(4):e004312
505. Njoroge JN, Cheema B, Ambrosy AP, Greene SJ, Collins SP, Vaduganathan M, Mebazaa A, Chioncel O, **Butler J**, Gheorghiade M. Expanded algorithm for managing patients with acute decompensated heart failure. *Heart Fail Rev.* 2018 Jul;23(4):597-607
506. Greene SJ, Hernandez AF, Sun JL, **Butler J**, Armstrong PW, Ezekowitz JA, Zannad F, Ferreira JP, Coles A, Metra M, Voors AA, Califf RM, O'Connor CM, Mentz RJ. Relationship

- Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. *Circ Cardiovasc Qual Outcomes*. 2018 Oct;11(10):e004783
507. Greene SJ, Mentz RJ, Fiuzat M, **Butler J**, Solomon SD, Ambrosy AP, Mehta C, Teerlink JR, Zannad F, O'Connor CM. Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure. *Circulation*. 2018 Sep 4;138(10):1039-1053
508. DeVore AD, Hill CL, Thomas L, Sharma PP, Albert NM, **Butler J**, Patterson JH, Spertus JA, Williams FB, Duffy CI, McCague K, Hernandez AF, Fonarow GC. Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States. *Circ Heart Fail*. 2018 Sep;11(9):e005400
509. Voors AA, Shah SJ, Bax JJ, **Butler J**, Gheorghiade M, Hernandez AF, Kitzman DW, McMurray JJV, Wirtz AB, Lanius V, van der Laan M, Solomon SD. Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. *Eur J Heart Fail*. 2018 Nov;20(11):1601-1610. doi: 10.1002/ejhf.1295.
510. Hamo CE, O'Connor C, Metra M, Udelson JE, Gheorghiade M, **Butler J**. A Critical Appraisal of Short-Term End Points in Acute Heart Failure Clinical Trials. *J Card Fail*. 2018 Nov;24(11):783-792. doi: 10.1016/j.cardfail.2018.08.007. Epub 2018 Sep 11.
511. Bounthavong M, **Butler J**, Dolan CM, Dunn JD, Fisher KA, Oestreicher N, Pitt B, Hauptman PJ, Veenstra DL. Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. *Pharmacoeconomics*. 2018 Dec;36(12):1463-1473
512. **Butler J**, Vijayakumar S, Pitt B. Revisiting hyperkalaemia guidelines: rebuttal. *Eur J Heart Fail*. 2018 Sep;20(9):1255
513. Arundel C, Sheriff H, Bearden DM, Morgan CJ, Heidenreich PA, Fonarow GC, **Butler J**, Allman RM, Ahmed A. Discharge home health services referral and 30-day all-cause readmission in older adults with heart failure. *Arch Med Sci*. 2018 Aug;14(5):995-1002
514. Bowes CD, Lien LF, **Butler J**. Treatment of Diabetes in Patients with Heart Failure. *Curr Cardiol Rep*. 2018 Aug 27;20(10):97
515. Tahhan AS, Vaduganathan M, Greene SJ, Fonarow GC, Fiuzat M, Jessup M, Lindenfeld J, O'Connor CM, **Butler J**. Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review. *JAMA Cardiol*. 2018 1;3:1011-1019
516. Hedley JS, Samman-Tahhan A, McCue AA, Bjork JB, **Butler J**, Georgiopoulou VV, Morris AA, Kalogeropoulos AP. Definitions of Stage D heart failure and outcomes among outpatients with heart failure and reduced ejection fraction. *Int J Cardiol*. 2018 Dec 1;272:250-254
517. Teressa G, Zhang M, Lavenburg P, Cantor G, Noack P, Yang J, Goyfman M, Feldmann EJ, **Butler J**, Poon M. Validity of Coronary Artery Disease Consortium Models for Predicting Obstructive Coronary Artery Disease & Cardiovascular Events in Patients with Acute Chest Pain Considered for Coronary Computed Tomographic Angiography. *Am J Cardiol*. 2018 Oct 15;122(8):1310-1321.
518. Samman-Tahhan A, Hedley JS, McCue AA, Bjork JB, Georgiopoulou VV, Morris AA, **Butler J**, Kalogeropoulos AP. INTERMACS Profiles and Outcomes Among Non-Inotrope-Dependent Outpatients With Heart Failure and Reduced Ejection Fraction. *JACC Heart Fail*. 2018 Sep;6(9):743-753
519. Sharma A, Cooper LB, Fiuzat M, Mentz RJ, Ferreira JP, **Butler J**, Fitchett D, Moses AC, O'Connor C, Zannad F. Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus. *JACC Heart Fail*. 2018 Oct;6(10):813-822.
520. Patel RB, Venkateswaran RV, Singh A, Bhatt DL, Fonarow GC, Passman R, **Butler J**, Yancy CW, Vaduganathan M. The Current Landscape of Atrial Fibrillation and Atrial Flutter

- Clinical Trials: A Report of 348 Studies Registered With ClinicalTrials.gov. *JACC Clin Electrophysiol.* 2018 Jul;4(7):944-954. doi: 10.1016/j.jacep.2018.04.008. Epub 2018 Jun 27.
521. Greene SJ, **Butler J**, Albert NM, DeVore AD, Sharma PP, Duffy CI, Hill CL, McCague K, Mi X, Patterson JH, Spertus JA, Thomas L, Williams FB, Hernandez AF, Fonarow GC. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. *J Am Coll Cardiol.* 2018 Jul 24;72(4):351-366.
 522. Anker SD, **Butler J**. Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle. *ESC Heart Fail.* 2018 Aug;5(4):549-551
 523. Grodin JL, **Butler J**, Metra M, Felker GM, Voors AA, McMurray JJ, Armstrong PW, Hernandez AF, O'Connor C, Starling RC, Tang WHW. Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. *J Card Fail.* 2018 Aug;24(8):512-519
 524. Samman Tahhan A, Vaduganathan M, Kumar S, Okafor M, Greene SJ, **Butler J**. Design Elements and Enrollment Patterns of Contemporary Trials in Heart Failure With Preserved Ejection Fraction: A Systematic Review. *JACC Heart Fail.* 2018 Aug;6(8):714-717.
 525. Chioncel O, Collins SP, Ambrosy AP, Pang PS, Antohi EL, Iliescu VA, Maggioni AP, **Butler J**, Mebazaa A. Improving Postdischarge Outcomes in Acute Heart Failure. *Am J Ther.* 2018 Jul/Aug;25(4):e475-e486
 526. Peri-Okonny PA, Mi X, Khariton Y, Patel KK, Thomas L, Fonarow GC, Sharma PP, Duffy CI, Albert NM, **Butler J**, Hernandez AF, McCague K, Williams FB, DeVore AD, Patterson JH, Spertus JA. Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry. *JACC Heart Fail.* 2019 Feb 4. pii: S2213-1779(18)30857-6
 527. Chikwe J, Anyanwu A, **Butler J**, McLarty A. Failure predicting failure: The right ventricle after left ventricular assist device implantation. *J Thorac Cardiovasc Surg.* 2018 Dec 27. pii: S0022-5223(18)33498-6.
 528. Piccini JP, Xu H, Cox M, Matsouaka RA, Fonarow GC, **Butler J**, Curtis AB, Desai N, Fang M, McCabe PJ, Page RL, Turakhia M, Russo AM, Knight BP, Sidhu M, Hurwitz JL, Ellenbogen KA, Lewis WR; Get With The Guidelines-AFIB Clinical Working Group and Hospitals. Adherence to Guideline-Directed Stroke Prevention Therapy for Atrial Fibrillation is Achievable: First Results from Get With The Guidelines-Atrial Fibrillation (GWTG-AFIB). *Circulation.* 2019 Jan 31.
 529. Kalogeropoulos AP, **Butler J**. The other serelaxin in acute heart failure study: lessons from a pragmatic clinical trial. *Eur J Heart Fail.* 2019 Jan 28.
 530. Clark D 3rd, Cain LR, Blaha MJ, DeFilippis AP, Mentz RJ, Kamimura D, White WB, Butler KR, Robertson RM, Bhatnagar A, **Butler J**, Correa A, Benjamin EJ, Hall ME. Cigarette Smoking and Subclinical Peripheral Arterial Disease in Blacks of the Jackson Heart Study. *J Am Heart Assoc.* 2019 Feb 5;8(3):e010674.
 531. Savvoulidis P, **Butler J**, Kalogeropoulos A. Cardiomyopathy and Heart Failure in Patients With HIV Infection. *Can J Cardiol.* 2018 Oct 19
 532. Greene SJ, **Butler J**. Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus. *Circulation.* 2019 Jan 8;139(2):152-154. doi: 10.1161/CIRCULATIONAHA.118.037599.
 533. Voors AA, Kremer D, Geven C, Ter Maaten JM, Struck J, Bergmann A, Pickkers P, Metra M, Mebazaa A, Düngen HD, **Butler J**. Adrenomedullin in heart failure: pathophysiology and therapeutic application. *Eur J Heart Fail.* 2019 Feb;21(2):163-171.
 534. Patel RB, Warraich HJ, **Butler J**, Vaduganathan M. Surprise, surprise: improving the referral pathway to palliative care interventions in advanced heart failure. *Eur J Heart Fail.* 2019 Feb;21(2):235-237

535. Pandey A, Kondamudi N, Patel KV, Ayers C, Simek S, Hall ME, Musani SK, Blackshear C, Mentz RJ, Khan H, Terry JG, Correa A, **Butler J**, Neeland IJ, Berry JD. Association Between Regional Adipose Tissue Distribution and Risk of Heart Failure Among Blacks. *Circ Heart Fail*. 2018 Nov;11(11):e005629.
536. Fudim M, Ambrosy AP, Sun JL, Anstrom KJ, Bart BA, **Butler J**, AbouEzzeddine O, Greene SJ, Mentz RJ, Redfield MM, Reddy YNV, Vaduganathan M, Braunwald E, Hernandez AF, Borlaug BA, Felker GM. High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network. *J Am Heart Assoc*. 2018 Dec 18;7(24):e010364
537. Ambrosy AP, Lewis GD, Malhotra R, Jones AD, Greene SJ, Fudim M, Coles A, **Butler J**, Sharma A, Hernandez AF, Mentz RJ. Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial. *J Cardiovasc Med*. 2018 Dec 3.
538. Marti CN, Fonarow GC, Anker SD, Yancy C, Vaduganathan M, Greene SJ, Ahmed A, Januzzi JL, Gheorghiade M, Filippatos G, **Butler J**. Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges. *Eur J Heart Fail*. 2018 Dec 10.
539. Morris AA, McAllister P, Grant A, Geng S, Kelli HM, Kalogeropoulos A, Quyyumi A, **Butler J**. Relation of Living in a "Food Desert" to Recurrent Hospitalizations in Patients With Heart Failure. *Am J Cardiol*. 2019 Jan 15;123(2):291-296
540. Khan H, Anker SD, Januzzi JL Jr, McGuire DK, Sattar N, Woerle HJ, **Butler J**. Heart Failure Epidemiology in Patients With Diabetes Mellitus Without Coronary Heart Disease. *J Card Fail*. 2018 Nov 10. pii: S1071-9164(18)31120-5.
541. Greene SJ, Fonarow GC, Solomon SD, Subacius HP, Vaduganathan M, Ambrosy AP, Fudim M, Böhm M, Maggioni AP, Lewis EF, Zannad F, **Butler J**. Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial. *Eur J Heart Fail*. 2018 Dec;20(12):1760-1763
542. Bhagat AA, Greene SJ, Vaduganathan M, Fonarow GC, **Butler J**. Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. *JACC Heart Fail*. 2019 Jan;7(1):1-12
543. Patel RB, Vaduganathan M, Rikhi A, Chakraborty H, Greene SJ, Hernandez AF, Felker GM, Redfield MM, **Butler J**, Shah SJ. History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure. *JACC Heart Fail*. 2019 Jan;7(1):47-55.
544. Vaduganathan M, Sathiyakumar V, Singh A, McCarthy CP, Qamar A, Januzzi JL Jr, Scirica BM, **Butler J**, Cannon CP, Bhatt DL. Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. *J Am Coll Cardiol*. 2018 Dec 25;72(25):3370-3372.
545. Greene SJ, Felker GM, **Butler J**. Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care. *Eur J Heart Fail*. 2019 Jan;21(1):121-12
546. **Butler J**, Khan MS, Anker SD. Novel potassium binders as enabling therapy in heart failure. *Eur J Heart Fail*. 2019 Apr 16. doi: 10.1002/ejhf.1474. [Epub ahead of print]
547. Watson M, Dardari Z, Kianoush S, Hall ME, DeFilippis AP, Keith RJ, Benjamin EJ, Rodriguez CJ, Bhatnagar A, Lima JA, **Butler J**, Blaha MJ, Rifai MA. Relation Between Cigarette Smoking and Heart Failure (from the Multiethnic Study of Atherosclerosis). *Am J Cardiol*. 2019 Mar 18. pii: S0002-9149(19)30312-1.
548. Grodin JL, Liebo MJ, **Butler J**, Metra M, Felker GM, Hernandez AF, Voors AA, McMurray JJ, Armstrong PW, O'Connor C, Starling RC, Troughton RW, Wilson Tang WH. Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights from ASCEND-HF. *J Card Fail*. 2019 Apr 3. pii: S1071-9164(18)30979-5. doi: 10.1016/j.cardfail.2019.04.002. [Epub ahead of print]

549. Vaduganathan M, Patel RB, Singh A, McCarthy CP, Qamar A, Januzzi JL Jr, Scirica BM, **Butler J**, Cannon CP, Bhatt DL. Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists. *J Am Coll Cardiol*. 2019 Apr 2;73(12):1596-1598. doi: 10.1016/j.jacc.2019.01.029.
550. Patel RB, Vaduganathan M, Felker GM, **Butler J**, Redfield MM, Shah SJ. Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial). *Am J Cardiol*. 2019 Feb 23. pii: S0002-9149(19)30230-9. doi: 10.1016/j.amjcard.2019.02.025. [Epub ahead of print]
551. Savarese G, Sattar N, Januzzi J, Verma S, Lund LH, Fitchett D, Zeller C, George JT, Brueckmann M, Ofstad AP, Inzucchi SE, Wanner C, Zinman B, **Butler J**. Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. *Circulation*. 2019 Mar 12;139(11):1458-1460
552. Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, Duffy CI, Hill CL, McCague K, Patterson JH, Spertus JA, Thomas L, Williams FB, Hernandez AF, **Butler J**. Longitudinal Titration of Medical Therapy for Heart Failure with Reduced Ejection Fraction: CHAMP-HF Registry. *J Am Coll Cardiol*. 2019 Feb 20. pii: S0735-1097(19)30566-2. doi: 10.1016/j.jacc.2019.02.015. [Epub ahead of print]
553. Chioncel O, Collins SP, Ambrosy AP, Pang PS, Radu RI, Antohi EL, Masip J, **Butler J**, Iliescu VA. Therapeutic Advances in the Management of Cardiogenic Shock. *Am J Ther*. 2019 Mar/Apr;26(2):e234-e247.
554. Antohi EL, Ambrosy AP, Collins SP, Ahmed A, Iliescu VA, Cotter G, Pang PS, **Butler J**, Chioncel O. Therapeutic Advances in the Management of Acute Decompensated Heart Failure. *Am J Ther*. 2019 Mar/Apr;26(2):e222-e233
555. Vijayakumar S, **Butler J**, Anker SD. New treatments for hyperkalaemia: clinical use in cardiology. *Eur Heart J Suppl*. 2019 Feb;21(Suppl A):A41-A47.
556. Vijayakumar S, Butler J, Bakris GL. Barriers to guideline mandated renin-angiotensin inhibitor use: focus on hyperkalaemia. *Eur Heart J Suppl*. 2019 Feb;21(Suppl A):A20-A27.
557. Chang AM, Pang PS, **Butler J**, Storrow AB, Levy PD, Lindenfeld J, Collins SP. Early Treatment in Emergency Department Patients with Acute Heart Failure: Does Time Matter? *Curr Heart Fail Rep*. 2019 Feb;16(1):12-20. doi: 10.1007/s11897-019-0419-y.
558. **Butler J**, Yang M, Manzi MA, Hess GP, Patel MJ, Rhodes T, Givertz MM. Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction. *J Am Coll Cardiol*. 2019 Mar 5;73(8):935-944
559. Valero-Elizondo J, Khera R, Saxena A, Grandhi GR, Virani SS, **Butler J**, Samad Z, Desai NR, Krumholz HM, Nasir K. Financial Hardship From Medical Bills Among Nonelderly U.S. Adults With Atherosclerotic Cardiovascular Disease. *J Am Coll Cardiol*. 2019 Feb 19;73(6):727-732.
560. Peri-Okonny PA, Mi X, Khariton Y, Patel KK, Thomas L, Fonarow GC, Sharma PP, Duffy CI, Albert NM, **Butler J**, Hernandez AF, McCague K, Williams FB, DeVore AD, Patterson JH, Spertus JA. Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry. *JACC Heart Fail*. 2019 Apr;7(4):350-358
561. Valero-Elizondo J, Khera R, Saxena A, Grandhi GR, Virani SS, **Butler J**, Samad Z, Desai NR, Krumholz HM, Nasir K. Financial Hardship From Medical Bills Among Nonelderly U.S. Adults With Atherosclerotic Cardiovascular Disease. *J Am Coll Cardiol*. 2019 Feb 19;73(6):727-732.
562. **Butler J**, Yang M, Manzi MA, Hess GP, Patel MJ, Rhodes T, Givertz MM. Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction. *J Am Coll Cardiol*. 2019 Mar 5;73(8):935-944. doi: 10.1016/j.jacc.2018.11.049.
563. Vaduganathan M, Tahhan AS, Alrohaibani A, Greene SJ, Fonarow GC, Vardeny O, Lindenfeld J, Jessup M, Fiuzat M, O'Connor CM, Butler J. Do Women and Men Respond

- Similarly to Therapies in Contemporary Heart Failure Clinical Trials? *JACC Heart Fail.* 2019 Mar;7(3):267-271.
564. Chang AM, Pang PS, **Butler J**, Storrow AB, Levy PD, Lindenfeld J, Collins SP. Early Treatment in Emergency Department Patients with Acute Heart Failure: Does Time Matter? *Curr Heart Fail Rep.* 2019 Feb;16(1):12-20.
 565. Vijayakumar S, **Butler J**, Bakris GL. Barriers to guideline mandated renin-angiotensin inhibitor use: focus on hyperkalaemia. *Eur Heart J Suppl.* 2019 Feb;21(Suppl A):A20-A27
 566. Vijayakumar S, **Butler J**, Anker SD. New treatments for hyperkalaemia: clinical use in cardiology. *Eur Heart J Suppl.* 2019 Feb;21(Suppl A):A41-A47
 567. Antohi EL, Ambrosy AP, Collins SP, Ahmed A, Iliescu VA, Cotter G, Pang PS, **Butler J**, Chioncel O. Therapeutic Advances in the Management of Acute Decompensated Heart Failure. *Am J Ther.* 2019 Mar/Apr;26(2):e222-e233.
 568. Chioncel O, Collins SP, Ambrosy AP, Pang PS, Radu RI, Antohi EL, Masip J, **Butler J**, Iliescu VA. Therapeutic Advances in the Management of Cardiogenic Shock. *Am J Ther.* 2019 Mar/Apr;26(2):e234-e247.
 569. Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, Duffy CI, Hill CL, McCague K, Patterson JH, Spertus JA, Thomas L, Williams FB, Hernandez AF, **Butler J**. Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. *J Am Coll Cardiol.* 2019 May 21;73(19):2365-2383.
 570. Savarese G, Sattar N, Januzzi J, Verma S, Lund LH, Fitchett D, Zeller C, George JT, Brueckmann M, Ofstad AP, Inzucchi SE, Wanner C, Zinman B, **Butler J**. Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. *Circulation.* 2019 Mar 12;139(11):1458-1460.
 571. Patel RB, Vaduganathan M, Felker GM, **Butler J**, Redfield MM, Shah SJ. Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial). *Am J Cardiol.* 2019 May 15;123(10):1660-1666.
 572. Vaduganathan M, Patel RB, Singh A, McCarthy CP, Qamar A, Januzzi JL Jr, Scirica BM, **Butler J**, Cannon CP, Bhatt DL. Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists. *J Am Coll Cardiol.* 2019 Apr 2;73(12):1596-1598.
 573. Triposkiadis F, **Butler J**, Abboud FM, Armstrong PW, Adamopoulos S, Atherton JJ, Baks J, Bauersachs J, Burkhoff D, Bonow RO, Chopra VK, de Boer RA, de Windt L, Hamdani N, Hasenfuss G, Heymans S, Hulot JS, Konstam M, Lee RT, Linke WA, Lunde IG, Lyon AR, Maack C, Mann DL, Mebazaa A, Mentz RJ, Nihoyannopoulos P, Papp Z, Parissis J, Pedrazzini T, Rosano G, Rouleau J, Seferovic PM, Shah AM, Starling RC, Tocchetti CG, Trochu JN, Thum T, Zannad F, Brutsaert DL, Segers VF, De Keulenaer GW. The continuous heart failure spectrum: moving beyond an ejection fraction classification. *Eur Heart J.* 2019 Jul 1;40(26):2155-2163.
 574. Watson M, Dardari Z, Kianoush S, Hall ME, DeFilippis AP, Keith RJ, Benjamin EJ, Rodriguez CJ, Bhatnagar A, Lima JA, Butler J, Blaha MJ, Rifai MA. Relation Between Cigarette Smoking and Heart Failure (from the Multiethnic Study of Atherosclerosis). *Am J Cardiol.* 2019 Jun 15;123(12):1972-1977
 575. **Butler J**, Khan MS, Anker SD. Novel potassium binders as enabling therapy in heart failure. *Eur J Heart Fail.* 2019 May;21(5):550-552.
 576. Bajaj NS, Vaduganathan M, Qamar A, Gupta K, Gupta A, Golwala H, **Butler J**, Goldhaber SZ, Mehra MR. Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: A trial sequential and cumulative meta-analysis. *PLoS Med.* 2019 Apr 29;16(4):e1002797.
 577. Khan MS, **Butler J**. Heart failure prevention with sodium-glucose cotransporter 2 inhibitors. *J Diabetes.* 2019 Jul;11(7):601-604.

578. House AA, Wanner C, Sarnak MJ, Piña IL, McIntyre CW, Komenda P, Kasiske BL, Deswal A, deFilippi CR, Cleland JGF, Anker SD, Herzog CA, Cheung M, Wheeler DC, Winkelmayr WC, McCullough PA; Conference Participants. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int.* 2019 Jun;95(6):1304-1317.
579. Stergiopoulos K, Lima FV, **Butler J**. Heart Failure in Pregnancy: A Problem Hiding in Plain Sight. *J Am Heart Assoc.* 2019 May 7;8(9):e012905.
580. Khan MS, **Butler J**. Targeting Mitochondrial Function in Heart Failure: Makes Sense But Will it Work? *JACC Basic Transl Sci.* 2019 Apr 29;4(2):158-160
581. Bounthavong M, **Butler J**, Dolan CM, Dunn JD, Fisher KA, Oestreicher N, Pitt B, Hauptman PJ, Veenstra DL. Correction to: Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. *Pharmacoeconomics.* 2019 Aug;37(8):1071
582. **Butler J**, Lam CSP, Anstrom KJ, Ezekowitz J, Hernandez AF, O'Connor CM, Pieske B, Ponikowski P, Shah SJ, Solomon SD, Voors AA, Wu Y, Carvalho F, Bamber L, Blaustein RO, Roessig L, Armstrong PW. Rationale and Design of the VITALITY-HFpEF Trial. *Circ Heart Fail.* 2019 May;12(5)
583. Ferreira JP, Verdonschot J, Collier T, Wang P, Pizard A, Bär C, Björkman J, Boccanelli A, **Butler J**, Clark A, Cleland JG, Delles C, Diez J, Girerd N, González A, Hazebroek M, Huby AC, Jukema W, Latini R, Leenders J, Levy D, Mebazaa A, Mischak H, Pinet F, Rossignol P, Sattar N, Sever P, Staessen JA, Thum T, Vodovar N, Zhang ZY, Heymans S, Zannad F. Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. *Circ Heart Fail.* 2019 May;12(5)
584. Spinowitz BS, Fishbane S, Pergola PE, Roger SD, Lerma EV, **Butler J**, von Haehling S, Adler SH, Zhao J, Singh B, Lavin PT, McCullough PA, Kosiborod M, Packham DK; ZS-005 Study Investigators. Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study. *Clin J Am Soc Nephrol.* 2019 Jun 7;14(6):798-809
585. Bowes CD, Lien LF, Butler J. Assessment of Heart Failure in Diabetes Cardiovascular Outcomes Trials: Is What We Are Currently Capturing Adequate? *Curr Diab Rep.* 2019 May 24;19(7):39.
586. McGee BT, Phillips V, Higgins MK, **Butler J**. Prescription Drug Spending and Medication Adherence Among Medicare Beneficiaries with Heart Failure. *J Manag Care Spec Pharm.* 2019 Jun;25(6):705-713
587. **Butler J**, Zannad F, Fitchett D, Zinman B, Koitka-Weber A, von Eynatten M, Zwiener I, George J, Brueckmann M, Cheung AK, Wanner C. Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure. *Circ Heart Fail.* 2019 Jun;12(6):e005875
588. Thomas M, Khariton Y, Fonarow GC, Arnold SV, Hill L, Nassif ME, Sharma PP, **Butler J**, Thomas L, Duffy CI, DeVore AD, Hernandez A, Albert NM, Patterson JH, Williams FB, McCague K, Spertus JA. Association of Changes in Heart Failure Treatment With Patients' Health Status: Real-World Evidence From CHAMP-HF. *JACC Heart Fail.* 2019 Jul;7(7):615-625
589. Papadimitriou L, Moore CK, **Butler J**, Long RC. The Limitations of Symptom-based Heart Failure Management. *Card Fail Rev.* 2019 May 24;5(2):74-77
590. Abraham WT, Ponikowski P, Brueckmann M, Zeller C, Macesic H, Peil B, Brun M, Ustyugova A, Jamal W, Salsali A, Lindenfeld J, Anker SD; EMPERIAL Investigators and National Coordinators. Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure. *Eur J Heart Fail.* 2019 Jul;21(7):932-942
591. Verma S, Sharma A, Kanumilli N, **Butler J**. Predictors of heart failure development in type 2 diabetes: a practical approach. *Curr Opin Cardiol.* 2019 Sep;34(5):578-583

592. Greene SJ, Felker GM, Giczewska A, Kalogeropoulos AP, Ambrosy AP, Chakraborty H, DeVore AD, Fudim M, McNulty SE, Mentz RJ, Vaduganathan M, Hernandez AF, **Butler J**. Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. *Can J Cardiol*. 2019 Sep;35(9):1097-1105.
593. Bowes CD, Lien LF, **Butler J**. Clinical aspects of heart failure in individuals with diabetes. *Diabetologia*. 2019 Sep;62(9):1529-1538.
594. Chioncel O, **Butler J**. Mid-regional pro-atrial natriuretic peptide for diagnosis of heart failure in non-acute settings: biomarkers plus clinical sense make good sense. *Eur J Heart Fail*. 2019 Aug 1. doi: 10.1002/ejhf.1578
595. Triposkiadis F, Xanthopoulos A, **Butler J**. Cardiovascular Aging and Heart Failure: JACC Review Topic of the Week. *J Am Coll Cardiol*. 2019 Aug 13;74(6):804-813.
596. Psofka MA, Fiuzat M, Carson PE, Kao DP, Cerkenvenik J, Schaber DE, Verta P, Kazmierski RT, Shinnar M, Stockbridge N, Unger EF, Zuckerman B, **Butler J**, Felker GM, Konstam MA, Lindenfeld J, Solomon SD, Teerlink JR, O'Connor CM, Abraham WT. Design of a "Lean" Case Report Form for Heart Failure Therapeutic Development. *JACC Heart Fail*. 2019 Aug 7. pii: S2213-1779(19)30542-6
597. Patel RB, Nohria A, Butler J, Vaduganathan M. Dying is not what it used to be! Impact of evolving epidemiology and treatment on mode of death in heart failure. *Eur J Heart Fail*. 2019 Aug 13.
598. Khan MS, Jones DW, **Butler J**. Salt, No Salt or Less Salt For Heart Failure Patients? *Am J Med*. 2019 Aug 13.
599. Schelbert EB, **Butler J**, Diez J. Why Clinicians Should Care About the Cardiac Interstitium. *ACC Cardiovasc Imaging*. 2019 Aug 8.
600. Gracia E, Hamid A, **Butler J**. Timely Management of New-Onset Heart Failure. *Circulation*. 2019 Aug 20;140(8):621-623.
601. Blumer V, Greene SJ, Sun JL, Bart BA, Ambrosy AP, **Butler J**, DeVore AD, Fudim M, Hernandez AF, McNulty SE, Felker GM, Mentz RJ. Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial. *Eur J Heart Fail*. 2019 Aug 27.
602. Kalogeropoulos AP, Goulbourne C, **Butler J**. Diagnosis and Prevention of Hypertensive Heart Failure. *Heart Fail Clin*. 2019 Oct;15(4):435-445
603. Januzzi JL Jr, Prescott MF, **Butler J**, Felker GM, Maisel AS, McCague K, Camacho A, Piña IL, Rocha RA, Shah AM, Williamson KM, Solomon SD; PROVE-HF Investigators. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. *JAMA*. 2019 Sep 2:1-11
604. Greene SJ, Fonarow GC, **Butler J**. Reply: Titration of Guideline-Directed Medical Therapy Improves Patient-Centered Outcomes in Heart Failure With Reduced Ejection Fraction. *J Am Coll Cardiol*. 2019 Sep 10;74(10):1426-1427
605. Myhre PL, Januzzi JL Jr, **Butler J**, Vaduganathan M. De novo heart failure: where the journey begins. *Eur J Heart Fail*. 2019 Sep 9.
606. **Butler J**, Anker SD, Packer M. Redefining Heart Failure With a Reduced Ejection Fraction. *JAMA*. 2019 Sep 13.
607. Segar MW, Vaduganathan M, Patel KV, McGuire DK, **Butler J**, Fonarow GC, Basit M, Kannan V, Grodin JL, Everett B, Willett D, Berry J, Pandey A. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. *Diabetes Care*. 2019 Sep 13
608. Khariton Y, Fonarow GC, Arnold SV, Hellkamp A, Nassif ME, Sharma PP, **Butler J**, Thomas L, Duffy CI, DeVore AD, Albert NM, Patterson JH, Williams FB, McCague K,

- Spertus JA. Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction. *JACC Heart Fail.* 2019 Sep 7.
609. Voors AA, Bax JJ, Hernandez AF, Wirtz AB, Pap AF, Ferreira AC, Senni M, van der Laan M, **Butler J**; PANTHEON Investigators. Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial. *Eur J Heart Fail.* 2019 Sep 16
610. Anker SD, **Butler J**, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Zannad F, Packer M; EMPEROR-Preserved Trial Committees and Investigators. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. *Eur J Heart Fail.* 2019 Sep 16.
611. Writing Committee, Hollenberg SM, Warner Stevenson L, Ahmad T, Amin VJ, Bozkurt B, **Butler J**, Davis LL, Drazner MH, Kirkpatrick JN, Peterson PN, Reed BN, Roy CL, Storrow AB. 2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure: A Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol.* 2019 Sep 10
612. Chang TE, Park S, Yang Q, Loustalot F, **Butler J**, Ritchey MD. Association between long-term adherence to class-I recommended medications and risk for potentially preventable heart failure hospitalizations among younger adults. *PLoS One.* 2019 Sep 23;14(9)
613. Sumarsono A, Everett BM, McGuire DK, Fonarow GC, **Butler J**, Pandey A, Vaduganathan M. Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies Among US Medicare Beneficiaries Between 2012 and 2017. *JAMA Intern Med.* 2019 Sep 30.
614. Packer M, **Butler J**, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Anker SD, Zannad F; EMPEROR-Reduced Trial Committees and Investigators. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. *Eur J Heart Fail.* 2019 Jul 16
615. Greene SJ, DeVore AD, Sheng S, Fonarow GC, **Butler J**, Califf RM, Hernandez AF, Matsouka RA, Samman Tahhan A, Thomas KL, Vaduganathan M, Yancy CW, Peterson ED, O'Connor CM, Mentz RJ. Representativeness of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HF. *JACC Heart Fail.* 2019 Nov;7(11):980-992. doi: 10.1016/j.jchf.2019.07.011. Epub 2019 Oct 9.
616. Abdellatif W, Ding J, Jalal S, Chopra S, **Butler J**, Ali IT, Shah S, Khosa F. Leadership Gender Disparity Within Research-Intensive Medical Schools: A Transcontinental Thematic Analysis. *J Contin Educ Health Prof.* 2019 Fall;39(4):243-250
617. Rachwan RJ, Butler J, Collins SP, Cotter G, Davison BA, Senger S, Ezekowitz JA, Filippatos G, Levy PD, Metra M, Ponikowski P, Teerlink JR, Voors AA, de Boer RA, Soergel DG, Felker GM, Pang PS. Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial. *Eur J Heart Fail.* 2019 Dec;21(12):1561-1570. doi: 10.1002/ejhf.1607. Epub 2019 Oct 23.
618. Giblin EM, Adams KF Jr, Hill L, Fonarow GC, Williams FB, Sharma PP, Albert NM, **Butler J**, DeVore AD, Duffy CI, Hernandez AF, McCague K, Spertus JA, Thomas L, Patterson JH. Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). *Am J Cardiol.* 2019 Dec 15;124(12):1900-1906. doi: 10.1016/j.amjcard.2019.09.020. Epub 2019 Sep 26.

619. **Butler J**, Greene SJ, Shah SH, Shah SJ, Anstrom KJ, Kim RJ, Kalogeropoulos AP, Velazquez EJ, Hernandez AF, Desvigne-Nickens P, Scherzer R, Hsue PY, Braunwald E. Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. *J Card Fail.* 2019 Nov 2. pii: S1071-9164(19)30584-6. doi: 10.1016/j.cardfail.2019.10.011.
620. Vaduganathan M, **Butler J**. SGLT-2 inhibitors in heart failure: a new therapeutic avenue. *Nat Med.* 2019 Nov;25(11):1653-1654. doi: 10.1038/s41591-019-0647-4. No abstract available.
621. Savvoulidis P, Snider JV, Rawal S, Morris AA, **Butler J**, Georgiopoulou VV, Kalogeropoulos AP. Serum ST2 and hospitalization rates in Caucasian and African American outpatients with heart failure. *Int J Cardiol.* 2020 Apr 1;304:116-121. doi: 10.1016/j.ijcard.2019.11.002. Epub 2019 Nov 6.
622. Pandey A, Patel KV, Vongpatanasin W, Ayers C, Berry JD, Mentz RJ, Blaha MJ, McEvoy JW, Muntner P, Vaduganathan M, Correa A, **Butler J**, Shimbo D, Nambi V, deFilippi C, Seliger SL, Ballantyne CM, Selvin E, de Lemos JA, Joshi PH. Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline: A Pooled Cohort Analysis. *Circulation.* 2019 Dec 17;140(25):2076-2088. doi: 10.1161/CIRCULATIONAHA.119.043337. Epub 2019 Nov
623. Konstam MA, Udelson JE, **Butler J**, Klein HU, Parker JD, Teerlink JR, Wedge PM, Saville BR, Ardell JL, Libbus I, DiCarlo LA. Impact of Autonomic Regulation Therapy in Patients with Heart Failure: ANTHEM-HFrEF Pivotal Study Design. *Circ Heart Fail.* 2019 Nov;12(11):e005879. doi: 10.1161/CIRCHEARTFAILURE.119.005879. Epub 2019 Nov 14.
624. Vaduganathan M, Fonarow GC, Greene SJ, DeVore AD, Albert NM, Duffy CI, Hill CL, Spertus JA, Thomas LE, **Butler J**. Health-Related Quality of Life in Comorbid Heart Failure With Reduced Ejection Fraction and Diabetes Mellitus. *J Am Coll Cardiol.* 2019 Dec 24;74(25):3176-3178. doi: 10.1016/j.jacc.2019.10.020. Epub 2019 Nov 11. No abstract available.
625. Khan MS, Kalogeropoulos AP, **Butler J**. Variation in Placebo Effect on Health-Related Quality of Life in Heart Failure (from the TOPCAT Trial). *Am J Cardiol.* 2020 Jan 1;125(1):82-86. doi: 10.1016/j.amjcard.2019.09.037. Epub 2019 Nov 17.
626. Khan MS, **Butler J**. Sodium-Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes. *Card Fail Rev.* 2019 Nov 4;5(3):169-172. doi: 10.15420/cfr.2019.06.R1. eCollection 2019 Nov. Review.
627. DeVore AD, Granger BB, Fonarow GC, Al-Khalidi HR, Albert NM, Lewis EF, **Butler J**, Piña IL, Heidenreich PA, Allen LA, Yancy CW, Cooper LB, Felker GM, Kaltenbach LA, McRae AT, Lanfear DE, Harrison RW, Kociol RD, Disch M, Ariely D, Miller JM, Granger CB, Hernandez AF. Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. *Am Heart J.* 2020 Feb;220:41-50. doi: 10.1016/j.ahj.2019.09.012. Epub 2019 Oct 23.
628. Xanthopoulos A, **Butler J**, Parissis J, Polyzogopoulou E, Skoularigis J, Triposkiadis F. Acutely decompensated versus acute heart failure: two different entities. *Heart Fail Rev.* 2019 Dec 4. doi: 10.1007/s10741-019-09894-y. [Epub ahead of print] Review.
629. Barutaut M, Fournier P, Peacock WF, Evaristi MF, Caubère C, Turkieh A, Desmoulin F, Eurlings LWM, van Wijk S, Rocca HB, **Butler J**, Koukoui F, Dambrin C, Mazeret S, Le Page S, Delmas C, Galinier M, Jung C, Smih F, Rouet P. Insulin-like Growth Factor Binding Protein 2 predicts mortality risk in heart failure. *Int J Cardiol.* 2020 Feb 1;300:245-251. doi: 10.1016/j.ijcard.2019.09.032. Epub 2019 Nov 18.
630. Pieske B, Patel MJ, Westerhout CM, Anstrom KJ, **Butler J**, Ezekowitz J, Hernandez AF, Koglin J, Lam CSP, Ponikowski P, Roessig L, Voors AA, O'Connor CM, Armstrong PW; VICTORIA Study Group. Baseline features of the VICTORIA (Vericiguat Global Study in

- Subjects with Heart Failure with Reduced Ejection Fraction) trial. *Eur J Heart Fail.* 2019 Dec;21(12):1596-1604. doi: 10.1002/ejhf.1664. Epub 2019 Dec 9.
631. Bhatt AS, Vaduganathan M, **Butler J.** Angiotensin-neprilysin inhibition in de novo heart failure - starting off strong. *Eur J Heart Fail.* 2020 Feb;22(2):313-314. doi: 10.1002/ejhf.1675. Epub 2019 Dec 16.
632. **Butler J,** Packer M, Greene SJ, Fiuzat M, Anker SD, Anstrom KJ, Carson PE, Cooper LB, Fonarow GC, Hernandez AF, Januzzi JL Jr, Jessup M, Kalyani RR, Kaul S, Kosiborod M, Lindenfeld J, McGuire DK, Sabatine MS, Solomon SD, Teerlink JR, Vaduganathan M, Yancy CW, Stockbridge N, O'Connor CM. Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. *Circulation.* 2019 Dec 17;140(25):2108-2118. doi: 10.1161/CIRCULATIONAHA.119.042155. Epub 2019 Dec 16.
633. Patel RB, Alenezi F, Sun JL, Alhanti B, Vaduganathan M, Oh JK, Redfield MM, **Butler J,** Hernandez AF, Velazquez EJ, Shah SJ Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. *J Card Fail.* 2020 Mar;26(3):270-275. doi: 10.1016/j.cardfail.2019.12.001. Epub 2019 Dec 17.
634. Müller ML, Butler J, Heidecker B. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy? *Eur J Heart Fail.* 2020 Jan;22(1):39-53. doi: 10.1002/ejhf.1695. Epub 2020 Jan 7. Review.
635. Khan MS, Memon MM, Murad MH, Vaduganathan M, Greene SJ, Hall M, Triposkiadis F, Lam CSP, Shah AM, **Butler J,** Shah SJ. Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis. *Eur J Heart Fail.* 2020 Mar;22(3):472-485. doi: 10.1002/ejhf.1643. Epub 2020 Jan 9.
636. **Butler J,** Handelsman Y, Bakris G, Verma S. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. *Eur J Heart Fail.* 2020 Jan 11. doi: 10.1002/ejhf.1708. [Epub ahead of print] Review.
637. Düngen HD, Dordevic A, Felix SB, Pieske B, Voors AA, McMurray JJV, **Butler J.** β 1-Adrenoreceptor Autoantibodies in Heart Failure: Physiology and Therapeutic Implications. *Circ Heart Fail.* 2020 Jan;13(1):e006155. doi: 10.1161/CIRCHEARTFAILURE.119.006155. Epub 2020 Jan 20.
638. Bhatt AS, Vaduganathan M, **Butler J.** Growing Mismatch Between Evidence Generation and Implementation in Heart Failure. *Am J Med.* 2020 Jan 17. pii: S0002-9343(20)30013-9. doi: 10.1016/j.amjmed.2019.11.032. [Epub ahead of print]
639. Kalogeropoulos A, Papadimitriou L, Georgiopoulou VV, Dunbar SB, Skopicki H, **Butler J.**
640. Low- Versus Moderate-Sodium Diet in Patients With Recent Hospitalization for Heart Failure: The PROHIBIT (Prevent Adverse Outcomes in Heart Failure by Limiting Sodium) Pilot Study. *Circ Heart Fail.* 2020 Jan;13(1):e006389. doi: 10.1161/CIRCHEARTFAILURE.119.006389. Epub 2020 Jan 21.
641. Iborra-Egea O, Santiago-Vacas E, Yurista SR, Lupón J, Packer M, Heymans S, Zannad F, **Butler J,** Pascual-Figal D, Lax A, Núñez J, de Boer RA, Bayés-Genís A. Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes. *JACC Basic Transl Sci.* 2019 Oct 23;4(7):831-840. doi: 10.1016/j.jacbts.2019.07.010. eCollection 2019 Nov.
642. Roger SD, Lavin PT, Lerma EV, McCullough PA, Butler J, Spinowitz BS, von Haehling S, Kosiborod M, Zhao J, Fishbane S, Packham DK. Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3

- study. *Nephrol Dial Transplant*. 2020 Feb 6. pii: gfz285. doi: 10.1093/ndt/gfz285. [Epub ahead of print]
643. **Butler J**, Khan MS, Anker SD, Fonarow GC, Kim RJ, Nodari S, O'Connor CM, Pieske B, Pieske-Kraigher E, Sabbah HN, Senni M, Voors AA, Udelson JE, Carr J, Gheorghiu M, Filippatos G. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. *J Card Fail*. 2020 Feb 14. pii: S1071-9164(19)31583-0. doi: 10.1016/j.cardfail.2020.02.001. [Epub ahead of print]
644. Khan MS, **Butler J**, Greene SJ. Patient-reported outcomes for heart failure with preserved ejection fraction: conducting quality studies on quality of life. *Eur J Heart Fail*. 2020 Mar 10. doi: 10.1002/ejhf.1762. [Epub ahead of print].
645. Ibrahim NE, Burnett JC Jr, **Butler J**, Camacho A, Felker GM, Fiuzat M, O'Connor C, Solomon SD, Vaduganathan M, Zile MR, Januzzi JL Jr. Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC Heart Failure Position Paper. *JACC Heart Fail*. 2020 Mar 3. pii: S2213-1779(20)30020-2. doi: 10.1016/j.jchf.2019.12.010. [Epub ahead of print] Review.
646. Parikh PB, Wang TY, Sharma N, Kort S, Skopicki HA, Gruberg L, Jeremias A, Pyo R, Chikwe J, **Butler J**. Sex-Related Differences in Early- and Long-Term Mortality After Transcatheter and Surgical Aortic Valve Replacement: A Systematic Review and Meta-Analysis. *J Invasive Cardiol*. 2020 Mar 20. pii: JIC20200320-2. [Epub ahead of print]
647. Tahhan AS, Vaduganathan M, Greene SJ, Alrohaibani A, Raad M, Gafeer M, Mehran R, Fonarow GC, Douglas PS, Bhatt DL, **Butler J**. Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials: A Systematic Review. *JAMA Cardiol*. 2020 Mar 25. doi: 10.1001/jamacardio.2020.0359. [Epub ahead of print]
648. Bhatt AS, Ambrosy AP, Dunning A, DeVore AD, **Butler J**, Reed S, Voors A, Starling R, Armstrong PW, Ezekowitz JA, Metra M, Hernandez AF, O'Connor CM, Mentz RJ. The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND-HF. *Eur J Heart Fail*. 2020 Mar 25. doi: 10.1002/ejhf.1795. [Epub ahead of print]
649. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, **Butler J**, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O'Connor CM; VICTORIA Study Group. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med*. 2020 Mar 28. doi: 10.1056/NEJMoa1915928. [Epub ahead of print]
650. **Butler J**, Anstrom KJ, Armstrong PW; VICTORIA Study Group. Comparing the Benefit Of Novel Therapies Across Clinical Trials: Insights from the VICTORIA Trial. *Circulation*. 2020 Mar 28. doi: 10.1161/CIRCULATIONAHA.120.047086. [Epub ahead of print]
651. Verma S, Sharma A, Zinman B, Ofstad AP, Fitchett D, Brueckmann M, Wanner C, Zwiener I, George JT, Inzucchi SE, **Butler J**, Mazer CD. Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial. *Diabetes Obes Metab*. 2020 Mar 29. doi: 10.1111/dom.14015. [Epub ahead of print]
652. de Denus S, Leclair G, Dubé MP, St-Jean I, Zada YF, Oussaïd E, Jutras M, Givertz MM, Mentz RJ, Tang WHW, Ferreira JP, Rouleau J, **Butler J**, Kalogeropoulos AP. Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial. *Eur J Heart Fail*. 2020 Apr 1. doi: 10.1002/ejhf.1802. [Epub ahead of print]
653. **Butler J**, Khan MS, Mori C, Filippatos GS, Ponikowski P, Comin-Colet J, Roubert B, Spertus JA, Anker SD. Minimal clinically important difference in quality of life scores for

- patients with heart failure and reduced ejection fraction. *Eur J Heart Fail*. 2020 Apr 2. doi: 10.1002/ejhf.1810. [Epub ahead of print]
654. **Butler J**, Januzzi JL, Rosenstock J. Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy. *Diabetes Obes Metab*. 2020 Apr 3. doi: 10.1111/dom.14042. [Epub ahead of print] Review.
655. Vaduganathan M, Singh A, Sharma A, Januzzi JL Jr, Scirica BM, **Butler J**, Zannad F, McGuire DK, Cannon CP, Bhatt DL. Contemporary Trends in Prescription of Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. *Am J Cardiol*. 2020 Mar 4. pii: S0002-9149(20)30175-2. doi: 10.1016/j.amjcard.2020.01.053. [Epub ahead of print]
656. Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, Suda N, Siwakoti K, Ahmad T, Jacoby D, Riello R, Bellumkonda L, Cox Z, Collins S, Jeon S, Turner JM, Wilson FP, **Butler J**, Inzucchi SE, Testani JM. Griffin M, et al. Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects. *Circulation*. 2020 May 15. doi: 10.1161/CIRCULATIONAHA.120.045691. Online ahead of print. *Circulation*. 2020. PMID 32811111.
657. Fiuzat M, Lowy N, Stockbridge N, Sbolli M, Latta F, Lindenfeld J, Lewis EF, Abraham WT, Teerlink J, Walsh M, Heidenreich P, Bozkurt B, Starling RC, Solomon S, Felker GM, **Butler J**, Yancy C, Stevenson LW, O'Connor C, Unger E, Temple R, McMurray J. Fiuzat M, et al. Endpoints in Heart Failure Drug Development: History and Future. *JACC Heart Fail*. 2020 Jun;8(6):429-440.
658. Zhang Y, Coats AJS, Zheng Z, Adamo M, Ambrosio G, Anker SD, **Butler J**, Xu D, Mao J, Khan MS, Bai L, Mebazaa A, Ponikowski P, Tang Q, Ruschitzka F, Seferovic P, Tschöpe C, Zhang S, Gao C, Zhou S, Senni M, Zhang J, Metra M. Zhang Y, et al. Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail*. 2020 May 28. doi: 10.1002/ejhf.1915. Online ahead of print.
659. Ferreira JP, **Butler J**, Rossignol P, Pitt B, Anker SD, Kosiborod M, Lund LH, Bakris GL, Weir MR, Zannad F. Ferreira JP, et al. Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2020 Jun 9;75(22):2836-2850. doi: 10.1016/j.jacc.2020.04.021.
660. Triposkiadis F, Xanthopoulos A, Parissis J, **Butler J**, Farmakis D. Triposkiadis F, et al. Pathogenesis of chronic heart failure: cardiovascular aging, risk factors, comorbidities, and disease modifiers. *Heart Fail Rev*. 2020 Jun 10. doi: 10.1007/s10741-020-09987-z. Online ahead of print
661. Anker SD, **Butler J**, Khan MS, Abraham WT, Bauersachs J, Bocchi E, Bozkurt B, Braunwald E, Chopra VK, Cleland JG, Ezekowitz J, Filippatos G, Friede T, Hernandez AF, Lam CSP, Lindenfeld J, McMurray JJV, Mehra M, Metra M, Packer M, Pieske B, Pocock SJ, Ponikowski P, Rosano GMC, Teerlink JR, Tsutsui H, Van Veldhuisen DJ, Verma S, Voors AA, Wittes J, Zannad F, Zhang J, Seferovic P, Coats AJS. Anker SD, et al. *Eur Heart J*. 2020 Jun 7;41(22):2109-2117.
662. Bhatt AS, Moscone A, McElrath EE, Varshney AS, Claggett BL, Bhatt DL, Januzzi JL, **Butler J**, Adler DS, Solomon SD, Vaduganathan M. Bhatt AS, et al. Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic. *J Am Coll Cardiol*. 2020 Jul 21;76(3):280-288.
663. Khan MS, Samman Tahhan A, Vaduganathan M, Greene SJ, Alrohaibani A, Anker SD, Vardeny O, Fonarow GC, **Butler J**. Khan MS, et al. Trends in prevalence of comorbidities in heart failure clinical trials. *Eur J Heart Fail*. 2020 Apr 15. doi: 10.1002/ejhf.1818. Online ahead of print
664. Quarta G, Gori M, Iorio A, D'Elia E, Moon JC, Iacovoni A, Burocchi S, Schelbert EB, Brambilla P, Sironi S, Caravita S, Parati G, Gavazzi A, Maisel AS, **Butler J**, Lam CS, Senni

- M.Quarta G, et al. Cardiovascular magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities. *Eur J Heart Fail*. 2020 Jul 12. doi: 10.1002/ejhf.1961. Online ahead of print
665. Khan MS, Hayat J, Marsia S, Yamani N, Doukky R, **Butler J**, Manning WJ, Mookadam F, Khosa F. Khan MS, et al. How well do we represent ourselves: an analysis of cardiology fellowships website content. *Future Cardiol*. 2020 Jul;16(4):281-287.
666. Nayak A, Liu C, Mehta A, Ko YA, Tahhan AS, Dhindsa DS, Uppal K, Jones DP, **Butler J**, Morris AA, Quyyumi AA. Nayak A, et al. N8-Acetylspermidine: A Polyamine Biomarker in Ischemic Cardiomyopathy With Reduced Ejection Fraction. *J Am Heart Assoc*. 2020 Jun 2;9(11):e016055. doi: 10.1161/JAHA.120.016055. Epub 2020 May 27. *J Am Heart Assoc*. 2020. PMID: 32458724
667. Fröjdh F, Fridman Y, Bering P, Sayeed A, Maanja M, Niklasson L, Olausson E, Pi H, Azeem A, Wong TC, Kellman P, Feingold B, Christopher A, Fukui M, Cavalcante JL, Miller CA, **Butler J**, Ugander M, Schelbert EB. Fröjdh F, et al. Extracellular Volume and Global Longitudinal Strain Both Associate With Outcomes But Correlate Minimally. *JACC Cardiovasc Imaging*. 2020 Jun 16:S1936-878X(20)30422-8.
668. Oshunbade AA, Yimer WK, Valle KA, Clark D 3rd, Kamimura D, White WB, DeFilippis AP, Blaha MJ, Benjamin EJ, O'Brien EC, Mentz RJ, Fox ER, O'Mara CS, **Butler J**, Correa A, Hall ME. Oshunbade AA, et al. Cigarette Smoking and Incident Stroke in Blacks of the Jackson Heart Study. *J Am Heart Assoc*. 2020 Jun 16;9(12):e014990. doi: 10.1161/JAHA.119.014990. Epub 2020 Jun
669. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. *Lancet*. 2020 Aug 28:S0140-6736(20)31824-9. doi: 10.1016/S0140-6736(20)31824-9. Online ahead of print.
670. Tahhan AS, Vaduganathan M, Greene SJ, Alrohaibani A, Raad M, Gafeer M, Mehran R, Fonarow GC, Douglas PS, Bhatt DL, **Butler J**. Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials: A Systematic Review. *JAMA Cardiol*. 2020 Mar 25. doi: 10.1001/jamacardio.2020.0359. Online ahead of print.
671. Anand IS, Konstam MA, Klein HU, Mann DL, Ardell JL, Gregory DD, Massaro JM, Libbus I, DiCarlo LA, Udelson JJE, **Butler J**, Parker JD, Teerlink JR. Comparison of symptomatic and functional responses to vagus nerve stimulation in ANTHEM-HF, INOVATE-HF, and NECTAR-HF. *ESC Heart Fail*. 2020 Feb;7(1):75-83.
672. **Butler J**, Djatche LM, Sawhney B, Chakladar S, Yang L, Brady JE, Yang M. Clinical and Economic Burden of Chronic Heart Failure and Reduced Ejection Fraction Following a Worsening Heart Failure Event. *Adv Ther*. 2020 Sep;37(9):4015-4032. doi: 10.1007/s12325-020-01456-1. Epub 2020 Aug 6.
673. Khan MS, Fonarow GC, Friede T, Lateef N, Khan SU, Anker SD, Harrell FE Jr, **Butler J**. Application of the Reverse Fragility Index to Statistically Nonsignificant Randomized Clinical Trial Results. *JAMA Netw Open*. 2020 Aug 3;3(8)
674. DeVore AD, Hellkamp AS, Thomas L, Albert NM, **Butler J**, Patterson JH, Spertus JA, Williams FB, Duffy CI, Hernandez AF, Fonarow GC. Improvement in Left Ventricular Ejection Fraction in Outpatients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP-HF. *Circ Heart Fail*. 2020 Jul;13(7):e006833.
675. Hamid A, Vaduganathan M, Oshunbade A, Ayyalasomayajula KK, Kalogeropoulos AP, Lien LF, Shafi T, Hall M, **Butler J**. Antihyperglycemic Therapies with Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events: Prescribing Patterns within an Academic Medical Center. *J Cardiovasc Pharmacol*. 2020 Jun 17

676. Srivastava P, **Butler J**, Shroyer AL, Templeton R, Parikh PB. Regional variations in cardiovascular risk factors and access to care among US veterans with cardiovascular disease. *Coron Artery Dis*. 2020 May 11
677. Kalogeropoulos AP, Thankachen J, **Butler J**, Fang JC. Diuretic and renal effects of spironolactone and heart failure hospitalizations: a TOPCAT Americas analysis. *Eur J Heart Fail*. 2020 May 29.
678. Segar MW, Patel KV, Vaduganathan M, Caughey MC, **Butler J**, Fonarow GC, Grodin JL, McGuire DK, Pandey A. Association of Long-term Change and Variability in Glycemia With Risk of Incident Heart Failure Among Patients With Type 2 Diabetes: A Secondary Analysis of the ACCORD Trial. *Diabetes Care*. 2020 Aug;43(8):1920-1928
679. Reza N, Tahhan AS, Mahmud N, DeFilippis EM, Alrohaibani A, Vaduganathan M, Greene SJ, Ho AH, Fonarow GC, **Butler J**, O'Connor C, Fiuzat M, Vardeny O, Piña IL, Lindenfeld J, Jessup M. Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials. *Circ Heart Fail*. 2020 Aug;13(8):e006605.
680. Packer M, Anker SD, **Butler J**, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F; EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. *N Engl J Med*. 2020 Aug 29. doi: 10.1056/NEJMoa2022190. Online ahead of print.
681. Khan MS, Butler J, Greene SJ. The real world of de novo heart failure: the next frontier for heart failure clinical trials? *Eur J Heart Fail*. 2020 May 6.
682. Hall ME, Vaduganathan M, Khan MS, Papadimitriou L, Long RC, Hernandez GA, Moore CK, Lennep BW, McMullan MR, **Butler J**. Reductions in Heart Failure Hospitalizations During the COVID-19 Pandemic. *J Card Fail*. 2020 Jun;26(6):462-463.
683. Anker MS, **Butler J**, Anker SD. Roxadustat for Anemia in Patients with Chronic Kidney Disease. *N Engl J Med*. 2020 Jul 2;383(1):e3.
684. Januzzi JL Jr, Camacho A, Piña IL, Rocha R, Williamson KM, Maisel AS, Felker GM, Prescott MF, **Butler J**, Solomon SD; PROVE-HF Investigators. Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan. *Circ Heart Fail*. 2020 Jun;13(6):e006946.
685. Khan MZ, Khan SU, Khan MS, **Butler J**, Alkhouli M.. Disparities in discharge disposition after hospitalizations for decompensated heart failure. *Cardiovasc Revasc Med*. 2020 Jul 25:S1553-8389(20)30452-8. doi: 10.1016/j.carrev.2020.07.026. Online ahead of print.
686. Triposkiadis F, Xanthopoulos A, **Butler J**. From PARADIGM to PARAGON further evidence supporting continuous heart failure spectrum. *Eur J Heart Fail*. 2020 Apr 15. doi: 10.1002/ejhf.1837. Online ahead of print.
687. Greene SJ, Fonarow GC, **Butler J**. Risk Profiles in Heart Failure: Baseline, Residual, Worsening, and Advanced Heart Failure Risk. *Circ Heart Fail*. 2020 Jun;13(6):e007132. doi: 10.1161/CIRCHEARTFAILURE.120.007132. Epub 2020 Jun 2.
688. Khan MS, **Butler J**. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. *N Engl J Med*. 2020 Jul 15;383:10.1056/NEJMc2023617#sa2. doi: 10.1056/NEJMc2023617. Online ahead of print.
689. Khan MS, **Butler J**, Greene SJ. Recognizing the Significance of Outpatient Worsening Heart Failure. *J Am Heart Assoc*. 2020 Jul 21;9(14):e017485.
690. Butler J, Khan MS. Heart Failure Prevention for All: Treatment Is Good, Prevention Is Better. *J Am Coll Cardiol*. 2020 Aug 14:S0735-1097(20)36305-1. doi: 10.1016/j.jacc.2020.08.020. Online ahead of print.

691. Chioncel O, Collins SP, **Butler J**. Istaroxime in acute heart failure: the holy grail is at HORIZON? *Eur J Heart Fail*. 2020 May 6. doi: 10.1002/ejhf.1843. Online ahead of print.
692. Farmakis D, **Butler J**, Filippatos G. Sodium-glucose co-transporter 2 inhibitors: 'a tale of two sisters', diabetes and heart failure. *Eur J Heart Fail*. 2020 Jun 13. doi: 10.1002/ejhf.1935. Online ahead of print.
693. Triposkiadis F, Starling RC, Xanthopoulos A, **Butler J**, Boudoulas H. Renin-angiotensin-system inhibition in the context of corona virus disease-19: experimental evidence, observational studies, and clinical implications. *Heart Fail Rev*. 2020 Sep 1. doi: 10.1007/s10741-020-10022-4. Online ahead of print.
694. Packer M, Anker SD, **Butler J**, Filippatos G, Ferreira JP, Pocock SJ, Carson P, Anand I, Doehner W, Haass M, Komajda M, Miller A, Pehrson S, Teerlink JR, Brueckmann M, Jamal W, Zeller C, Schnaidt S, Zannad F. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. *Circulation*. 2021 Jan 26;143(4):326-336. doi: 10.1161/CIRCULATIONAHA.120.051783. Epub 2020 Oct 21. *Circulation*. 2021. PMID: 33081531 Free PMC article.
695. Zannad F, Ferreira JP, Pocock SJ, Zeller C, Anker SD, **Butler J**, Filippatos G, Hauske SJ, Brueckmann M, Pfarr E, Schnee J, Wanner C, Packer M. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced. *Circulation*. 2021 Jan 26;143(4):310-321. doi:10.1161/CIRCULATIONAHA.120.051685. Epub 2020 Oct 23. *Circulation*. 2021. PMID: 33095032 Free PMC article.
696. Anker SD, **Butler J**, Filippatos G, Khan MS, Marx N, Lam CSP, Schnaidt S, Ofstad AP, Brueckmann M, Jamal W, Bocchi EA, Ponikowski P, Perrone SV, Januzzi JL, Verma S, Böhm M, Ferreira JP, Pocock SJ, Zannad F, Packer M, Anker SD, et al. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. *Circulation*. 2021 Jan 26;143(4):337-349. doi: 10.1161/CIRCULATIONAHA.120.051824. Epub 2020 Nov 11. *Circulation*. 2021. PMID: 33175585 Free PMC article.
697. Murphy SP, Prescott MF, Camacho A, Iyer SR, Maisel AS, Felker GM, **Butler J**, Piña IL, Ibrahim NE, Abbas C, Burnett JC Jr, Solomon SD, Januzzi JL. Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. *JACC Heart Fail*. 2021 Feb;9(2):127-136. doi: 10.1016/j.jchf.2020.09.013. Epub 2020 Nov 11. *JACC Heart Fail*. 2021. PMID: 33189632 Free article.
698. Garla V, Subauste A, **Butler J**, Lien LF. The role of sodium glucose co-transporter inhibitors in heart failure prevention. *J Diabetes Complications*. 2021 Mar;35(3):107811. doi: 10.1016/j.jdiacomp.2020.107811. Epub 2020 Nov 26. *J Diabetes Complications*. 2021. PMID: 33280983 Review.
699. Bhatt AS, Abraham WT, Lindenfeld J, Bristow M, Carson PE, Felker GM, Fonarow GC, Greene SJ, Psofka MA, Solomon SD, Stockbridge N, Teerlink JR, Vaduganathan M, Wittes J, Fiuzat M, O'Connor CM, **Butler J**. Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. *BJACC Heart Fail*. 2021 Jan;9(1):1-12. doi: 10.1016/j.jchf.2020.10.014. Epub 2020 Dec 9. *JACC Heart Fail*. 2021. PMID: 33309582 Review.
700. Roger SD, Lavin PT, Lerma EV, McCullough PA, **Butler J**, Spinowitz BS, von Haehling S, Kosiborod M, Zhao J, Fishbane S, Packham DK. Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study. *Nephrol Dial Transplant*. 2021 Jan 1;36(1):137-150. doi: 10.1093/ndt/gfz285. *Nephrol Dial Transplant*. 2021. PMID: 32030422 Free PMC article.

701. Writing Committee, Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, **Butler J**, Davis LL, Fonarow GC, Ibrahim NE, Lindenfeld J, Masoudi FA, Motiwala SR, Oliveros E, Patterson JH, Walsh MN, Wasserman A, Yancy CW, Youmans QR. Writing Committee, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2021 Jan 4:S0735-1097(20)37867-0. doi: 10.1016/j.jacc.2020.11.022. Online ahead of print. *J Am Coll Cardiol*. 2021. PMID: 33446410 No abstract available.
702. Hamo CE, Fonarow GC, Greene SJ, Vaduganathan M, Yancy CW, Heidenreich P, Lu D, Matsouka RA, DeVore AD, **Butler J**. Temporal trends in risk profiles among patients hospitalized for heart failure. *Am Heart J*. 2021 Feb;232:154-163. doi: 10.1016/j.ahj.2020.11.015. Epub 2020 Nov 29. *Am Heart J*. 2021. PMID: 33264607
703. Greene SJ, Adusumalli S, Albert NM, Hauptman PJ, Rich MW, Heidenreich PA, **Butler J**; Heart Failure Society of America Quality of Care Committee. Building a Heart Failure Clinic: A Practical Guide from the Heart Failure Society of America. *J Card Fail*. 2021 Jan;27(1):2-19. doi: 10.1016/j.cardfail.2020.10.008. Epub 2020 Oct 24. *J Card Fail*. 2021. PMID: 33289664
704. Piña IL, Camacho A, Ibrahim NE, Felker GM, **Butler J**, Maisel AS, Prescott MF, Williamson KM, Claggett BL, Desai AS, Solomon SD, Januzzi JL; PROVE-HF Investigators. Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction. *JACC Heart Fail*. 2021 Jan;9(1):42-51. doi: 10.1016/j.jchf.2020.09.012. Epub 2020 Nov 11. *JACC Heart Fail*. 2021. PMID: 33189630
705. Srivastava PK, DeVore AD, Hellkamp AS, Thomas L, Albert NM, **Butler J**, Patterson JH, Spertus JA, Williams FB, Duffy CI, Hernandez AF, Fonarow GC. Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients. *JACC Heart Fail*. 2021 Jan;9(1):28-38. doi: 10.1016/j.jchf.2020.08.017. Epub 2020 Dec 9. *JACC Heart Fail*. 2021. PMID: 33309579
706. Khan MS, Felker GM, Piña IL, Camacho A, Bapat D, Ibrahim NE, Maisel AS, Prescott MF, Ward JH, Solomon SD, Januzzi JL, **Butler J**. Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes. *JACC Heart Fail*. 2021 Feb;9(2):137-145. doi: 10.1016/j.jchf.2020.09.014. Epub 2020 Dec 9. *JACC Heart Fail*. 2021. PMID: 33309581
707. Januzzi JL Jr, **Butler J**, Sattar N, Xu J, Shaw W, Rosenthal N, Pfeifer M, Mahaffey KW, Neal B, Hansen MK. Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study. *Diabetes Care*. 2021 Jan;44(1):210-216. doi: 10.2337/dc20-1889. Epub 2020 Nov 6. *Diabetes Care*. 2021. PMID: 33158949
708. Yehya A, Shah KS, Mitter SS, Ibrahim NE, Sperry B, Shah M, Chaudhry SP, Rajagopalan N, Hernandez-Montfort J, Mohan R, Alexander KM, Sinha S, **Butler J**, Kittleson MM. Top of Form Challenges and the innovations in the care of advanced heart failure patients during COVID-19. *Heart Fail Rev*. 2021 Jan 12:1-4. doi: 10.1007/s10741-021-10074-0. Online ahead of print. *Heart Fail Rev*. 2021. PMID: 33432419 Free PMC article. Review.
709. Greene SJ, Tan X, Yeh YC, Bernauer M, Zaidi O, Yang M, **Butler J**. Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction. *Heart Fail Rev*. 2021 Jan 20. doi: 10.1007/s10741-021-10077-x. Online ahead of print. *Heart Fail Rev*. 2021. PMID: 33471236 Review.
710. Packer M, Anker SD, **Butler J**, Filippatos G, Ferreira JP, Pocock SJ, Rocca HB, Janssens S, Tsutsui H, Zhang J, Brueckmann M, Jamal W, Cotton D, Iwata T, Schnee J, Zannad F. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced

- trial. *Eur Heart J*. 2021 Jan 11;ehaa968. doi: 10.1093/eurheartj/ehaa968. Online ahead of print.*Eur Heart J*. 2021. PMID: 33459776
711. **Butler J**, Anker SD, Filippatos G, Khan MS, Ferreira JP, Pocock SJ, Giannetti N, Januzzi JL, Piña IL, Lam CSP, Ponikowski P, Sattar N, Verma S, Brueckmann M, Jamal W, Vedin O, Peil B, Zeller C, Zannad F, Packer M; EMPEROR-Reduced Trial Committees and Investigators. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. *Eur Heart J*. 2021 Jan 9;ehaa1007. doi: 10.1093/eurheartj/ehaa1007. Online ahead of print.*Eur Heart J*. 2021. PMID: 33420498
712. Collins SP, Liu D, Jenkins CA, Storrow AB, Levy PD, Pang PS, Chang AM, Char D, Diercks DJ, Fermann GJ, Han JH, Hiestand B, Hogan C, Kampe CJ, Khan Y, Lee S, Lindenfeld J, Martindale J, McNaughton CD, Miller KF, Miller-Reilly C, Moser K, Peacock WF, Robichaux C, Rothman R, Schrock J, Self WH, Singer AJ, Sterling SA, Ward MJ, Walsh C, **Butler J**. Effect of a Self-care Intervention on 90-Day Outcomes in Patients With Acute Heart Failure Discharged From the Emergency Department: A Randomized Clinical Trial. *JAMA Cardiol*. 2021 Feb 1;6(2):200-208. doi: 10.1001/jamacardio.2020.5763.*JAMA Cardiol*. 2021. PMID: 33206126 Free PMC article.
713. Perez AL, Grodin JL, Chaikijurajai T, Wu Y, Hernandez AF, **Butler J**, Metra M, Michael Felker G, Voors AA, McMurray JJ, Armstrong PW, O'Connor C, Starling RC, Wilson Tang WH. Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Sub-Study. *Card Fail*. 2021 Jan 23:S1071-9164(21)00009-9. doi: 10.1016/j.cardfail.2021.01.006. Online ahead of print.*J Card Fail*. 2021. PMID: 33497809
714. Arnold SV, **Butler J**, Spertus JA. Standardizing the Standard: Reporting Health Status in Clinical Trials. *Eur J Heart Fail*. 2021 Feb 5. doi: 10.1002/ejhf.2117. Online ahead of print.*Eur J Heart Fail*. 2021. PMID: 33543813 No abstract available.
715. Elkholey K, Papadimitriou L, **Butler J**, Thadani U, Stavrakis S. Effect of Obesity on Response to Spironolactone in Patients with Heart Failure with Preserved Ejection Fraction. *Am J Cardiol*. 2021 Jan 30:S0002-9149(21)00089-8. doi: 10.1016/j.amjcard.2021.01.018. Online ahead of print.*Am J Cardiol*. 2021. PMID: 33529620
716. Verma S, Mazer CD, Inzucchi SE, Wanner C, Ofstad AP, Johansen OE, Zwiener I, George JT, **Butler J**, Zinman B. Impact of polyvascular disease with and without coexistent kidney dysfunction on cardiovascular outcomes in diabetes: a post-hoc analysis of EMPA-REG OUTCOME®. *Diabetes Obes Metab*. 2021 Jan 27. doi: 10.1111/dom.14326. Online ahead of print.*Diabetes Obes Metab*. 2021. PMID: 33502090
717. Albert NM, Tyson RJ, Hill CL, DeVore AD, Spertus JA, Duffy C, **Butler J**, Patterson JH, Hernandez AF, Williams FB, Thomas L, Fonarow GC. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities. *Am Heart J*. 2021 Jan 23:S0002-8703(21)00028-4. doi: 10.1016/j.ahj.2021.01.017. Online ahead of print.*Am Heart J*. 2021. PMID: 33497697
718. Salah HM, Fudim M, Al'Aref SJ, Khan MS, Almarzooq ZI, Devabhaktuni SR, Mentz RJ, **Butler J**, Greene SJ. Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction. *Am J Cardiol*. 2021 Jan 30:S0002-9149(21)00084-9. doi: 10.1016/j.amjcard.2021.01.013. Online ahead of print.*Am J Cardiol*. 2021. PMID: 33529619 No abstract available.
719. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sørensen T, Böhm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlström U, Echeverria LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Li J, Lund M, Macdonald P, Mareev V, Momomura SI, O'Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J,

- Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg C, Varin C, Honarpour N, Abbasi SA, Malik FI, Kurtz CE; GALACTIC-HF Investigators. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. *N Engl J Med*. 2021 Jan 14;384(2):105-116.
720. Packer M, Anker SD, **Butler J**, Filippatos G, Ferreira JP, Pocock SJ, Rocca HB, Janssens S, Tsutsui H, Zhang J, Brueckmann M, Jamal W, Cotton D, Iwata T, Schnee J, Zannad F; EMPEROR-Reduced Trial Committees and Investigators. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. *Eur Heart J*. 2021 Feb 11;42(6):671-680.
721. Abraham WT, Lindenfeld J, Ponikowski P, Agostoni P, **Butler J**, Desai AS, Filippatos G, Gniot J, Fu M, Gullestad L, Howlett JG, Nicholls SJ, Redon J, Schenkenberger I, Silva-Cardoso J, Störk S, Krzysztof Wranicz J, Savarese G, Brueckmann M, Jamal W, Nordaby M, Peil B, Ritter I, Ustyugova A, Zeller C, Salsali A, Anker SD. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. *Eur Heart J*. 2021 Feb 11;42(6):700-710.
722. Anker MS, Landmesser U, von Haehling S, **Butler J**, Coats AJS, Anker SD. Weight loss, malnutrition, and cachexia in COVID-19: facts and numbers. *J Cachexia Sarcopenia Muscle*. 2021 Feb;12(1):9-13. doi: 10.1002/jcsm.12674. Epub 2020 Dec 31.
723. Bozkurt B, Hershberger RE, **Butler J**, Grady KL, Heidenreich PA, Isler ML, Kirklin JK, Weintraub WS. 2021 ACC/AHA Key Data Elements and Definitions for Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure). *J Am Coll Cardiol*. 2021 Apr 27;77(16):2053-2150.
724. Khan MS, Jones DW, **Butler J**. The Reply. *Am J Med*. 2021 May;134(5):e357. Bright RA, Lima FV, Avila C, Butler J, Stergiopoulos K. Maternal Heart Failure. *J Am Heart Assoc*. 2021 Jul 20;10(14):e021019. doi: 10.1161/JAHA.121.021019. Epub 2021 Jul 14.
725. Anker MS, Sanz AP, Zamorano JL, Mehra MR, **Butler J**, Riess H, Coats AJS, Anker SD. Advanced cancer is also a heart failure syndrome: a hypothesis. *Eur J Heart Fail*. 2021 Jan;23(1):140-144.
726. Sreenivasan J, Khan MS, Ochani RK, Bhinder J, Usman MS, Anker SD, Fonarow GC, **Butler J**. Major Depression and Anxiety Among Patients Hospitalized With Heart Failure. *Am J Cardiol*. 2021 Mar 1;142:153-155.
727. Khan MZ, Khan SU, Khan MS, **Butler J**, Alkhouli M. Disparities in Discharge Disposition After Hospitalizations for Decompensated Heart Failure. *Cardiovasc Revasc Med*. 2021 Jul;28:95-97.
728. Spertus JA, Birmingham MC, **Butler J**, Lingvay I, Lanfear DE, Abbate A, Kosiborod ML, Fawcett C, Burton P, Damaraju CV, Januzzi JL, Whang J. Novel Trial Design: CHIEF-HF. *Circ Heart Fail*. 2021 Mar;14(3):e007767.
729. Greene SJ, **Butler J**. Investigator-Reported Versus Adjudicated Clinical Events: 2 Versions of the Truth? *J Am Coll Cardiol*. 2021 Oct 12;78(15):1538-1540.
730. Sattar N, Anker SD, **Butler J**, Verma S. Obesity, heart failure, and SGLT2 inhibition: DECLARE-TIMI 58 provides insights. *Eur Heart J*. 2021 Oct 7:e021019.
731. **Butler J**, Piña IL. Hostile Work Environment: A Case of the Emperor's New Clothes. *J Am Coll Cardiol*. 2021 May 18;77(19):2410-2412. doi: 10.1016/j.jacc.2021.04.002.
732. Usman MS, Khan MS, **Butler J**. The Interplay Between Diabetes, Cardiovascular Disease, and Kidney Disease. 2021 Jun. In: *Chronic Kidney Disease and Type 2*

- Diabetes. Arlington (VA): American Diabetes Association; 2021 Jun.
733. Fudim M, Abraham WT, von Bardeleben RS, Lindenfeld J, Ponikowski PP, Salah HM, Khan MS, Sievert H, Stone GW, Anker SD, **Butler J**. Device Therapy in Chronic Heart Failure: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2021 Aug 31;78(9):931-956. doi: 10.1016/j.jacc.2021.06.040.
734. Honigberg MC, Patel RB, Pandey A, Fonarow GC, **Butler J**, McGuire DK, Vaduganathan M. Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease Among US Adults With Diabetes. *JAMA Cardiol*. 2021 Mar 1;6(3):354-357.
735. Rao VN, Fudim M, Savarese G, **Butler J**. Polypharmacy in Heart Failure with Reduced Ejection Fraction: Progress, Not Problem. *Am J Med*. 2021 Sep;134(9):1068-1070.
736. Zannad F, Cotter G, Alonso Garcia A, George S, Davison B, Figtree G, Prasad K, Rockhold F, Schilsky RL, Stockbridge N, Pitt B, **Butler J**. What can heart failure trialists learn from oncology trialists? *Eur Heart J*. 2021 Jun 21;42(24):2373-2383
737. Triposkiadis F, Starling RC, Xanthopoulos A, **Butler J**, Boudoulas H. Renin-angiotensin-system inhibition in the context of corona virus disease-19: experimental evidence, observational studies, and clinical implications. *Heart Fail Rev*. 2021 Mar;26(2):381-389. doi: 10.1007/s10741-020-10022-4. Epub 2020 Sep
738. Triposkiadis F, Starling RC, Xanthopoulos A, **Butler J**, Boudoulas H. The Counter Regulatory Axis of the Lung Renin-Angiotensin System in Severe COVID-19: Pathophysiology and Clinical Implications. *Heart Lung Circ*. 2021 Jun;30(6):786-794. doi: 10.1016/j.hlc.2020.11.008. Epub 2020 Dec 9.
739. Usman MS, Pitt B, **Butler J**. Target trial emulations: bridging the gap between clinical trial and real-world data. *Eur J Heart Fail*. 2021 Oct;23(10):1708-1711.
740. Honka H, Solis-Herrera C, Triplitt C, Norton L, **Butler J**, DeFronzo RA. Therapeutic Manipulation of Myocardial Metabolism: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2021 Apr 27;77(16):2022-2039.
741. Hamo CE, Fonarow GC, Greene SJ, Vaduganathan M, Yancy CW, Heidenreich P, Lu D, Matsouka RA, DeVore AD, **Butler J**. Temporal trends in risk profiles among patients hospitalized for heart failure. *Am Heart J*. 2021 Feb;232:154-163.
742. Khan MS, Usman MS, **Butler J**. Aetiology of heart failure is in the eye of the beholder: does it even matter? *Eur J Heart Fail*. 2021 Apr;23(4):614-616. doi: 10.1002/ejhf.2166. Epub 2021 Apr 5.
743. Anker MS, Sanz AP, Zamorano JL, Mehra MR, **Butler J**, Riess H, Coats AJS, Anker
744. SD. Advanced cancer is also a heart failure syndrome: a hypothesis. *J Cachexia Sarcopenia Muscle*. 2021 Jun;12(3):533-537. doi: 10.1002/jcsm.12694. Epub 2021 Mar 18.
745. Volpe M, Bauersachs J, Bayés-Genís A, **Butler J**, Cohen-Solal A, Gallo G, Deichl AS, Khan MS, Battistoni A, Pieske B, Saito Y, Zieroth S. Sacubitril/valsartan for the management of heart failure: A perspective viewpoint on current evidence. *Int J Cardiol*. 2021 Mar 15;327:138-145. doi: 10.1016/j.ijcard.2020.11.071.
746. Khan MS, Khan MAA, Irfan S, Siddiqi TJ, Greene SJ, Anker SD, Sreenivasan J, Friede T, Tahhan AS, Vaduganathan M, Fonarow GC, **Butler J**. Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials. *ESC Heart Fail*. 2021 Feb;8(1):26-36. doi: 10.1002/ehf2.13122. Epub 2020 Nov 30.
747. Haverkamp W, **Butler J**, Anker SD. Can we trust a smartwatch ECG? Potential and limitations. *Eur J Heart Fail*. 2021 Jun;23(6):850-853. doi: 10.1002/ejhf.2194. Epub 2021 May 7.

748. Khariton Y, Fonarow GC, Hellkamp A, Thomas L, Nassif ME, **Butler J**, Duffy CI, Albert NM, Spertus JA. Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP-HF registry. *ESC Heart Fail.* 2021 Feb;8(1):710-713. doi: 10.1002/ehf2.12981. Epub 2020 Nov 10.
749. Arnold SV, **Butler J**, Spertus JA. Standardizing the standard: reporting health status in clinical trials. *Eur J Heart Fail.* 2021 Feb;23(2):203-204. doi: 10.1002/ejhf.2117. Epub 2021 Feb 21
750. Bhatt AS, Fiuzat M, Lindenfeld J, O'Connor CM, **Butler J**. Reply: Improving Heart Failure Therapeutics: Thinking Outside the Pillbox? *JACC Heart Fail.* 2021 Apr;9(4):320-321. doi: 10.1016/j.jchf.2021.01.005
751. Garla VV, **Butler J**, Lien LF. SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives. *Curr Cardiol Rep.* 2021 May 7;23(6):59.
752. Greene SJ, **Butler J**, Metra M. Another reason to embrace quadruple medical therapy for heart failure: medications enabling tolerance of each other. *Eur J Heart Fail.* 2021 Sep;23(9):1525-1528. doi: 10.1002/ejhf.2301. Epub 2021 Jul 29.
753. Nassif M, **Butler J**. Moving in the right direction but not there yet: the utility, measurement, and analysis of health status in heart failure trials. *Eur J Heart Fail.* 2021 Apr;23(4):590-592. doi: 10.1002/ejhf.2193. Epub 2021 Apr 30.
754. Anker SD, **Butler J**, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. *N Engl J Med.* 2021 Oct 14;385(16):1451-1461.
755. Khan MS, **Butler J**, Greene SJ. Simultaneous or rapid sequence initiation of medical therapies for heart failure: seeking to avoid the case of 'too little, too late'. *Eur J Heart Fail.* 2021 Sep;23(9):1514-1517.
756. Pandey A, **Butler J**. Improving exercise tolerance and quality of life in heart failure with preserved ejection fraction - time to think outside the heart. *Eur J Heart Fail.* 2021 Sep;23(9):1552-1554. doi: 10.1002/ejhf.2313. Epub 2021 Aug 1.
757. Correale M, Petroni R, Coiro S, Antohi EL, Monitillo F, Leone M, Triggiani M, Ishihara S, Dungen HD, Sarwar CMS, Memo M, Sabbah HN, Metra M, **Butler J**, Nodari S. Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins? *Heart Fail Rev.* 2021 Jun 7.
758. Abdin A, Anker SD, **Butler J**, Coats AJS, Kindermann I, Lainscak M, Lund LH, Metra M, Mullens W, Rosano G, Slawik J, Wintrich J, Böhm M. 'Time is prognosis' in heart failure: time-to-treatment initiation as a modifiable risk factor. *ESC Heart Fail.* 2021 Oct 16. doi: 10.1002/ehf2.13646. Epub ahead of print.
759. Parikh PB, Bhatt DL, Bhasin V, Anker SD, Skopicki HA, Claessen BE, Fonarow GC, Hernandez AF, Mehran R, Petrie MC, **Butler J**. Impact of Percutaneous Coronary Intervention on Outcomes in Patients With Heart Failure: JACC State-of-the-Art Review. *J Am Coll Cardiol.* 2021 May 18;77(19):2432-2447.
760. Fudim M, Ashur N, Jones AD, Ambrosy AP, Bart BA, **Butler J**, Chen HH, Greene SJ, Reddy Y, Redfield MM, Sharma A, Hernandez AF, Felker GM, Borlaug BA, Mentz RJ. Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis. *ESC Heart Fail.* 2021 Feb;8(1):662-669.
761. Khan MS, Shahid I, Asad N, Greene SJ, Khan SU, Doukky R, Metra M, Anker SD, Filippatos GS, Fonarow GC, **Butler J**. Discontinuation and non-publication of

- heart failure randomized controlled trials: a call to publish all trial results. *ESC Heart Fail.* 2021 Feb;8(1):16-25. doi: 10.1002/ehf2.13099. Epub 2020 Nov 15.
762. Lin AY, Dinatolo E, Metra M, Sbolli M, Dasseni N, **Butler J**, Greenberg BH. Thromboembolism in Heart Failure Patients in Sinus Rhythm: Epidemiology, Pathophysiology, Clinical Trials, and Future Direction. *JACC Heart Fail.* 2021 Apr;9(4):243-253.
763. Anker MS, von Haehling S, Coats AJS, Riess H, Eucker J, Porthun J, **Butler J**, Karakas M, Haverkamp W, Landmesser U, Anker SD. Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study. *Eur J Heart Fail.* 2021 Jan;23(1):145-153
764. Patel RB, Fonarow GC, Greene SJ, Zhang S, Alhanti B, DeVore AD, **Butler J**, Heidenreich PA, Huang JC, Kittleson MM, Joynt Maddox KE, McDermott JJ, Owens AT, Peterson PN, Solomon SD, Vardeny O, Yancy CW, Vaduganathan M. Kidney Function and Outcomes in Patients Hospitalized With Heart Failure. *J Am Coll Cardiol.* 2021 Jul 27;78(4):330-343
765. Khan MS, Sreenivasan J, Lateef N, Abougergi MS, Greene SJ, Ahmad T, Anker SD, Fonarow GC, **Butler J**. Trends in 30- and 90-Day Readmission Rates for Heart Failure. *Circ Heart Fail.* 2021 Apr;14(4):e008335.
766. Pandey A, Shah SJ, **Butler J**, Kellogg DL Jr, Lewis GD, Forman DE, Mentz RJ, Borlaug BA, Simon MA, Chirinos JA, Fielding RA, Volpi E, Molina AJA, Haykowsky MJ, Sam F, Goodpaster BH, Bertoni AG, Justice JN, White JP, Ding J, Hummel SL, LeBrasseur NK, Taffet GE, Pipinos II, Kitzman D. Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction: JACC State-of-the-Art Review. *J Am Coll Cardiol.* 2021 Sep 14;78(11):1166-1187.
767. Das BB, Moskowitz WB, **Butler J**. Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials. *Children (Basel).* 2021 Apr 22;8(5):322.
768. Felker GM, **Butler J**, Januzzi JL Jr, Desai AS, McMurray JJV, Solomon SD. Probabilistic Readjudication of Heart Failure Hospitalization Events in the PARAGON-HF Study. *Circulation.* 2021 Jun 8;143(23):2316-2318. doi: 10.1161/CIRCULATIONAHA.121.054496. Epub 2021 Jun 7.
769. Salah HM, Fudim M, Al'Aref SJ, Khan MS, Almarzooq ZI, Devabhaktuni SR, Mentz RJ, **Butler J**, Greene SJ. Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. *Am J Cardiol.* 2021 Apr 15;145:165-168.
770. Segar MW, Khan MS, Patel KV, **Butler J**, Tang WHW, Vaduganathan M, Lam CSP, Verma S, McGuire DK, Pandey A. Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults. *J Am Coll Cardiol.* 2021 Oct 19;78(16):1587-1598.
771. **Butler J**, Anker SD, Filippatos G, Usman MS, Ferreira JP, Zannad F, Packer M. Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. *Eur Heart J.* 2021 Oct 30:ehab704.
772. Januzzi JL Jr, Zannad F, Anker SD, **Butler J**, Filippatos G, Pocock SJ, Ferreira JP, Sattar N, Verma S, Vedin O, Schnee J, Iwata T, Cotton D, Packer M; EMPEROR-Reduced Trial Committees and Investigators. Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial. *J Am Coll Cardiol.* 2021 Sep 28;78(13):1321-1332.
773. Ferreira JP, Zannad F, Pocock SJ, Anker SD, **Butler J**, Filippatos G, Brueckmann M, Jamal W, Steubl D, Schueler E, Packer M. Interplay of

- Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced. *J Am Coll Cardiol*. 2021 Mar 23;77(11):1397-1407
774. Colaco NA, Wang TS, Ma Y, Scherzer R, Ilkayeva OR, Desvigne-Nickens P, Braunwald E, Hernandez AF, **Butler J**, Shah SH, Shah SJ, Hsue PY. Transmethylamine-N-Oxide Is Associated With Diffuse Cardiac Fibrosis in People Living With HIV. *J Am Heart Assoc*. 2021 Aug 17;10(16):e020499
775. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, **Butler J**, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*. 2021 Sep 21;42(36):3599-3726.
776. Anker SD, Khan MS, Shahid I, Filippatos G, Coats AJS, **Butler J**. Sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism. *Eur J Heart Fail*. 2021 Aug;23(8):1250-1255. doi: 10.1002/ejhf.2279. Epub 2021 Jul 26.
777. Morris AA, Testani JM, **Butler J**. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Racial Differences and a Potential for Reducing Disparities. *Circulation*. 2021 Jun 15;143(24):2329-2331.
778. Felker GM, **Butler J**, Ibrahim NE, Piña IL, Maisel A, Bapat D, Camacho A, Ward JH, Williamson KM, Solomon SD, Januzzi JL; PROVE-HF Investigators. Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF. *Circulation*. 2021 Jul 13;144(2):180-182.
779. Blumer V, Greene SJ, Wu A, **Butler J**, Ezekowitz JA, Lindenfeld J, Alhanti B, Hernandez AF, O'Connor CM, Mentz RJ. Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure. *JACC Heart Fail*. 2021 May;9(5):336-345.
780. Packer M, Anker SD, **Butler J**, Filippatos G, Ferreira JP, Pocock SJ, Sattar N, Brueckmann M, Jamal W, Cotton D, Iwata T, Zannad F; EMPEROR-Reduced Trial Committees and Investigators. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. *J Am Coll Cardiol*. 2021 Mar 23;77(11):1381-1392.
781. Khan MS, Sreenivasan J, Shahid I, Bhinder J, Fudim M, Greene SJ, **Butler J**. Trends in Substance Abuse Disorders Among Patients Hospitalized for Heart Failure in the United States. *Circ Heart Fail*. 2021 Jul;14(7):e008147. doi: 10.1161/CIRCHEARTFAILURE.120.008147. Epub 2021 Jul 8
782. Segar MW, Singh S, Goyal P, Hummel SL, Maurer MS, Forman DE, **Butler J**, Pandey A. Prefrailty, impairment in physical function, and risk of incident heart failure among older adults. *J Am Geriatr Soc*. 2021 Sep;69(9):2486-2497.
783. Vaduganathan M, Fonarow GC, Greene SJ, Devore AD, Albert NM, Duffy CI, Hill CL, Patterson JH, Spertus JA, Thomas LE, Williams FB, Hernandez AF, **Butler J**. Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction. *J Card Fail*. 2021 Aug 21:S1071-9164(21)00341-9.
784. Chyou JY, Tay WT, Anand IS, Teng TK, Yap JYL, MacDonald MR, Chopra V, Loh SY, Shimizu W, Abidin IZ; ASIAN-HF Investigators, Richards AM, **Butler J**, Lam CSP. Electroanatomic Ratios and Mortality in Patients With Heart Failure: Insights from the ASIAN-HF Registry. *J Am Heart Assoc*. 2021 Mar 16;10(6):e017932

785. **Butler J**, Djatche LM, Lautsch D, Yang L, Patel MJ, Mentz RJ. Representativeness of the VICTORIA Trial Population in Clinical Practice: Analysis of the PINNACLE Registry. *J Card Fail*. 2021 Jul 13;S1071-9164(21)00267-0.
786. Böhm M, Anker SD, **Butler J**, Filippatos G, Ferreira JP, Pocock SJ, Mahfoud F, Brueckmann M, Jamal W, Ofstad AP, Schüler E, Ponikowski P, Wanner C, Zannad F, Packer M; EMPEROR-Reduced Trial Committees and Investigators. Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. *J Am Coll Cardiol*. 2021 Sep 28;78(13):1337-1348.
787. Khan MS, Khan F, Fonarow GC, Sreenivasan J, Greene SJ, Khan SU, Usman MS, Vaduganathan M, Fudim M, Anker SD, **Butler J**. Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map. *Eur J Heart Fail*. 2021 Sep;23(9):1468-1476.
788. Blumer V, Mentz RJ, Sun JL, **Butler J**, Metra M, Voors AA, Hernandez AF, O'Connor CM, Greene SJ. Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. *Circ Heart Fail*. 2021 Apr;14(4):e007871.
789. Anker SD, Starling RC, Khan MS, Friede T, Filippatos G, Lindenfeld J, Stephan von Bardeleben R, Coats AJS, **Butler J**. Percutaneous Mitral Valve Annuloplasty in Patients With Secondary Mitral Regurgitation and Severe Left Ventricular Enlargement. *JACC Heart Fail*. 2021 Jun;9(6):453-462
790. Filippatos G, Bakris GL, Pitt B, Agarwal R, Rossing P, Ruilope LM, **Butler J**, Lam CSP, Kolkhof P, Roberts L, Tasto C, Joseph A, Anker SD; FIDELIO-DKD Investigators. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. *J Am Coll Cardiol*. 2021 Jul 13;78(2):142-152. doi: 10.1016/j.jacc.2021.04.079.
791. Packer M, Zannad F, **Butler J**, Filippatos G, Ferreira JP, Pocock SJ, Brueckmann M, Zeller C, Hauske S, Anker SD; EMPEROR-Preserved Trial Study Group. Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial. *Eur J Heart Fail*. 2021 Oct;23(10):1798-1799. doi: 10.1002/ehhf.2334.
792. **Butler J**, Yang M, Sawhney B, Chakladar S, Yang L, Djatche LM. Treatment patterns and clinical outcomes among patients <65 years with a worsening heart failure event. *Eur J Heart Fail*. 2021 Aug;23(8):1334-1342. doi: 10.1002/ehhf.2252. Epub 2021 Jun 17.
793. Mentz RJ, Ambrosy AP, Ezekowitz JA, Lewis GD, **Butler J**, Wong YW, De Pasquale CG, Troughton RW, O'Meara E, Rockhold FW, Garg J, Samsky MD, Leloudis D, Dugan M, Mundy LM, Hernandez AF; HEART-FID Trial Investigators. Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. *Circ Heart Fail*. 2021 May;14(5):e008100.
794. Segar MW, Khan MS, Patel KV, Vaduganathan M, Kannan V, Willett D, Peterson E, Tang WHW, **Butler J**, Everett BM, Fonarow GC, Wang TJ, McGuire DK, Pandey A. Incorporation of Natriuretic Peptides with Clinical Risk-scores to Predict Heart Failure Among Individuals with Dysglycemia. *Eur J Heart Fail*. 2021 Nov 3.
795. Chow C, Greene SJ, North R, Blumer V, Truby LK, Alhanti B, **Butler J**, Ezekowitz JA, Starling RC, Mentz RJ. Sex-Differences in Cause of Death for Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction (from the ASCEND-HF Trial). *Am J Cardiol*. 2021 Sep 1;154:123-126.
796. Bozkurt B, Hershberger RE, **Butler J**, Grady KL, Heidenreich PA, Isler ML, Kirklin JK, Weintraub WS. 2021 ACC/AHA Key Data Elements and Definitions for Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop

- Clinical Data Standards for Heart Failure). *Circ Cardiovasc Qual Outcomes*. 2021 Apr;14(4):e000102.
797. Greene SJ, **Butler J**, Fonarow GC. Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure-Optimizing Therapy With the Need for Speed. *JAMA Cardiol*. 2021 Jul 1;6(7):743-744.
 798. Pocock SJ, Ferreira JP, Gregson J, Anker SD, **Butler J**, Filippatos G, Gollop ND, Iwata T, Brueckmann M, Januzzi JL, Voors AA, Zannad F, Packer M. Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. *Eur Heart J*. 2021 Aug 23;ehab579.
 799. Murphy SP, Prescott MF, Maisel AS, **Butler J**, Piña IL, Felker GM, Ward JH, Williamson KM, Camacho A, Kandanelly RR, Solomon SD, Januzzi JL. Association Between Angiotensin Receptor-Nepriylsin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. *Circ Heart Fail*. 2021 Jun;14(6):e008410.
 800. Packer M, Januzzi JL, Ferreira JP, Anker SD, **Butler J**, Filippatos G, Pocock SJ, Brueckmann M, Jamal W, Cotton D, Iwata T, Zannad F; EMPEROR-Reduced Trial Committees and Investigators. Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial. *Eur J Heart Fail*. 2021 Sep;23(9):1529-1538.
 801. DeVore AD, Granger BB, Fonarow GC, Al-Khalidi HR, Albert NM, Lewis EF, **Butler J**, Piña IL, Allen LA, Yancy CW, Cooper LB, Felker GM, Kaltenbach LA, McRae AT, Lanfear DE, Harrison RW, Disch M, Ariely D, Miller JM, Granger CB, Hernandez AF. Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction: The CONNECT-HF Randomized Clinical Trial. *JAMA*. 2021 Jul 27;326(4):314-323.
 802. Khan MS, Siddiqi TJ, **Butler J**, Friede T, Levy WC, Witte KK, Lipiecki J, Sievert H, Coats AJS. Functional outcomes with Carillon device over 1 year in patients with functional mitral regurgitation of Grades 2+ to 4+: results from the REDUCE-FMR trial. *ESC Heart Fail*. 2021 Apr;8(2):872-878. doi: 10.1002/ehf2.13273. Epub 2021 Feb 22.
 803. Savarese G, **Butler J**, Lund LH, Bhatt DL, Anker SD. CARDIOVASCULAR EFFECTS OF NON-INSULIN GLUCOSE-LOWERING AGENTS: A COMPREHENSIVE REVIEW OF TRIAL EVIDENCE AND POTENTIAL CARDIOPROTECTIVE MECHANISMS. *Cardiovasc Res*. 2021 Aug 13;cvab271.
 804. Reilly CM, Higgins M, **Butler J**, Esiashvili N, Fei B, Flynn T, Dormer JD, Schreibmann E. The Contribution of Thoracic Radiation Dose Volumes to Subsequent Development of Cardiovascular Disease in Cancer Survivors. *J Cardiovasc Nurs*. 2021 Jul 6.
 805. Mentz RJ, Mulder H, Mosterd A, Sweitzer NK, Senni M, **Butler J**, Ezekowitz JA, Lam CSP, Pieske B, Ponikowski P, Voors AA, Anstrom KJ, Armstrong PW, O'Connor CM; VICTORIA Study Group. Clinical Outcome Predictions for the VeriCiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial: VICTORIA Outcomes Model. *J Card Fail*. 2021 May 26;S1071-9164(21)00206-2.
 806. Greene SJ, **Butler J**, Spertus JA, Hellkamp AS, Vaduganathan M, DeVore AD, Albert NM, Duffy CI, Patterson JH, Thomas L, Williams FB, Hernandez AF, Fonarow GC. Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction. *JAMA Cardiol*. 2021 May 1;6(5):522-531.
 807. Tran AT, Fonarow GC, Arnold SV, Jones PG, Thomas LE, Hill CL, DeVore AD, Butler J, Albert NM, Spertus JA. Risk Adjustment Model for Preserved Health

- Status in Patients With Heart Failure and Reduced Ejection Fraction: The CHAMP-HF Registry. *Circ Cardiovasc Qual Outcomes*. 2021 Oct;14(10):e008072.
808. Thomas M, Khariton Y, Fonarow GC, Arnold SV, Hill L, Nassif ME, Chan PS, **Butler J**, Thomas L, DeVore AD, Hernandez AF, Albert NM, Patterson JH, Williams FB, Spertus JA. Association between sacubitril/valsartan initiation and real-world health status trajectories over 18 months in heart failure with reduced ejection fraction. *ESC Heart Fail*. 2021 Aug;8(4):2670-2678.
809. Lam CSP, Ferreira JP, Pfarr E, Sim D, Tsutsui H, Anker SD, **Butler J**, Filippatos G, Pocock SJ, Sattar N, Verma S, Brueckmann M, Schnee J, Cotton D, Zannad F, Packer M. Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. *Eur Heart J*. 2021 Jun 29;ehab360.
810. Oshunbade AA, Kassahun-Yimer W, Valle KA, Hamid A, Kipchumba RK, Kamimura D, Clark D 3rd, White WB, DeFilippis AP, Blaha MJ, Benjamin EJ, O'Brien EC, Mentz RJ, Rodriguez CJ, Fox ER, **Butler J**, Keith RJ, Bhatnagar A, Marie Robertson R, Correa A, Hall ME. Cigarette Smoking, Incident Coronary Heart Disease, and Coronary Artery Calcification in Black Adults: The Jackson Heart Study. *J Am Heart Assoc*. 2021 Apr 6;10(7):e017320
811. Verma S, Mazer CD, Inzucchi SE, Wanner C, Ofstad AP, Johansen OE, Zwiener I, George JT, **Butler J**, Zinman B. Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME. *Diabetes Obes Metab*. 2021 May;23(5):1173-1181.
812. Segar MW, Jaeger BC, Patel KV, Nambi V, Ndumele CE, Correa A, **Butler J**, Chandra A, Ayers C, Rao S, Lewis AA, Raffield LM, Rodriguez CJ, Michos ED, Ballantyne CM, Hall ME, Mentz RJ, de Lemos JA, Pandey A. Development and Validation of Machine Learning-Based Race-Specific Models to Predict 10-Year Risk of Heart Failure: A Multicohort Analysis. *Circulation*. 2021 Jun 15;143(24):2370-2383.
813. Khan MS, Friede T, Anker SD, **Butler J**. Effect of Carillon Mitral Contour System on patient-reported outcomes in functional mitral regurgitation: an individual participant data meta-analysis. *ESC Heart Fail*. 2021 Jun;8(3):1885-1891
814. Packer M, **Butler J**, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, Carson P, Anand I, Doehner W, Haass M, Komajda M, Miller A, Pehrson S, Teerlink JR, Schnaidt S, Zeller C, Schnee JM, Anker SD. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. *Circulation*. 2021 Oct 19;144(16):1284-1294.
815. Mentz RJ, Mulder H, Mosterd A, Sweitzer NK, Senni M, **Butler J**, Ezekowitz JA, Lam CSP, Pieske B, Ponikowski P, Voors AA, Anstrom KJ, Armstrong PW, O'connor CM, Hernandez AF; VICTORIA Study Group. Clinical Outcome Predictions for the Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. *J Card Fail*. 2021 Jun 24:S1071-9164(21)00206-2
816. Voors AA, Mulder H, Reyes E, Cowie MR, Lassus J, Hernandez AF, Ezekowitz JA, **Butler J**, O'Connor CM, Koglin J, Lam CSP, Pieske B, Roessig L, Ponikowski P, Anstrom KJ, Armstrong PW; VICTORIA Study Group. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial. *Eur J Heart Fail*. 2021 Aug;23(8):1313-1321
817. Stubblefield WB, Jenkins CA, Liu D, Storrow AB, Spertus JA, Pang PS, Levy PD, **Butler J**, Chang AM, Char D, Diercks DB, Fermann GJ, Han JH, Hiestand BC, Hogan CJ, Khan Y, Lee S, Lindenfeld JM, McNaughton CD, Miller K, Peacock WF, Schrock JW, Self WH, Singer AJ, Sterling SA, Collins SP. Improvement in Kansas

- City Cardiomyopathy Questionnaire Scores After a Self-Care Intervention in Patients With Acute Heart Failure Discharged From the Emergency Department. *Circ Cardiovasc Qual Outcomes*. 2021 Oct;14(10):e007956
818. Becher PM, Schrage B, Ferrannini G, Benson L, **Butler J**, Carrero JJ, Cosentino F, Dahlström U, Mellbin L, Rosano GMC, Sinagra G, Stolfo D, Lund LH, Savarese G. Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry. *Eur J Heart Fail*. 2021 Jun;23(6):1012-1022.
820. Albert NM, Tyson RJ, Hill CL, DeVore AD, Spertus JA, Duffy C, **Butler J**, Patterson JH, Hernandez AF, Williams FB, Thomas L, Fonarow GC. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities. *Am Heart J*. 2021 May;235:82-96
821. Vaduganathan M, Inzucchi SE, Sattar N, Fitchett DH, Ofstad AP, Brueckmann M, George JT, Verma S, Mattheus M, Wanner C, Zinman B, **Butler J**. Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial. *Diabetes Obes Metab*. 2021 Aug 31
822. Jankowska EA, Kirwan BA, Kosiborod M, **Butler J**, Anker SD, McDonagh T, Dorobantu M, Drozd J, Filippatos G, Keren A, Khintibidze I, Kragten H, Martinez FA, Metra M, Milicic D, Nicolau JC, Ohlsson M, Parkhomenko A, Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Lewis BS, Comin-Colet J, von Haehling S, Cohen-Solal A, Danchin N, Doehner W, Dargie HJ, Motro M, Friede T, Fabien V, Dorigotti F, Pocock S, Ponikowski P. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. *Eur Heart J*. 2021 Jun 3;42(31):3011–20.
823. Maffeis C, Inciardi RM, Khan MS, Tafciu E, Bergamini C, Benfari G, Setti M, Ribichini FL, Cicoira M, **Butler J**, Rossi A. Determinants of exercise intolerance symptoms considered non-specific for heart failure in patients with stage A and B: role of the left atrium in the transition phase to overt heart failure. *Int J Cardiovasc Imaging*. 2021 Aug 30.
824. Savarese G, Uijl A, Lund LH, Anker SD, Asselbergs F, Fitchett D, Inzucchi SE, Koudstaal S, Ofstad AP, Schrage B, Vedin O, Wanner C, Zannad F, Zwiener I, **Butler J**. Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. *J Card Fail*. 2021 Aug;27(8):888-895.
825. Ferreira JP, Konstam MA, McMurray JJV, **Butler J**, Girerd N, Rossignol P, Sharma A, Voors AA, Lam CSP, Packer M, Zannad F. Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial. *Eur J Heart Fail*. 2021 Sep;23(9):1477-1484. doi: 10.1002/ejhf.2255. Epub 2021 Jun 17
826. Segar MW, Patel KV, Vaduganathan M, Caughey MC, Jaeger BC, Basit M, Willett D, **Butler J**, Sengupta PP, Wang TJ, McGuire DK, Pandey A. Development and validation of optimal phenomapping methods to estimate long-term atherosclerotic cardiovascular disease risk in patients with type 2 diabetes. *Diabetologia*. 2021 Jul;64(7):1583-1594.
827. Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, Anker SD, Atherton J, Böhm M, **Butler J**, Drazner MH, Felker GM, Filippatos G, Fonarow GC, Fiuzat M, Gomez-Mesa JE, Heidenreich P, Imamura T, Januzzi J, Jankowska EA, Khazanie P, Kinugawa K, Lam CSP, Matsue Y, Metra M, Ohtani T, Francesco Piepoli M,

- Ponikowski P, Rosano GMC, Sakata Y, Seferović P, Starling RC, Teerlink JR, Vardeny O, Yamamoto K, Yancy C, Zhang J, Zieroth S. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. *J Card Fail.* 2021 Mar 1:S1071-9164(21)00050-6.
829. Khan MS, Kristensen SL, Vaduganathan M, Kober L, Abraham WT, Desai AS, Solomon SD, Swedberg K, Dickstein K, Zile MR, Packer M, McMurray JJ, **Butler J**. Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. *Am Heart J.* 2021 Jul;237:45-53
830. Ponikowski P, Alemayehu W, Oto A, Bahit MC, Noori E, Patel MJ, **Butler J**, Ezekowitz JA, Hernandez AF, Lam CSP, O'Connor CM, Pieske B, Roessig L, Voors AA, Westerhout C, Armstrong PW; VICTORIA Study Group. Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. *Eur J Heart Fail.* 2021 Aug;23(8):1300-1312.
831. Kamimura D, Cain-Shields LR, Clark D, Oshunbade AA, Ashley KE, Guild CS, Loprinzi PD, Newton R, Blaha MJ, Suzuki T, **Butler J**, Hall JE, Correa A, Hall ME. Physical Activity, Inflammation, Coronary Artery Calcification, and Incident Coronary Heart Disease in African Americans: Insights From the Jackson Heart Study. *Mayo Clin Proc.* 2021 Apr;96(4):901-911.
832. Givertz MM, Yang M, Hess GP, Zhao B, Rai A, **Butler J**. Resource utilization and costs among patients with heart failure with reduced ejection fraction following a worsening heart failure event. *ESC Heart Fail.* 2021 Jun;8(3):1915-1923. doi: 10.1002/ehf2.13155. Epub 2021 Mar 10. P
833. Zile MR, Costanzo MRR, Ippolito EM, Zhang Y, Stapleton R, Sadhu A, Jimenez J, Hobbs J, Sharma V, Warman EN, Streeter L, **Butler J**. INTERVENE-HF: feasibility study of individualized, risk stratification-based, medication intervention in patients with heart failure with reduced ejection fraction. *ESC Heart Fail.* 2021 Apr;8(2):849-860. doi: 10.1002/ehf2.13231.
834. Oshunbade AA, Lirette ST, Windham BG, Shafi T, Hamid A, Gbadamosi SO, Tin A, Yimer WK, Tibuakuu M, Clark D 3rd, Kamimura D, Lutz EA, Mentz RJ, Fox ER, **Butler J**, Butler KR, Garovic VD, Turner ST, Mosley TH Jr, Hall ME. Hypertensive Diseases in Pregnancy and Kidney Function Later in Life: The Genetic Epidemiology Network of Arteriopathy (GENOA) Study. *Mayo Clin Proc.* 2021 Sep 23:S0025-6196(21)00609-1.
835. Hadzibegovic S, Lena A, Churchill TW, Ho JE, Potthoff S, Denecke C, Rösnick L, Heim KM, Kleinschmidt M, Sander LE, Witzenrath M, Suttorp N, Krannich A, Porthun J, Friede T, **Butler J**, Wilkenshoff U, Pieske B, Landmesser U, Anker SD, Lewis GD, Tschöpe C, Anker MS. Heart failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings. *Eur J Heart Fail.* 2021 May 1:10.1002/ejhf.2210.
836. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, Anker SD, Atherton J, Böhm M, **Butler J**, Drazner MH, Michael Felker G, Filippatos G, Fiuzat M, Fonarow GC, Gomez-Mesa JE, Heidenreich P, Imamura T, Jankowska EA, Januzzi J, Khazanie P, Kinugawa K, Lam CSP, Matsue Y, Metra M, Ohtani T, Francesco Piepoli M, Ponikowski P, Rosano GMC, Sakata Y, Seferović P, Starling RC, Teerlink JR, Vardeny O, Yamamoto K, Yancy C, Zhang J, Zieroth S. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the

- Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. *Eur J Heart Fail.* 2021 Mar;23(3):352-380. doi: 10.1002/ejhf.2115. Epub 2021 Mar 3.
837. Parrinello G, Greene SJ, Torres D, Alderman M, Bonventre JV, Pasquale PD, Gargani L, Nohria A, Fonarow GC, Vaduganathan M, **Butler J**, Paterna S, Stevenson LW, Gheorghiade M. Editorial Expression of Concern: Water and sodium in heart failure: a spotlight on congestion. *Heart Fail Rev.* 2021 Nov;26(6):1529.
838. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, **Butler J**, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J.* 2021 Oct 14;ehab670.
839. **Butler J**, Filippatos G, Jamal Siddiqi T, Brueckmann M, Böhm M, Chopra VK, Pedro Ferreira J, Januzzi JL, Kaul S, Piña IL, Ponikowski P, Shah SJ, Senni M, Vedin O, Verma S, Peil B, Pocock SJ, Zannad F, Packer M, Anker SD. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. *Circulation.* 2022 Jan 18;145(3):184-193. doi: 10.1161/CIRCULATIONAHA.121.057812.
840. **Butler J**, Packer M, Filippatos G, Ferreira JP, Zeller C, Schnee J, Brueckmann M, Pocock SJ, Zannad F, Anker SD. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. *Eur Heart J.* 2022 Feb 3;43(5):416-426. doi: 10.1093/eurheartj/ehab798.PMID: 34878502
841. Verma S, Dhingra NK, **Butler J**, Anker SD, Ferreira JP, Filippatos G, Januzzi JL, Lam CSP, Sattar N, Peil B, Nordaby M, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Reduced trial committees and investigators. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. *Lancet Diabetes Endocrinol.* 2022 Jan;10(1):35-45. doi: 10.1016/S2213-8587(21)00292-8. Epub 2021 Nov 30.PMID: 34861154
842. Rao VN, Murray E, **Butler J**, Cooper LB, Cox ZL, Fiuzat M, Green JB, Lindenfeld J, McGuire DK, Nassif ME, O'Brien C, Pagidipati N, Sharma K, Vaduganathan M, Vardeny O, Fonarow GC, Mentz RJ, Greene SJ. In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. *J Am Coll Cardiol.* 2021 Nov 16;78(20):2004-2012.
843. Tomasoni D, Fonarow GC, Adamo M, Anker SD, **Butler J**, Coats AJS, Filippatos G, Greene SJ, McDonagh TA, Ponikowski P, Rosano G, Seferovic P, Vaduganathan M, Voors AA, Metra M. Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. *Eur J Heart Fail.* 2021 Dec 10. doi: 10.1002/ejhf.2397.
844. Lam CSP, Ferreira JP, Pfarr E, Sim D, Tsutsui H, Anker SD, **Butler J**, Filippatos G, Pocock SJ, Sattar N, Verma S, Brueckmann M, Schnee J, Cotton D, Zannad F, Packer M. Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. *Eur Heart J.* 2021 Nov 14;42(43):4442-4451.

845. Wish JB, Anker SD, **Butler J**, Cases A, Stack AG, Macdougall IC. Iron Deficiency in CKD Without Concomitant Anemia. *Kidney Int Rep.* 2021 Aug 10;6(11):2752-2762.
846. Greene SJ, Butler J, Fonarow GC. Contextualizing Risk Among Patients With Heart Failure. *JAMA.* 2021 Dec 14;326(22):2261-2262.
847. Parrinello G, Greene SJ, Torres D, Alderman M, Bonventre JV, Pasquale PD, Gargani L, Nohria A, Fonarow GC, Vaduganathan M, **Butler J**, Paterna S, Stevenson LW, Gheorghiade M. Editorial Expression of Concern: Water and sodium in heart failure: a spotlight on congestion. *Heart Fail Rev.* 2021 Nov;26(6):1529
848. Abdin A, Anker SD, **Butler J**, Coats AJS, Kindermann I, Lainscak M, Lund LH, Metra M, Mullens W, Rosano G, Slawik J, Wintrich J, Böhm M. 'Time is prognosis' in heart failure: time-to-treatment initiation as a modifiable risk factor. *ESC Heart Fail.* 2021 Dec;8(6):4444-4453.
849. Handelsman Y, Anderson JE, Bakris GL, Ballantyne CM, Beckman JA, Bhatt DL, Bloomgarden ZT, Bozkurt B, Budoff MJ, **Butler J**, Dagogo-Jack S, de Boer IH, DeFronzo RA, Eckel RH, Einhorn D, Fonseca VA, Green JB, Grunberger G, Guerin C, Inzucchi SE, Jellinger PS, Kosiborod MN, Kushner P, Lepor N, Mende CW, Michos ED, Plutzky J, Taub PR, Umpierrez GE, Vaduganathan M, Weir MR. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. *J Diabetes Complications.* 2022 Feb;36(2):108101.
850. Greene SJ, **Butler J**, Fonarow GC. In-hospital initiation of quadruple medical therapy for heart failure: making the post-discharge vulnerable phase far less vulnerable. *Eur J Heart Fail.* 2022 Jan;24(1):227-229. doi: 10.1002/ejhf.2382. Epub 2021 Nov 23
851. Khan MS, Bakris GL, Packer M, Shahid I, Anker SD, Fonarow GC, Wanner C, Weir MR, Zannad F, **Butler J**. Kidney function assessment and endpoint ascertainment in clinical trials. *Eur Heart J.* 2021 Dec 30;ehab832. doi: 10.1093/eurheartj/ehab832.
852. Ostrominski JW, Hirji S, Bhatt AS, **Butler J**, Fiuzat M, Fonarow GC, Heidenreich PA, Januzzi JL Jr, Lam CSP, Maddox TM, O'Connor CM, Vaduganathan M. Cost and Value in Contemporary Heart Failure Clinical Guidance Documents. *JACC Heart Fail.* 2022 Jan;10(1):1-11. doi: 10.1016/j.jchf.2021.08.002. Epub 2021 Nov 10. PMID: 34969491
853. **Butler J**, Anker SD, Filippatos G, Usman MS, Ferreira JP, Zannad F, Packer M. Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. *Eur Heart J.* 2021 Dec 21;42(48):4887-4890.
854. Mujaj B, Zhang ZY, Yang WY, Thijs L, Wei FF, Verhamme P, Delles C, **Butler J**, Sever P, Latini R, Gf Cleland J, Zannad F, Staessen JA; Heart Omics in Ageing Investigators. Aspirin use is associated with increased risk for incident heart failure: a patient-level pooled analysis. *ESC Heart Fail.* 2022 Feb;9(1):685-694. doi: 10.1002/ehf2.13688. Epub 2021 Nov 22. PMID: 34808706 Free PMC article.
855. Khan MS, Solomon N, DeVore AD, Sharma A, Felker GM, Hernandez AF, Heidenreich PA, Matsouaka RA, Green JB, **Butler J**, Yancy CW, Peterson PN, Fonarow GC, Greene SJ. Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes. *JACC Heart Fail.* 2021 Nov 30;S2213-1779(21)00538-2. doi: 10.1016/j.jchf.2021.11.001. Online ahead of print. PMID: 34895861
856. **Butler J**, Djatche LM, Lautsch D, Yang L, Patel MJ, Mentz RJ. Representativeness of the VICTORIA Trial Population in Clinical Practice: Analysis of the PINNACLE Registry. *J Card Fail.* 2021 Dec;27(12):1374-1381. doi: 10.1016/j.cardfail.2021.06.019. Epub 2021 Jul 13. PMID: 34271161
857. Segar MW, Khan MS, Patel KV, Vaduganathan M, Kannan V, Willett D, Peterson E, Tang WHW, **Butler J**, Everett BM, Fonarow GC, Wang TJ, McGuire DK, Pandey A. Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. *Eur J Heart Fail.* 2022 Jan;24(1):169-180. doi: 10.1002/ejhf.2375. Epub 2021 Nov 23. PMID: 34730265

858. Pocock SJ, Ferreira JP, Gregson J, Anker SD, **Butler J**, Filippatos G, Gollop ND, Iwata T, Brueckmann M, Januzzi JL, Voors AA, Zannad F, Packer M. Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. *Eur Heart J*. 2021 Nov 14;42(43):4455-4464.
859. Vaduganathan M, Greene SJ, Zhang S, Solomon N, Chiswell K, DeVore AD, **Butler J**, Heidenreich PA, Huang JC, Kittleson MM, Joynt Maddox KE, Mcdermott JJ, Owens AT, Peterson PN, Solomon SD, Vardeny O, Yancy CW, Fonarow GC. Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. *J Card Fail*. 2021 Nov 14:S1071-9164(21)00470-X.
860. DeVore AD, Hill CL, Thomas LE, Albert NM, **Butler J**, Patterson JH, Hernandez AF, Williams FB, Shen X, Spertus JA, Fonarow GC. Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT-HF risk model. *ESC Heart Fail*. 2022 Feb;9(1):178-185. doi: 10.1002/ehf2.13709
861. **Butler J**, Anker SD, Siddiqi TJ, Coats AJS, Dorigotti F, Filippatos G, Friede T, Göhring UM, Kosiborod MN, Lund LH, Metra M, Moreno Quinn C, Piña IL, Pinto FJ, Rossignol P, Szecsödy P, Van Der Meer P, Weir M, Pitt B. Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial. *Eur J Heart Fail*. 2022 Jan;24(1):230-238.
862. Hadzibegovic S, Lena A, Churchill TW, Ho JE, Potthoff S, Denecke C, Rösnick L, Heim KM, Kleinschmidt M, Sander LE, Witzernath M, Suttorp N, Krannich A, Porthun J, Friede T, **Butler J**, Wilkenshoff U, Pieske B, Landmesser U, Anker SD, Lewis GD, Tschöpe C, Anker MS. Heart failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings. *Eur J Heart Fail*. 2021 Nov;23(11):1891-1902. doi: 10.1002/ejhf.2210. Epub 2021 Jul 12. PMID: 33932255 Free PMC article.
863. Ezekowitz JA, Zheng Y, Cohen-Solal A, Melenovský V, Escobedo J, **Butler J**, Hernandez AF, Lam CSP, O'Connor CM, Pieske B, Ponikowski P, Voors AA, deFilippi C, Westerhout CM, McMullan C, Roessig L, Armstrong PW. Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). *ECirculation*. 2021 Nov 2;144(18):1489-1499.
864. Vaduganathan M, Inzucchi SE, Sattar N, Fitchett DH, Ofstad AP, Brueckmann M, George JT, Verma S, Mattheus M, Wanner C, Zinman B, **Butler J**. Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial. *Diabetes Obes Metab*. 2021 Dec;23(12):2775-2784. doi: 10.1111/dom.14535. Epub 2021 Oct 7. PMID: 34463409 Clinical Trial.
865. Ferreira JP, Anker SD, **Butler J**, Filippatos G, Iwata T, Salsali A, Zeller C, Pocock SJ, Zannad F, Packer M. Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced. *Eur J Heart Fail*. 2021 Dec 26. doi: 10.1002/ejhf.2409. Online ahead of print. PMID: 34957660
866. Khan MS, Greene SJ, Hellkamp AS, DeVore AD, Shen X, Albert NM, Patterson JH, Spertus JA, Thomas LE, Williams FB, Hernandez AF, Fonarow GC, **Butler J**. Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry. *Circ Heart Fail*. 2021 Nov;14(11):e008351.
867. Ivey-Miranda JB, Wetterling F, Gaul R, Sheridan S, Asher JL, Rao VS, Maulion C, Mahoney D, Mebazaa A, Gray AP, Burkhoff D, Cowie MR, Cox ZL, **Butler J**, Fudim M, McDonald K, Damman K, Borlaug BA, Testani. Changes in inferior vena cava area represent a more sensitive metric than changes in filling pressures during experimental manipulation of intravascular volume and tone. *JM. Eur J Heart Fail*. 2021 Nov 27

868. Yehya A, Shah KS, Mitter SS, Ibrahim NE, Sperry B, Shah M, Chaudhry SP, Rajagopalan N, Hernandez-Montfort J, Mohan R, Alexander KM, Sinha S, **Butler J**, Kittleson MM. Challenges and the innovations in the care of advanced heart failure patients during COVID-19.. *Heart Fail Rev.* 2022 Jan;27(1):235-238. doi: 10.1007/s10741-021-10074-0. Epub 2021 Jan 12. PMID: 33432419 Free PMC article.
869. Triposkiadis F, Xanthopoulos A, Parissis J, **Butler J**, Farmakis D. Pathogenesis of chronic heart failure: cardiovascular aging, risk factors, comorbidities, and disease modifiers. *Heart Fail Rev.* 2022 Jan;27(1):337-344. doi: 10.1007/s10741-020-09987-z. PMID: 32524327 Review.
870. Greene SJ, **Butler J**, Fonarow GC. In-hospital initiation of quadruple medical therapy for heart failure: making the post-discharge vulnerable phase far less vulnerable. *Eur J Heart Fail.* 2022 Jan;24(1):227-229. doi: 10.1002/ejhf.2382. Epub 2021 Nov 23. PMID: 34779112
871. Ostrominski JW, Hirji S, Bhatt AS, Butler J, Fiuzat M, Fonarow GC, Heidenreich PA, Januzzi JL Jr, Lam CSP, Maddox TM, O'Connor CM, Vaduganathan M. Cost and Value in Contemporary Heart Failure Clinical Guidance Documents. *JACC Heart Fail.* 2022 Jan;10(1):1-11. doi: 10.1016/j.jchf.2021.08.002.
872. Fiuzat M, Hamo CE, **Butler J**, Abraham WT, DeFilippis EM, Fonarow GC, Lindenfeld J, Mentz RJ, Psotka MA, Solomon SD, Teerlink JR, Vaduganathan M, Vardeny O, McMurray JJV, O'Connor CM. Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week. *J Am Coll Cardiol.* 2022 Feb 8;79(5):504-510.
873. Usman MS, Khan MS, Fonarow GC, Greene SJ, Friede T, Vaduganathan M, Filippatos G, Coats AJS, Anker SD, **Butler J**. Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failure. *ESC Heart Fail.* 2022 Jan 13. doi: 10.1002/ehf2.13785. Online ahead of print.
874. Shah A, Mentz RJ, Sun JL, Rao VN, Alhanti B, Blumer V, Starling R, **Butler J**, Greene SJ. Emergency Department Visits Versus Hospital Readmissions Among Patients Hospitalized for Heart Failure. *J Card Fail.* 2022 Jan 2:S1071-9164(21)00491-7. doi: 10.1016/j.cardfail.2021.11.025. Online ahead of print.
875. **Butler J**, Siddiqi TJ, Filippatos G, Ferreira JP, Pocock SJ, Zannad F, Anker SD. Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial. *Eur J Heart Fail.* 2022 Jan 5. doi: 10.1002/ejhf.2420. Online ahead of print. PMID: 34989083 No abstract available.
876. Mujaj B, Zhang ZY, Yang WY, Thijs L, Wei FF, Verhamme P, Delles C, **Butler J**, Sever P, Latini R, Gf Cleland J, Zannad F, Staessen JA; Heart Omics in Ageing Investigators. Aspirin use is associated with increased risk for incident heart failure: a patient-level pooled analysis. *ESC Heart Fail.* 2022 Feb;9(1):685-694. doi: 10.1002/ehf2.13688.
877. Piepoli MF, Adamo M, Barison A, Bestetti RB, Biegus J, Böehm M, **Butler J**, Carapetis J, Ceconi C, Chioncel O, Coats A, Crespo-Leiro MG, de Simone G, Drexel H, Emdin M, Farmakis D, Halle M, Heymans S, Jaarsma T, Jankowska E, Lainscak M, Lam CSP, Løchen ML, Lopatin Y, Maggioni A, Matrone B, Metra M, Noonan K, Pina I, Prescott E, Rosano G, Seferovic PM, Sliwa K, Stewart S, Uijl A, Vaartjes I, Vermeulen R, Verschuren WM, Volterrani M, Von Hehling S, Hoes A. Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. *Eur J Prev Cardiol.* 2022 Jan 27:zwab147. doi: 10.1093/eurjpc/zwab147.
878. Greene SJ, Fonarow GC, **Butler J**. Annals for Hospitalists Inpatient Notes - Clinical Pearls-Stopping, Starting, and Optimizing Guideline-Directed Medical Therapy in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. *Ann Intern Med.* 2022 Jan;175(1):HO2-HO3. doi: 10.7326/M21-4558. PMID: 35038400 No abstract available.

879. Khan MS, Bakris GL, Shahid I, Weir MR, **Butler J**. Potential Role and Limitations of Estimated Glomerular Filtration Rate Slope Assessment in Cardiovascular Trials: A Review. *JAMA Cardiol*. 2022 Jan 5. doi: 10.1001/jamacardio.2021.5151.
880. Oshunbade AA, Lirette ST, Windham BG, Shafi T, Hamid A, Gbadamosi SO, Tin A, Yimer WK, Tibuakuu M, Clark D 3rd, Kamimura D, Lutz EA, Mentz RJ, Fox ER, **Butler J**, Butler KR, Garovic VD, Turner ST, Mosley TH Jr, Hall ME. Hypertensive Diseases in Pregnancy and Kidney Function Later in Life: The Genetic Epidemiology Network of Arteriopathy (GENOA) Study. *Mayo Clin Proc*. 2022 Jan;97(1):78-87. doi: 10.1016/j.mayocp.2021.07.018. Epub 2021 Sep 24. PMID: 34565606
881. DeVore AD, Hill CL, Thomas LE, Albert NM, **Butler J**, Patterson JH, Hernandez AF, Williams FB, Shen X, Spertus JA, Fonarow GC. Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT-HF risk model. *ESC Heart Fail*. 2022 Feb;9(1):178-185. doi: 10.1002/ehf2.13709. Epub 2021 Nov 17. PMID: 34791838
882. Authors/Task Force Members:, McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, **Butler J**, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibellund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail*. 2022 Jan;24(1):4-131.
883. Maffei C, Inciardi RM, Khan MS, Tafciu E, Bergamini C, Benfari G, Setti M, Ribichini FL, Cicoira M, **Butler J**, Rossi A. Determinants of exercise intolerance symptoms considered non-specific for heart failure in patients with stage A and B: role of the left atrium in the transition phase to overt heart failure. *Int J Cardiovasc Imaging*. 2022 Jan;38(1):103-112.
884. Patel KV, Segar MW, Lavie CJ, Kondamudi N, Neeland IJ, Almandoz JP, Martin CK, Carbone S, **Butler J**, Powell-Wiley TM, Pandey A. Diabetes Status Modifies the Association Between Different Measures of Obesity and Heart Failure Risk Among Older Adults: A Pooled Analysis of Community-Based NHLBI Cohorts. *Circulation*. 2022 Jan 25;145(4):268-278. doi: 10.1161/CIRCULATIONAHA.121.055830. Epub 2021 Dec 3. PMID: 34860539
885. Vaduganathan M, Sattar N, Xu J, **Butler J**, Mahaffey KW, Neal B, Shaw W, Rosenthal N, Pfeifer M, Hansen MK, Januzzi JL Jr. Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin. *J Am Coll Cardiol*. 2022 Feb 8;79(5):432-444. doi: 10.1016/j.jacc.2021.11.027. PMID: 35115099

Complete list of publications: <https://pubmed.ncbi.nlm.nih.gov/?term=butler+javed>

Books

1. **Butler J**, Mills R, Young J. *Clinical Management of Heart Failure* (3rd Edition), Professional Communications, 2016

Book chapters

1. **Butler J**. Risk Factors for Heart Failure. *Congestive Heart Failure*, 3rd edition. Editors: Greenberg B and Hosenpud J. Lippincott Williams and Wilkins 2007, Pages 263-284
2. Tawakol A, **Butler J**, Hoffman U. Evaluating the Vulnerable Plaque by CT and PET-CT. *Cardiac PET and PET/CT Imaging* 1st Edition. Editors DiCarli M and Lipton M. Springer Inc. 2007 Page 347-360

3. Giamouzis G, Agha SA, **Butler J**. Role of Digoxin, Diuretics, and Vasodilators in the Management of Heart Failure. *Comprehensive Management of Heart Failure*. Editors: Baliga R, Pitt B, Givertz M, and Smidera N. 1st edition. Springer London 2008, Pages 77-94
4. Giamouzis G, Laskar S, **Butler J**. Congestive Heart Failure. Evaluation and Treatment. *BMJ Reference Guide, Point of Care*, 2008, accessible at <https://www.pointofcare.bmj.com>
5. Khadim G, **Butler J**, and Migrino M. Editors Dieter RS, Dieter RA Jr, Dieter RA III. Vulnerable plaque and the role of inflammation in vascular disease. *Peripheral Arterial Disease*, 1st edition, Editor Dieter RS. McGraw Hill. 2009 Pages 49-64
6. Georgiopoulou VV, Kalgeropoulos AP, Sperling L, **Butler J**. Incident Heart Failure Prevention. *Prevention of Cardiovascular Diseases: A Companion to Braunwald's Heart Disease*, 1st Edition, Editors Blumenthal R, Foody JM, Wong ND. Elsevier. 2010, Pages 141-161
7. Cole RT, **Butler J**. Clinical Assessment of Heart Failure: Prognosis, Functional Capacity, and Quality of Life. *American College of Cardiology -Cardiovascular Self-Assessment Program – 8*, 2011
8. Norton C, Cole RT, Giamouzis G, **Butler J**. Digoxin, Diuretics, and Vasodilators in the Management of Heart Failure. *Comprehensive Management of Heart Failure*. Editors: Baliga R, Pitt B, Givertz M, and Smidera N. 2nd edition. Springer London 2011, in press
9. Qureshi WT, Butler J, Collins SP, Moorman AJ, Gheorghide M. Early Medical Management of Hospitalization for Heart Failure (HHF). *Medical Management of Heart Failure*. In Print, *Textbook of Cardiology*, McGraw Hill
10. Kay J, **Butler J**: Heart Failure Prevention. *American Society of Preventive Cardiology – Primer on Preventive Cardiology*. Editor: Blumenthal RA. Demos Medical Publishing, LLC 2013
11. Cole RC, **Butler J**: Use of Pulmonary Artery Catheter. Editors: Maisel A and Filipatos G. *Practical Procedures in Cardiology*. Jaypee Brothers 2013
12. Kalogeropoulos AP, Georgiopoulou VV, **Butler J**: Epidemiology of Heart Failure. *Heart Failure: A Companion to Braunwald's Heart Disease*, 2nd Edition, Editors Mann, D and Felker M. Elsevier. 2014, Pages 273-281
13. Qureshi W, **Butler J**, Collins SP, Moorman AJ, Gheorghide M. Early medical management of hospitalization for heart failure (HHF). In: Baliga RR, Haas GJ (eds.), *Management of Heart Failure: Volume 1*: London: Springer-Verlag, 2015: 113 - 149.
14. Bloom MW, Cole RC, **Butler J**: Acute Heart Failure. *Hurst The Heart*. 2017
15. Ahmed T, **Butler J**, Borlaug B: Chronic Heart Failure. *Hurst The Heart*. 2017
16. Kalogeropoulos A., Papadimitriou L., **Butler J**. Chapter Epidemiology of Heart Failure. *Heart Failure: A Companion to Braunwald's Heart Disease*, 4th Edition, 2019

Editorials

1. **Butler J**, Ness R, Speroff T. Improving Care For Elderly Patients With Peptic Ulcer Disease. Should the Focus Be On Drugs or Bugs? *JAMA*, 2001;286:16,2023-24
2. **Butler J**. More risk factors affecting heart failure outcomes: Time for hope or despair? *J Am Coll Cardiol* 2005;20;46(6):1027-8
3. Hoffman U, **Butler J**. MDCT- based Coronary Angiography: A Rosetta stone for understanding coronary disease? *Eur J Radiol* 2006;57(3):329-30
4. **Butler J**, Leon A. The Elusive Scourge of Sudden Cardiac Death. Is Rational Decision Making Possible? Should there be Standards of Risks and Predictions in Medicine? *J Am Coll Cardiol* 2007;49(13):1434-5.
5. Giamouzis G, **Butler J**. The relation between heart failure and lipids: The evolving paradigm. *J Card Fail* 2007 13(4) 254-258
6. Mangalat D, Smith AL, **Butler J**. Healthcare Quality Improvement. The Devil Really is in Details. *J Card Fail* 2008 Mar;14(2):103-5.

7. **Butler J**, Kalogeropoulos A. Worsening Heart Failure Epidemic: We Don't Know How to Treat and We Don't Know How To Prevent! *J Am Coll Cardiol* 2008 5;52(6):435-7
8. Georgiopoulos V, **Butler J**. Regional Variation in Outcomes: Biology, Barriers, or Bias? *Congest Heart Fail*, 2008;14:281-282
9. **Butler J**, Kalogeropoulos A. Registries and Healthcare Quality Improvement. *J Am Coll Cardiol* 2009 29;54(14):1290-2
10. Giamouzis G, Triposkiadis F, **Butler J**. Metformin in patients with diabetes mellitus and heart failure: Friend or foe? *J Card Fail* 2010;16(3):207-10
11. Triposkiadis F, Giamouzis G, **Butler J** The Importance of Managing Diabetes Correctly to Prevent Heart Failure. *Expert Rev Cardiovascular Ther* 2011;9(3):257-9
12. Giamouzis G, Triposkiadis F, **Butler J**, Westermann D, Giannakoulas G Heart failure epidemic: in search for novel approaches. *Cardiovascular Res Pract* 2011; 159608, 1-2
13. **Butler J**. Advanced Heart Failure. *Congest Heart Fail* 2011;17(4):159
14. **Butler J**, Georgiopoulos V. The Science of Quality of Life Directed Care. *Circ Cardiovascular Qual Outcomes* 2011 1;4(4):379-81
15. **Butler J**, Kalogeropoulos AP. Hospital Strategies to Reduce Heart Failure Readmissions: Where is the Evidence? *J Am Coll Cardiol* 2012 14; 60(7):615-7
16. Giamouzis G, Giannakoulas G, **Butler J**, Eleftheriades JA, Tschöpe C, Triposkiadis F. Heart failure 2012. *Cardiol Res Pract*. 2012;2012:126324
17. Mehra MR, **Butler J**. A world view of heart failure hospitalization. *Heart Fail Clin* 2013;9:3
18. Mehra MR, **Butler J**. Atrial fibrillation and heart failure: it takes two to tango. *Heart Fail Clin* 2013;9:4
19. Mehra MR, **Butler J**. Adults with congenital heart disease: growing pains. *Heart Fail Clin* 2014;10:1
20. Mehra MR, **Butler J**. Comorbid conditions in heart failure: an unhappy marriage. *Heart Fail Clin*. 2014 Apr;10(2):10
21. Shaw L, **Butler J**. Health Equity for All – Targeting Priority Populations to Reduce Disparities in Cardiovascular Care. *J Am Coll Cardiol* 2014;64(4):346
22. Mehra MR, **Butler J**. Heart failure with preserved ejection fraction: a bouillabaisse. *Heart Fail Clin*. 2014;10(3):2
23. Mehra MR, **Butler J**. Pharmacotherapy for Heart failure: The more we get to know, the more we need to know. *Heart Fail Clin*. 2014;10(4):2
24. Morris A, Butler J, Konstam M. HFnEF, HFpEF, diastolic heart failure, or huff-puff. Time for a new taxonomy for the hypertensive-metabolic heart failure. *J Card Failure* 2014;20(10):779-81
25. Mentz RJ, Butler J. Cardiac contractility modulation: the next cardiac resynchronization therapy or another renal sympathetic denervation? *J Card Fail*. 2015;21(1):24-6
26. Mehra MR, **Butler J**. Heart Failure: A Global Pandemic and Not Just a Disease of the West. *Heart Fail Clin*. 2015 Oct;11(4):xiii-xiv.
27. Mehra MR, **Butler J**. Get a Move on Heart Failure. *Heart Fail Clin*. 2015;11(1):1
28. Greene SJ, Fonarow GC, **Butler J**. REPORT-HF: the unique blend of global heart failure registry and longitudinal cohort study. *Eur J Heart Fail*. 2015 May;17(5):472-4
29. Vaduganathan M, Kumar V, Voors AA, Butler J. Unsolved challenges in diuretic therapy for acute heart failure: a focus on diuretic response. *Expert Rev Cardiovasc Ther*. 2015 Oct;13(10):1075-8
30. Mehra MR, Butler J. Foreword. The Winning Team in Heart Failure: Dimensionality of Care Redesign. *Heart Fail Clin*. 2015 Jul;11(3):ix-x.
31. Ahmad T, Butler J. Disrupting Virchow's triad: can factor X inhibition reduce risk of adverse outcomes in patients with ischaemic cardiomyopathy? *Eur J Heart Fail*. 2015 Jul;17(7):647-51

32. **Butler J.** Diabetes Mellitus in Patients with Heart Failure: Bad for All, Worse for Some. *JACC Heart Failure*, 2016
33. A. Kalogeropoulos, J. Butler. Left Ventricular Ejection Fraction in Patients With Acute Heart Failure: A Limited Tool? *Rev Esp Cardiol (Engl Ed)*. 2017 Jan 7. pii: S1885-5857(16)30406-6.
34. Sarwar CMS, **Butler J**, Anker SD. The Syndrome of Heart Failure With Preserved Systolic Function. *Rev Esp Cardiol*. 2016;
35. Papadimitriou L, **Butler J**. Evaluation of Therapeutics for Heart Failure and other Severely-Debilitating or Life-Threatening Diseases. Accepted in *Clinical Pharmacology & Therapeutics*.

Letters

1. **Butler J**, Giannakoulas G, Giamouzis G. A struggle to SURVIVE: to abandon or not to abandon levosimendan. *Cardiovascular Drugs Ther* 2007 21(5):401-2
2. Hoffmann U, Moselewski F, Pena A, Ferencik M, Seneviratne SK, Cury RC, **Butler J**, Abbara S, Nichols JH, Brady TJ, Nagurney JT, Brown DF, Manini A, Chae CU, Achenbach S. Response to Letter Regarding Article, "Coronary Multidetector Computed Tomography in the Assessment of Patients With Acute Chest Pain". *Circulation*, 2007; 115: 449
3. Giamouzis G, Giannakoulas G, Tsarpalis K, Agha SA, Georgiopoulou V, Kalogeropoulos A, Karvounis A, **Butler J**. Natriuretic peptide-guided levosimendan therapy for heart failure: A promising new approach. *Int J Cardiol* 2008 1;128(1):91-3
4. Gopal DM, Kalogeropoulos AP, Georgiopoulou VV, **Butler J**. Response to Arques. Serum Albumin Concentration and Heart Failure Risk: The Health, Aging, and Body Composition Study. *Am Heart J* 2010;160(6):e41
5. Kalogeropoulos AP, Georgiopoulou VV, Defilippi CR, Gottdiener JS, **Butler J**. *JACC Cardiovasc Imaging*. 2012 May;5(5):572-3. Response to Echocardiography, Natriuretic Peptides, and Risk for Incident Heart Failure in Older Adults: The Cardiovascular Health Study. *JACC Imaging* 2012;5(5):572-573.
6. Vaduganathan M, Greene S, **Butler J**, Gheorghiade M. Endpoints for Diuresis - Are We There Yet? In press, *J Am Coll Cardiol*
7. Morris AA, Butler J. Ethnic diversity and immunological barriers in heart transplantation. *J Am Coll Cardiol*. 2014: S0735-1097(14)01387-4
8. Butler J, Fonarow GC, Gheorghiade M. Strategies to reduce heart failure readmissions--reply. *JAMA*. 2014;19;311(11):1160-1. doi: 10.1001/jama.2014.68

Case Reports

1. Shih JA, Williams BR, Merlino J, **Butler J**, Smith AL, Book W, Laskar SR Rapid Onset and Resolution of Cardiogenic Shock in a Patient With Pheochromocytoma. *Congest Heart Fail* 2009 15(3):151-3
2. Malik AS, Lee M, Laskar SR, Sica G, **Butler J**, Vega JD. Angioinvasive Fungal Infection Causing Disseminated Intravascular Coagulation and Acute Myocardial Infarction in a Patient with Left-Ventricular Assist Device

Abstracts

Over 400 published abstracts as of December 2020

GRANT SUPPORT

Current Federal

1. **Tobacco Regulation and Addiction Center**
(PI: Rose Marie Robertson and Aruni Bhatnagar, Pilot Project Core PI: Javed Butler)

NHLBI/FDA
Proposed Dates: 10/01/2013-08/31/2020
Percentage Effort: 10%
Total Direct Cost: \$19,600,000

Pending Federal

1. **Perinephric Fat, Subclinical Renal Dysfunction and Heart Failure with Preserved Ejection Fraction in African Americans**
Role: Co-Investigator
Institute: NHLBI
2. **Vascular Pulsatility Relation to Neurological and Cardiovascular Health in African Americans: JHS NIH/NHLBI**
Role: Co-Investigator
Institute: NHLBI

Past Federal

1. **GUIDED HF: GWTG Interventions to Reduce Disparities in AHF Patients Discharged from the Emergency Department (MPI: Sean Collins and Javed Butler)**
07/01/2015-10/14/2019
Percentage Effort: 15%
Patient Centered Outcomes Research Institute
Total Direct Cost: \$2,083,575
2. **Diastolic Dysfunction in Individuals with Human Immunodeficiency Virus Infection**
U 10 (PI: Javed Butler)
Dates: 07/01/2016-10/31/2018
Effort: 20%
Institute: NHLBI
Direct Cost: \$5,600, 000
3. **PROHIBIT-Sodium (Prevention Of Heart failure hospitalization By Intervening on Sodium)**
R 34 (PI: Javed Butler)
Dates: 07/01/2014-06/30/2018
Effort: 10%
Institute: NHLBI
Annual Direct Cost: \$225, 000
4. **Targeting Cardiac Fibrosis for Heart Failure Treatment**
European Commission FP7 (PI: Faiez Zannad, Validation Core PI for Health ABC Study: Javed Butler)
Dates: 01/01/2013-1/31/2019
Effort: 5%
Total Direct Cost: \$275,000
5. **NHLBI Heart Failure Clinical Trials Network**
U-10 (PI: Kenneth Margulis and Thomas Cappola; Stony Brook site PI Javed Butler)
Dates: 01/01/2012-12/31/2018
Effort: 5%
Institute: NHLBI

Annual Direct Cost: \$47, 000 plus per patient for individual trials

6. NIH Heart Failure Clinical Trials Network

U-10 (PI: Keneth Margulis and Thomas Cappola; Emory site PI Javed Butler)

Dates: 01/01/2012-12/31/2015

Effort: 25%

Institute: NHLBI

Annual Direct Cost: \$230, 000 plus per patient for individual trials

7. ATHENA HF: Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure (PI: Javed Butler)

Dates: 07/01/2015-06/30/2016

Effort: 5%

Institute: NHLBI

Total Direct Cost: 1,500,000

8. Improving Self Management and Outcomes in Heart Failure Patients with Diabetes

R 21 (PI: Sandra Dunbar)

Effort: 5%

Institute: NINR

Total Cost: \$375,000

Dates: 12/01/2009-08/21/2011

9. Cost Effectiveness of Quality of Life in Heart Failure Patients with Diabetes

R 01 – (PI: Sandra Dunbar)

Proposed Dates: 12/01/2009-11/30/2012

Effort: 5%

Institute: NINR

Total Cost: \$1,395,000

10. Caregiver Stress: Interventions to Promote Health and Wellbeing

P 01 (PI: Bauer-Wu)

Dates: 10/01/2009-09/30/2014

Effort: 5%

Institute: NINR

Total Cost: \$3,470,993

11. Inter-professional Collaborative Practice in Palliative Care

(PI: Tammie Quest, Heart Failure Core PI: Javed Butler)

Dates: 01/01/2013-12/31/2015

Effort: 5%

Institute: Health Resource and Services Administration – US DHHS

Total Cost: \$1,494,559

12. Interventions to Improve Outcomes in Chronic Conditions

T 32 (PI: Sandra Dunbar)

Dates: 07/01/2011-06/30/2016

Institute: NINR

Annual Direct Cost: \$190, 454

13. Center for Education and Research in Therapeutics

AHRQ – (PI Wayne Ray)
Effort: 10%
Total: \$2,551,635
Dates: 9/30/02 – 9/29/05

14. Vaccine Trial Evaluation Unit

NIH (PI: Kathryn Edwards)
Effort: 5%
Total \$12,673,932
Dates: 6/01/02 - 05/31/07

Past Non-Federal

1. The Atlanta Cardiomyopathy Consortium

Emory Healthcare. (PI: Javed Butler)
Total: \$1,000,000
2/20/07 – 12/31/10

2. Novel Risk Markers for Heart Failure

Emory Healthcare. (PI: Javed Butler)
Total: \$150,000
7/20/07 – 12/3/08

3. A Preliminary Test of iHealth-Home for Improving outcomes in Persons with Heart Failure and Diabetes (PI: Sandra Dunbar)

The Emory/Georgia Tech Healthcare Innovation Program (HIP)
Proposed Dates: 6/12-6/13
Total Cost: 25, 000

4. Predicting Right Ventricular Dysfunction in Patients Undergoing LVAD Implantation

(PI: Andreas Kalogeropoulos)
Emory University Research Commission
Proposed Dates: 3/12-12/12
Total Cost: 30,000

5. Epigenetic Control of Inflammatory Pathways in Heart Failure (PI: Javed Butler)

The Emory University Research Commission
Proposed Dates: 7/14-6/15
Total Cost: 30,000

Clinical Trials

- 1 A Multicenter, Multi-National Randomized, Double-Blind, Placebo Controlled Study To Determine The Effect Of Carvedilol On Mortality In Patients With Severe Chronic Heart Failure.
Glaxo Smith Kline - 03/98 - 06/99 - Co-Investigator
\$ 67,341.00
- 2 An Open Safety Study Of Carvedilol In Patients Who Participated In The Copernicus Study That Determined The Effect Of Carvedilol On Mortality In Patients With Severe CHF.
GlaxoSmithKline- 07/99 – 06/00 - Co-Investigator
\$ 22,654.00

- 3 A Retrospective Chart Review Study to Examine the Relationship between Renal Function and In-Hospital Heart Failure Outcomes. Biogen Inc
Biogen - 6/99 – 12/00 Principal Investigator
\$ 10,000.00
- 4 Multicenter Study of Efficacy and Safety of SDZ RAD versus Azathioprine as Part of Triple Immunosuppressive Therapy in Heart Transplant Recipients
Novartis 7/99 – 8/01 Co-Investigator
\$ 84,523.00
- 5 A Double-blind, Placebo-controlled, Multicenter Study of Conivaptan to Assess Efficacy and Safety in Patients With Nonhypovolemic Hyponatremia Associated With Inappropriate ADH
Parke Davis 3/99 – 3/00 Co-Investigator
\$ 12,000.00
- 6 ADHERE Registry – Acute Decompensated Heart Failure National Registry.
Scios 7/01 – 6/04 Principal Investigator
\$ 8934.00
- 7 Evaluation study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE)
National Institutes of Health 6/01 – 12/03 Principal Investigator
\$ 68,124.00
- 8 Bio-Impedance Cardiography in Advanced Heart Failure (BIG): A Substudy of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness
National Institutes of Health 8/02 – 12/03 Principal Investigator
\$ 4544.00
- 9 A-Heft (African-American Heart Failure Trial: A placebo-controlled trial of BiDil® added to standard therapy for African American patients with heart failure.
NitroMed 3/01 – 8/04 Principal Investigator
\$ 122,890.00
- 10 SCDHeFT (Sudden Cardiac Death in Heart Failure Trial). A study to evaluate the impact of cardiac defibrillator and amiodarone on sudden death prevention in patients with heart failure
Medtronics 1/01 – 8/04 Co-Investigator
\$ 109,250.00
- 11 A Twelve-Month Single-blinded Randomized Parallel Group Multi-center Study to Investigate the Efficacy and Safety of ERL080A compared with MMF in de novo Heart Transplant
Novartis 4/02 – 6/04 Principal Investigator
\$ 89,200.00
- 12 A Double Blind, Placebo Controlled, Multi-center Study to Asses the Impact of Subcutaneous Darbopeotin Alfa on Exercise Tolerance in Subjects with Symptomatic CHF and Anemia
Amgen 6/02 – 5/05 Principal Investigator
\$ 104,220.00
- 13 STAMINA-HFP. A Multi-center, Prospective Observational Heart Failure Registry
Amgen 6/02 – 6/05 Principal Investigator
\$ 8900.00
- 14 Multi center, randomized, double blind, placebo controlled, efficacy study on the effects of oral Tolvaptan on left ventricular dilatation and function in patients with HF rEF
Otsuka 1/02-12/02 Co-Investigator
\$ 5000.00

- 15 SYNERGY. Evaluation of Synergy Between Natreacor[®] and Furosemide on Renal and Neurohormone Responses in Chronic Heart Failure: A Phase IV pilot study. SCIOS Inc. 2003-04
Scios 3/03 – 6/04 Principal Investigator
\$ 56,700.00
- 16 OPTIMIZE Organized Program To Initiate Life-Saving Treatment In Hospitalized Patients with Heart Failure.
GlaxoSmithKline 4/03 – 6/05 Principal Investigator
\$ 11,560.00
- 17 A Phase II, Multi-Center, Randomized, Double-Blind, Study of ZP120 Administered as Add-On Therapy in Patients with Decompensated CHF Treated with Furosemide
Zealand Pharma A/S 03/2006 Co-Investigator
\$ 24, 650.00
- 18 Multicenter, double-blind, randomized, placebo-controlled, parallel group study to assess the efficacy, safety, and tolerability of tezosentan in patients with acute heart failure.
Actelion 6/03 – 3/04 Principal Investigator
\$ 10,000.00
- 19 Multicenter, double-blind, randomized, placebo-controlled, efficacy and safety study of the effects of oral tolvaptan in patients with hyponatremia.
Otsuka Maryland Research Institute 8/03 – 6/04 Co-Investigator
\$ 12,235.00
- 20 A Phase 2, Dose Escalation Evaluation of the Pharmacokinetic and Hemodynamic Effects of Carperitide in Subjects with Congestive Heart Failure.
Fugisawa 1/04 – 12/04 Co-Investigator
\$ 10,235.00
- 21 A prospective, open label, multicenter extension study on the efficacy and safety of ERL 080A in heart transplant recipients.
Novartis 7/04 – 6/05 Principal Investigator
\$ 8900.00
- 22 A facilitated access program to provide Everolimus maintenance for patients completing therapy in RAD trials of solid organ transplantation
Novartis 7/04 – 6/05 Principal Investigator
\$ 5455.00
- 23 Follow-up Serial Infusions of Nesiritide for the Management of Heart Failure FUSION II
Scios 3/04 – 6/06 Principal Investigator
\$ 12,240.00
- 24 A Multi-Center, Randomized, Double-Blind, Flexible Dose Study of ZP120 Administered as I.V. Infusion as Add-On Therapy in Patients with Decompensated HF Treated with Furosemide
Zealand Pharma A/S 03/2006-12-06 Co-Investigator
\$ 9500.00
- 25 Transplant-Eligible Patient Management For Congestive Heart Failure (TMAC) With Continuous Infusion of Nesiritide or Placebo
Scios Inc 09/2006-6-2007 Co-Investigator
\$ 8150.00
- 26 A Pilot Study to Assess Change in Exercise Heart Rate as a Dosing Strategy for Beta Blocker Therapy in Heart Failure Due to Left Ventricular Systolic Dysfunction (TARGET-HR)
AstraZeneca 6/04 – 6/05 Principal Investigator
\$ 10000.00

- 27 A Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Oral Tolvaptan on Left Ventricular Dilatation and Function in HF and Systolic Dysfunction
Otsuka Maryland Research Institute 3/04 – 6/05 Co-Investigator
\$ 28,500.00
- 28 The BALANCE Study: Treatment of Hyponatremia Based on Lixivaptanin NYHA Class III/IV Cardiac Patient Evaluation
CardioKine Biopharma, LLC 9/08 – 6/09 Co-Investigator
\$5200.00
- 29 A Randomized, double-blind, repeat dose, parallel group study to evaluate the effect of GW501516 on exercise capacity, symptoms, and cardiac function in patients with LVSD
Medpace Inc 03/2007 – 6/2008 Co-Investigator
\$ 6700.00
- 30 RAD001A2310 A 24-Month, Multi-center, Randomized, Open-label, study of Efficacy and Safety of Concentration-Controlled Certican with reduced Neoral versus 3.0g MMF with standard dose Neoral in de novo Heart Transplant
Novartis 12/06 – 4/09 Co-Investigator
\$ 183,440.46
- 31 Multicenter Trial of the Orqis Medical CRS for the ENhanced Treatment of CHF Unresponsive to Medical Therapy
ORQIS® 02/2007-6/08 Co-Investigator
\$ 10,280.00
- 32 TELE-HF: A Study of Telemonitoring to Improve Outcomes in Patients with Heart Failure
National Institutes of Health 8/07 – 9/09 Co-Investigator
\$ 97,920.00
- 33 CHAMPION: CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients CM-06-04
CardioMEMS, Inc 6/08 – 6/09 Co-Investigator
\$ 132,097.00
- 34 The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients with V122I or Wild-Type TTR Amyloid Cardiomyopathy
FoldRX Pharmaceuticals, Inc. 10/08 –06/10 Co-Investigator
\$ 8600.00
- 35 PRECEDE-HF-Prospective, Randomized Evaluation of Cardiac Compass with OptiVol in the Early Detection of Decompensation Events for Heart Failure
Medtronic 6/2008 – 7/2010 Co-Investigator
\$ 68,000.00
- 36 MULTISENSE - Multisensor Chronic Evaluations in Ambulatory Heart Failure Patients
Boston Scientific - 6/2009 – 7/2011 Co-Investigator
\$ 84,246.00
- 37 VIVID: Valvular and Ventricular Improvement via iCoapsys Delivery Feasibility Study
iCoapsys 6/2008 – 4/2010 Co-Investigator
\$ 44,221.00
- 38 ECHO-CRT: Echocardiography guided Cardiac Resynchronization Therapy
Biotronic, Inc 1/2010 – 4/2012 Co-Investigator
\$ 14,000.00
- 39 PAPER - The HeartMate II LVAS Pivotal Study Protocol
Thoratec 1/2010 – 3/2013 Co-Investigator
\$ 6800.00
- 40 RAPID RF: Remote Active Monitoring in Patients with Heart Failure

- Boston Scientific 10/2009 – 10-2012 Co-Investigator
\$ 24,560.00
- 41 A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin alfa Treatment on Mortality and Morbidity in Heart Failure (HF)
Amgen Inc 03/2007 – 6/2013 Principle Investigator
\$ 108,230.00
- 42 Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure (ASCEND-HF). Protocol A093
Scios, Inc 1/2008 – 3/2011 Principal Investigator
\$ 124,000.00
- 43 A Double-blind, Randomized, Placebo-controlled, Multicenter Phase II Study to Evaluate the Safety and Efficacy of Omecamtiv Mecarbil Infusion in LVSD patients Hospitalized for AHF
AMGEN, Inc 12/2011 – 2-2013 Principal Investigator
\$ 24,650.00
- 44 An Open-Label, Multicenter, Phase 2 Study Evaluating the results of Tc99m-Maraciclalide scintigraphy in Subjects with Diabetes and Heart Failure with Preserved Ejection Fraction
GE Healthcare, Inc 12/2011 – 12/2012 Principal Investigator
\$ 15,040.00
- 45 IMPROVE HF Bridge
Medtronic, Inc 11/2011 – 3/2013 Principal Investigator
\$ 23,000.00
- 46 Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients: EXACT-HF
NIH 1/2012 – 6/14 Principal Investigator
\$ 87,600.00
- 47 Reliable Evaluation of Dyspnea in the Heart Failure Network ROSE Study - RED ROSE
NIH 1/2012 – 6/2014 Principal Investigator
\$ 78,300.00
- 48 Renal Optimization Strategies Evaluation in Acute Heart Failure - ROSE-AHF
NIH 1/2012 – 6/2-14 Principal Investigator
As above
- 49 TACTICS-HF - The Targeting Acute Congestion with Tolvaptan In Heart Failure Study
Otsuka 10/2012 – 6/2014 Site Investigator
\$ 12,060.00
- 50 Increase of Vagal Tone in chronic Heart Failure - INNOVATE
BioControl 10/2012 – 2/2014 Site Investigator
\$ 20,030.00
- 51 FIGHT - Functional Impact of GLP-1 for Heart Failure Treatment
NHLBI 11/2012 – 9/2014
\$ 30,000.00 Principal Investigator
- 52 PRESERVE - Preserving Renal Sodium Excretion by Renal Sympathetic Denervation in CHF
NHLBI 11/2012 – 8/2013 Principal Investigator
\$ 12,000
- 53 ART-HF - Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic HF and LVSD and Either T2DM With or Without CKD or CKD Alone
Bayer 6/2013 – 6/2014 Site Investigator
\$ 5600.00

- 54 SECRET of CHF - Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Worsening HF With Challenging Volume Management
Otsuka 7/2013 – 9/2014 Site Investigator
\$ 12460.00
- 55 The Evaluation of VAD InterVENTion Before Inotropic Therapy
NHLBI 7/2013 – 4/2014 Site Investigator
\$ 4800.00
- 56 AVOID HF: Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment
Gambro 3/2013 – 6/2014 Site Investigator
\$ 16,800.00
- 57 SILVER-AMI: Outcomes in Older Persons With Heart Attacks
NHLBI 4/2013 – 6/2014 Site Investigator
\$ 18,000.00
- 58 SOCRATES-Preserved. Randomized parallel-group, placebo-controlled, double-blind, dose finding phase IIb studies of 4 dose regimens of the oral sGC stimulator BAY1021189 over 12 wk
Bayer 10/2013 – 8/2014 Site Investigator
\$ 5400.00
- 59 SOCRATES-Reduced. Randomized parallel-group, placebo-controlled, double-blind, dose finding phase IIb studies of 4 dose regimens of the oral sGC stimulator BAY1021189 over 12 wk
Bayer 10/2013 – 8/2014 Site Investigator
\$ 4800.00
- 60 COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure
AMGEN 10/2013 – 8/2014 Site Investigator
\$ 18,460.00
- 61 IRONOUT – Oral Iron Repletion Effects on Oxygen Uptake in Heart Failure
NHLBI 12/2014 – 04/2017 Site Investigator
\$ 16,425.00
- 63 A Phase IIa, Single-blind, Placebo-controlled, Crossover, Multi-center, Randomized Study to Assess the Safety, Tolerability, and Efficacy of a Single Intravenous Dose of Ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Non-Ischemic HF
Cardiocell 12/2014 – 12/2017 Principal Investigator
\$ 178,000.00
- 64 International Registry to Assess Medical Practice with longitudinal Observation for Treatment of Heart Failure (Report-HF)
Novartis Pharmaceuticals 10/2015-18 Site Investigator
\$ 10,000.00
- 65 Integrated Diagnostics Driven Diuretic & Chronic Medication Management for Heart Failure (INTERVENE-HF)
Medtronic Inc. 8/2016-2018 Site Investigator
\$ 22,000.00
- 66 Inorganic Nitrate Delivery to Improve Exercise Capacity in HFpEF (INDIE HFpEF)
NHLBI 9/2016-18 Principal Investigator
\$8435.00

- 67 Observational registry of Treatment Patterns in Heart Failure with Reduced Ejection Fraction
Novartis Pharmaceuticals 10/2016-18 Site Investigator
\$ 6800.00
- 68 Entresto (LCZ696) In Hospitalized Advanced Heart Failure (LIFE Study)
NHLBI 2/2017-2018 Site Investigator
\$ 12,000.00
- 69 Phase II Trial to Study the Efficacy, Safety Pharmacokinetic & Pharmacodynamic Effects of the Oral Partial Adenosine A1 Receptor Agonist Neladenoson Bialanate Over 20 Weeks in HFrEF
Bayer Healthcare Pharmaceuticals 04/2017-2018 Site Investigator
\$ 24,450.00
- 70 PREVENTion of Non-Surgical Bleeding by Management of Heart Mate II Patients without Antiplatelet Therapy (PREVENT II)
St Jude Medical Buisness Services Inc. 5/2017-18 Site Investigator
\$ 6500.00
- 71 EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
Co-Principal Investigator
Boehringer Ingelheim, 03/2017- 11/2020
- 72 Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
Principal Investigator
Vifor Pharma, 04/2019-03/2022
- 73 EMPAgliflozin for the prevention of Chronic heart failure and morTality after an acute Myocardial Infarction. (EMPACT-MI)
Principal Investigator
Boehringer Ingelheim, 11/2020-12/2022
- 74 ALgorithm using LINQ Sensors for EValuatlon And TreatmEnt of Heart Failure (ALLEVIATE-HF)
Principal Investigator
Medtronic, 6/2020-